FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU CAIRNS, T
SIEGMUND, EG
RADER, B
AF CAIRNS, T
SIEGMUND, EG
RADER, B
TI ANALYSIS OF TESTOSTERONE ESTERS BY TANDEM MASS-SPECTROMETRY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID LIQUID-CHROMATOGRAPHY; CONFIRMATION; PROPIONATE
AB The electron ionization (EI) and chemical ionization (CI) mass spectra of 12 representative testosterone esters were examined to explore the various analytical options available for identification and confirmation of the esters. Using EI, a number of fragment ions indicated the identification of the testosterone moiety, but structural confirmation of the individual esters often required the observance of the molecular ion at very low relative abundance ratios. The acceptable analytical method involved CI/tandem mass spectrometry based on the production of the 2 generic product ions derived from the protonated molecule ion.
RP CAIRNS, T (reprint author), US FDA,DEPT HLTH & HUMAN SERV,LOS ANGELES DIST LAB,1521 W PICO BLVD,LOS ANGELES,CA 90015, USA.
NR 11
TC 2
Z9 2
U1 1
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 306
EP 312
PG 7
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000009
PM 8471857
ER
PT J
AU CARSON, MC
AF CARSON, MC
TI SIMULTANEOUS DETERMINATION OF MULTIPLE TETRACYCLINE RESIDUES IN MILK
USING METAL CHELATE AFFINITY-CHROMATOGRAPHY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; OXYTETRACYCLINE; TISSUES;
CHLORTETRACYCLINE; BLOOD
AB A method was developed for the determination of 7 tetracyclines in milk. Raw milk samples are defatted, acidified, and centrifuged to remove proteins, and the tetracyclines are specifically absorbed from the milk by chelation with metal ions bound to small Chelating Sepharose Fast Flow columns. The tetracyclines are removed from these columns with EDTA-containing buffer, and the extracts are further cleaned up by centrifugal ultra-filtration. Finally, the extracts are concentrated and analyzed simultaneously by on-line concentration. This method has limits of detection for individual tetracyclines of <5 ng/mL and was validated with fortified milk samples at 15, 30, and 60 ng/mL. Recoveries exceeded 60% for all tetracyclines at all levels, with good precision. The method was also tested on milk from cows dosed with each of the tetracyclines. Advantages of this method over existing methods include its sensitivity, minimal use of organic solvents, and speed; with an autosampler, at least 14 samples can be processed and analyzed in 1 day.
RP CARSON, MC (reprint author), US FDA,CTR VET MED,DIV VET MED RES,BELTSVILLE,MD 20705, USA.
NR 12
TC 41
Z9 42
U1 0
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 329
EP 334
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000013
PM 8471858
ER
PT J
AU DANIELSON, JW
AF DANIELSON, JW
TI EVALUATION OF MICROBIAL LOADS OF BACILLUS-SUBTILIS SPORES ON
PENICYLINDERS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID ADHESION
AB Three types of penicylinders were compared for their retention of spores of Bacillus subtilis testing for sporicidal activity of disinfectants. Glass, porcelain, and stainless steel penicylinders are inoculated with a water suspension of B. subtilis var. niger (ATCC 9372) spores and dried. One set of each type of penicylinder is submerged 1 h in 0.9% saline. One set of porcelain penicylinders is submerged 15 h in a neutralized chemical germicide, and one set is also inoculated with a culture filtrate of B. subtilis (ATCC 19659), dried according to the AOAC method, and submerged 1 h in 0.9% saline. Microbial loads simulate those held on carriers used to test sporicidal activity of disinfectants. Carriers are immersed in chemical germicide, transferred to a neutralizer, and placed in a culture medium. Average percentages of B. subtilis var. niger spores retained on 10 carriers after 1 h submersion in saline and in water were as follows: glass, 93.6%; porcelain, 99.9%; and stainless steel, 99.5%. Retention of spores after 15 h submersion in a neutralized chemical germicide and in water was 98.9%. Porcelain penicylinders inoculated from a culture filtrate of B. subtilis (ATCC 19659) retained 26% of the spores after being submerged 1 h in saline and placed in water. Glass penicylinders, which retained the lowest and most variable number of spores, were the least suitable for sporicidal activity testing. B. subtilis (ATCC 19659) spores tested on porcelain penicylinders met only the minimum HCI resistance requirements of greater-than-or-equal-to 2 min. On porcelain penicylinders, the resistance of B. subtilis var. niger spores to 2.5N HCl was relative to the number of spores inoculated.
RP DANIELSON, JW (reprint author), US FDA,STERIL ANAL RES CTR,240 HENNEPIN AVE,MINNEAPOLIS,MN 55401, USA.
NR 9
TC 11
Z9 11
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 355
EP 360
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000016
PM 8471861
ER
PT J
AU CHASE, GW
LANDEN, WO
SOLIMAN, AGM
EITENMILLER, RR
AF CHASE, GW
LANDEN, WO
SOLIMAN, AGM
EITENMILLER, RR
TI LIQUID-CHROMATOGRAPHIC ANALYSIS OF NIACIN IN FORTIFIED FOOD-PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT 105TH INTERNATIONAL ANNUAL MEETING OF THE ASSOC OF OFFICIAL ANALYTICAL
CHEMISTS
CY AUG 12-15, 1991
CL PHOENIX, AZ
SP ASSOC OFFICIAL ANAL CHEMISTS
ID RIBOFLAVIN; THIAMIN
AB An ion exchange liquid chromatographic (LC) method using an anion exchange resin column was developed for the determination of niacin in fortified foods. Samples were extracted by autoclaving with H2SO4 (1 + 1). Florisil open column chromatography was used to remove interferences from the sample extracts. Niacin levels were quantitated by an LC system using a 250 x 4.1 mm Hamilton PRP-X100 column, a mobile phase of 2% glacial acetic acid in water, and UV detection at 254 nm. The limit of detection was 0.11 mug niacin/mL, and the standard curve was linear from 0.24 to 0.80 mug niacin/mL. The system reproducibility was evaluated by completing 10 repetitive analyses on an infant formula and a macaroni product, which gave an average CV of 2.7%. Mean recovery (+/- standard deviation) was 99.8 +/- 7.7 (n = 15). The results compared favorably with those by the AOAC microbiological method.
RP CHASE, GW (reprint author), US FDA,60 8TH ST NE,ATLANTA,GA 30309, USA.
NR 9
TC 13
Z9 13
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 390
EP 393
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000023
PM 8471863
ER
PT J
AU KIRCHHOEFFER, RD
HIPP, S
AF KIRCHHOEFFER, RD
HIPP, S
TI NIACIN-I - DISSOLUTION PROFILES OF SUSTAINED-RELEASE NIACIN PRODUCTS BY
AUTOMATED AND MANUAL PROCEDURES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID HYPERCHOLESTEROLEMIA
AB Automated and manual procedures were developed to obtain dissolution profiles of sustained-release niacin formulations. The procedures are based on the United States Pharmacopeia XXII apparatus 1 (basket) at 1 00 rpm with 900 mL 0.1 N HCl as the dissolution medium. Filtered aliquots are read at 260 nm. No interference was found from excipients. The procedures are straightforward and will discriminate between sustained-release and regular niacin formulations.
RP KIRCHHOEFFER, RD (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV DRUG ANAL,1114 MARKET ST,ROOM 1002,ST LOUIS,MO 63101, USA.
NR 13
TC 3
Z9 3
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 394
EP 398
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000024
PM 8471864
ER
PT J
AU TANNER, JT
BARNETT, SA
MOUNTFORD, MK
AF TANNER, JT
BARNETT, SA
MOUNTFORD, MK
TI ANALYSIS OF MILK-BASED INFANT FORMULA .5. VITAMIN-A AND VITAMIN-E,
FOLIC-ACID, AND PANTOTHENIC-ACID - FOOD-AND-DRUG-ADMINISTRATION INFANT
FORMULA COUNCIL - COLLABORATIVE STUDY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT 105TH INTERNATIONAL ANNUAL MEETING OF THE ASSOC OF OFFICIAL ANALYTICAL
CHEMISTS
CY AUG 12-15, 1991
CL PHOENIX, AZ
SP ASSOC OFFICIAL ANAL CHEMISTS
AB In 1982, the U.S. Food and Drug Administration, the Infant Formula Council and its member companies, contract laboratories, and other government laboratories began a study of analytical methods for the nutrients listed in the Infant Formula Act of 1980 (P.L. 96-359). Four phases of the study have been completed and are discussed in earlier reports. The present report provides data on Phase V, in which 13 laboratories collaboratively studied individual methods for folic acid, pantothenic acid, and vitamin E, in addition to 2 methods for vitamin A. Vitamins A and E are determined by liquid chromatography. Folic acid and pantothenic acid are determined by microbiological methods using acidimetric and/or turbidimetric assays as the determinative step. In most cases, relative standard deviations for repeatability, RSD(r), and reproducibility, RSD(R), are as good as those that would be predicted from other collaborative studies. RSD(r) and RSD(R) values obtained for the 5 methods are 9.35 and 25.44% for folic acid, 4.59 and 10.23% for pantothenic acid, 8.46 and 11.69% for vitamin E, 3.62 and 9.72% for vitamin A (retinol isomers), and 4.9 and 10.5% for vitamin A (retinol). The 5 methods have been adopted first action by AOAC International.
C1 TMS ANALYT SERV,INDIANAPOLIS,IN 46268.
INFANT FORMULA COUNCIL,ATLANTA,GA 30342.
RP TANNER, JT (reprint author), US FDA,DIV NUTR,WASHINGTON,DC 20204, USA.
NR 8
TC 23
Z9 23
U1 0
U2 6
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 399
EP 413
PG 15
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000025
PM 8471865
ER
PT J
AU KIM, HS
ANGYAL, G
AF KIM, HS
ANGYAL, G
TI COMPARISON OF LIQUID-CHROMATOGRAPHIC METHOD TO AOAC MICROBIOLOGICAL
METHOD FOR DETERMINATION OF L-TRYPTOPHAN IN TABLETS AND CAPSULES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Note
ID DERIVATIZATION
AB A reversed-phase liquid chromatographic (LC) method coupled with precolumn derivatization of L-tryptophan with phenylisothiocyanate was compared to the AOAC microbiological method for determining L-tryptophan in tablets and capsules. For the microbiological method, the concentrations of L-tryptophan were 4-8% lower in autoclaved test samples (hot method) than in test samples that were not autoclaved (cold method). When L-tryptophan values obtained by the LC method were compared to those obtained by the cold microbiological method, no significant differences were observed (P > 0.05). The mean relative standard deviations were 2.9% for the LC method and 1.6% for the cold microbiological method. The mean recoveries of standard L-tryptophan added before analysis were 99% for the LC method and 101% for the cold microbiological method. These results demonstrate that both methods are reliable for determining free L-tryptophan contained in tablets and capsules. However, the LC method has the advantages of using a smaller test portion and having a shorter analysis time.
RP KIM, HS (reprint author), US FDA,DIV NUTR,WASHINGTON,DC 20204, USA.
NR 6
TC 3
Z9 3
U1 1
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 414
EP 417
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000026
PM 8471866
ER
PT J
AU LEADBETTER, MG
MATUSIK, JE
AF LEADBETTER, MG
MATUSIK, JE
TI LIQUID-CHROMATOGRAPHIC DETERMINATION AND LIQUID-CHROMATOGRAPHIC
THERMOSPRAY MASS-SPECTROMETRIC CONFIRMATION OF NICARBAZIN IN CHICKEN
TISSUES - INTERLABORATORY STUDY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Note
AB The U.S. Food and Drug Administration sponsored an interlaboratory study of a liquid chromatographic determination with ultraviolet detection of nicarbazin in chicken liver and muscle tissues. The method determined the 4,4'-dinitrocarbanilide (DNC) portion of nicarbazin. The interlaboratory study of the determinative method was successful for nicarbazin at the 4 ppm level. Results showed good reproducibility for the fortified liver and muscle samples. Mean interlaboratory recoveries and percent coefficients of variation at about 4 ppm were 87.1 and 10.9%, respectively, for muscle and 87.4 and 7.5%, respectively, for liver. The interlaboratory analyses of the dosed liver and muscle tissues produced concentration levels similar to those obtained by the sponsor. The confirmatory procedure, which identified DNC in purified tissue extracts, used liquid chromatography-thermospray/mass spectrometry. The confirmatory procedure was successfully evaluated by one FDA laboratory.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
RP LEADBETTER, MG (reprint author), US FDA,CTR VET MED,BLDG 328-A,BARC E,BELTSVILLE,MD 20705, USA.
NR 4
TC 9
Z9 9
U1 0
U2 3
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 420
EP 423
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000028
PM 8471868
ER
PT J
AU MISLIVEC, PB
BANDLER, R
ALLEN, G
AF MISLIVEC, PB
BANDLER, R
ALLEN, G
TI INCIDENCE OF FUNGI IN SHARED-USE COSMETICS AVAILABLE TO THE PUBLIC
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Note
AB A survey was conducted to assess both the potential health risk from shared-use cosmetics caused by microorganisms and the microbial efficacy of preservatives in cosmetics. Samples of 3027 shared-use cosmetic products were collected from 171 retail establishments nationwide. Fungi were present in 10.4% of the products, and 3.9% contained fungal pathogens or opportunistic pathogens. The 423 fungal isolates identified represented 33 genera and at least 69 species. A disproportionately large share of the fungal isolates were from eye products; fewer were from lip products. Pathogenic or opportunistic pathogens made up 32.2% of the fungal isolates. A slightly lower percentage of samples that contained preservatives had fungi, a fact suggesting that preservatives reduce the incidence of fungi in cosmetics. Results of this survey indicate potential microbiological problems concerning the safety of shared-use cosmetics.
C1 US FDA,DIV MICROBIOL,WASHINGTON,DC 20204.
NR 9
TC 7
Z9 8
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD MAR-APR
PY 1993
VL 76
IS 2
BP 430
EP 436
PG 7
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KT990
UT WOS:A1993KT99000030
PM 8471870
ER
PT J
AU LOVE, LA
RADER, JI
CROFFORD, LJ
RAYBOURNE, RB
PRINCIPATO, MA
PAGE, SW
TRUCKSESS, MW
SMITH, MJ
DUGAN, EM
TURNER, ML
ZELAZOWSKI, E
ZELAZOWSKI, P
STERNBERG, EM
AF LOVE, LA
RADER, JI
CROFFORD, LJ
RAYBOURNE, RB
PRINCIPATO, MA
PAGE, SW
TRUCKSESS, MW
SMITH, MJ
DUGAN, EM
TURNER, ML
ZELAZOWSKI, E
ZELAZOWSKI, P
STERNBERG, EM
TI PATHOLOGICAL AND IMMUNOLOGICAL EFFECTS OF INGESTING L-TRYPTOPHAN AND
1,1'-ETHYLIDENEBIS(L-TRYPTOPHAN) IN LEWIS RATS
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE EOSINOPHILIA-MYALGIA SYNDROME; IMMUNE ACTIVATION; FIBROSIS;
PANCREATITIS; SUPPLEMENT
ID EOSINOPHILIA-MYALGIA-SYNDROME; SCLERODERMA; FASCIITIS; ILLNESS; EMS
AB The eosinophilia-myalgia syndrome (EMS) has been associated with ingestion of L-tryptophan (L-TRP) produced by a single manufacturer. Epidemiological data implicated 1,1'-ethylidenebis(L-tryptophan) (EBT) (peak 97 or peak E) as a possible etiologic agent. We showed previously that Lewis rats treated with the L-TRP implicated in EMS develop fasciitis and perimyositis similar to those seen in human EMS. We now report the pathology associated with the treatment of Lewis rats with synthetic EBT and/Or L-TRP. Atl animals treated for 6 wk with case-associated L-TRP or EBT developed significant myofascial thickening, compared with animals in the vehicle control and control L-TRP groups. However, even those animals receiving the control L-TRP showed a mild but significant increase in the thickness of the myofascia, compared with vehicle-treated control animals. All animals except vehicle controls also exhibited significant pancreatic pathology, including fibrosis and acinar changes. Only animals treated with case-associated L-TRP for 6 wk showed evidence of immune activation with increased frequency of CD8, Ia, and IL-2 receptor-positive cells in the peripheral blood. Animals receiving L-TRP or EBT for < 6 wk did not show significant differences in myofascial thickness, although these animals did show pancreatic acinar changes. Although these results demonstrate for the first time the pathological effects of EBT, they do not rule out the possibility that other impurities in the EMS-case-associated L-TRP may also contribute to some of the features of EMS.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
NCI,BETHESDA,MD 20892.
NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,BETHESDA,MD 20892.
NIAMSD,BETHESDA,MD 20892.
RI Crofford, Leslie/J-8010-2013
NR 35
TC 53
Z9 53
U1 0
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 1993
VL 91
IS 3
BP 804
EP 811
DI 10.1172/JCI116300
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KR461
UT WOS:A1993KR46100010
PM 8450062
ER
PT J
AU GOLDEN, DA
RHODEHAMEL, EJ
KAUTTER, DA
AF GOLDEN, DA
RHODEHAMEL, EJ
KAUTTER, DA
TI GROWTH OF SALMONELLA SPP IN CANTALOUPE, WATERMELON, AND HONEYDEW MELONS
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
AB The ability of Salmonella spp. to grow on the interior tissues of cantaloupe, watermelon, and honeydew melons was investigated. Pieces of rind-free melons (pH 5.90-6.67) and tryptic soy broth (TSB, pH 5.90) were inoculated with a mixed culture (approximately 100 CFU/g or ml) containing equal proportions of five species of Salmonella (S. anatum, S. chester, S. havana, S. poona, and S. senftenberg). Inoculated melon pieces and TSB were incubated for 24 h at 5 or 23-degrees-C. Viable populations of salmonellae were determined by surface plating test portions on Hektoen enteric agar. Results indicated that Salmonella growth was rapid and prolific on the melons and in TSB at 23-degrees-C incubation. Final populations on watermelons were approximately 1.0 log10 greater than populations on cantaloupe and honeydew and in TSB. Although viable Salmonella populations on melons and in TSB did not increase during the 24-h incubation at 5-degrees-C, little or no decrease in viable populations was observed.
RP GOLDEN, DA (reprint author), US FDA,DIV HACCP PROGRAMS,WASHINGTON,DC 20204, USA.
NR 10
TC 90
Z9 91
U1 0
U2 4
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD MAR
PY 1993
VL 56
IS 3
BP 194
EP 196
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA KR950
UT WOS:A1993KR95000001
ER
PT J
AU HAMMACK, TS
SATCHELL, FB
ANDREWS, WH
AMAGUANA, RM
JUNE, GA
SHERROD, PS
KOOPMAN, L
AF HAMMACK, TS
SATCHELL, FB
ANDREWS, WH
AMAGUANA, RM
JUNE, GA
SHERROD, PS
KOOPMAN, L
TI ABBREVIATED PREENRICHMENT PERIOD FOR RECOVERY OF SALMONELLA SPP FROM
SELECTED LOW-MOISTURE DAIRY FOODS
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID ENRICHMENT CONDITIONS; TYPHIMURIUM; MEDIA; FEEDS
AB A 6-h and a 24-h preenrichment procedure were compared for their ability to recover Salmonella spp. from selected low-moisture dairy foods. The foods were artificially inoculated several days before analysis, and 20 replicate test portions per procedure from each food were examined in each experiment. Samples examined by the 6-h abbreviated procedure were preenriched for 6 h at 35-degrees-C in an air incubator or water bath and centrifuged at 4,100 x g for 10 min. Pellets were suspended in tetrathionate broth and incubated for 24 h at 35-degrees-C. For the 24-h standard procedure, test portions were preenriched for 24 h at 35-degrees-C in an air incubator, subcultured to tetrathionate broth, and incubated for 24 h at 35-degrees-C. Selective enrichment broths from both procedures were streaked onto selective agar plates, and presumptive Salmonella isolates were identified by conventional biochemical and serological tests. Recovery of Salmonella spp. from instant nonfat dry milk and dry whole milk was equivalent for both preenrichment procedures. However, the relative effectiveness of the two procedures varied in the recovery of Salmonella spp. from noninstant nonfat dry milk, lactic casein, and rennet casein.
RP HAMMACK, TS (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 23
TC 4
Z9 4
U1 0
U2 2
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD MAR
PY 1993
VL 56
IS 3
BP 201
EP 204
PG 4
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA KR950
UT WOS:A1993KR95000003
ER
PT J
AU CASTERLINE, JL
KU, Y
AF CASTERLINE, JL
KU, Y
TI BINDING OF ZINC TO APPLE FIBER, WHEAT BRAN, AND FIBER COMPONENTS
SO JOURNAL OF FOOD SCIENCE
LA English
DT Article
DE APPLE; WHEAT; FIBER; ZINC; BIOAVAILABILITY
ID DIETARY FIBER; IRON; FOODS; PH
AB Zinc ion binding to commercial brans, fiber, and fiber components was studied by equilibrium dialysis. Maximum initial concentration of zinc bound by 50 mg of apple fiber (AF) and wheat bran (WB) at pH 7.2 was 220 mug. AF and WB binding capacities were significantly lower for soluble fractions than for unfractionated materials. The water-soluble fraction's binding capacity was 90% lower for AF than for WB. Hemicellulase and phytase slightly increased AF binding capacity but reduced WB capacity. Pectinase increased both AF and WB capacity slightly. Binding capacities of commercially available individual fiber components decreased in the order: lignin > polypectin > pectin > gum > cellulose. Zinc-binding capacities of various dietary fiber types differ, accounting for different zinc bioavailabilties of some foods.
RP CASTERLINE, JL (reprint author), US FDA,DIV FOOD CHEM & TECHNOL,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 11
TC 14
Z9 14
U1 1
U2 2
PU INST FOOD TECHNOLOGISTS
PI CHICAGO
PA SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291
SN 0022-1147
J9 J FOOD SCI
JI J. Food Sci.
PD MAR-APR
PY 1993
VL 58
IS 2
BP 365
EP 368
DI 10.1111/j.1365-2621.1993.tb04276.x
PG 4
WC Food Science & Technology
SC Food Science & Technology
GA LV597
UT WOS:A1993LV59700033
ER
PT J
AU LARNER, AC
PETRICOIN, EF
NAKAGAWA, Y
FINBLOOM, DS
AF LARNER, AC
PETRICOIN, EF
NAKAGAWA, Y
FINBLOOM, DS
TI IL-4 ATTENUATES THE TRANSCRIPTIONAL ACTIVATION OF BOTH IFN-ALPHA-INDUCED
AND IFN-GAMMA-INDUCED CELLULAR GENE-EXPRESSION IN MONOCYTES AND
MONOCYTIC CELL-LINES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERFERON-INDUCIBLE GENE; BINDING PROTEIN; INTERLEUKIN-4; SECRETION;
ELEMENT; IDENTIFICATION; RECEPTOR
AB The interaction of IFN-alpha and IFN-gamma with monocytes results in several actions that significantly influence the course of an immune response. Many of these effects are proinflammatory and can contribute to the degree of tissue injury at a site of inflammation. Whereas recent investigations target IL-4 as a T cell product that can antagonize some of the responses induced by IFN, little is known regarding the mechanisms involved. We have taken advantage of two well defined systems: the transcriptional activation of the cellular genes ISG-54 by IFN-alpha and IP-10 by IFN-gamma. IL-4 treatment of both the monocytic leukemia cell line, THP-1, and normal peripheral blood monocytes resulted in inhibition of IFN-induced RNA levels for both genes. Nuclear run-on assays in THP-1 cells indicated that the effects of IL-4 were due to the inhibition of the transcriptional activation of these genes by both IFN-alpha and IFN-gamma. This inhibition was not due to alteration in the binding characteristics of IFN-alpha or IFN-gamma to the cell. In the IFN-alpha system, we were able to show that IL-4 treatment resulted in reduced formation of the transcriptional activator, IFN-stimulated gene factor 3. This reduction appears to be the result of a defect in the ability of IFNalpha to activate the IFN-stimulated gene factor 3alpha component of IFN-stimulated gene factor 3.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
NR 37
TC 55
Z9 55
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 1993
VL 150
IS 5
BP 1944
EP 1950
PG 7
WC Immunology
SC Immunology
GA KN532
UT WOS:A1993KN53200033
PM 8436826
ER
PT J
AU SMITH, PD
EISNER, MS
MANISCHEWITZ, JF
GILL, VJ
MASUR, H
FOX, CF
AF SMITH, PD
EISNER, MS
MANISCHEWITZ, JF
GILL, VJ
MASUR, H
FOX, CF
TI ESOPHAGEAL DISEASE IN AIDS IS ASSOCIATED WITH PATHOLOGICAL PROCESSES
RATHER THAN MUCOSAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNE-DEFICIENCY SYNDROME; DIAGNOSIS; INFECTION; HIV-1; CELLS; SYMPTOMS
AB Twenty-five patients with AIDS and esophageal symptoms were evaluated for the presence of esophageal disease and human immunodeficiency virus type 1 (HIV-1) in the esophageal mucosa. A single infectious process caused by Candida albicans, cytomegalovirus, herpes simplex virus, varicella-zoster virus, or Mycobacterium avium-intracellulare complex or a single noninfectious process caused by Kaposi's sarcoma or reflux esophagitis was identified in 20 patients. Two processes were identified in 5 patients. HIV-1 mRNA was detected by in situ hybridization in mononuclear cells in esophageal lamina propria in 36% of patients. The presence of HIV-1 in the esophageal mucosa was not associated with a specific esophageal symptom, mucosal inflammation or ulceration, Kaposi's sarcoma, specific opportunistic infection, or response of the infection(s) to therapy. Esophageal disease in patients with AIDS appears to be associated with specific pathologic processes rather than the presence of HIV-1 in esophageal mucosa.
C1 US FDA,NIDR,IMMUNOL LAB,BETHESDA,MD 20014.
US FDA,DEPT CLIN PATHOL,MICROBIOL SERV,BETHESDA,MD 20014.
US FDA,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20014.
US FDA,NIH,NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20014.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
NR 34
TC 47
Z9 48
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1993
VL 167
IS 3
BP 547
EP 552
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KN152
UT WOS:A1993KN15200005
PM 8440925
ER
PT J
AU ACHARYA, A
AF ACHARYA, A
TI TRENDS IN GOVERNMENT-REGULATION OF DEVICE RESEARCH
SO JOURNAL OF INVASIVE CARDIOLOGY
LA English
DT Review
RP ACHARYA, A (reprint author), US FDA,OFF DEVICE EVALUAT,1390 PICCARD DR,ROCKVILLE,MD 20850, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU HEALTH MANAGEMENT PUBLICATIONSINC
PI WAYNE
PA 950 WEST VALLEY RD, STE 2800, WAYNE, PA 19087
SN 1042-3931
J9 J INVASIVE CARDIOL
JI J. Invasive Cardiol.
PD MAR
PY 1993
VL 5
IS 2
BP 69
EP 73
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA KT617
UT WOS:A1993KT61700005
PM 10148627
ER
PT J
AU LEVY, AS
FEIN, SB
STEPHENSON, M
AF LEVY, AS
FEIN, SB
STEPHENSON, M
TI NUTRITION KNOWLEDGE LEVELS ABOUT DIETARY FATS AND CHOLESTEROL -
1983-1988
SO JOURNAL OF NUTRITION EDUCATION
LA English
DT Article
AB Consumer knowledge of dietary fats and cholesterol was analyzed for trends over time and for relationships with demographic characteristics and health and dieting behaviors. The data were obtained from three-approximately biennial Health and Diet Surveys conducted by the Food and Drug Administration and the National Heart, Lung and Blood Institute between 1983 and 1988. Statistical methods included regression analysis and factor analysis. The results indicate that consumer knowledge about dietary fats and cholesterol is poor. Respondents with greater knowledge in 1988 were those who were more educated, middle-aged, or white, and those who were on a cholesterol-lowering diet. The regression analysis of 1988 scores indicated that education was the most important predictor of knowledge scores. Being on a self-prescribed cholesterol-lowering diet was related to higher knowledge, but being on a physician-recommended diet was related to higher knowledge scores only for younger respondents. None of the health behaviors, except engaging in regular exercise, was associated with higher knowledge levels.
RP LEVY, AS (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 0
TC 52
Z9 52
U1 0
U2 5
PU DECKER PERIODICALS INC
PI HAMILTON
PA 4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA
SN 0022-3182
J9 J NUTR EDUC
JI J. Nutr. Educ.
PD MAR-APR
PY 1993
VL 25
IS 2
BP 60
EP 66
PG 7
WC Education, Scientific Disciplines; Nutrition & Dietetics
SC Education & Educational Research; Nutrition & Dietetics
GA KY092
UT WOS:A1993KY09200002
ER
PT J
AU BARR, DB
AF BARR, DB
TI FDAS ASEPTIC PROCESSING - PROPOSED REGULATION
SO JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY
LA English
DT Editorial Material
RP BARR, DB (reprint author), US FDA,DIV MFG & PROD QUAL,POLICY & GUIDANCE BRANCH,ROCKVILLE,MD 20857, USA.
RI Barr, Dana/E-2276-2013
NR 0
TC 2
Z9 2
U1 0
U2 0
PU PARENTERAL DRUG ASSOC, INC
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE, 620, BETHESDA, MD 20814
SN 0279-7976
J9 J PARENT SCI TECHN
PD MAR-APR
PY 1993
VL 47
IS 2
BP 57
EP 59
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LX959
UT WOS:A1993LX95900003
PM 8515345
ER
PT J
AU MADENJIAN, JJ
EIFERT, JD
LAWRENCE, JF
AF MADENJIAN, JJ
EIFERT, JD
LAWRENCE, JF
TI CIIDAE - NEWLY RECOGNIZED BEETLE PESTS OF COMMERCIAL DRIED MUSHROOMS
SO JOURNAL OF STORED PRODUCTS RESEARCH
LA English
DT Article
DE FUNGI; COMMERCIAL DRIED MUSHROOMS; BASIDIOMYCETES; COLEOPTERA; BEETLES
ID COLEOPTERA
AB One hundred sixty-seven samples representing 8 species of packaged, dried mushrooms were collected from 29 markets in the downtown Los Angeles area. The packages were visually examined for obvious insect infestations. Ciid material, representing 3 species, was found in 6 samples. One of these samples had been stored by the collector for about 8 months before huge numbers of live ciid adults and larvae were noticed in the one package. This finding represents direct evidence of post-harvest development and thereby establishes stored product pest status for the family. No previous literature exists on ciids as pests of commercial, stored, dried mushrooms.
C1 CSIRO,CANBERRA,ACT 2601,AUSTRALIA.
RP MADENJIAN, JJ (reprint author), US FDA,1521 W PICO BLVD,LOS ANGELES,CA 90015, USA.
NR 26
TC 5
Z9 7
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0022-474X
J9 J STORED PROD RES
JI J. Stored Prod. Res.
PD MAR
PY 1993
VL 29
IS 1
BP 45
EP 48
DI 10.1016/0022-474X(93)90020-5
PG 4
WC Entomology
SC Entomology
GA KJ326
UT WOS:A1993KJ32600008
ER
PT J
AU HERMAN, BA
CAREY, RF
RINALDI, JE
AF HERMAN, BA
CAREY, RF
RINALDI, JE
TI SENSITIVITY OF WATER LEAK TESTS FOR LATEX CONDOMS
SO JOURNAL OF TESTING AND EVALUATION
LA English
DT Article
DE LATEX; CONDOMS; LEAKAGE TESTS
AB As part of quality assurance testing, latex condoms are often screened for pinholes using water leak tests. This report analyzes the sensitivity of two similar tests, both requiring that a condom be filled with 300 mL of water and then examined visually for leakage. One test, a Food and Drug Administration protocol, specifies that the condom be filled vertically, the open end pinched off, and then rolled horizontally on a towel. The second test, developed by the American Society for Testing and Materials, is the same, except the condom is not rolled, merely placed in a horizontal position and examined. Detectability of a defect is dependent on the pressure developed within the condom, wettability of the condom surface by the water, thickness, and expansion of the condom. Three brands and nine different models were studied to determine the range of values for these variables and the sensitivity of the tests were then calculated. Sensitivity (minimum hole size detectable) varies from approximately 100 mum radius to 3 mum radius. Note that the smallest defect observable is larger than the HIV virus.
RP HERMAN, BA (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,DIV PHYS SCI,ROCKVILLE,MD 20857, USA.
NR 10
TC 9
Z9 9
U1 0
U2 0
PU AMER SOC TESTING MATERIALS
PI W CONSHOHOCKEN
PA 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959
SN 0090-3973
J9 J TEST EVAL
JI J. Test. Eval.
PD MAR
PY 1993
VL 21
IS 2
BP 124
EP 128
PG 5
WC Materials Science, Characterization & Testing
SC Materials Science
GA LB485
UT WOS:A1993LB48500005
ER
PT J
AU GRAKOUI, A
WYCHOWSKI, C
LIN, C
FEINSTONE, SM
RICE, CM
AF GRAKOUI, A
WYCHOWSKI, C
LIN, C
FEINSTONE, SM
RICE, CM
TI EXPRESSION AND IDENTIFICATION OF HEPATITIS C VIRUS POLYPROTEIN CLEAVAGE
PRODUCTS
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRAL DIARRHEA VIRUS; WEST NILE FLAVIVIRUS; YELLOW-FEVER VIRUS;
HOG-CHOLERA VIRUS; NON-B HEPATITIS; VACCINIA VIRUS; NUCLEOTIDE-SEQUENCE;
NON-A; POSTTRANSFUSION HEPATITIS; PROTEOLYTIC CLEAVAGE
AB Hepatitis C virus (HCV) is the major cause of transfusion-acquired non-A, non-B hepatitis. HCV is an enveloped positive-sense RNA virus which has been classified as a new genus in the flavivirus family. Like the other two genera in this family, the flaviviruses and the pestiviruses, HCV polypeptides appear to be produced by translation of a long open reading frame and subsequent proteolytic processing of this polyprotein. In this study, a cDNA clone encompassing the long open reading frame of the HCV H strain (3,011 amino acid residues) has been assembled and sequenced. This clone and various truncated derivatives were used in vaccinia virus transient-expression assays to map HCV-encoded polypeptides and to study HCV polyprotein processing. HCV polyproteins and cleavage products were identified by using convalescent human sera and a panel of region-specific polyclonal rabbit antisera. Similar results were obtained for several mammalian cell lines examined, including the human HepG2 hepatoma line. The data indicate that at least nine polypeptides are produced by cleavage of the HCV H strain polyprotein. Putative structural proteins, located in the N-terminal one-fourth of the polyprotein, include the capsid protein C (21 kDa) followed by two possible virion envelope proteins, El (31 kDa) and E2 (70 kDa), which are heavily modified by N-linked glycosylation. The remainder of the polyprotein probably encodes nonstructural proteins including NS2 (23 kDa), NS3 (70 kDa), NS4A (8 kDa), NS4B (27 kDa), NS5A (58 kDa), and NS5B (68 kDa). An 82- to 88-kDa glycoprotein which reacted with both E2 and NS2-specific HCV antisera was also identified (called E2-NS2). Preliminary results suggest that a fraction of El is associated with E2 and E2-NS2 via disulfide linkages.
C1 WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,BOX 8230,660 S EUCLID AVE,ST LOUIS,MO 63110.
US FDA,CBER,DIV VIROL,BETHESDA,MD 20892.
FU NCI NIH HHS [CA57973]
NR 73
TC 760
Z9 781
U1 10
U2 30
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 1993
VL 67
IS 3
BP 1385
EP 1395
PG 11
WC Virology
SC Virology
GA KM613
UT WOS:A1993KM61300031
PM 7679746
ER
PT J
AU IGARASHI, K
DAVID, M
FINBLOOM, DS
LARNER, AC
AF IGARASHI, K
DAVID, M
FINBLOOM, DS
LARNER, AC
TI INVITRO ACTIVATION OF THE TRANSCRIPTION FACTOR GAMMA-INTERFERON
ACTIVATION FACTOR BY GAMMA-INTERFERON - EVIDENCE FOR A TYROSINE
PHOSPHATASE KINASE SIGNALING CASCADE
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID GUANYLATE-BINDING PROTEIN; CYTOPLASMIC ACTIVATION; ALPHA-INTERFERON;
IFN-GAMMA; GENE; RECEPTOR; PHOSPHORYLATION; TRANSDUCTION; EXPRESSION;
INDUCTION
AB Although it has been well documented that the biological activities of gamma interferon (IFN-gamma) are initiated through interaction with its cell surface receptor, the signal transduction mechanisms which mediate the effects of this cytokine have remained unclear. In order to facilitate a better understanding of IFN-gamma signaling, we have designed an assay using human fibroblast cell homogenates in which IFN-gamma activates the formation of the IFN-gamma activation factor (GAF) transcription complex. GAF mediates the rapid transcriptional activation of the guanylate-binding protein gene by IFN-gamma. Activation of GAF in homogenates required ATP, but not Ca2+ or GTP. Fractionation of homogenates indicated that both the pellet (18,000 x g) and the remaining cytoplasmic fraction were required for GAF activation by IFN-gamma. In intact cells and cell homogenates, the activation of GAF was prevented by the specific tyrosine kinase inhibitor genistein. Treatment of GAF-containing nuclear extracts with either monoclonal antiphosphotyrosine antibody or protein tyrosine phosphatase prevented the assembly of the transcription complex, indicating that its formation required phosphorylation of tyrosine residues. Furthermore, the tyrosine phosphatase inhibitors phenylarsine oxide and zinc chloride also inhibited GAF formation in vitro, but only if these agents were added to cell homogenates before IFN-gamma was added. The addition of either agent 5 min after IFN-gamma had no effect. These results provide the first evidence for an IFN-gamma-regulated tyrosine phosphatase/kinase signaling cascade that permits this cytokine to activate the transcription of an early-response gene.
C1 CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 29
TC 74
Z9 74
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAR
PY 1993
VL 13
IS 3
BP 1634
EP 1640
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN579
UT WOS:A1993KN57900036
PM 7680098
ER
PT J
AU ROHLFF, C
SAFA, B
RAHMAN, A
CHOCHUNG, YS
KLECKER, RW
GLAZER, RI
AF ROHLFF, C
SAFA, B
RAHMAN, A
CHOCHUNG, YS
KLECKER, RW
GLAZER, RI
TI REVERSAL OF RESISTANCE TO ADRIAMYCIN BY 8-CHLORO-CYCLIC AMP IN
ADRIAMYCIN-RESISTANT HL-60 LEUKEMIA-CELLS IS ASSOCIATED WITH REDUCTION
OF TYPE-I CYCLIC AMP-DEPENDENT PROTEIN-KINASE AND CYCLIC-AMP RESPONSE
ELEMENT-BINDING PROTEIN DNA-BINDING ACTIVITIES
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID MULTIDRUG RESISTANCE; REGULATORY SUBUNIT; TRANSCRIPTION FACTORS;
GENE-TRANSCRIPTION; CATALYTIC SUBUNIT; FACTOR CREB; CAMP; GROWTH;
DIFFERENTIATION; PHOSPHORYLATION
AB 8-Chloro-cyclic AMP (8-Cl-cAMP) produces growth-inhibitory and differentiating activity in the promyelocytic leukemia cell line HL-60. Adriamycin (ADR)-resistant HL-60 (HL-60/AR) cells exhibit the multidrug-resistant phenotype but do not express the mdr1 gene product P-glycoprotein. To explore potential signaling processes that may be involved in this atypical form of drug resistance, 8-Cl-cAMP was used as a modulator of the cAMP second messenger signal transduction pathway. Treatment for 48 hr with a 10% inhibitory concentration of 8-Cl-cAMP potentiated ADR cytotoxicity 14-fold in HL-60/AR cells but not in the parental cell line. 8-Cl-cAMP was stable to hydrolysis in the medium after 48 hr and was present intracellularly predominantly as phosphorylated metabolites (70%) and the parent compound (30%). No difference occurred in ADR accumulation in HL-60/AR cells after treatment with 8-Cl-cAMP. Accompanying the 8-Cl-cAMP-mediated increase in ADR cytotoxicity in HL-60/AR cells was a reduction in the cytosolic type I cAMP-dependent protein kinase (PKA) and disappearance of the nuclear PKA holoenzyme. Coincident with these changes in drug-resistant cells was a marked reduction in the DNA-binding activity of the cAMP response element-binding protein to levels equivalent to those in sensitive cells. This effect appears to result from reduced phosphorylation of the cAMP response element-binding protein. These results suggest that the potentiation by 8-Cl-cAMP of ADR cytotoxicity in HL-60/AR cells occurs through down-regulation of nuclear type I PKA and cAMP response element-binding factors whose activities are regulated by PKA.
C1 GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007.
GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT PHARMACOL,WASHINGTON,DC 20007.
GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT MED,WASHINGTON,DC 20007.
NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892.
US FDA,DIV CLIN PHARMACOL,ROCKVILLE,MD 20850.
NR 37
TC 31
Z9 31
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAR
PY 1993
VL 43
IS 3
BP 372
EP 379
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KT629
UT WOS:A1993KT62900009
PM 8383802
ER
PT J
AU ALI, SF
DAVID, SN
NEWPORT, GD
AF ALI, SF
DAVID, SN
NEWPORT, GD
TI AGE-RELATED SUSCEPTIBILITY TO MPTP-INDUCED NEUROTOXICITY IN MICE
SO NEUROTOXICOLOGY
LA English
DT Article
DE MPTP; REACTIVE OXYGEN SPECIES; OXIDATIVE STRESS; DICHLOROFLUORESCEIN;
DOPAMINE NEUROTOXICITY; C57/B6N MICE
ID NERVOUS-SYSTEM TRAUMA; MONOAMINE OXIDASE-B; OXYGEN RADICALS;
DOPAMINERGIC NEUROTOXICITY; LIPID-PEROXIDATION; RISK ASSESSMENT; BRAIN;
1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE; TOXICITY; NEURONS
AB 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to cause neurotoxicity in rodents and nonhuman primates. In this study the ontogeny of MPTP-induced DA depletion and formation of reactive oxygen species (ROS) were evaluated in mouse striatum. C57/B6N mice were injected four times with 0 or 10 mg/kg MPTP (i.p.) at two-hour intervals on either postnatal day 23, at about 7 months of age, and at one year of age. Animals were sacrificed 1, 2, 4, 8, 12, 24, 48 and 72 hours after the last dose. Brains were rapidly removed and striata were dissected for neurochemical analysis. Dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured by HPLC/EC. ROS formation was measured by a fluorescence probe, 2,7'-dichlorofluorescein-diacetate (DCFH-DA). MPTP produced a slight but significant decrease of DA only 4 hours post dosing on PND 23. DOPAC and HVA levels decreased up to 4 and 8 hours post dosing respectively and returned to control values thereafter. At 7 months of age, MPTP produced a 50-65 % decrease of DA and its metabolites (DOPAC and HVA) in striatum 24 hours post dosing. In one year old mice MPTP produced an 80 % decrease of DA and 60 - 80 % decrease of DOPAC and HVA in striatum. In contrast, ROS formation in striatum was not significantly increased by MPTP treatment at any age but was decreased at 1 hour only in PND 23 and 7 month old mice. These studies suggest that MPTP-induced neurotoxicity is age-dependent in the mouse. The lack of effect on ROS formation suggests that, if MPTP neurotoxicity is mediated via oxidative stress it cannot be measured by fluorescence probe techniques used in these experiments. (C) 1993 Intox Press, Inc.
C1 UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205.
ARKANSAS STATE UNIV,DEPT BIOL SCI,STATE UNIV,AR 72467.
RP ALI, SF (reprint author), NATL CTR TOXICOL RES,DIV NEUROTOXICOL,NEUROCHEM LAB,HFT-132,NCTR DR,JEFFERSON,AR 72079, USA.
NR 42
TC 80
Z9 80
U1 0
U2 0
PU INTOX PRESS INC
PI LITTLE ROCK
PA PO BOX 24865, LITTLE ROCK, AR 72221
SN 0161-813X
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD SPR
PY 1993
VL 14
IS 1
BP 29
EP 34
PG 6
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA LK375
UT WOS:A1993LK37500006
PM 8361676
ER
PT J
AU TANDON, P
BARONE, S
BONNER, MJ
ALI, SF
TILSON, HA
AF TANDON, P
BARONE, S
BONNER, MJ
ALI, SF
TILSON, HA
TI THE ROLE OF THE SEPTOHIPPOCAMPAL PATHWAY IN THE MEDIATION OF
COLCHICINE-INDUCED COMPENSATORY CHANGES IN THE RAT HIPPOCAMPUS
SO NEUROTOXICOLOGY
LA English
DT Article
DE INOSITOL PHOSPHATE; ACETYLCHOLINESTERASE; ACHE; CHOLINE
ACETYLTRANSFERASE; CHAT; QNB BINDING; REACTIVE SYNAPTOGENESIS
ID STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; LESION-INDUCED SYNAPTOGENESIS;
DENTATE GYRUS; ADULT-RAT; SEPTAL-LESIONS; BRAIN; PROJECTIONS;
METABOLISM; DEAFFERENTATION; CONNECTIONS
AB To study the involvement of the septohippocampal pathway in colchicine-induced changes in the hippocampus, colchicine was used to lesion the septum and/or hippocampus of male, Fischer-344 rats. Rats were killed 12 weeks post-lesion and histochemical and biochemical measurements were performed. [H-3]-QNB binding, choline acetyltransferase (ChAT) activity and agonist-stimulated release of inositol phosphates (IPs) were measured in hippocampal slices. AChE histochemistry was also performed to visualize AChE positive fibers in the hippocampus. Increases in ChAT activity, AChE staining and carbachol-stimulated IP release observed in hippocampal-lesioned animals were attenuated in animals receiving both septal and hippocampal lesions. However, the decrease observed in [H-3]-QNB binding sites after intradentate colchicine was not affected by septal lesions. Subsequent studies also found enhanced sensitivity to excitatory amino acid (EAA)-stimulated IP release in hippocampal-lesioned animals. Similar to the changes observed in carbachol-stimulated PI hydrolysis, this increase was also long-lasting. However, the hyperstimulation of EAA-induced IP release was not attenuated by the septal lesion. Thus, it appears that the neurochemical and morphological changes observed in the hippocampus following intradentate colchicine are dependent upon more than one afferent projection to the hippocampus. (C) 1993 Intox Press, Inc.
C1 MANTECH ENVIRONM TECHNOL INC, RES TRIANGLE PK, NC 27711 USA.
NCTR, DIV REPROD & DEV TOXICOL, JEFFERSON, AR 72079 USA.
NIEHS, MOLEC & INTEGRAT NEUROSCI LAB, RES TRIANGLE PK, NC 27709 USA.
NR 54
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
EI 1872-9711
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD SPR
PY 1993
VL 14
IS 1
BP 41
EP 50
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA LK375
UT WOS:A1993LK37500008
PM 8361677
ER
PT J
AU ALI, SF
NEWPORT, GD
SCALLET, AC
BINIENDA, Z
FERGUSON, SA
BAILEY, JR
PAULE, MG
SLIKKER, W
AF ALI, SF
NEWPORT, GD
SCALLET, AC
BINIENDA, Z
FERGUSON, SA
BAILEY, JR
PAULE, MG
SLIKKER, W
TI ORAL-ADMINISTRATION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) PRODUCES
SELECTIVE SEROTONERGIC DEPLETION IN THE NONHUMAN PRIMATE
SO NEUROTOXICOLOGY AND TERATOLOGY
LA English
DT Article
DE METHYLENEDIOXYMETHAMPHETAMINE (MDMA); NONHUMAN PRIMATE; MONKEY;
SEROTONIN; 5-HIAA; MACACA MULATTA; HOME CAGE BEHAVIOR
ID METHYLENEDIOXYMETHAMPHETAMINE MDMA; BEHAVIOR; MONKEYS; ECSTASY; NEURONS;
RAT
AB MDMA (3,4-methylenedioxymethamphetamine) has been reported to produce serotonergic depletion in nonhuman primates at doses as low as 2.5 mg/kg (1-2 times the typical human dose). The current study evaluated the dose-response relationships of MDMA (1.25-20.0 mg/kg) using regional concentrations of serotonin (5-HT) and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), and home cage behavior as endpoints. Adult female rhesus monkeys (n = 16) were treated orally with 0, 1.25, 2.5, or 20.0 mg/kg MDMA twice daily for 4 consecutive days. Eighteen behaviors were measured in the home cage prior to, during, and after MDMA treatment. One month after the last dose, the animals were sacrificed and brains dissected into several regions for neurochemical analyses. 5-HT and 5-HIAA were analyzed via HPLC/EC. The lower doses of MDMA (1.25 and 2.5 mg/kg) did not significantly alter 5-HT or 5-HIAA concentrations in any brain region except hippocampus in which 5-HT concentrations were decreased after 2.5 mg/kg. MDMA at 20.0 mg/kg significantly decreased 5-HT and 5-HIAA concentrations in several cortical and midbrain structures. However, 5-HT and 5-HIAA concentrations in brain stem and hypothalamus were not significantly altered after any dose of MDMA. Combined with previous data from this laboratory, these results indicate that the decreased concentrations of 5-HT and 5-HIAA in selected brain regions show a selective dose-response relationship for MDMA-induced neurotoxicity as measured by serotonergic depletion in the nonhuman primate.
C1 UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205.
RP ALI, SF (reprint author), NATL CTR TOXICOL RES,DIV NEUROTOXICOL,NEUROCHEM LAB,NCTR DR,HFT-132,JEFFERSON,AR 72079, USA.
NR 21
TC 50
Z9 50
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0892-0362
J9 NEUROTOXICOL TERATOL
JI Neurotoxicol. Teratol.
PD MAR-APR
PY 1993
VL 15
IS 2
BP 91
EP 96
DI 10.1016/0892-0362(93)90067-X
PG 6
WC Neurosciences; Toxicology
SC Neurosciences & Neurology; Toxicology
GA KZ131
UT WOS:A1993KZ13100003
PM 7685472
ER
PT J
AU HALL, CB
GRANOFF, DM
GROMISCH, DS
HALSEY, NA
KOHL, S
MARCUSE, EK
MARKS, MI
NANKERVIS, GA
PICKERING, LK
SCOTT, GB
STEELE, RW
YOGEV, R
PETER, G
BART, KJ
BROOME, C
HARDEGREE, MC
JACOBS, RF
MACDONALD, NE
ORENSTEIN, WA
RABINOVICH, G
AF HALL, CB
GRANOFF, DM
GROMISCH, DS
HALSEY, NA
KOHL, S
MARCUSE, EK
MARKS, MI
NANKERVIS, GA
PICKERING, LK
SCOTT, GB
STEELE, RW
YOGEV, R
PETER, G
BART, KJ
BROOME, C
HARDEGREE, MC
JACOBS, RF
MACDONALD, NE
ORENSTEIN, WA
RABINOVICH, G
TI THE USE OF ORAL ACYCLOVIR IN OTHERWISE HEALTHY-CHILDREN WITH VARICELLA
SO PEDIATRICS
LA English
DT Article
ID HERPES-SIMPLEX VIRUS; ZOSTER VIRUS; ANTIBODY-RESPONSE; CHICKENPOX;
COMPLICATIONS; INFECTION; RESISTANT; THERAPY; IMPACT
C1 CTR DIS CONTROL,ATLANTA,GA 30333.
US FDA,WASHINGTON,DC 20204.
NIH,BETHESDA,MD 20892.
RI Steele, Russell/A-6075-2011
NR 22
TC 35
Z9 39
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 1993
VL 91
IS 3
BP 674
EP 676
PG 3
WC Pediatrics
SC Pediatrics
GA KP638
UT WOS:A1993KP63800034
ER
PT J
AU SHAH, VP
ELKINS, JS
WILLIAMS, RL
AF SHAH, VP
ELKINS, JS
WILLIAMS, RL
TI IN-VITRO DRUG-RELEASE MEASUREMENT FOR TOPICAL GLUCOCORTICOID CREAMS
SO PHARMACOPEIAL FORUM
LA English
DT Article
ID DOSAGE FORMS; DIFFUSION CELL; HYDROCORTISONE; RATES
RP SHAH, VP (reprint author), US FDA,CTR DRUG EVALUAT & RES,OFF GENER DRUGS,ROCKVILLE,MD 20857, USA.
NR 12
TC 15
Z9 15
U1 0
U2 2
PU US PHARMACOPEIAL CONVENTION
PI ROCKVILLE
PA 12601 TWINBROOK PKWY, ROCKVILLE, MD 20852
SN 0363-4655
J9 PHARMACOPEIAL FORUM
JI Pharmacop. Forum
PD MAR-APR
PY 1993
VL 19
IS 2
BP 5048
EP 5060
PG 13
WC Medicine, Legal; Pharmacology & Pharmacy
SC Legal Medicine; Pharmacology & Pharmacy
GA MD845
UT WOS:A1993MD84500003
ER
PT J
AU GREEN, S
ONEILL, R
DEMETS, D
WITTES
BUYSE
MEIER
BROWN
POCOCK
TEMPLE
ARMITAGE
YUSUF
FRIEDEWALD, W
MEINERT
SIMON
AF GREEN, S
ONEILL, R
DEMETS, D
WITTES
BUYSE
MEIER
BROWN
POCOCK
TEMPLE
ARMITAGE
YUSUF
FRIEDEWALD, W
MEINERT
SIMON
TI MONITORING CLINICAL-TRIALS - EXPERIENCE OF, AND PROPOSALS UNDER
CONSIDERATION BY THE CANCER-THERAPY-COMMITTEE OF THE
BRITISH-MEDICAL-RESEARCH-COUNCIL - THE USE OF DATA MONITORING COMMITTEES
IN CANADIAN TRIAL GROUPS - INTERIM ANALYSES, STOPPING RULES AND DATA
MONITORING IN CLINICAL-TRIALS IN EUROPE - DISCUSSION
SO STATISTICS IN MEDICINE
LA English
DT Discussion
C1 US FDA,CTR DRUG EVALUAT & RES,OFF EPIDEMIOL & BIOSTAT,PARKLAWN BLDG,ROCKVILLE,MD 20857.
UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND.
STAT COLLABERAT,WASHINGTON,DC 20036.
INT INST DRUG DEV,B-1050 BRUSSELS,BELGIUM.
NCI,BIOMETR RES BRANCH,BETHESDA,MD 20892.
NHLBI,BETHESDA,MD 20892.
RI Friedewald, William/C-8034-2011
NR 0
TC 1
Z9 1
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD MAR
PY 1993
VL 12
IS 5-6
BP 521
EP 525
PG 5
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA KX071
UT WOS:A1993KX07100017
ER
PT J
AU YUSUF
WHITLEY, R
ASSENZO, R
FLEMING, T
DEYKIN
HAWKINS, B
MEIER
GENT
TOGNONI
ELLENBERG, J
WITTES
ARMITAGE
MONSEES, D
GREEN
SIMON
BOISSEL, JP
BRISTOW, D
MEINERT
POCOCK
WILLIAMS
TOGNONI
HARTMAN, A
TEMPLE
ASSENZO
ELLENBERG, S
GELLER, N
TAYLOR, W
BRISTOW
PAPERMASTER, B
ROCKHOLD
DIXON, D
AF YUSUF
WHITLEY, R
ASSENZO, R
FLEMING, T
DEYKIN
HAWKINS, B
MEIER
GENT
TOGNONI
ELLENBERG, J
WITTES
ARMITAGE
MONSEES, D
GREEN
SIMON
BOISSEL, JP
BRISTOW, D
MEINERT
POCOCK
WILLIAMS
TOGNONI
HARTMAN, A
TEMPLE
ASSENZO
ELLENBERG, S
GELLER, N
TAYLOR, W
BRISTOW
PAPERMASTER, B
ROCKHOLD
DIXON, D
TI THE OPERATION OF DATA MONITORING COMMITTEES - DISCUSSION
SO STATISTICS IN MEDICINE
LA English
DT Discussion
C1 UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195.
STAT COLLABORAT,WASHINGTON,DC 20036.
FRED HUTCHINSON CANC RES CTR,SW ONCOL GRP,SEATTLE,WA 98104.
MERCK SHARP & DOHME LTD,BIOSTAT & RES DATA SYST,W POINT,PA 19486.
US FDA,CBER,OELPS,DIV BIOSTAT & EPIDEMIOL,ROCKVILLE,MD 20892.
NHLBI,BETHESDA,MD 20892.
RP YUSUF (reprint author), NHLBI,BETHESDA,MD 20892, USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD MAR
PY 1993
VL 12
IS 5-6
BP 527
EP 542
PG 16
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA KX071
UT WOS:A1993KX07100018
ER
PT J
AU SIMON, R
ARMITAGE
HARRINGTON
BRISTOW, D
WALKER, M
GENT, M
ARMITAGE
ELLENBERG, S
PROSCHAN, M
FRIEDEWALD, W
POCOCK, S
TOGNONI
FRIEDEWALD
FREEDMAN, L
BOISSEL, JP
POCOCK
PATER, J
HERSON
GREEN, S
GAIL, M
GEHAN, E
BUYSE
MYERS, M
AF SIMON, R
ARMITAGE
HARRINGTON
BRISTOW, D
WALKER, M
GENT, M
ARMITAGE
ELLENBERG, S
PROSCHAN, M
FRIEDEWALD, W
POCOCK, S
TOGNONI
FRIEDEWALD
FREEDMAN, L
BOISSEL, JP
POCOCK
PATER, J
HERSON
GREEN, S
GAIL, M
GEHAN, E
BUYSE
MYERS, M
TI SCIENTIFIC ISSUES IN DATA MONITORING - DISCUSSION
SO STATISTICS IN MEDICINE
LA English
DT Discussion
C1 UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND.
UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,HOUSTON,TX 77030.
US FDA,CBER,OELPS,DIV BIOSTAT & EPIDEMIOL,ROCKVILLE,MD 20852.
NHLBI,BETHESDA,MD 20892.
RP SIMON, R (reprint author), NCI,BIOMETR RES BRANCH,BETHESDA,MD 20892, USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD MAR
PY 1993
VL 12
IS 5-6
BP 583
EP 600
PG 18
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA KX071
UT WOS:A1993KX07100027
ER
PT J
AU ONEILL, RT
AF ONEILL, RT
TI SOME FDA PERSPECTIVES ON DATA MONITORING IN CLINICAL-TRIALS IN DRUG
DEVELOPMENT
SO STATISTICS IN MEDICINE
LA English
DT Article
ID INTERIM ANALYSIS
AB The FDA's interest in data monitoring of clinical trials derives from its public health responsibility to assure the safety and efficacy of new drugs based on evidence from adequate and well-controlled studies. Therefore the FDA is concerned that clinical trials of new drugs are designed and carried out in a manner that will insure the integrity and validity of study inferences. The FDA regulation and guidelines recognize the role of data monitoring and the variety and diversity of situations utilizing a data monitoring process in clinical studies. This paper describes relevant aspects of the regulations and guidelines, some concerns the FDA has with regard to monitoring of both government- and industry-sponsored trials and the consequences of early termination of trials of new drugs in the investigational and marketed stages. Comments include advice on communication between the FDA and data monitoring committees.
RP ONEILL, RT (reprint author), US FDA, CTR DRUG EVALUAT & RES, OFF EPIDEMIOL & BIOSTAT, PARKLAWN BLDG, ROCKVILLE, MD 20857 USA.
NR 13
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD MAR
PY 1993
VL 12
IS 5-6
BP 601
EP 608
DI 10.1002/sim.4780120529
PG 8
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA KX071
UT WOS:A1993KX07100028
PM 8493434
ER
PT J
AU MEIER
ONEILL
POCOCK
HERSON
YUSUF
BLACKWELDER, W
ZUCKER, D
FEIGAL, D
AF MEIER
ONEILL
POCOCK
HERSON
YUSUF
BLACKWELDER, W
ZUCKER, D
FEIGAL, D
TI SOME FDA PERSPECTIVES ON DATA MONITORING IN CLINICAL-TRIALS IN DRUG
DEVELOPMENT - DISCUSSION
SO STATISTICS IN MEDICINE
LA English
DT Discussion
C1 US FDA,CTR DRUG EVALUAT & RES,OFF EPIDEMIOL & BIOSTAT,PARKLAWN BLDG,ROCKVILLE,MD 20857.
UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND.
NHLBI,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD MAR
PY 1993
VL 12
IS 5-6
BP 609
EP 614
PG 6
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA KX071
UT WOS:A1993KX07100029
ER
PT J
AU WEISMAN, Y
CASSORLA, F
MALOZOWSKI, S
KRIEG, RJ
GOLDRAY, D
KAYE, AM
SOMJEN, D
AF WEISMAN, Y
CASSORLA, F
MALOZOWSKI, S
KRIEG, RJ
GOLDRAY, D
KAYE, AM
SOMJEN, D
TI SEX-SPECIFIC RESPONSE OF BONE-CELLS TO GONADAL-STEROIDS - MODULATION IN
PERINATALLY ANDROGENIZED FEMALES AND IN TESTICULAR FEMINIZED MALE-RATS
SO STEROIDS
LA English
DT Article
DE GONADAL STEROIDS; DIAPHYSEAL BONE; CALVARIA CELLS; ANDROGENIZED FEMALE
RATS; TESTICULAR FEMINIZED MALE RATS; ESTRADIOL; DIHYDROTESTOSTERONE;
SEXUAL DIFFERENTIATION
ID GROWTH-HORMONE SECRETION; OSTEOBLAST-LIKE CELLS; CREATINE-KINASE;
PARATHYROID-HORMONE; ESTROGEN-RECEPTORS; DNA-SYNTHESIS; PROLIFERATION;
PROTEIN; 17-BETA-ESTRADIOL; IDENTIFICATION
AB We have found previously that rat diaphyseal bone in vivo, as well as rat embryo calvaria cells in culture, show a sex-specific response to gonadal steroids in stimulation of creatine kinase (CK)-specific activity, and the rate of [H-3]thymidine incorporation into DNA; male-derived cells responded only to testosterone or to dihydrotestosterone (DHT), whereas female-derived cells were stimulated exclusively by estradiol (E2). In this study, we tested whether developmental hormone manipulation could alter this sex specificity. We showed that diaphyseal bone of prenatally or neonatally androgenized female rats responds to a single injection of either E2 (5 mug/rat) or DHT (50 mug/rat) at 3-4 weeks postandrogenization. This response of androgenized female diaphyseal bone to androgen gradually declines; 3 months posttreatment, diaphyseal bone no longer responds to DHT and reverts to its original sex specificity. Rat embryo calvaria cell cultures prepared from female fetuses androgenized in utero showed the same lack of hormonal specificity, that is, the cells responded to both E2 (30 nM) or DHT (300 nM). Cells derived from the male siblings of the prenatally androgenized rats were not affected and responded only to DHT. In contrast to experiments in utero, in vitro administration of testosterone (1 muM) or E2 (1 muM) to calvaria cells from female embryos failed to cause the cells to respond to DHT. Androgen receptor-deficient (Tfm) male rats, which have approximately 10% of the normal response to androgens, also showed a response to both testosterone and E2 in comparison to their normal male siblings, whose bones responded only to androgens. Estrogen injection into Tfm males resulted in as large an increase in the specific activity of CK as found after DHT injection. These results suggest that during development the receptor-mediated pathway of response to both androgens and estrogens exists in the bones of both sexes. However, the sex-specific response to sex steroid hormones by diaphyseal bone appears to depend on both prior and continuing exposure to the dominant sex steroid in each sex.
C1 TEL AVIV UNIV,ICHILOV HOSP,SACKLER FAC MED,ENDOCRINE UNIT,TEL AVIV,ISRAEL.
TEL AVIV UNIV,ICHILOV HOSP,SACKLER FAC MED,DEPT GERIATR B,TEL AVIV,ISRAEL.
NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892.
US FDA,DIV METAB & ENDOCRINE DRUG PROD,ROCKVILLE,MD 20857.
VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298.
WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL.
RP WEISMAN, Y (reprint author), TEL AVIV UNIV,ICHILOV HOSP,SACKLER FAC MED,BONE DIS UNIT,6 WEIZMANN ST,IL-64239 TEL AVIV,ISRAEL.
NR 36
TC 32
Z9 32
U1 0
U2 1
PU BUTTERWORTH-HEINEMANN
PI WOBURN
PA 225 WILDWOOD AVE #UNITB PO BOX 4500, WOBURN, MA 01801-2084
SN 0039-128X
J9 STEROIDS
JI Steroids
PD MAR
PY 1993
VL 58
IS 3
BP 126
EP 133
DI 10.1016/0039-128X(93)90049-S
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA KU168
UT WOS:A1993KU16800006
PM 8475517
ER
PT J
AU KIMMEL, CA
CUFF, JM
KIMMEL, GL
HEREDIA, DJ
TUDOR, N
SILVERMAN, PM
CHEN, J
AF KIMMEL, CA
CUFF, JM
KIMMEL, GL
HEREDIA, DJ
TUDOR, N
SILVERMAN, PM
CHEN, J
TI SKELETAL DEVELOPMENT FOLLOWING HEAT EXPOSURE IN THE RAT
SO TERATOLOGY
LA English
DT Article
ID NEURAL-TUBE DEFECTS; MATERNAL HYPERTHERMIA; SEGMENTAL ANOMALIES;
DEVELOPMENT INVITRO; CHICK-EMBRYO; SHOCK; MICE; THERMOTOLERANCE;
MALFORMATIONS; PROPORTIONS
AB The effects of gestation day (GD) 10 heat exposure in the rat were studied to determine the temperature-response relationship for the induction of skeletal and other defects. Conscious pregnant rats (Experiment 1) were exposed to various temperatures in a warm air chamber. Body temperature was measured using a rectal probe, and these measurements were confirmed as representing core body temperature in separate animals using telemetric procedures. Those animals whose core body temperature was raised to 41-41.9-degrees-C had over 90% malformed pups (examined at postnatal day (PND) 3), and a 25% reduction in the percent of live pups per litter. Animals whose temperature was raised to 39.2-40.9-degrees-C had a low incidence of pups with similar types of malformations. The primary types of malformations were of the axial skeleton, consisting of fusions and other abnormalities of the ribs and vertebral elements, and a decrease in the total number of ribs and centra. The acute maternal effects of these temperature increases were signs of heat exhaustion during and 1-2 hr after exposure, but there were no permanent changes in weight gain or other signs. When temperatures were raised to greater-than-or-equal-to 42-degrees-C, all maternal animals died. In a second study (Experiment 2), pregnant rats (from a different supplier) were anesthetized to determine the effect of reducing maternal stress and were exposed to heat as in Experiment 1. Those animals whose core body temperature was raised to 42-42.5-degrees-C for 5 min had pups with similar responses to those in Experiment 1 at 41-41.9-degrees-C, although the reduction in litter size was not as great. Animals whose temperature was raised to 41-degrees-C had a much lower incidence of pups with similar defects, and animals whose temperature was raised to 43-degrees-C did not survive. A more detailed analysis of the skeletal defects in Experiment 2 showed rib and vertebral malformations that appear to be related to the stage of somite development at the time of exposure.
C1 THIEL COLL,DEPT BIOL,GRENNVILLE,PA 16125.
BIOCON INC,DIV LIFE SCI,HLTH SCI BRANCH,ROCKVILLE,MD.
US FDA,CTR DEVICES & RADIOL HLTH,DIV BIOMETR SCI,STAT BRANCH,ROCKVILLE,MD 20857.
RP KIMMEL, CA (reprint author), US EPA,DHEA,ORD,HUMAN HLTH ASSESSMENT GRP,REPROD & DEV TOXICOL BRANCH,WASHINGTON,DC 20460, USA.
NR 47
TC 61
Z9 62
U1 1
U2 6
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0040-3709
J9 TERATOLOGY
JI Teratology
PD MAR
PY 1993
VL 47
IS 3
BP 229
EP 242
DI 10.1002/tera.1420470307
PG 14
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA KU804
UT WOS:A1993KU80400006
PM 8475466
ER
PT J
AU KIMMEL, GL
CUFF, JM
KIMMEL, CA
HEREDIA, DJ
TUDOR, N
SILVERMAN, PM
AF KIMMEL, GL
CUFF, JM
KIMMEL, CA
HEREDIA, DJ
TUDOR, N
SILVERMAN, PM
TI EMBRYONIC-DEVELOPMENT INVITRO FOLLOWING SHORT-DURATION EXPOSURE TO HEAT
SO TERATOLOGY
LA English
DT Article
ID RAT EMBRYOS; HYPERTHERMIA; SHOCK; THERMOTOLERANCE; CULTURE; GROWTH
AB Gestation day (GD) 10 rat embryos (10-12 somites) were exposed in vitro for 10 to 25 minutes at 42 or 43-degrees-C and evaluated 24 hrs later for alterations in growth and specific morphological parameters, using a modified Brown-Fabro (Brown and Fabro: Teratology, 24:65-78,'81) scoring system that allowed evaluation of development relative to gestational age. At 42-degrees-C, crown-rump length appeared to be particularly sensitive, responding to only 10 mins exposure. A 15-min exposure resulted in decreased total protein, somite number and morphological score. No system was uniquely sensitive, since all parameters demonstrated some degree of response. Rather, systems affected were those that would be developing most rapidly at this time in gestation. At 43-degrees-C, all of the parameters measured were affected by a 10-min exposure. These results demonstrate alterations in vitro after much shorter exposure periods than previously reported on GD10, which may be due, in part, to the use of a modified scoring system that permitted the evaluation of graded individual end point changes relative to gestational age. The response patterns demonstrated a clear temperature- and exposure duration-dependency, with a shift from a more shallow duration-response curve to a more dramatic inhibition of development as temperature increased from 42-degrees-C to 43-degrees-C.
C1 THIEL COLL,DEPT BIOL,GREENVILLE,PA 16125.
BIOCON INC,DIV LIFE SCI,HLTH SCI BRANCH,ROCKVILLE,MD.
US FDA,CTR DEVICES & RADIOL HLTH,DIV BIOMETR SCI,STAT BRANCH,ROCKVILLE,MD 20857.
RP KIMMEL, GL (reprint author), US EPA,OHEA,ORD,HUMAN HLTH ASSESSMENT GRP,REPROD & DEV TOXICOL BRANCH,WASHINGTON,DC 20460, USA.
NR 19
TC 23
Z9 23
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0040-3709
J9 TERATOLOGY
JI Teratology
PD MAR
PY 1993
VL 47
IS 3
BP 243
EP 251
DI 10.1002/tera.1420470308
PG 9
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA KU804
UT WOS:A1993KU80400007
PM 8475467
ER
PT J
AU FARRIS, FF
DEDRICK, RL
ALLEN, PV
SMITH, JC
AF FARRIS, FF
DEDRICK, RL
ALLEN, PV
SMITH, JC
TI PHYSIOLOGICAL MODEL FOR THE PHARMACOKINETICS OF METHYL MERCURY IN THE
GROWING RAT
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
ID INORGANIC MERCURY; BILIARY-EXCRETION; METHYLMERCURY SECRETION;
GLUTATHIONE; TRANSPORT; CHLORIDE; BIOTRANSFORMATION; MOUSE; BRAIN;
DEPENDENCE
C1 NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892.
UNIV ROCHESTER,SCH MED,ENVIRONM HLTH SCI CTR,ROCHESTER,NY 14620.
RP FARRIS, FF (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV CLIN PHARMACOL,4 RES COURT,ROOM 314,ROCKVILLE,MD 20850, USA.
FU NIEHS NIH HHS [ES-01247, ES-01248]
NR 79
TC 62
Z9 63
U1 0
U2 13
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0041-008X
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD MAR
PY 1993
VL 119
IS 1
BP 74
EP 90
DI 10.1006/taap.1993.1046
PG 17
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR292
UT WOS:A1993KR29200010
PM 8470126
ER
PT J
AU BERKOWITZ, DB
AF BERKOWITZ, DB
TI SMITTEN BY QUAIL
SO SCIENCE
LA English
DT Letter
RP BERKOWITZ, DB (reprint author), US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857, USA.
NR 5
TC 2
Z9 2
U1 0
U2 0
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 26
PY 1993
VL 259
IS 5099
BP 1238
EP 1239
DI 10.1126/science.8446889
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KN883
UT WOS:A1993KN88300003
PM 8446889
ER
PT J
AU LABORDA, J
SAUSVILLE, EA
HOFFMAN, T
NOTARIO, V
AF LABORDA, J
SAUSVILLE, EA
HOFFMAN, T
NOTARIO, V
TI DLK, A PUTATIVE MAMMALIAN HOMEOTIC GENE DIFFERENTIALLY EXPRESSED IN
SMALL-CELL LUNG-CARCINOMA AND NEUROENDOCRINE TUMOR-CELL LINE
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Note
ID EPIDERMAL GROWTH-FACTOR; DROSOPHILA-MELANOGASTER; BLOOD-COAGULATION;
SEQUENCE; NOTCH; PROTEINS; DELTA; ENCODES; CANCER; IDENTIFICATION
AB Gastrin releasing peptide is mitogenic for mouse Swiss 3T3 fibroblasts and certain human small cell lung carcinoma (SCLC) cells but not for mouse Balb/c 3T3 fibroblasts. To identify new molecules associated with the gastrin releasing peptide-responsive phenotype, clones isolated from a differential cDNA library between Swiss and Balb/c 3T3 fibroblasts were used to screen for their expression in human SCLC cell lines. Using this approach, we have isolated and characterized human and mouse cDNA clones encoding a novel protein. This protein is a putative transmembrane protein belonging to the epidermal growth factor-like superfamily. In vitro transcription and translation studies detect a 42-kDa protein, in agreement with the size predicted from the translated cDNA sequence. This protein (termed Delta-like or dlk) is highly homologous to invertebrate homeotic proteins, including Delta, and Notch, the products of neurogenic loci involved in normal neural differentiation in Drosophila. dlk is expressed in tumors with neuroendocrine features, such as neuroblastoma, pheochromocytoma, and a subset of SCLC cell lines. However, its expression in normal tissues is restricted to the adrenal gland and placenta. These data suggest that dlk may be involved in neuroendocrine differentiation and, because of its cellular location and restricted expression in normal tissues, it may be a potential therapeutic target in neuroendocrine tumors, particularly SCLC.
C1 US FDA,CTR BIOLOG EVALUAT & RES,BETHESDA,MD 20892.
GEORGETOWN UNIV,DEPT MED,DIV MED ONCOL,WASHINGTON,DC 20007.
GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT RADIAT MED,WASHINGTON,DC 20007.
RI Laborda, Jorge/L-5726-2014
OI Laborda, Jorge/0000-0002-9210-838X
NR 33
TC 172
Z9 181
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 25
PY 1993
VL 268
IS 6
BP 3817
EP 3820
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KN533
UT WOS:A1993KN53300006
PM 8095043
ER
PT J
AU NAIR, J
ROUSE, D
MORRIS, S
AF NAIR, J
ROUSE, D
MORRIS, S
TI NUCLEOTIDE-SEQUENCE ANALYSIS OF THE RIBOSOMAL S12 GENE OF
MYCOBACTERIUM-INTRACELLULARE
SO NUCLEIC ACIDS RESEARCH
LA English
DT Note
ID ESCHERICHIA-COLI; STREPTOMYCIN; PROTEIN; OPERON
C1 US FDA,CTR BIOL EVALUAT & RES,MYCOBACTERIA LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 9
TC 4
Z9 6
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 25
PY 1993
VL 21
IS 4
BP 1039
EP 1039
DI 10.1093/nar/21.4.1039
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KR189
UT WOS:A1993KR18900038
PM 8451173
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW FOOD LABEL TO ENHANCE HEALTHFUL DIETS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 24
PY 1993
VL 269
IS 8
BP 974
EP 974
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KM603
UT WOS:A1993KM60300005
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI TREATMENT IND FOR MULTIPLE-SCLEROSIS DRUG
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 24
PY 1993
VL 269
IS 8
BP 974
EP 974
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KM603
UT WOS:A1993KM60300003
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI PROPOSAL FOR SUBMISSION OF DATA ON SALINE-FILLED BREAST IMPLANTS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 24
PY 1993
VL 269
IS 8
BP 974
EP 974
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KM603
UT WOS:A1993KM60300004
ER
PT J
AU BETZ, J
OBERMEYER, W
AF BETZ, J
OBERMEYER, W
TI EFFECTS OF PROCESSING ON THE GLUCOSINOLATE CONTENT OF BROCCOLI
(BRASSICA-OLERACEA VAR BOTRYTIS-L SUBVAR CYMOSA LAM)
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A863
EP A863
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501977
ER
PT J
AU BLAKELY, SR
MISLO, BL
BROWN, ED
JENKINS, MY
MITCHELL, GV
AF BLAKELY, SR
MISLO, BL
BROWN, ED
JENKINS, MY
MITCHELL, GV
TI GENDER DIFFERENCES IN THE INDUCTION OF HEPATIC DETOXIFICATION ENZYMES IN
GARLIC-FED HYPERCHOLESTEROLEMIC OR IRON-LOADED MATURE RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A864
EP A864
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501983
ER
PT J
AU CALVEY, EM
ROACH, JAG
AF CALVEY, EM
ROACH, JAG
TI THE USE OF SUPERCRITICAL FLUID TECHNOLOGIES IN THE ANALYSIS OF GARLIC
PRODUCTS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A863
EP A863
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501981
ER
PT J
AU CASSIDY, MM
SATCHITHANDAM, S
CALVERT, RJ
KLURFELD, D
AF CASSIDY, MM
SATCHITHANDAM, S
CALVERT, RJ
KLURFELD, D
TI MODULATION OF THE COLONIC GOBLET CELL-POPULATION BY CHRONIC FEEDING OF
CELLULOSE OR RICE BRAN
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 GEORGE WASHINGTON UNIV,MED CTR,WASHINGTON,DC 20037.
US FDA,WASHINGTON,DC 20204.
WAYNE STATE UNIV,DETROIT,MI 48202.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A814
EP A814
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501693
ER
PT J
AU CHANDERBHAN, R
BROCKINGTON, R
WHITTAKER, P
AF CHANDERBHAN, R
BROCKINGTON, R
WHITTAKER, P
TI EFFECT OF DIETARY GARLIC EXTRACT ON BLOOD-LIPIDS IN THE RAT
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,DIV NUTR,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A864
EP A864
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501982
ER
PT J
AU DEFELICE, A
FEIN, S
DAUDISS, K
FRERING, R
HORAN, P
AF DEFELICE, A
FEIN, S
DAUDISS, K
FRERING, R
HORAN, P
TI ECHOCARDIOGRAPHY OF AORTIC REGURGITANT (AR) RABBITS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
UNION UNIV,ALBANY,NY 12208.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A752
EP A752
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501336
ER
PT J
AU ELLWOOD, KC
ROEBUCK, BD
LYNCOOK, B
HATHCOCK, JN
AF ELLWOOD, KC
ROEBUCK, BD
LYNCOOK, B
HATHCOCK, JN
TI EFFECTS OF SOYBEAN TRYPSIN-INHIBITOR CONCENTRATE AND ZINC ON PANCREATIC
CARCINOGENESIS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,HANOVER,NH 03756.
US FDA,LAUREL,MD 20708.
NCTR,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A734
EP A734
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501234
ER
PT J
AU HERMAN, EH
ZHANG, J
CHADWICK, DP
FERRANS, VJ
GREEN, MD
AF HERMAN, EH
ZHANG, J
CHADWICK, DP
FERRANS, VJ
GREEN, MD
TI THE ANTIVIRAL DRUG FIAC CAUSES MYOCARDIAL ALTERATIONS IN RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NHLBI,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A683
EP A683
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97500946
ER
PT J
AU LATHERS, CM
CHARLES, JB
AF LATHERS, CM
CHARLES, JB
TI ORTHOSTATIC HYPOTENSION IN PATIENTS, BED REST SUBJECTS, AND ASTRONAUTS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058.
US FDA,ROCKVILLE,MD 20857.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A666
EP A666
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97500851
ER
PT J
AU OBERMEYER, WR
WARNER, C
CASEY, RE
MUSSER, S
AF OBERMEYER, WR
WARNER, C
CASEY, RE
MUSSER, S
TI FLAXSEED LIGNANS - ISOLATION, METABOLISM AND BIOLOGICAL EFFECTS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A863
EP A863
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501980
ER
PT J
AU RHEE, HM
LEE, SM
CHARAIS, J
PARK, DH
AF RHEE, HM
LEE, SM
CHARAIS, J
PARK, DH
TI EFFECTS OF NALOXONE AND NALOXONE METHOBROMIDE (NM) ON
TYROSINE-HYDROXYLASE (TH), DOPAMINE BETA-HYDROXYLASE (DBH) AND
PHENYLETHANOLAMINE N-METHYLTRANSFERASE (PNMT) ACTIVITIES IN
SPRAGUE-DAWLEY (SD) AND SPONTANEOUSLY HYPERTENSIVE (SH) RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
CORNELL UNIV,MED CTR,COLL MED,BURKE REHABIL CTR,NEW YORK,NY 10021.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A748
EP A748
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501312
ER
PT J
AU SATCHITHANANDAM, S
WIESENFELD, P
CHANDERBAHN, R
CALVERT, RJ
KLURFELD, D
AF SATCHITHANANDAM, S
WIESENFELD, P
CHANDERBAHN, R
CALVERT, RJ
KLURFELD, D
TI EFFECT OF FEEDING SESAME OIL ON LIVER WEIGHT, LIVER CHOLESTEROL AND
LIVER TRIGLYCERIDES IN RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD.
WAYNE STATE UNIV,DETROIT,MI 48202.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A799
EP A799
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501612
ER
PT J
AU SUNDARESAN, PR
AF SUNDARESAN, PR
TI INFLUENCE OF DIETARY GARLIC ON VITAMIN-A STATUS IN WEANLING
SPRAGUE-DAWLEY RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A864
EP A864
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501985
ER
PT J
AU VICK, J
CHADWICK, D
SCOTT, R
HERMAN, E
AF VICK, J
CHADWICK, D
SCOTT, R
HERMAN, E
TI EFFECT OF PHENYLPROPANOLAMINE ON BLOOD-PRESSURE AND WEIGHT CHANGE
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A635
EP A635
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97500671
ER
PT J
AU WIESENFELD, P
CHANDERBHAN, R
WHITTAKER, P
AF WIESENFELD, P
CHANDERBHAN, R
WHITTAKER, P
TI BLOOD PARAMETERS AND FE STATUS IN RATS FED DIETARY GARLIC EXTRACT AND
NIACIN
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,DIV NUTR,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A743
EP A743
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501282
ER
PT J
AU ZHANG, J
HERMAN, EH
FERRANS, VJ
AF ZHANG, J
HERMAN, EH
FERRANS, VJ
TI THE EFFECT OF ICRF-186 ON CARDIAC IMMUNE-RESPONSES AND MYOCYTE
ALTERATIONS INDUCED BY DOXORUBICIN (DXR) IN SPONTANEOUSLY HYPERTENSIVE
RATS (SHR)
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NHLBI,BETHESDA,MD 20892.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A685
EP A685
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP975
UT WOS:A1993KP97500959
ER
PT J
AU BABU, U
JENKINS, MY
AF BABU, U
JENKINS, MY
TI IMPACT OF FLAXSEED ON MITOGENIC RESPONSE OF SPLENOCYTES FROM YOUNG MALE
AND FEMALE RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A73
EP A73
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97400418
ER
PT J
AU JENKINS, MY
MITCHELL, GV
GRUNDEL, E
BLAKELY, SR
AF JENKINS, MY
MITCHELL, GV
GRUNDEL, E
BLAKELY, SR
TI DIETARY FLAXSEED (GFL) ALTERS ALPHA-TOCOPHEROL LEVELS BUT NOT SELECTED
DETOXIFICATION ENZYME-ACTIVITY IN YOUNG-RATS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A286
EP A286
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97401657
ER
PT J
AU KAUP, SM
HIGHT, SC
RADER, JI
AF KAUP, SM
HIGHT, SC
RADER, JI
TI RESPONSE OF CALCIUM (CA), MAGNESIUM (MG) AND PHOSPHORUS (P) STATUS IN
IMMATURE FEMALE AND MALE-RATS TO DIETARY FLAXSEED
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A88
EP A88
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97400504
ER
PT J
AU KIMBALL, RW
SPURLOCK, SL
VICK, J
AF KIMBALL, RW
SPURLOCK, SL
VICK, J
TI MODIFICATION OF HUMAN AND EQUINE PHAGOCYTIC-ACTIVITY BY CALCIUM-CHANNEL
ANTAGONISTS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A474
EP A474
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97402743
ER
PT J
AU MITCHELL, G
SUNDARESAN, P
JENKINS, M
GRUNDEL, E
BLAKELY, S
AF MITCHELL, G
SUNDARESAN, P
JENKINS, M
GRUNDEL, E
BLAKELY, S
TI ALTERATIONS IN VITAMIN-A AND VITAMIN-E STATUS OF MALE AND FEMALE RATS
FED HIGH DIETARY NICOTINIC-ACID (NA)
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A304
EP A304
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97401758
ER
PT J
AU ROSS, IA
IKEDA, GJ
CHIRTEL, SJ
AF ROSS, IA
IKEDA, GJ
CHIRTEL, SJ
TI EVALUATION OF A NONINVASIVE METHOD FOR MEASUREMENT OF CARDIOVASCULAR
PARAMETERS IN UNANESTHETIZED DOGS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CFSAN,DIV TOXICOL RES,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A251
EP A251
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97401452
ER
PT J
AU VARRICCHIO, F
OBIRI, NI
HAAS, GP
PURI, RK
AF VARRICCHIO, F
OBIRI, NI
HAAS, GP
PURI, RK
TI IMMUNOSTAINING OF INTERLEUKIN-4 RECEPTORS ON HUMAN RENAL-CELL CARCINOMA
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CBER,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A267
EP A267
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97401544
ER
PT J
AU WHITTAKER, P
CHANDERBHAN, R
AF WHITTAKER, P
CHANDERBHAN, R
TI EFFECT OF INCREASING IRON SUPPLEMENTATION ON SERUM FREE FATTY-ACIDS,
PHOSPHOLIPIDS AND CHOLESTEROL
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 FDA,DIV NUTR,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 19
PY 1993
VL 7
IS 3
BP A297
EP A297
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA KP974
UT WOS:A1993KP97401720
ER
PT J
AU LIN, LA
AF LIN, LA
TI DETECTION OF ALKALOIDS IN FOODS WITH A MULTIDETECTOR HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHIC SYSTEM
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Article
ID AQUEOUS IONIC ELUENTS; BASIC DRUGS
AB A general screening method for alkaloid drugs in foods is described based on high-performance liquid chromatography with ultraviolet detection at three wavelengths, followed by fluorescence and electrochemical detectors in series. The chromatographic conditions include an ion-pairing reagent, which makes it possible to chromatograph acidic and basic drugs with one screen. Relative response ratios were determined from the peak areas of the alkaloids on the basis of all the detector signals. These ratios were used to create a ''fingerprint'' of the drugs and to predict the identity of an unknown component in a sample matrix. The fluorescence and electrochemical detectors allowed a detection limit for many of the alkaloids which would not be attainable with the ultraviolet detector alone. Typical detection limits with the electrochemical detector were 5-50 ng/ml and with the fluorescence detector 5-500 ng/ml, while the ultraviolet detector had detection limits of 1-20 mug/ml. The spiking concentrations in the relative response ratio experiments were approximately five times above the lowest detection limit. The extraction method investigated for orange juice yielded recoveries for most alkaloids of 80-100%. A stability study of ergot alkaloids in various food matrices demonstrated degradation, depending on the matrix, temperature, and duration of the experiment.
RP LIN, LA (reprint author), US FDA,CTR NATL FORENS CHEM,1141 CENT PKWY,CINCINNATI,OH 45202, USA.
NR 5
TC 11
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PD FEB 19
PY 1993
VL 632
IS 1-2
BP 69
EP 78
DI 10.1016/0021-9673(93)80027-6
PG 10
WC Chemistry, Analytical
SC Chemistry
GA KN834
UT WOS:A1993KN83400009
PM 8454720
ER
PT J
AU MILLER, HI
AF MILLER, HI
TI FOODS OF THE FUTURE - THE NEW BIOTECHNOLOGY AND FDA REGULATION
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP MILLER, HI (reprint author), US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857, USA.
NR 2
TC 5
Z9 5
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 17
PY 1993
VL 269
IS 7
BP 910
EP 912
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA KL474
UT WOS:A1993KL47400031
PM 8426451
ER
PT J
AU YOKOZAKI, H
BUDILLON, A
TORTORA, G
MEISSNER, S
BEAUCAGE, SL
MIKI, K
CHOCHUNG, YS
AF YOKOZAKI, H
BUDILLON, A
TORTORA, G
MEISSNER, S
BEAUCAGE, SL
MIKI, K
CHOCHUNG, YS
TI AN ANTISENSE OLIGODEOXYNUCLEOTIDE THAT DEPLETES RI-ALPHA SUBUNIT OF
CYCLIC AMP-DEPENDENT PROTEIN-KINASE INDUCES GROWTH-INHIBITION IN HUMAN
CANCER-CELLS
SO CANCER RESEARCH
LA English
DT Article
ID I REGULATORY SUBUNIT; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; RECEPTOR
PROTEINS; GENE-EXPRESSION; HL-60 LEUKEMIA; MESSENGER-RNA; HUMAN TESTIS;
DIFFERENTIATION; CDNA
AB Enhanced expression of the RI(alpha) subunit of cyclic AMP-dependent protein kinase type I has been correlated with cancer cell growth. We provide evidence that RI(alpha) is a growth-inducing protein that may be essential for neoplastic cell growth. Human colon, breast, and gastric carcinoma and neuroblastoma cell lines exposed to a 21-mer human RI(alpha) antisense phosphorothioate oligodeoxynucleotide (S-oligodeoxynucleotide) exhibited growth inhibition with no sign of cytotoxicity. Mismatched sequence (random) S-oligodeoxynucleotides of the same length exhibited no effect. The growth inhibitory effect of RI(alpha) antisense oligomer correlated with a decrease in the RI(alpha) mRNA and protein levels and with an increase in RII(beta) (the regulatory subunit of protein kinase type II) expression. The growth inhibition was abolished, however, when cells were exposed simultaneously to both RI(alpha) and RII(beta) antisense S-oligodeoxynucleotides. The RII(beta) antisense S-oligodeoxynucleotide alone, exhibiting suppression of RII(beta) along with enhancement of RI(alpha) expression, led to slight stimulation of cell growth. These results demonstrate that two isoforms of cyclic AMP receptor proteins, RI(alpha) and RII(beta), are reciprocally related in the growth control of cancer cells and that the RI(alpha) antisense oligodeoxynucleotide, which efficiently depletes the growth stimulatory RI(alpha), is a powerful biological tool toward suppression of malignancy.
C1 NCI,CELLULAR IMMUNOL SECT,BLDG 10,ROOM 5B38,BETHESDA,MD 20892.
NCI,EXPTL ONCOL SECT,BETHESDA,MD 20892.
NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892.
US FDA,BETHESDA,MD 20014.
TERUMO CO LTD,KANAGAWA,JAPAN.
OI Budillon, Alfredo/0000-0002-6330-6053; Yokozaki,
Hiroshi/0000-0001-5276-3331
NR 33
TC 87
Z9 88
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
PHILADELPHIA, PA 19106
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 1993
VL 53
IS 4
BP 868
EP 872
PG 5
WC Oncology
SC Oncology
GA KL963
UT WOS:A1993KL96300031
PM 8428367
ER
PT J
AU JOHNSON, VG
NICHOLLS, PJ
HABIG, WH
YOULE, RJ
AF JOHNSON, VG
NICHOLLS, PJ
HABIG, WH
YOULE, RJ
TI THE ROLE OF PROLINE-345 IN DIPHTHERIA-TOXIN TRANSLOCATION
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PLANAR LIPID BILAYERS; NUCLEOTIDE-SEQUENCE; PROLYL ISOMERASE;
FRAGMENT-B; LOW PH; MEMBRANE TRANSLOCATION; PROTEIN TRANSLOCATION;
OVERLAP EXTENSION; VERO CELLS; GENE
AB Diphtheria toxin (DT) can translocate across endosomal membranes in response to low pH. Buried hydrophobic domains localized in the 37-kDa toxin B chain become exposed in response to acidic conditions and are thought to participate in the membrane translocation process. The crystal structure of DT has revealed a structurally distinct translocation domain composed of nine alpha-helices with their interconnecting loops (Choe, S., Bennett, M., Fujii, G., Curmi, P., Kantardjieff, K., Collier, R., and Eisenberg, D. (1992) Nature 357, 216-222). Two of these alpha-helices, TH8 and TH9, are unusually apolar and constitute the central core of the translocation domain. It has been proposed that these domains and the highly charged interconnecting loop undergo a conformation change under acidic conditions producing a dagger-like structure capable of inserting into the membrane thus initiating the translocation process. Proline 345 occupies a strategic location at the end of the TH8 alpha-helix. Proline residues have the ability to undergo a cis-trans isomerization reaction and because of this have been proposed to play a role in the conformational change that is a prerequisite for toxin translocation. The role of the proline at position 345 in membrane translocation was investigated. Pro was mutagenized to Glu and to Gly using a two-step recombinant polymerase chain reaction procedure, and the mutant proteins were expressed in vitro. Glu, an alpha-helix former, and Gly, an alpha-helix breaker, were selected for mutagenesis to distinguish between a structural role for Pro as an alpha-helix breaker and alternative roles, perhaps involving cistrans isomerization-related conformational changes. Replacing Pro at position 345 with Glu or Gly resulted in a 99% reduction in toxicity to Vero cells. The enzymatic and binding activity of the toxin were not altered by the mutations. Instead, the reduction in toxicity is due to decreased translocation ability, suggesting that the Pro at position 345 plays a specific role in toxin membrane translocation.
C1 NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892.
RP JOHNSON, VG (reprint author), US FDA,CBER,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BLDG 29,RM 103,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 66
TC 27
Z9 27
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 15
PY 1993
VL 268
IS 5
BP 3514
EP 3519
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KM161
UT WOS:A1993KM16100076
PM 8429026
ER
PT J
AU HU, BL
PAZ, JP
ZHANG, YH
AF HU, BL
PAZ, JP
ZHANG, YH
TI QUANTUM BROWNIAN-MOTION IN A GENERAL ENVIRONMENT .2. NONLINEAR COUPLING
AND PERTURBATIVE APPROACH
SO PHYSICAL REVIEW D
LA English
DT Article
ID PATH FUNCTIONAL FORMALISM; BACK-REACTION PROBLEMS; INTEGRAL APPROACH;
CURVED SPACETIME; DISSIPATION; DECOHERENCE; TRANSITION; DYNAMICS
AB We develop a perturbation scheme to treat the dynamics of a quantum Brownian particle (coordinate x) coupled nonlinearly to a bath of oscillators (coordinates q(n)) with an interaction action in the form lambdaf(x)q(n)k. We derive the influence functionals for the k = 2,3,4 cases to order lambda2 and derive the master equations for the special cases of local dissipation and white noise, as well as the general cases of nonlocal dissipation and colored noise for f(x) = x and x2. We show that a generalized fluctuation-dissipation relation exists between the lth-order noise kernels of the kth-order coupling and their corresponding dissipation kernels.
C1 LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545.
US FDA,CBER,BIOPHYS LAB,BETHESDA,MD 20982.
RP HU, BL (reprint author), UNIV MARYLAND,DEPT PHYS,COLL PK,MD 20742, USA.
RI Paz, Juan/C-5947-2008
NR 57
TC 199
Z9 199
U1 0
U2 7
PU AMERICAN PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 0556-2821
J9 PHYS REV D
JI Phys. Rev. D
PD FEB 15
PY 1993
VL 47
IS 4
BP 1576
EP 1594
DI 10.1103/PhysRevD.47.1576
PG 19
WC Astronomy & Astrophysics; Physics, Particles & Fields
SC Astronomy & Astrophysics; Physics
GA KN182
UT WOS:A1993KN18200036
ER
PT J
AU TURUJMAN, SA
AF TURUJMAN, SA
TI RAPID DIRECT RESOLUTION OF THE STEREOISOMERS OF ALL-TRANS ASTAXANTHIN ON
A PIRKLE COVALENT L-LEUCINE COLUMN
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Article
AB Astaxanthin, 3,3'-dihydroxy-beta,beta-carotene-4,4'-dione, gives salmon flesh its distinctive color. Synthetic all-trans astaxanthin consists of a racemic mixture of two enantiomers (3R,3'R and 3S,3'S) and a meso form (3R,3'S). The stereoisomeric composition of endogenous astaxanthin in wild salmon differs from that of synthetic astaxanthin added to the fish feed of pond-bred salmon. In order to determine the origin of astaxanthin in salmon flesh, a method is needed that can distinguish the various isomeric forms. HPLC conditions are described for the rapid direct resolution of the three stereoisomers of all-trans astaxanthin on a Pirkle covalent L-leucine column. This method also partially resolves the stereoisomeric forms of the major cis isomer.
RP TURUJMAN, SA (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,HFF-445,WASHINGTON,DC 20204, USA.
NR 7
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PD FEB 12
PY 1993
VL 631
IS 1-2
BP 197
EP 199
DI 10.1016/0021-9673(93)80521-9
PG 3
WC Chemistry, Analytical
SC Chemistry
GA KM847
UT WOS:A1993KM84700020
ER
PT J
AU JOHNSON, GR
KANNAN, B
SHOYAB, M
STROMBERG, K
AF JOHNSON, GR
KANNAN, B
SHOYAB, M
STROMBERG, K
TI AMPHIREGULIN INDUCES TYROSINE PHOSPHORYLATION OF THE EPIDERMAL
GROWTH-FACTOR RECEPTOR AND P185(ERBB2) - EVIDENCE THAT AMPHIREGULIN ACTS
EXCLUSIVELY THROUGH THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT THE SURFACE
OF HUMAN EPITHELIAL-CELLS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID EGF-RECEPTOR; HUMAN-BREAST; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION;
KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS; PROTEIN; GENE; LINE
AB The COOH-terminal half of the amphiregulin (AR) molecule has sequence homology to epidermal growth factor (EGF). The ability of AR to elicit in vivo phosphorylation of the EGF receptor (EGFR) and p185erbB2 was studied in four human epithelial cell lines which expressed either or both of the receptor tyrosine kinases. AR induced the phosphorylation of the EGFR and p185erbB2, and phosphoamino acid analysis revealed enhanced phosphorylation of tyrosine residues in both receptor proteins. A monoclonal antibody (mAb) which binds to the extracellular domain of the EGFR blocked the phosphorylation of the EGFR and p185erbB2 as well as AR-induced mitogenesis indicating that the EGFR mediated these responses. In MDA-MB-453 cells which lack EGFRs, AR did not induce phosphorylation of p185erbB2, did not affect proliferation, and had no detectable effect on the phosphorylation of cellular proteins isolated using an anti-phosphotyrosine mAb. Qualitatively, in vivo phosphorylations induced by AR and EGF were found to be indistinguishable as demonstrated by analysis of cellular P-32-labeled proteins isolated with the anti-phosphotyrosine mAb. Moreover, in the presence of the anti-EGFR mAb, AR had no effect on the proliferation of cells. These results provide strong evidence that the EGFR is the sole cell surface mediator of the action of AR in human epithelial cells.
C1 BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,SEATTLE,WA 98121.
RP JOHNSON, GR (reprint author), US FDA,DIV CYTOKINE BIOL,CELL BIOL LAB,HFM-511,BLDG 29A,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 60
TC 127
Z9 129
U1 2
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 5
PY 1993
VL 268
IS 4
BP 2924
EP 2931
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KK815
UT WOS:A1993KK81500098
PM 7679104
ER
PT J
AU TRUCKSESS, MW
AF TRUCKSESS, MW
TI SEPARATION AND ISOLATION OF TRACE IMPURITIES IN L-TRYPTOPHAN BY
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Article
ID EOSINOPHILIA-MYALGIA-SYNDROME
AB A high-performance liquid chromatographic (HPLC) profiling method was developed to separate trace impurities in L-tryptophan products associated with the eosinophilia-myalgia syndrome (EMS) epidemic. The test portion was dissolved in water, and the solution was filtered and chromatographed on a silica-based C18 reversed-phase HPLC column by using linear gradient elution with water and acetonitrile-water (80:20); both solvents contained 0.1% trifluoroacetic acid for ion-pairing. The method was used to profile 200 test samples from six manufacturers Of L-tryptophan. The method was modified to include the use of a C18 disposable cartridge to retain the 1,1'-ethylidenebis(L-tryptophan) (peak E, peak 97 or EBT). the impurity most strongly associated with EMS, and to remove the L-tryptophan before HPLC separation and quantitation. Recoveries of EBT added to test portions (2 mug/g and above) averaged 80%.
RP TRUCKSESS, MW (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV CONTAMINANTS CHEM HFS-346,WASHINGTON,DC 20204, USA.
NR 14
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PD FEB 5
PY 1993
VL 630
IS 1-2
BP 147
EP 150
DI 10.1016/0021-9673(93)80450-M
PG 4
WC Chemistry, Analytical
SC Chemistry
GA KL947
UT WOS:A1993KL94700013
PM 8444999
ER
PT J
AU PATEL, M
YANAGISHITA, M
RODERIQUEZ, G
BOUHABIB, DC
ORAVECZ, T
HASCALL, VC
NORCROSS, MA
AF PATEL, M
YANAGISHITA, M
RODERIQUEZ, G
BOUHABIB, DC
ORAVECZ, T
HASCALL, VC
NORCROSS, MA
TI CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCAN MEDIATES HIV-1 INFECTION OF
T-CELL LINES
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY
RECEPTOR; DEXTRAN SULFATE; SELECTIVE INHIBITORS; VIRION BINDING;
POLYSACCHARIDES; INVITRO; POTENT; REPLICATION
AB The role of cell-surface proteoglycans in human immunodeficiency virus (HIV) infection of T-cell lines was investigated. HIV-1-susceptible lymphoblastic T-cell lines, MT-4 and H9, were analyzed for proteoglycan synthesis and found to make heparan sulfate (HS) and chondroitin sulfate proteoglycans. Enzymatic treatment of these cells with heparitinase, but not chondroitinase, significantly prevented HIV-1(IIIB) infection as measured by inhibition of cytopathicity, reverse transcriptase production, and syncytia formation. Sulfation of glycosaminoglycans HS chains was critical to viral entry as shown by inhibition of viral infection with sodium chlorate and its specific reversal with exogenous sulfate addition. Quantitation of direct virus binding to cells showed that treatment of cells with heparitinase inhibited HIV-1 binding to the T-cell surface. Exogenous HS added to cultures inhibited virus infection in a manner analogous to dextran sulfate, further supporting a functional role for HS in HIV-1 binding. These results provide evidence for participation of cell-surface HS proteoglycans in HIV-cell attachment and virus entry.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,NIH BLDG 29A,ROOM 2D-20,BETHESDA,MD 20892.
NIDR,BONE RES BRANCH,BETHESDA,MD 20892.
NR 23
TC 209
Z9 212
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 1993
VL 9
IS 2
BP 167
EP 174
DI 10.1089/aid.1993.9.167
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA KQ327
UT WOS:A1993KQ32700011
PM 8096145
ER
PT J
AU WRIGHT, C
MOORE, RD
GRODIN, DM
SPYKER, DA
GILL, EV
AF WRIGHT, C
MOORE, RD
GRODIN, DM
SPYKER, DA
GILL, EV
TI SCREENING FOR DISULFIRAM-INDUCED LIVER TEST DYSFUNCTION IN AN INPATIENT
ALCOHOLISM PROGRAM
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE DISULFIRAM; ANTABUSE; DISULFIRAM-ASSOCIATED LIVER TOXICITY;
DISULFIRAM-ASSOCIATED FULMINANT HEPATITIS; DISULFIRAM-ASSOCIATED
TRANSAMINITIS
AB The objective of this study was to report the frequency of disulfiram-related elevations of four commonly used hepatic screening chemistries using a retrospective record review design. An inpatient alcoholism program was selected for the setting. Patients who had initial laboratory values within the normal range started daily supervised doses of disulfiram, then underwent follow-up testing after 2 and 4 weeks on the drug. The study population consisted of 108 patients receiving disulfiram and 27 patients who did not receive disulfiram (controls). The four screening serum chemistries performed were aspartate aminotransferase (SGOT), alanine amino-transferase (SGPT), alkaline phosphatase, and gamma-glutamyl transferase. Twenty-seven (25%) of the 108 patients who were taking 250 mg of disulfiram a day for 2 to 4 weeks had disulfiram-related elevations in alanine aminotransferase above the upper limit of normal, as opposed to one elevation in 27 patients (4%) for whom disulfiram was not prescribed. In the 108 patients (with initially normal serum chemistries) who were prescribed disulfiram, 32 were discontinued from the drug at 2 weeks and an additional 11 were discontinued from the drug at 4 weeks because of one or more abnormal serum chemistries. Alanine aminotransferase was the most specific and sensitive indicator of the four screening chemistries performed.
C1 US PHS,FOOD & DRUG ADM,CTR DRUG EVALUAT & RES,PILOT DRUG EVALUAT STAFF,ROOM 9B-45,HFD-007,ROCKVILLE,MD 20857.
UNIV HLTH SCI,SCH MED,UNIFORMED SERV,BETHESDA,MD.
NR 8
TC 12
Z9 12
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD FEB
PY 1993
VL 17
IS 1
BP 184
EP 186
DI 10.1111/j.1530-0277.1993.tb00745.x
PG 3
WC Substance Abuse
SC Substance Abuse
GA KP433
UT WOS:A1993KP43300028
PM 8383924
ER
PT J
AU COUIG, MP
AF COUIG, MP
TI THE NEW FOOD LABEL
SO AMERICAN JOURNAL OF NURSING
LA English
DT Article
RP COUIG, MP (reprint author), US FDA,OFF HLTH AFFAIRS,ROCKVILLE,MD 20857, USA.
NR 4
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0002-936X
J9 AM J NURS
JI Am. J. Nurs.
PD FEB
PY 1993
VL 93
IS 2
BP 68
EP 72
PG 5
WC Nursing
SC Nursing
GA KL166
UT WOS:A1993KL16600029
ER
PT J
AU DOMKOWSKI, PW
MESSIER, RH
CRESCENZO, DG
ALY, HS
ABDELFATTAH, AS
HILBERT, SL
WALLACE, RB
HOPKINS, RA
AF DOMKOWSKI, PW
MESSIER, RH
CRESCENZO, DG
ALY, HS
ABDELFATTAH, AS
HILBERT, SL
WALLACE, RB
HOPKINS, RA
TI PREIMPLANTATION ALTERATION OF ADENINE-NUCLEOTIDES IN CRYOPRESERVED
HEART-VALVES
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID TERM FOLLOW-UP; CELLULAR VIABILITY; REPLACEMENT; ADENOSINE; TISSUE
AB To assess the initial metabolic phase of cellular injury from cardiac valve processing, high-energy phosphate concentrations were analyzed in valve leaflets subsequent to critical processing steps. Using a porcine model, valves were processed in a manner identical to human homografts, with 58 randomly assigned to five groups representing distinct preparation phases. Group I (controls) sustained 40 minutes of warm ischemia concluded by liquid nitrogen immersion. Remaining groups similarly endured 40 minutes of ischemia, but were subsequently prepared according to stepwise design: II, warm ischemia + 24 hours of 4-degrees-C ischemia; III, warm ischemia + 24 hours of 4C antibiotic disinfection; IV, warm ischemia + 24 hours at 4-degrees-C (without antibiotics) + cryopreservation (-1-degrees-C/min cryoprotected freezing); and V, warm ischemia + disinfection + cryopreservation. At each regimen's conclusion leaflet extracts were assayed by high-performance liquid chromatography for high-energy adenine nucleotides (adenosine triphosphate, adenosine diphosphate, adenosine monophosphate) and catabolites. A 47% and 86% decrease in cellular adenosine triphosphate level was. observed in group III and group V leaflets, respectively. The level of total adenine nucleotides was maintained up to cryopreservation; thereafter a 74% decrease was noted. Catabolite analysis confirmed incomplete degradation of adenine nucleotides indicating cellular metabolic resilience throughout standard homograft preparation in valves previously exposed to 40 minutes of warm ischemia.
C1 GEORGETOWN UNIV,SCH MED,DEPT SURG,3800 RESERVOIR RD NW,WASHINGTON,DC 20007.
VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298.
US FDA,ROCKVILLE,MD 20857.
NR 33
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 1993
VL 55
IS 2
BP 413
EP 419
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA KK914
UT WOS:A1993KK91400020
PM 8431053
ER
PT J
AU WRIGHT, AC
MICELI, GA
LANDRY, WL
CHRISTY, JB
WATKINS, WD
MORRIS, JG
AF WRIGHT, AC
MICELI, GA
LANDRY, WL
CHRISTY, JB
WATKINS, WD
MORRIS, JG
TI RAPID IDENTIFICATION OF VIBRIO-VULNIFICUS ON NONSELECTIVE MEDIA WITH AN
ALKALINE PHOSPHATASE-LABELED OLIGONUCLEOTIDE PROBE
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; UNITED-STATES; HEMOLYSIN GENE; INFECTIONS;
FEATURES; OYSTERS
AB An oligonucleotide DNA probe (VVAP) was constructed from a portion of the Vibrio vulnificus cytolysin gene (hlyA) sequence and labeled with alkaline phosphatase covalently linked to the DNA. Control and environmental isolates probed with VVAP showed an exact correlation with results obtained with a plasmid DNA probe (derived from pCVD702) previously described as having 100% specificity and sensitivity for this organism. Identification of V. vulnificus strains was confirmed independently by analysis of the cellular fatty acid composition and by API 20E. Naturally occurring V. vulnificus bacteria were detected without enrichment or selective media by VVAP in unseeded oyster homogenates and seawater collected from a single site in Chesapeake Bay during June at concentrations of 6 x 10(2) and 2 x 10(1) bacteria per ml, respectively. V. vulnificus bacteria were also enumerated by VVAP in oysters seeded with known concentrations of bacteria and plated on nonselective medium. The VVAP method provides a rapid, accurate means of identifying and enumerating V. vulnificus in seawater and oysters without the use of selective media or additional biochemical tests.
C1 UNIV MARYLAND,SCH MED,DEPT MED,DIV GEOG MED,10 S PINE ST,BALTIMORE,MD 21201.
UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21201.
DEPT VET AFFAIRS MED CTR,BALTIMORE,MD 21218.
US FDA,N KINGSTOWN,RI 02852.
US FDA,DALLAS,TX 75204.
NR 25
TC 114
Z9 115
U1 2
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD FEB
PY 1993
VL 59
IS 2
BP 541
EP 546
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA KK916
UT WOS:A1993KK91600029
PM 8434919
ER
PT J
AU KOCH, WH
PAYNE, WL
WENTZ, BA
CEBULA, TA
AF KOCH, WH
PAYNE, WL
WENTZ, BA
CEBULA, TA
TI RAPID POLYMERASE CHAIN-REACTION METHOD FOR DETECTION OF VIBRIO-CHOLERAE
IN FOODS
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID NUCLEOTIDE-SEQUENCE ANALYSIS; ESCHERICHIA-COLI; GULF-COAST; B-SUBUNIT;
TOXIN; OPERON; IDENTIFICATION; MEAT; DNA
AB The polymerase chain reaction was used to selectively amplify sequences within the cholera toxin operon from Vibrio cholerae O1. Oysters, crabmeat, shrimp, and lettuce were seeded with V. cholerae and then homogenized or washed with alkaline peptone water, followed by short-term (6- to 8-h) enrichment. A detection limit of as few as 1 V. cholerae CFU per 10 g of food was obtained with amplification reactions from crude bacterial lysates. The method is extremely rapid and obviates the need for DNA isolation from a variety of complex food matrices.
RP KOCH, WH (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 28
TC 76
Z9 84
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD FEB
PY 1993
VL 59
IS 2
BP 556
EP 560
PG 5
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA KK916
UT WOS:A1993KK91600032
PM 8434922
ER
PT J
AU ESTELA, LA
SOFOS, JN
AF ESTELA, LA
SOFOS, JN
TI COMPARISON OF CONVENTIONAL AND REVERSED PHAGE TYPING PROCEDURES FOR
IDENTIFICATION OF LISTERIA SPP
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Note
ID MONOCYTOGENES; SYSTEM
AB Of 225 Listeria isolates evaluated, 199 had the same bacteriophage patterns by both the conventional (A. Audurier, A. G. Taylor, B. Carbonelle, and J. McLaughlin, Clin. Invest. Med. 7:229-232, 1984) and the new, easier to apply, ''reversed'' (M. J. Loessner, Appl. Environ. Microbiol. 57:882-884, 1991) phage typing procedures, 5 had different phage reactions, and the remaining 21 isolates were untypeable. Thus, the overall typeability rate was 90.7%, and 97.6% of the typeable isolates had the same phage patterns by both procedures.
C1 UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262.
COLORADO STATE UNIV,DEPT ANIM SCI,FT COLLINS,CO 80523.
COLORADO STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,FT COLLINS,CO 80523.
RP ESTELA, LA (reprint author), US FDA,DENVER DIST LAB,POB 25087,DENVER,CO 80225, USA.
NR 15
TC 14
Z9 15
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD FEB
PY 1993
VL 59
IS 2
BP 617
EP 619
PG 3
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA KK916
UT WOS:A1993KK91600044
PM 8434928
ER
PT J
AU WAYNANT, RW
OSHRY, S
FINK, M
AF WAYNANT, RW
OSHRY, S
FINK, M
TI INFRARED MEASUREMENTS OF SAPPHIRE FIBERS FOR MEDICAL APPLICATIONS
SO APPLIED OPTICS
LA English
DT Note
DE FIBER; SAPPHIRE; OPTICAL TRANSMISSION; DAMAGE THRESHOLD
ID CRYSTAL
AB Infrared transmission losses as low as 8 dB/km at 1060 nm and damage a threshold above 1.3 kJ/cm2 at 2940 nm have been measured for experimental single-crystal sapphire fibers.
C1 SACHS FREEMAN INC, LANDOVER, MD 20785 USA.
RP WAYNANT, RW (reprint author), US FDA, CTR DEVICES & RADIOL HLTH, 1901 CHAPMAN AVE, ROCKVILLE, MD 20857 USA.
NR 5
TC 9
Z9 9
U1 0
U2 0
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0003-6935
J9 APPL OPTICS
JI Appl. Optics
PD FEB 1
PY 1993
VL 32
IS 4
BP 390
EP 392
PG 3
WC Optics
SC Optics
GA KJ631
UT WOS:A1993KJ63100004
PM 20802702
ER
PT J
AU PETTIT, GH
EDIGER, MN
WEIBLINGER, RP
AF PETTIT, GH
EDIGER, MN
WEIBLINGER, RP
TI DYNAMIC OPTICAL-PROPERTIES OF COLLAGEN-BASED TISSUE DURING ARF EXCIMER
LASER ABLATION
SO APPLIED OPTICS
LA English
DT Article
DE ARF EXCIMER LASER; UV PHOTOABLATION; TISSUE REFLECTANCE; TISSUE
TRANSMITTANCE
ID TIME-RESOLVED REFLECTIVITY; CORNEA; POLYIMIDE
AB Various attenuation mechanisms affecting the absorption of ArF excimer laser light in collagenous tissues have been studied. Temporal distortion of the laser pulse reflected from the cornea has been observed over a range of incident pulse fluences including the ablation threshold. Reflected pulse shortening begins near the ablation threshold and advances with increasing fluence. The measurement of laser light scattered 30-degrees off specular axis from collagen gel targets indicates that the reflected-pulse distortion is partially a result of scattering. Collagen film transmission studies show an increase in 193-nm light transmission in ablation conditions. These nonlinear attenuation mechanisms may impact significantly on the photoablation process.
RP PETTIT, GH (reprint author), US FDA, CTR DEVICES & RADIOL HLTH, 1901 CHAPMAN AVE, ROCKVILLE, MD 20906 USA.
NR 21
TC 14
Z9 15
U1 0
U2 1
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0003-6935
J9 APPL OPTICS
JI Appl. Optics
PD FEB 1
PY 1993
VL 32
IS 4
BP 488
EP 493
PG 6
WC Optics
SC Optics
GA KJ631
UT WOS:A1993KJ63100018
PM 20802716
ER
PT J
AU NOLAN, MF
HARTSFIELD, JK
WITTERS, DM
WASON, PJ
AF NOLAN, MF
HARTSFIELD, JK
WITTERS, DM
WASON, PJ
TI FAILURE OF TRANSCUTANEOUS ELECTRICAL NERVE-STIMULATION IN THE
CONVENTIONAL AND BURST MODES TO ALTER DIGITAL SKIN TEMPERATURE
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE ELECTROANALGESIA; PAIN CONTROL; TENS; TRANSCUTANEOUS ELECTRICAL NERVE
STIMULATION
ID COLD-INDUCED PAIN; LOW-BACK-PAIN; SYMPATHETIC TONE; ANTIDROMIC
VASODILATATION; DIFFERENT FREQUENCIES; PLASMA EXTRAVASATION; PERIPHERAL
ISCHEMIA; POSTOPERATIVE PAIN; CONTROLLED TRIAL; CLINICAL REPORT
C1 UNIV S FLORIDA,DEPT ANAT & NEUROL,TAMPA,FL 33620.
UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620.
OFF SCI & TECHNOL,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MA.
STIMTECH PROD INC,MARBOROUGH,MA.
RP NOLAN, MF (reprint author), UNIV S FLORIDA,COLL MED,DEPT ANAT,12901 BRUCE B DOWNES BLVD,TAMPA,FL 33612, USA.
NR 55
TC 8
Z9 8
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD FEB
PY 1993
VL 74
IS 2
BP 182
EP 187
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA KL171
UT WOS:A1993KL17100013
PM 8431104
ER
PT J
AU ALAYASH, AI
FRATANTONI, JC
BONAVENTURA, J
CASHON, RE
AF ALAYASH, AI
FRATANTONI, JC
BONAVENTURA, J
CASHON, RE
TI REDOX REACTIVITY OF NITRIC-OXIDE WITH HUMAN METHEMOGLOBIN AND 2
CROSS-LINKED HEMOGLOBIN DERIVATIVES
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
DUKE UNIV,MARINE LAB,BEAUFORT,NC 28516.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A47
EP A47
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51700258
ER
PT J
AU ASZALOS, A
PINE, PS
SZABO, G
AF ASZALOS, A
PINE, PS
SZABO, G
TI ASSOCIATION OF L-SELECTIN (LEU-8, LAM1) WITH THE T-CELL RECEPTOR
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CDER,DIV RES & TESTING,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A384
EP A384
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51702211
ER
PT J
AU BAO, JZ
RHEE, KW
DAVIS, CC
PRASAD, KU
URRY, DW
SWICORD, ML
AF BAO, JZ
RHEE, KW
DAVIS, CC
PRASAD, KU
URRY, DW
SWICORD, ML
TI DIELECTRIC-DISPERSION OF WATER-POLYPENTAPEPTIDE SYSTEM IN THE GHZ RANGE
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CDRH,ROCKVILLE,MD 20857.
UNIV MARYLAND,DEPT ELECT ENGN,COLL PK,MD 20742.
UNIV ALABAMA,MOLEC BIOPHYS LAB,BIRMINGHAM,AL 35294.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A127
EP A127
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51700724
ER
PT J
AU HIRSHFIELD, KM
TOPTYGIN, D
PACKARD, BZ
BRAND, L
AF HIRSHFIELD, KM
TOPTYGIN, D
PACKARD, BZ
BRAND, L
TI TIME-RESOLVED FLUORESCENCE MEASUREMENTS OF CALCIUM-CHELATING PROBES -
QUANTITATION OF CATION BINDING
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218.
US FDA,CBER,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A162
EP A162
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51700931
ER
PT J
AU KRAUTHAMER, V
BRYANT, HJ
DAVIS, CC
AF KRAUTHAMER, V
BRYANT, HJ
DAVIS, CC
TI SINGLE-ENDED FIBER OPTIC SYSTEMS FOR RECORDING FROM MYOCARDIUM AND NERVE
AXON
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 USUHS,DEPT PHYS,BETHESDA,MD.
U MD,DEPT ELECT ENGN,COLL PK,MD.
US FDA,DIV PHYS SCI,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A208
EP A208
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51701196
ER
PT J
AU PACKARD, BZ
HARVATH, L
AF PACKARD, BZ
HARVATH, L
TI ONCOIMMUNIN-M (OI-M) INDUCES HUMAN LEUKEMIC-CELL (HL-60) MOTILITY TO
HUMAN C5A
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 CBER,FDA,DCB & DH,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1993
VL 64
IS 2
BP A368
EP A368
PN 2
PG 1
WC Biophysics
SC Biophysics
GA KP517
UT WOS:A1993KP51702115
ER
PT J
AU NAWAZ, MS
FRANKLIN, W
CERNIGLIA, CE
AF NAWAZ, MS
FRANKLIN, W
CERNIGLIA, CE
TI DEGRADATION OF ACRYLAMIDE BY IMMOBILIZED CELLS OF A PSEUDOMONAS SP AND
XANTHOMONAS-MALTOPHILIA
SO CANADIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE ACRYLAMIDE; BIODEGRADATION; IMMOBILIZATION
ID MICROBIAL-DEGRADATION; BIODEGRADATION; ACETONITRILE; PURIFICATION;
METABOLISM; KINETICS; AMIDASE; MONOMER
AB Two bacterial isolates capable of utilizing acrylamide as the sole source of carbon and nitrogen were isolated from herbicide-contaminated soil samples and identified as Pseudomonas sp. and Xanthomonas maltophilia. Batch cultures of Pseudomonas sp. and X. maltophilia completely degraded 62.8 mM acrylamide to acrylic acid and ammonia in 24 and 48 h, respectively. Pseudomonas sp. and X. maltophilia, when immobilized in calcium alginate, markedly increased the rate of degradation of acrylamide over batch cultures. Cells of the isolates immobilized in calcium alginate degraded acrylamide to acrylic acid and ammonia in less than 6 h. Initial metabolism of acrylamide by immobilized cells of Pseudomonas sp. followed by inoculation with nonimmobilized cells after 6 h totally removed acrylamide and its metabolites in 72 h. A similar procedure with X. maltophilia resulted in the total metabolism of acrylamide in 96 h. An inducible, intracellular amidase was responsible for the hydrolysis of acrylamide to acrylic acid and ammonia. The specific activity of Pseudomonas sp. amidase was higher than the specific activity of X. maltophilia amidase.
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 23
TC 40
Z9 40
U1 1
U2 2
PU NATL RESEARCH COUNCIL CANADA
PI OTTAWA
PA RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA
SN 0008-4166
J9 CAN J MICROBIOL
JI Can. J. Microbiol.
PD FEB
PY 1993
VL 39
IS 2
BP 207
EP 212
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Immunology; Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Immunology; Microbiology
GA KR097
UT WOS:A1993KR09700009
PM 8467421
ER
PT J
AU TOYOKUNI, S
SAGRIPANTI, JL
AF TOYOKUNI, S
SAGRIPANTI, JL
TI DNA SINGLE-STRAND AND DOUBLE-STRAND BREAKS PRODUCED BY FERRIC
NITRILOTRIACETATE IN RELATION TO RENAL TUBULAR CARCINOGENESIS
SO CARCINOGENESIS
LA English
DT Article
ID LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; CELL CARCINOMA; FE-NTA; IRON;
NEPHROTOXICITY; DAMAGE; ACID; TRANSFORMATION; RESTRICTION
AB Fe(III) bound to a chelator, nitrilotriacetate (NTA), has been reported to induce a high frequency of adenocarcinoma localized to the proximal tubules of the kidney in rodents. In order to examine possible mechanisms for the carcinogenic activity, we investigated the in vitro production of single- and double-strand breaks in DNA mediated by iron alone or Fe-NTA chelate using supercoiled plasmid pZ189. Neither Fe(III) nor NTA alone broke DNA. Fe(III) plus NTA together mediated the efficient oxidative production of DNA single- and double-strand breaks in the presence of reducing agents (ascorbate much greater than H2O2 > CYSteine). The Fe(III):NTA ratio (1:4) that was found to be optimal for DNA strand breakage was similar to the ratio that produced adenocarcinomas in rodents. Maximal Fe-NTA-mediated DNA damage in vitro was induced under conditions of neutral pH, low ionic strength, presence of reducing agent and absence of albumin. These conditions are present exclusively in the cortical proximal tubules of the kidney, the only location where toxicity and carcinogenicity of Fe-NTA has been observed. Thus, localized DNA damage may explain the anatomic site preferred by Fe-NTA-induced carcinogenesis.
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV LIFE SCI,ROCKVILLE,MD 20857.
RI Toyokuni, Shinya/C-1358-2010
OI Toyokuni, Shinya/0000-0002-5757-1109
NR 33
TC 66
Z9 66
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 1993
VL 14
IS 2
BP 223
EP 227
DI 10.1093/carcin/14.2.223
PG 5
WC Oncology
SC Oncology
GA KM153
UT WOS:A1993KM15300010
PM 8435863
ER
PT J
AU WEST, RW
BARRETT, JC
AF WEST, RW
BARRETT, JC
TI INACTIVATION OF A TUMOR SUPPRESSOR FUNCTION IN IMMORTAL SYRIAN-HAMSTER
CELLS BY N-METHYL-N'-NITRO-N-NITROSOGUANIDINE AND BY
5-AZA-2'-DEOXYCYTIDINE
SO CARCINOGENESIS
LA English
DT Article
ID V-HA-RAS; NEOPLASTIC TRANSFORMATION; EMBRYO CELLS; MUTATIONS; GENES;
CHROMOSOME-5Q21; IDENTIFICATION; PROGRESSION; PROTEIN
AB Clonal lines of immortal Syrian hamster cells were previously isolated that either suppressed (supB+) tumorigenicity in hybrids with a malignant hamster cell line (BP6T) or had lost this suppression ability (supB-). Neither line was tumorigenic or showed anchorage-independent growth in normal growth medium. SupB- cells, but not supB+ cells, grew in agar supplemented with the growth factors EGF. PDGF and insulin (EPI), providing a selective assay for the supB- phenotype. After treatment of supB+ cells with either N-methyl-N'-nitro-N-nitrosoguanidine (10-300 ng/ml) or 5-aza-2'-deoxycytidine (25-250 ng/ml), and an expression period of 4-8 weeks, a dose-dependent increase in altered cells that grew in agar supplemented with EPI was observed. Cell lines derived from colonies in agar showed persistent EPI-stimulated growth in agar, and decreased suppression of growth in agar for hybrids with BP6T cells. Thus, carcinogen-induced loss of the tumor suppressor phenotype has been demonstrated.
C1 NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709.
RP WEST, RW (reprint author), NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079, USA.
NR 27
TC 108
Z9 108
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 1993
VL 14
IS 2
BP 285
EP 289
DI 10.1093/carcin/14.2.285
PG 5
WC Oncology
SC Oncology
GA KM153
UT WOS:A1993KM15300020
PM 7679613
ER
PT J
AU GRAUMLICH, JF
SPYKER, DA
CANTILENA, LR
AF GRAUMLICH, JF
SPYKER, DA
CANTILENA, LR
TI PHARMACOKINETIC MODEL OF VERAPAMIL (SUSTAINED-RELEASE) PROFILE IN TOXIC
OVERDOSE
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 UNIFORMED SERV UNIV HLTH SCI,DIV CLIN PHARMACOL,BETHESDA,MD 20814.
US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 156
EP 156
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900086
ER
PT J
AU HARTER, J
KATZPER, M
AF HARTER, J
KATZPER, M
TI MODELING PAIN AND ITS RESPONSE TO ANALGESICS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 171
EP 171
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900143
ER
PT J
AU WIDMARK, RM
STEIN, R
SMITH, R
AF WIDMARK, RM
STEIN, R
SMITH, R
TI AN EMPIRICAL-APPROACH IN ESTIMATING ONSET AND DURATION OF ANALGESIC
EFFECT
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 CIBA GEIGY CORP,SUMMIT,NJ 07901.
US FDA,PILOT DRUG EVALUAT STAFF,ROCKVILLE,MD 20857.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 171
EP 171
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900145
ER
PT J
AU WRIGHT, C
KAIKO, R
BASHAW, D
AF WRIGHT, C
KAIKO, R
BASHAW, D
TI USE OF NALTREXONE IN OPIOID PK STUDIES
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
PURDUE FREDERICK CO,NORWALK,CT.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 185
EP 185
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900200
ER
PT J
AU BAWEJA, R
LONGLEY, R
JOHNSON, S
MALINOWSKI, HJ
LEONARD, EM
TEMPLE, RJ
LUDDEN, TM
BURKE, G
AF BAWEJA, R
LONGLEY, R
JOHNSON, S
MALINOWSKI, HJ
LEONARD, EM
TEMPLE, RJ
LUDDEN, TM
BURKE, G
TI ASSESSMENT OF THE PHARMACOKINETIC PHARMACODYNAMIC (PK PD) PERFORMANCE OF
CONTROLLED RELEASE DOSAGE FORMS (CRDF) INVOLVING PARTIAL AUCS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 186
EP 186
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900202
ER
PT J
AU SALE, M
LAVELLE, J
OLEARY, CR
JAMES, DS
SALETAN, S
WOOSLEY, RL
TRAPNELL, CB
AF SALE, M
LAVELLE, J
OLEARY, CR
JAMES, DS
SALETAN, S
WOOSLEY, RL
TRAPNELL, CB
TI A COMPARTMENTAL MODEL FOR LIPOSOMAL GENTAMICIN
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 GEORGETOWN UNIV,WASHINGTON,DC 20057.
US FDA,CDER,ROCKVILLE,MD 20857.
LIPOSOME CO,PRINCETON,NJ.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 186
EP 186
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900204
ER
PT J
AU BASHAW, ED
LIEBERMAN, R
AF BASHAW, ED
LIEBERMAN, R
TI OPTIMAL SAMPLING THEORY VS GEOMETRIC SAMPLING-A PROSPECTIVE-STUDY
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 187
EP 187
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900208
ER
PT J
AU TRAPNELL, CB
LAVELLE, JP
OLEARY, CR
JAMES, DS
LI, R
COLBURN, D
WOOSLEY, RL
NARANG, PK
AF TRAPNELL, CB
LAVELLE, JP
OLEARY, CR
JAMES, DS
LI, R
COLBURN, D
WOOSLEY, RL
NARANG, PK
TI RIFABUTIN DOES NOT ALTER FLUCONAZOLE PHARMACOKINETICS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 GEORGETOWN UNIV,WASHINGTON,DC 20057.
US FDA,CDER,ROCKVILLE,MD 20857.
ADRIA LABS INC,COLUMBUS,OH.
NR 0
TC 11
Z9 11
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 196
EP 196
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900245
ER
PT J
AU SPYKER, D
HYDE, J
SCALLY, D
STEIN, R
BASHAW, D
LIU, A
JOH, T
DAMASK, M
AF SPYKER, D
HYDE, J
SCALLY, D
STEIN, R
BASHAW, D
LIU, A
JOH, T
DAMASK, M
TI RESPONSE-SURFACE FOR DESFLURANE MINIMUM ALVEOLAR CONCENTRATION (MAC) FOR
PATIENT AGE AND CONCOMITANT NITROUS-OXIDE
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 FDA,ROCKVILLE,MD.
ANAQUEST,LIBERTY CORNER,NJ.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 206
EP 206
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900281
ER
PT J
AU BASHAW, ED
WIDMARK, RM
YACIW, CA
HARTER, JG
AF BASHAW, ED
WIDMARK, RM
YACIW, CA
HARTER, JG
TI RATE OF ABSORPTION EFFECTS THE ONSET OF PAIN RELIEF
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,PILOT DRUG EVALUAT STAFF,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 207
EP 207
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900287
ER
PT J
AU AJAYI, F
BREWER, T
GREENFIELD, R
FLECKENSTEIN, L
AF AJAYI, F
BREWER, T
GREENFIELD, R
FLECKENSTEIN, L
TI ABSOLUTE BIOAVAILABILITY OF HALOFANTRINE-HCL - EFFECT OF GASTRIC PH
ALTERATIONS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 WRAIR,WASHINGTON,DC.
US FDA,ROCKVILLE,MD 20857.
UNIV IOWA,COLL PHARM,IOWA CITY,IA 52242.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 208
EP 208
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900291
ER
PT J
AU YASUDA, SU
WELLSTEIN, A
BARBEY, JT
HEWITTMEULMANN, J
BURKE, G
JOHNSON, S
WOOSLEY, RL
AF YASUDA, SU
WELLSTEIN, A
BARBEY, JT
HEWITTMEULMANN, J
BURKE, G
JOHNSON, S
WOOSLEY, RL
TI CHLORPHENIRAMINE ANTAGONIST ACTIVITY IN PLASMA SAMPLES
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 GEORGETOWN UNIV,MED CTR,DIV CLIN PHARMACOL,WASHINGTON,DC 20007.
US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 210
EP 210
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900300
ER
PT J
AU HALE, VG
LUDDEN, T
AF HALE, VG
LUDDEN, T
TI DEMOGRAPHIC-ANALYSIS OF PHARMACOKINETICS (PK) STUDIES SUBMITTED FOR A
NEW DRUG
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,DIV BIOPHARMACEUT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 213
EP 213
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900309
ER
PT J
AU ELTAHTAWY, A
JACKSON, A
LUDDEN, T
AF ELTAHTAWY, A
JACKSON, A
LUDDEN, T
TI COMPARISON OF SINGLE (SD) AND MULTIPLE DOSE (MD) PHARMACOKINETICS USING
CLINICAL BIOEQUIVALENCE DATA AND MONTE-CARLO SIMULATIONS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CTR DRUG EVALUAT & RES,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 216
EP 216
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900322
ER
PT J
AU ETTE, E
KELMAN, A
HOWIE, C
WHITING, B
AF ETTE, E
KELMAN, A
HOWIE, C
WHITING, B
TI INFLUENCE OF INTER-ANIMAL VARIABILITY ON THE ESTIMATION OF POPULATION
PHARMACOKINETIC (PK) PARAMETERS IN PRECLINICAL STUDIES
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
WESTERN INFIRM & ASSOCIATED HOSP,GLASGOW G11 6NT,SCOTLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 216
EP 216
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900321
ER
PT J
AU SPYKER, D
LUDDEN, T
BASHAW, D
PLASSE, T
BASS, J
AF SPYKER, D
LUDDEN, T
BASHAW, D
PLASSE, T
BASS, J
TI PHARMACODYNAMICS OF DRONABINOL-INDUCED EFFECTS ON MOOD, APPETITE, AND
WEIGHT IN PATIENTS WITH AIDS-RELATED WEIGHT-LOSS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
UNIMED INC,SOMERVILLE,NJ.
ROXANE LAB INC,COLUMBUS,OH.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 216
EP 216
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900323
ER
PT J
AU WRIGHT, C
SPYKER, D
HARTER, JG
AF WRIGHT, C
SPYKER, D
HARTER, JG
TI RECOVERY FROM MIDAZOLAM SEDATION
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 218
EP 218
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900329
ER
PT J
AU KATZ, LM
STEIN, RA
AF KATZ, LM
STEIN, RA
TI ANALYSIS OF OTC DRUG USAGE STUDIES
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1993
VL 53
IS 2
BP 221
EP 221
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KP269
UT WOS:A1993KP26900342
ER
PT J
AU PIPKIN, JL
ANSON, JF
HINSON, WG
LYNCOOK, LE
SCHOL, HM
BURNS, ER
FEUERS, RJ
CASCIANO, DA
SHEEHAN, DM
AF PIPKIN, JL
ANSON, JF
HINSON, WG
LYNCOOK, LE
SCHOL, HM
BURNS, ER
FEUERS, RJ
CASCIANO, DA
SHEEHAN, DM
TI COMPARATIVE-STUDIES OF SYNTHESIS, PHOSPHORYLATION, DNA-BINDING AND
PROTEOLYTIC CHARACTERISTICS OF A NOVEL PROTEIN DURING PHASES OF THE
MOUSE SPLEEN-CELL CYCLE
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
BIOLOGY
LA English
DT Article
ID HEAT-SHOCK PROTEINS; STRESS PROTEINS; POLYACRYLAMIDE GELS; DROSOPHILA
CELLS; SODIUM ARSENITE; SALIVARY-GLANDS; NUCLEAR-PROTEIN; INDUCTION;
ISOPROTERENOL; ELECTROPHORESIS
AB 1. Cultured mouse spleen cells were exposed to the mitogen Concanavalin A followed by isoproterenol, and nuclei were electronically sorted from seven partitions of the cell cycle.
2. Several nuclear proteins, including stress proteins, which were cell-cycle-stage specific, were elicited by isoproterenol as determined by micro-electrophoresis and fluorography.
3. Two novel S-phase proteins (X0 and X') demonstrated differing synthesis and phosphorylation patterns during the cell-cycle phases.
4. X' showed DNA binding characteristics and proteolytic properties (hydrolyzing X0 or beta-galactosidase); both proteins were cell-cycle regulated.
RP PIPKIN, JL (reprint author), US FDA,DEPT HLTH & HUMAN SERV,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 50
TC 3
Z9 3
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0305-0491
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD FEB
PY 1993
VL 104
IS 2
BP 361
EP 370
DI 10.1016/0305-0491(93)90380-N
PG 10
WC Biochemistry & Molecular Biology; Zoology
SC Biochemistry & Molecular Biology; Zoology
GA KN062
UT WOS:A1993KN06200021
PM 8462285
ER
PT J
AU MURGO, AJ
WEINBERGER, BB
AF MURGO, AJ
WEINBERGER, BB
TI PHARMACOLOGICAL BONE-MARROW PURGING IN AUTOLOGOUS TRANSPLANTATION -
FOCUS ON THE CYCLOPHOSPHAMIDE DERIVATIVES
SO CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
LA English
DT Review
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC
PROGENITOR CELLS; ACUTE NONLYMPHOCYTIC LEUKEMIA; HIGH-DOSE CHEMOTHERAPY;
ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; COLONY-FORMING
CELLS; 4-HYDROPEROXYCYCLOPHOSPHAMIDE PURGED MARROWS; ALDEHYDE
DEHYDROGENASE INHIBITORS
RP MURGO, AJ (reprint author), US FDA,CTR DRUG EVALUAT & RES,HFD-150,ROCKVILLE,MD 20857, USA.
NR 158
TC 8
Z9 8
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 1040-8428
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD FEB
PY 1993
VL 14
IS 1
BP 41
EP 60
DI 10.1016/1040-8428(93)90005-O
PG 20
WC Oncology; Hematology
SC Oncology; Hematology
GA LD883
UT WOS:A1993LD88300004
PM 8373540
ER
PT J
AU ALTEKRUSE, S
KOEHLER, J
HICKMANBRENNER, F
TAUXE, RV
FERRIS, K
AF ALTEKRUSE, S
KOEHLER, J
HICKMANBRENNER, F
TAUXE, RV
FERRIS, K
TI A COMPARISON OF SALMONELLA-ENTERITIDIS PHAGE TYPES FROM EGG-ASSOCIATED
OUTBREAKS AND IMPLICATED LAYING FLOCKS
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID UNITED-STATES; INFECTED HENS
AB Infections due to Salmonella enteritidis are increasing worldwide. In the United States, between 1985 and 1989, 78 % of the S. enteritidis outbreaks in which a food vehicle was identified implicated a food containing raw or lightly cooked shell eggs.
Under a US Department of Agriculture regulation published in 1990, eggs implicated in human food-borne S. enteritidis outbreaks were traced back to the source flock. The flock environment and the internal organs of a sample of hens were tested for S. enteritidis. We compared the S. enteritidis phage types of isolates from 18 human, egg-associated outbreaks and the 15 flocks implicated through traceback of these outbreaks. The predominant human outbreak phage type was recovered from the environment in 100 % of implicated flocks and from the internal organs of hens in 88 % of implicated flocks we tested. The results support the use of phage typing as a tool to identify flocks involved in human S. enteritidis outbreaks.
C1 USDA,AMES,IA 50010.
CTR DIS CONTROL,ATLANTA,GA 30333.
RP ALTEKRUSE, S (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,HFF 265,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 19
TC 69
Z9 69
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD FEB
PY 1993
VL 110
IS 1
BP 17
EP 22
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA KL759
UT WOS:A1993KL75900003
PM 8432319
ER
PT J
AU HILL, RN
CHAMBERS, WA
GREEN, S
GUPTA, KC
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF HILL, RN
CHAMBERS, WA
GREEN, S
GUPTA, KC
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI WORKSHOP ON UPDATING EYE IRRITATION TEST METHODS - PROPOSALS FOR
REGULATORY CONSENSUS
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Editorial Material
AB Multiple procedures for the conduct and evaluation of eye irritation testing are currently used in the USA and worldwide. An international workshop on the eye irritation test in rabbits was held to identify different testing and evaluation practices, develop proposals for change that minimize differences in these methods and determine areas of consensus in the scientific community. These efforts are intended to culminate in the development of a more uniform US position and serve as a point of discussion for international harmonization. The following seven papers delineate the proposals that were presented at the workshop. A summary of the presentations and discussion as well as future directions is also presented.
C1 US FDA,WASHINGTON,DC 20204.
US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
RP HILL, RN (reprint author), US EPA,401 M ST SW,WASHINGTON,DC 20460, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 79
EP 79
DI 10.1016/0278-6915(93)90117-H
PG 1
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300001
ER
PT J
AU GREEN, S
CHAMBERS, WA
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF GREEN, S
CHAMBERS, WA
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI CRITERIA FOR INVITRO ALTERNATIVES FOR THE EYE IRRITATION TEST
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID AGAROSE DIFFUSION METHOD; OCULAR IRRITANCY; COSMETIC PRODUCTS
AB A proposal encompassing considerations and criteria for the development of in vitro alternatives to the eye irritation test has been developed and is presented here. Two factors need to be considered initially in developing an alternative test. The first is to determine whether the alternative assay is to be used as a screen or as a replacement for the eye irritation test. Less stringent acceptance criteria are required for an assay used as a screen than for that used as a replacement test. A screen is a preliminary test for the assessment of eye irritation. It is used for making preliminary decisions or establishing the direction for further testing. Screens answer fewer and less complex questions than a replacement test would, since the results from screens are usually confirmed by more definitive testing. A replacement test, however, must provide the same answers as in vivo methods for the assessment of eye irritation and must provide data for making a definitive toxicological assessment of eye irritation. The second factor to be considered is knowledge of the in vivo assay intended to be replaced. This knowledge should include the procedural aspects of the test and the regulatory information it provides. The following may be considered as criteria for in vitro tests used as screens or as replacements for the eye irritation test in rabbits: rationale (there should be a clear statement regarding the rationale for the use of a particular test in relation to the availability of other tests); relevance (the in vitro endpoint should have biological or physiological relevance to the effect to be detected in vivo): and validational (intralaboratory as well as interlaboratory validation must be conducted).
C1 US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
US EPA,WASHINGTON,DC 20460.
RP GREEN, S (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 18
TC 21
Z9 21
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 81
EP 85
DI 10.1016/0278-6915(93)90118-I
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300002
PM 8449460
ER
PT J
AU HURLEY, PM
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF HURLEY, PM
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI SCREENING PROCEDURES FOR EYE IRRITATION
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID OCULAR IRRITANCY
AB Screens aid in identifying some severe irritants or corrosives and eliminating them from consideration for in vivo eye irritation testing. Products may be evaluated for ocular irritation potential in a stepwise progression as follows: (1) products at pH extremes of 2 or below or of 11.5 or above may be considered to be ocular irritants; (2) based on chemical structure-activity considerations, some products may be judged to have ocular irritation potential; (3) validated and accepted in vitro systems may possibly be used as a screen in the future; (4) when a test material demonstrates severe acute dermal toxicity (lethality at less-than-or-equal-to 200 mg/kg body weight), further testing for either dermal or ocular irritation may not need to be undertaken; (5) if a substance shows a primary dermal irritation index of 5 or above, it may be considered to be an ocular irritant; (6) materials that are not removed from consideration based on these proposed screens may then be considered for testing for ocular irritation in rabbits under accepted procedures. In a survey given to participants in the workshop, a high percentage believed that screens should be used. However, opinions on the use of the individual screens varied between the different interested groups attending, with the possible future use of in vitro screens for specific product lines having the highest percentage of agreement (57-100%).
C1 US FDA,WASHINGTON,DC 20204.
US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
RP HURLEY, PM (reprint author), US EPA,401 M ST SW,WASHINGTON,DC 20460, USA.
NR 23
TC 7
Z9 7
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 87
EP 94
DI 10.1016/0278-6915(93)90119-J
PG 8
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300003
PM 8449461
ER
PT J
AU SEABAUGH, VM
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SPRINGER, JA
WILCOX, NL
AF SEABAUGH, VM
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SPRINGER, JA
WILCOX, NL
TI USE OF OPHTHALMIC TOPICAL ANESTHETICS
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID PRESERVATIVES
AB Pretreatment of the eyes of rabbits with a topical anaesthetic can be viewed as a refinement of the test for eye irritation. It reduces pain at the time of test-material administration, decreases animal distress and permits easier application of the test agent to the eye. In some cases, however, use of an anaesthetic either alone or in combination with the test substance may alter ocular responses or provide little benefit. Although anaesthetic pretreatment may result in decreased pain at the time of test-compound administration, it does not affect possible pain after the effects of the anaesthetic have dissipated. Some anaesthetics are themselves irritating to eyes. In addition, anaesthetics reduce blinking and tearing, thereby maintaining the test-material concentration at the surface of the eye longer. Corneal permeability may also be increased with pretreatment use of an anaesthetic, and may bring the test agent into contact with more structures of the eye. Some anaesthetics delay healing after ocular injury. All of these varied effects may result in increased irritation to the eye. Overall, pretreatment with anaesthetics has usually resulted in a tendency for slightly higher irritation scores; eye irritancy classification is usually unaffected.
C1 US FDA,WASHINGTON,DC 20204.
US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
RP SEABAUGH, VM (reprint author), US EPA,401 M ST SW,WASHINGTON,DC 20460, USA.
NR 28
TC 4
Z9 4
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 95
EP 98
DI 10.1016/0278-6915(93)90120-N
PG 4
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300004
PM 8449462
ER
PT J
AU LAMBERT, LA
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF LAMBERT, LA
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI THE USE OF LOW-VOLUME DOSING IN THE EYE IRRITATION TEST
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID OCULAR IRRITANCY; RABBIT EYE; DOSAGE
AB The Draize rabbit eye test was developed to provide a method for assessing the irritation potential of materials that might come in contact with human eyes. The method involves the instillation of 0.1 ml of a test liquid (100 mg solid) into the conjunctival sac of an animal's eye. A refinement of the Draize test is the low-volume eye test in which 0.01 ml of a substance is placed directly on the cornea of the eye. Studies indicate that the low-volume method provides a better correlation to human eye irritation experience for some substances. The Interagency Regulatory Alternatives Group (IRAG) proposes that the low-volume eye test can be used to substantiate the irritancy of suspect severe ocular irritants that have not been eliminated by various pre-eye test 'screens'. A substance testing positive by the low-volume method can be classified as an irritant; one that tests negative will require further testing by the use of the 0.1-ml volume procedure. For all other definitive testing, the Draize test (0.1 ml) should be used. Results from a questionnaire distributed at the IRAG workshop showed that many workshop participants thought that the low-volume test should be used as an eye irritation screening procedure.
C1 US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
US EPA,WASHINGTON,DC 20460.
RP LAMBERT, LA (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 16
TC 16
Z9 16
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 99
EP 103
DI 10.1016/0278-6915(93)90121-E
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300005
PM 8449463
ER
PT J
AU SPRINGER, JA
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
WILCOX, NL
AF SPRINGER, JA
CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
WILCOX, NL
TI NUMBER OF ANIMALS FOR SEQUENTIAL TESTING
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID IRRITATION
AB US regulatory agencies have used six animals in eye irritation tests. Analyses of eye irritation tests on pesticides (n = 48), consumer products and cosmetics (n = 53), Marzulli and Ruggles database (n = 139), and cleaning products and ingredients (n = 30) have greatly extended previous investigations of the merit of reducing animal sample size in the eye test. Given the existing scoring system for positive animal responses (corneal opacity greater-than-or-equal-to 1, iritis greater-than-or-equal-to 1, conjunctival redness greater-than-or-equal-to 2 and conjunctival chemosis greater-than-or-equal-to 2), the accuracy of the classification systems currently used by these agencies was determined. The US Consumer Product Safety Commission, US Food and Drug Administration, and US Occupational Safety and Health Administration use a classification system by which a substance is designated as an irritant when at least four of six animals give a positive response. This decision rule leads to a very high accuracy of at least 99% with essentially no false positive and false negative judgments. In contrast, the system used by the US Environmental Protection Agency pesticide program, in which only one or more of six treated animals result in an irritant decision, has an accuracy of only 50-80% with very high false positive rates. Analyses indicated that test sample size could be reduced to three and still preserve very good accuracy, whereas two-animal and one-animal tests did not give satisfactory responses. A two-stage test, in which two animals are tested and evaluated in the first stage before the need for testing one more animal in the second stage is determined, also demonstrated good operating characteristics. Both the one-stage/three-animal test and the two-stage test deserve consideration.
C1 US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
US EPA,WASHINGTON,DC 20460.
RP SPRINGER, JA (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 8
TC 8
Z9 9
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 105
EP 109
DI 10.1016/0278-6915(93)90122-F
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300006
PM 8449454
ER
PT J
AU CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HUNTLEY, K
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF CHAMBERS, WA
GREEN, S
GUPTA, KC
HILL, RN
HUNTLEY, K
HURLEY, PM
LAMBERT, LA
LEE, CC
LEE, JK
LIU, PT
LOWTHER, DK
ROBERTS, CD
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI SCORING FOR EYE IRRITATION TESTS
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
AB Scoring of the rabbit eye test and the resulting evaluation and classification should provide useful information about the likelihood that a test material may cause injury on contact with the human eye. When an animal test is necessary, a rabbit eye test based on the following characteristics is proposed for deriving the maximum information from the fewest animals. The ocular effects of interest should include corneal opacity, iritis and conjunctival redness. Animals should be scored for each ocular effect at 24, 48 and 72 hr after the test substance is administered. If an animal is negative at all three scoring times, it can be removed from the test at 72 hr. If it shows a positive effect at a scoring time but the lesion clears at 72 hr, it can be removed at 72 hr. If it shows a positive effect that does not clear at 72 hr, it should be scored again on day 7 when the test ends. However, if an animal shows severe effects at one or more scoring times, it can be removed from the test at 72 hr. An animal is positive if any one of the following criteria is observed at 24, 48 or 72 hr: corneal opacity of 1 or above, iritis of 1 or above, or conjunctival redness of 2 or above. Severe ocular effects (noted at 24, 48 or 72 hr) that may endanger sight deserve special recognition for the classification of chemicals and include corneal opacity of 3 or above, or iritis of 2. This proposal is consistent with the opinions of the majority of respondents who attended the Workshop on Updating Eye Irritation Test Methods, Proposals for Regulatory Consensus. The most notable exception was the suggestion by respondents to add conjunctival chemosis as one of the scoring parameters.
C1 US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD 20207.
US EPA,WASHINGTON,DC 20460.
RP CHAMBERS, WA (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 6
TC 10
Z9 10
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 111
EP 115
DI 10.1016/0278-6915(93)90123-G
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300007
PM 8449455
ER
PT J
AU GUPTA, KC
CHAMBERS, WA
GREEN, S
HILL, RN
HURLEY, PM
LAMBERT, LA
LIU, PT
LOWTHER, DK
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
AF GUPTA, KC
CHAMBERS, WA
GREEN, S
HILL, RN
HURLEY, PM
LAMBERT, LA
LIU, PT
LOWTHER, DK
SEABAUGH, VM
SPRINGER, JA
WILCOX, NL
TI AN EYE IRRITATION TEST PROTOCOL AND AN EVALUATION AND
CLASSIFICATION-SYSTEM
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
AB An in vivo test protocol and an evaluation and classification system for the determination of eye irritation potential of chemicals and mixtures (substances) is proposed. The protocol uses two or three rabbits and reduces distress in test animals. The test substances are classified as non-irritant, irritant or severe irritant to meet regulatory needs. They may be classified on the basis of past experience with similar compounds or mixtures. Screens such as structure-activity relationships, pH extremes, validated and accepted in vitro tests, severe dermal irritation (primary dermal irritation index greater-than-or-equal-to 5) or severe dermal toxicity (lethality at < 200 mg/kg body weight) should be used to classify irritant or severe irritant materials when one or more of the screens can provide convincing evidence. For suspected severe irritant materials, the proposed in vivo test permits the use of one rabbit and instillation of 0.01 ml (0.01 g) of the test material into the cornea. Materials that are not classified irritant or severe irritant by screens or severe irritant by one rabbit test are tested in two or three rabbits; 0.1 ml (0.1 g) is instilled into the conjunctival sac. The responses (corneal opacity, iritis and conjunctival redness) are scored according to the modified Draize scoring system at 24, 48 and 72 hr and 7 days post-instillation. A rabbit is considered positive when corneal opacity of 1 or above, iritis of 1 or above or conjunctival redness of 2 or above is present at 24, 48 or 72 hr post-instillation. The material is classified as a severe irritant when the rabbit in the one-animal test or two or more rabbits in the standard test have responses of corneal opacity of 3 or above and iritis of 2 at 24, 48 or 72 hr, or positive responses on day 7 after instillation. The material is classified as an eye irritant when two or more rabbits are positive but the responses are not severe and they clear 7 days after instillation. The material is classified as a non-irritant when no more than one rabbit is positive.
The opinions expressed in this article are those of the authors and do not necessarily reflect the views of US Federal agencies.
C1 US FDA,WASHINGTON,DC 20204.
US EPA,WASHINGTON,DC 20460.
RP GUPTA, KC (reprint author), US CONSUMER PROD SAFETY COMMISS,5401 WESTBARD AVE,BETHESDA,MD 20207, USA.
NR 7
TC 8
Z9 9
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1993
VL 31
IS 2
BP 117
EP 121
DI 10.1016/0278-6915(93)90124-H
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA KR863
UT WOS:A1993KR86300008
PM 8449456
ER
PT J
AU LLORENS, J
CROFTON, KM
TILSON, HA
ALI, SF
MUNDY, WR
AF LLORENS, J
CROFTON, KM
TILSON, HA
ALI, SF
MUNDY, WR
TI CHARACTERIZATION OF DISULFOTON-INDUCED BEHAVIORAL AND NEUROCHEMICAL
EFFECTS FOLLOWING REPEATED EXPOSURE
SO FUNDAMENTAL AND APPLIED TOXICOLOGY
LA English
DT Article
ID CHRONIC CHOLINESTERASE INHIBITION; MUSCARINIC RECEPTORS; RAT-BRAIN;
TOLERANCE; BINDING; DIISOPROPYLFLUOROPHOSPHATE; MICE
C1 US EPA,HLTH EFFECTS RES LAB,DIV NEUROTOXICOL,RES TRIANGLE PK,NC 27711.
NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
RI Llorens, Jordi/A-6959-2008; Crofton, Kevin/J-4798-2015
OI Llorens, Jordi/0000-0002-3894-9401; Crofton, Kevin/0000-0003-1749-9971
NR 24
TC 23
Z9 23
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0272-0590
J9 FUND APPL TOXICOL
JI Fundam. Appl. Toxicol.
PD FEB
PY 1993
VL 20
IS 2
BP 163
EP 169
DI 10.1006/faat.1993.1022
PG 7
WC Toxicology
SC Toxicology
GA KM857
UT WOS:A1993KM85700005
PM 8449387
ER
PT J
AU TARAZI, EM
HARTER, JG
ZIMMERMAN, HJ
ISHAK, KG
EATON, RA
AF TARAZI, EM
HARTER, JG
ZIMMERMAN, HJ
ISHAK, KG
EATON, RA
TI SULINDAC-ASSOCIATED HEPATIC-INJURY - ANALYSIS OF 91 CASES REPORTED TO
THE FOOD AND DRUG ADMINISTRATION
SO GASTROENTEROLOGY
LA English
DT Article
ID HEPATOTOXICITY; PANCREATITIS; DICLOFENAC; CLINORIL; THERAPY
C1 US FDA,CTR DRUG EVALUAT & RES,PILOT DRUG EVALUAT STAFF,HFD-007,ROCKVILLE,MD 20857.
ARMED FORCES INST PATHOL,WASHINGTON,DC 20306.
NR 32
TC 46
Z9 46
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 1993
VL 104
IS 2
BP 569
EP 574
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA KM861
UT WOS:A1993KM86100030
PM 8425699
ER
PT J
AU CIARDIELLO, F
PEPE, S
BIANCO, C
BALDASSARRE, G
RUGGIERO, A
BIANCO, C
SELVAM, MP
BIANCO, AR
TORTORA, G
AF CIARDIELLO, F
PEPE, S
BIANCO, C
BALDASSARRE, G
RUGGIERO, A
BIANCO, C
SELVAM, MP
BIANCO, AR
TORTORA, G
TI DOWN-REGULATION OF RI-ALPHA SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE
INDUCES GROWTH-INHIBITION OF HUMAN MAMMARY EPITHELIAL-CELLS TRANSFORMED
BY C-HA-RAS AND C-ERBB-2 PROTOONCOGENES
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
ID AMINO-ACID SEQUENCE; HUMAN-BREAST; MOLECULAR-CLONING; NODAL STATUS;
HUMAN TESTIS; EXPRESSION; CANCER; GENE; DIFFERENTIATION; MALIGNANCY
AB MCF-10A is a spontaneously immortalized, non-transformed human mammary epithelial cell line. We have recently obtained MCF-10A clones (MCF-10A HE cells) that are transformed following over-expression of both a human point-mutated c-Ha-ras and the c-erbB-2 proto-oncogenes. Two isoforms of the cAMP-dependent protein kinase (cAK) have been described in mammalian cells. Enhanced levels of type-I c-AK (cAKI) are generally found in tumor cells. To determine whether inhibition of cAKI expression may interfere with ras and erbB-2 oncogene-induced transformation of human mammary epithelial cells, we have tested the effects of 2 agents that specifically down-regulate cAKI, such as 8-chloro-cAMP and an anti-sense oligodeoxynucleotide targeted against the RIalpha regulatory subunit of cAKI on MCF-10A HE cells. Treatment of MCF-10A HE cells with 8-chloro-cAMP induces a dose-dependent growth inhibition under both monolayer and soft-agar growth conditions, that is correlated with an accumulation of MCF-10A HE cells in G0/G1 phases of the cell cycle and a reduction of the number of cells in S phase. In contrast, 8-chloro-cAMP has no effect on MCF-10A cell growth. Furthermore, 8-chloro-cAMP treatment of MCF-10A HE cells induces a 4- to 6-fold reduction in p185erbB-2 expression and brings p21 ras expression to levels comparable to those found in MCF-10A cells. Treatment of MCF-10A HE cells with an RIalpha anti-sense oligodeoxynucleotide determines a comparable inhibition of both anchorage-dependent and anchorage-independent cell growth. Our results suggest that cAKI may act as a mediator of ras and erbB-2 oncogene action in human breast cells and that interference with cAKI action provides a potential tool for inhibiting the growth-promoting effects of these oncogenes.
C1 US FDA,BETHESDA,MD 20892.
RP CIARDIELLO, F (reprint author), UNIV NAPLES,FAC MED & CHIRURG 2,CATTEDRA ONCOL MED,VIA S PANSINI 5,I-80131 NAPLES,ITALY.
RI Baldassarre, Gustavo/K-1350-2016
OI Baldassarre, Gustavo/0000-0002-9750-8825
NR 24
TC 52
Z9 53
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 1
PY 1993
VL 53
IS 3
BP 438
EP 443
DI 10.1002/ijc.2910530315
PG 6
WC Oncology
SC Oncology
GA KK633
UT WOS:A1993KK63300014
PM 8094073
ER
PT J
AU JOHNSON, BE
PARKER, R
TSAI, CM
BALTZ, J
MILLER, MJ
SHOEMAKER, R
PHELPS, R
BASTIAN, A
STOCKER, J
PHARES, J
MULSHINE, JL
GAZDAR, AF
IHDE, DC
AF JOHNSON, BE
PARKER, R
TSAI, CM
BALTZ, J
MILLER, MJ
SHOEMAKER, R
PHELPS, R
BASTIAN, A
STOCKER, J
PHARES, J
MULSHINE, JL
GAZDAR, AF
IHDE, DC
TI PHASE-I TRIAL OF DIHYDROLENPERONE IN LUNG-CANCER PATIENTS - A NOVEL
COMPOUND WITH INVITRO ACTIVITY AGAINST LUNG-CANCER
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE DIHYDROLENPERONE; DRUG EVALUATION; DRUG SCREENING ASSAYS; ANTITUMOR;
CARCINOMA; NONSMALL CELL LUNG CARCINOMA; OAT CELL
ID TUMOR-CELL-LINES; COLORIMETRIC ASSAY; GROWTH; FEASIBILITY; SENSITIVITY;
SURVIVAL
AB Antitumor activity of the butyrophenone dihydrolenperone in non-small cell lung cancer was initially suggested by in vitro screening against tumor cells derived from fresh surgical samples using the human tumor colony-forming assay. We have completed a directed phase I trial in patients with lung cancer. Thirty-two patients with lung cancer have completed 25 courses of therapy at doses of 10 to 60 mg/square meter orally on a twice daily schedule. Twenty-three men and 9 women with a median age of 55 (range 24-69) were entered. Twenty-four were performance status 0 or 1 and 8 were 2. The maximum tolerated dose was 50 mg/square meter orally twice daily and the dose limiting toxicity was somnolence. Of the 32 patients, 18 developed symptomatic hypotension (grade 1 or 2). There was no significant hematologic, renal, or hepatic toxicity. In vitro drug testing using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (thiazolyl blue)] assay confirmed 50% inhibition of non-small cell and small cell lung cancer cell line growth at 70-450 micromolar concentrations. Plasma dihydrolenperone levels were at least 75-fold less than levels at which in vitro activity was observed. We conclude: 1) the maximum tolerated dose in our study is 50 mg/square meter orally twice daily, 2) the dose-limiting side effect of dihydrolenperone is somnolence, and 3) the concentrations of dihydrolenperone observed in plasma are significantly lower than those associated with in vitro activity.
C1 NCI,NAVY MED ONCOL BRANCH,BETHESDA,MD 20889.
NATL NAVAL CTR,BETHESDA,MD 20889.
US FDA,ROCKVILLE,MD 20850.
NCI,DEV THERAPEUT PROGRAM,FREDERICK,MD 21701.
UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20889.
NR 16
TC 3
Z9 3
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0167-6997
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD FEB
PY 1993
VL 11
IS 1
BP 29
EP 37
DI 10.1007/BF00873907
PG 9
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA LF647
UT WOS:A1993LF64700004
PM 8349433
ER
PT J
AU DALLAS, HL
HITCHINS, AD
AF DALLAS, HL
HITCHINS, AD
TI ANTAGONISM OF BACTERIAL COMPETITORS TOWARD LISTERIA-MONOCYTOGENES IN
ENRICHMENT CULTURE
SO JOURNAL OF FOOD SAFETY
LA English
DT Article
ID PEDIOCOCCUS; PLASMID; FOODS
AB A study was made of the competitiveness toward Listeria monocytogenes (Lm82) in Listeria enrichment broth (LEB) by bacteria isolated from foods and by strains of Enterococcus and other Gram-positive bacteria. Competitive (i.e., able to mask during enrichment in LEB for 24 h) and noncompetitive bacteria were tested for production of anti-Lm82 agents in diffusion zone assays on deMann-Rogosa-Sharpe (MRS) agar with added beta-glycero-phosphate (MRSB) and in Listeria enrichment agar (LEA). Enterococci were the most active competitors. The presence of small (2-6 mm diameter) inhibitory zones on MRSB correlated significantly with competitive activity in LEB; however, the correlation was not due to the metabolic activity that produced inhibitory zones on MRSB. Zone-producing bacteria were more likely to be competitors than were nonzone producers, but not all zone producers were competitors. Similarly, about 15 % of bacteria that did not produce zones were competitive. The few inhibitory zones on LEA indicated that competitor activity in the selective enrichment broth may only rarely be due to the production of diffusible inhibitors. The most important factor in competitiveness was the ability of enterococci and some other bacteria to maintain superior numbers in the presence of prolisterial selective agents in LEB. With their superior numbers, competitors significantly decreased the pH of LEB faster than did noncompetitors. Diffusible inhibitors produced in LEA by bacteria may also contribute significantly to competitiveness.
C1 US FDA,DIV MICROBIOL,HFS-516,200 C ST SW,WASHINGTON,DC 20204.
NR 20
TC 2
Z9 2
U1 0
U2 0
PU FOOD NUTRITION PRESS INC
PI TRUMBULL
PA 6527 MAIN ST, P O BOX 374, TRUMBULL, CT 06611
SN 0149-6085
J9 J FOOD SAFETY
JI J. Food Saf.
PD FEB
PY 1993
VL 13
IS 2
BP 113
EP 123
DI 10.1111/j.1745-4565.1993.tb00099.x
PG 11
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA KY276
UT WOS:A1993KY27600004
ER
PT J
AU SHIRAI, A
HOLMES, K
KLINMAN, D
AF SHIRAI, A
HOLMES, K
KLINMAN, D
TI DETECTION AND QUANTITATION OF CELLS SECRETING IL-6 UNDER PHYSIOLOGICAL
CONDITIONS IN BALB/C MICE
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SYSTEMIC LUPUS-ERYTHEMATOSUS; TUMOR NECROSIS FACTOR; MARROW STROMAL
CELLS; MOUSE BONE-MARROW; GROWTH-FACTOR; T-CELL; B-CELLS;
ANTIBODY-FORMATION; MONOCLONAL-ANTIBODY; STIMULATING FACTORS
AB IL-6 is a pleiotropic cytokine involved in the regulation of hematopoiesis and lymphocyte activation. An extremely sensitive ELIspot assay was developed to detect and enumerate individual cells secreting IL-6 in normal BALB/c mice. Under physiologic conditions, the frequency of cells producing IL-6 in the bone marrow, spleen, and mesenteric lymph nodes of normal adult animals was approximately 0.5, 0.1, and 0.01%, respectively. FACS analysis revealed that macrophages and Macl- B220- cells accounted for the vast majority of IL-6 production in the bone marrow, whereas T and B lymphocytes accounted for 4% and 38% of IL-6 production in the spleen. Simultaneous studies comparing cell number with IL-6 levels indicated that the average activated cell produced approximately 85 molecules of IL-6/s.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,RETROVIRUS RES LAB,BLDG 29A,RM 3D10,BETHESDA,MD 20892.
NIAID,BIOL RESOURCES BRANCH,FLOW CYTOMETRY SECT,BETHESDA,MD 20892.
NR 60
TC 60
Z9 61
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 1993
VL 150
IS 3
BP 793
EP 799
PG 7
WC Immunology
SC Immunology
GA KJ095
UT WOS:A1993KJ09500010
PM 8423340
ER
PT J
AU LEHMAN, PA
FRANZ, TJ
AF LEHMAN, PA
FRANZ, TJ
TI EFFECT OF AGE AND DIET ON STRATUM-CORNEUM BARRIER FUNCTION IN THE
FISCHER-344 FEMALE RAT
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID CHRONIC CALORIC RESTRICTION; FATTY-ACID DEFICIENCY;
PERCUTANEOUS-ABSORPTION; PERMEABILITY BARRIER; SKIN
AB Stratum corneum barrier function in the female Fischer 344 rat was assessed in animals ranging from 11 to 144 weeks of age, which were either fed ad libitum or a caloric-restricted diet at 60% ad libitum. Caloric restriction has been shown to increase the life span of rodents and delay age-associated degenerative diseases. The penetration of water, lidocaine, and hydrocortisone were measured in vitro using the finite-dose technique in Franz diffusion chambers. Water permeability did not significantly change with either age or diet condition (with the single exception of the ad libitum 144-week animals). However, between 11 and 44 weeks, both lidocaine and hydrocortisone permeability increased with age in both diet groups. By 44 weeks the caloric restriction animals had significantly greater permeability to lidocaine and hydrocortisone then their ad libitum age cohorts. Between 44 and 144 weeks, skin permeability in the ad libitum animals continued to increase with age, whereas permeability in the caloric restriction animals declined. By 144 weeks the caloric restriction skin was less permeable than the age-matched ad libitum animals but still more permeable than the 11-week animals. The data show that the barrier properties of stratum corneum change with age in the female rat and that this change can be modulated by caloric restriction.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP LEHMAN, PA (reprint author), UNIV ARKANSAS MED SCI HOSP,DEPT DERMATOL,SLOT 576,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.
NR 28
TC 10
Z9 10
U1 0
U2 0
PU BLACKWELL SCIENCE INC
PI CAMBRIDGE
PA 238 MAIN ST, CAMBRIDGE, MA 02142
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD FEB
PY 1993
VL 100
IS 2
BP 200
EP 204
DI 10.1111/1523-1747.ep12462809
PG 5
WC Dermatology
SC Dermatology
GA KM220
UT WOS:A1993KM22000019
PM 8429243
ER
PT J
AU AGUILERA, J
PADROSGIRALT, C
HABIG, WH
YAVIN, E
AF AGUILERA, J
PADROSGIRALT, C
HABIG, WH
YAVIN, E
TI GT1B GANGLIOSIDE PREVENTS TETANUS TOXIN-INDUCED PROTEIN-KINASE-C
ACTIVATION AND DOWN-REGULATION IN THE NEONATAL BRAIN INVIVO
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE TETANUS TOXIN; PROTEIN KINASE-C; PHORBOL ESTER; GANGLIOSIDES; NEONATAL
BRAIN
ID RAT-BRAIN; BINDING; CULTURES; ASSOCIATION; SEROTONIN; RECEPTORS; CELLS;
INTOXICATION; NEUROTOXIN; MEMBRANES
AB A single dose of 0.25 ng of tetanus toxin (TeTx), equivalent to approximately 5 minimal lethal doses, injected intracerebrally to 1-day-old rats, caused translocation, i.e., activation, of Ca2+-phosphatidylserine-dependent protein kinase C (PKC) from the cytosolic to the membrane compartment within 1 h. Six hours after treatment with the toxin, a 4050% reduction in the total brain PKC (cytosolic plus membrane) activity was noticed. GT 1 b (2 mug per brain) ganglioside, a putative receptor for TeTx, completely prevented enzyme translocation when injected intracerebrally 30 min before toxin administration and abolished down-regulation after 6 h from the time of toxin injection. GM 1 (2 mug per brain), a ganglioside of lesser affinity for TeTx, produced by itself a 20-30% reduction of the total PKC activity and did not reverse TeTx-induced PKC down-regulation after 6 h. 12-0-Tetradecanoylphorbol 13-acetate (TPA) phorhol ester, administered at a concentration of 5 x 10(-5) M, caused activation and down-regulation of the enzyme, although with several orders of magnitude lesser potency. GT 1 b prevented the TPA-induced down-regulation.
C1 WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL.
US FDA,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BETHESDA,MD 20014.
RP AGUILERA, J (reprint author), UNIV AUTONOMA BARCELONA,DEPT BIOQUIM & BIOL MOLEC,E-08193 CERDANYOLA,SPAIN.
RI Aguilera, Jose/N-6519-2015
OI Aguilera, Jose/0000-0002-9906-8034
NR 31
TC 11
Z9 11
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB
PY 1993
VL 60
IS 2
BP 709
EP 713
DI 10.1111/j.1471-4159.1993.tb03205.x
PG 5
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA KG671
UT WOS:A1993KG67100041
PM 8419545
ER
PT J
AU JACKSON, CD
BLACKWELL, BN
AF JACKSON, CD
BLACKWELL, BN
TI 2-YEAR TOXICITY STUDY OF DOXYLAMINE SUCCINATE IN THE FISCHER-344 RAT
SO JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY
LA English
DT Article
ID BODY-WEIGHT; METHAPYRILENE; TUMORS; TESTS
AB Doxylamine succinate, a commonly used antihistamine, was administered as an admixture in the feed to groups of male and female Fischer 344 rats at dose levels of 0, 500, 1000, and 2000 parts per million (ppm) (based on free amine) for 65 weeks (9 per group) or two years (48 per group). There were no significant treatment-related differences in survival in either sex. Compared to controls, final body weights of rats in the 2000 ppm group were reduced 8.4% and 22.8% in males and females, respectively. Treatment-related, non-neoplastic lesions were found primarily in the liver and parotid salivary gland. Liver lesions consisted of fatty change and degeneration in both sexes; hyperplasia (resulting from degeneration due to leukemia) and atypical cells in males; and hypertrophy, chronic inflammation, and mixed cell foci in females. Both sexes exhibited a treatment-related increase in cytoplasmic alteration in the salivary glands. Liver neoplasms were found only in the highest dose group of male rats. The trend test was significant (p less-than-or-equal-to 0.05) for increased incidence of hepatocellular adenoma and carcinoma with increasing doses of doxylamine, but the increased incidence of either lesion in the high dose group was not significant compared to that in controls. However, when animals with carcinoma or adenoma were combined, the trend test remained significant (p less-than-or-equal-to 0.01), and the incidence of the highest dose group was significantly increased (p less-than-or-equal-to 0.05) over that in controls. No treatment-related increase in neoplasms was found in females, but doxylamine produced a marked dose-related decrease in mammary fibroadenomas. Although not statistically significant, a very rare pineal gland tumor was found in 1 male and 1 female rat in the 2000 ppm group.
C1 PATHOL ASSOCIATES INC,JEFFERSON,AR.
RP JACKSON, CD (reprint author), NATL CTR TOXICOL RES,DIV NUTR TOXICOL,1 NCTR DR,JEFFERSON,AR 72079, USA.
NR 19
TC 18
Z9 18
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0730-0913
J9 J AM COLL TOXICOL
JI J. Am. Coll. Toxicol.
PD FEB
PY 1993
VL 12
IS 1
BP 1
EP 11
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KU512
UT WOS:A1993KU51200002
ER
PT J
AU GOLDBERG, AM
FRAZIER, JM
BRUSICK, D
DICKENS, MS
FLINT, O
GETTINGS, SD
HILL, RN
LIPNICK, RL
RENSKERS, KJ
BRADLAW, JA
SCALA, RA
VERONESI, B
GREEN, S
WILCOX, NL
CURREN, RD
AF GOLDBERG, AM
FRAZIER, JM
BRUSICK, D
DICKENS, MS
FLINT, O
GETTINGS, SD
HILL, RN
LIPNICK, RL
RENSKERS, KJ
BRADLAW, JA
SCALA, RA
VERONESI, B
GREEN, S
WILCOX, NL
CURREN, RD
TI FRAMEWORK FOR VALIDATION AND IMPLEMENTATION OF INVITRO TOXICITY TESTS -
REPORT OF THE VALIDATION AND TECHNOLOGY-TRANSFER COMMITTEE OF THE
JOHNS-HOPKINS-CENTER FOR ALTERNATIVES TO ANIMAL TESTING
SO JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY
LA English
DT Article
ID EYE IRRITATION TEST; REGULATORY ACCEPTANCE; TOXICOLOGY; PROJECT
AB In toxicology the development and application of in vitro alternatives to reduce or replace animal testing, or to lessen the distress and discomfort of laboratory animals, is a rapidly developing trend. However, at present there is no formal administrative process to organize, coordinate, or evaluate these activities. A framework capable of fostering the validation of new methods is essential for the effective transfer of new technology from the research laboratory to practical use. This committee has identified four essential validation resources: chemical bank(s), cell and tissue banks, a data bank, and reference laboratories. We recommend the creation of a Scientific Advisory Board of experts in toxicity testing, representing the academic, industrial and regulatory communities. Test validation acceptance is contingent upon broad buy-in by disparate groups in the scientific community: academia, industry and government. We believe that this can be achieved by early and frequent communication among the parties and agreement upon common goals. The committee hopes that the creation of a validation infrastructure built with the elements described in this report will facilitate scientific acceptance and utilization of alternative methodologies and speed implementation of reduction, refinement and replacement alternatives in toxicity testing.
C1 HAZELTON LABS AMER INC,VIENNA,VA 22180.
AVON PROD INC,SUFFERN,NY.
BRISTOL MYERS CO LABS,SYRACUSE,NY 13221.
COSMET TOILETRY & FRAGRANCE ASSOC INC,WASHINGTON,DC.
US EPA,WASHINGTON,DC 20460.
US FDA,WASHINGTON,DC 20204.
EXXON BIOMED SCI INC,E MILLSTONE,NJ.
MICROBIOL ASSOCIATES INC,ROCKVILLE,MD.
RP GOLDBERG, AM (reprint author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.
NR 34
TC 15
Z9 15
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0730-0913
J9 J AM COLL TOXICOL
JI J. Am. Coll. Toxicol.
PD FEB
PY 1993
VL 12
IS 1
BP 23
EP 30
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KU512
UT WOS:A1993KU51200004
ER
PT J
AU BUSHAR, G
SAGRIPANTI, JL
AF BUSHAR, G
SAGRIPANTI, JL
TI REPLICATION AND PHYSICAL PARAMETERS IMPORTANT FOR PREPARING PURIFIED
JUNIN VIRUS
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE JUNIN VIRUS; ARGENTINE HEMORRHAGIC FEVER; XJC13
ID HEMORRHAGIC-FEVER; ARENAVIRUSES
AB Junin virus (JV) is an Arenavirus and the causative agent of Argentine hemorrhagic fever (AHF), an often fatal human disease. The attenuated strain XJ-clone 3 (XJCl3) of JV, after being tested in humans, has been considered a promising vaccine. We found that synthesis of JV XJCl3 reaches a peak 2 days after infection and the kinetics of synthesis are little affected by the multiplicity of infection (MOI) in a range from 0.125 to 1.00. Virus synthesis is sensitive to actinomycin D, indicating that cellular biosynthesis is required for viral replication. Combined precipitation and ultracentrifugation of supernatant from virus-infected cells yielded large amounts of concentrated and purified virion that banded in sucrose as a single peak with average density 1.177 +/-0.015 g/ml. Purified virions have an average diameter of 203 +/- 23 nm by electron microscopy and an average sedimentation coefficient of 454 +/- 27 S. The results from the present study should assist in the preparation of large amounts of attenuated Junin virus which are required for vaccination against and diagnosis of Argentine hemorrhagic fever.
C1 US FDA,CTR DEVICES & RADIOL HLTH,MOLEC BIOL BRANCH,12709 TWINBROOK PKWY,HFZ-113,ROCKVILLE,MD 20852.
NR 19
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD FEB
PY 1993
VL 41
IS 2
BP 147
EP 156
DI 10.1016/0166-0934(93)90122-8
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Virology
GA KL943
UT WOS:A1993KL94300002
PM 8388396
ER
PT J
AU KLONTZ, KC
MULLEN, RC
CORBYONS, TM
BARNARD, WP
AF KLONTZ, KC
MULLEN, RC
CORBYONS, TM
BARNARD, WP
TI VIBRIO WOUND INFECTIONS IN HUMANS FOLLOWING SHARK ATTACK
SO JOURNAL OF WILDERNESS MEDICINE
LA English
DT Article
DE SHARKS; VIBRIO INFECTIONS; WOUND INFECTION
AB There are few published reports of the infectious sequellae of shark attack in humans. Using patient medical records and epidemiologic data from Vibrio surveillance forms maintained by the Florida Department of Health and Rehabilitative Services, we describe the clinical features of three patients with shark-associated wounds from whom Vibrio organisms were recovered in pure culture from clinical specimens.
RP KLONTZ, KC (reprint author), US FDA,DIV NUTR,CLIN NUTR BRANCH,HFF-265,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0953-9859
J9 J WILDERNESS MED
PD FEB
PY 1993
VL 4
IS 1
BP 68
EP 72
DI 10.1580/0953-9859-4.1.68
PG 5
WC Medicine, General & Internal; Physiology
SC General & Internal Medicine; Physiology
GA KM371
UT WOS:A1993KM37100011
ER
PT J
AU JESSOP, JJ
HOFFMAN, T
AF JESSOP, JJ
HOFFMAN, T
TI PRODUCTION AND RELEASE OF IL-1-BETA BY HUMAN PERIPHERAL-BLOOD MONOCYTES
IN RESPONSE TO DIVERSE STIMULI - POSSIBLE ROLE OF MICRODAMAGE TO ACCOUNT
FOR UNREGULATED RELEASE
SO LYMPHOKINE AND CYTOKINE RESEARCH
LA English
DT Article
ID HUMAN PROINTERLEUKIN-1-BETA; HUMAN INTERLEUKIN-1; ACTIVATING FACTOR;
SIGNAL SEQUENCE; PROTEIN-KINASE; SECRETION; CALCIUM; IL-1; LOCALIZATION;
EXOCYTOSIS
AB Three different stimuli [lipopolysaccharide (LPS), concanavalin A (Con A), and phorbol myristate acetate (PMA)] all induced production and release of interleukin-1beta (IL-1beta) from human monocytes in vitro. Of the three, LPS demonstrated the greatest potency for IL-1beta production. LPS and Con A demonstrated similar efficacy with respect to IL-1beta release. LPS was approximately 1000 times more potent than Con A in this regard. LPS- and Con A-induced IL-1beta release occurred within 3 h and 12-24 h, respectively. Challenge with PMA induced low levels of IL-1beta production with a relatively large percentage released. IL-1beta release by all three stimuli occurred at concentrations greater than or equal to those required for optimal IL-1beta production. The amount of IL-1beta released correlated with total IL-1beta produced and was associated with release of lactate dehydrogenase (LDH), a cytosolic enzyme marker used to evaluate cell membrane integrity. IL-1beta release preceded LDH release temporally. LPS and Con A had no effect on total cell protein synthesis, a measure of overt toxicity, while PMA inhibited protein synthesis in a dose-dependent fashion. LPS and Con A both induced expression of a 33- and 29-kDa precursor IL-1beta, but only the 17-kDa form was released. These data suggest that IL-1beta is released by a process different from regulated secretion. While PMA induces a more profound damage, LPS and Con A may stimulate release of IL-1beta from human monocytes in vitro through induction of microdamage to the cell membrane.
RP JESSOP, JJ (reprint author), US FDA,PHS,CTR BIOL EVALUAT & RES,OBR,DIV HEMATOL,CELL BIOL LAB,NIH CAMPUS,BLDG 29,RM 223,BETHESDA,MD 20892, USA.
NR 32
TC 12
Z9 12
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0277-6766
J9 LYMPHOKINE CYTOK RES
JI Lymphokine Cytokine Res.
PD FEB
PY 1993
VL 12
IS 1
BP 51
EP 58
PG 8
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA KQ623
UT WOS:A1993KQ62300008
PM 8457632
ER
PT J
AU MCLAUGHLIN, GL
HOWE, DK
BIGGS, DR
SMITH, AR
LUDWINSKI, P
FOX, BC
TRIPATHY, DN
FRASCH, CE
WENGER, JD
CAREY, RB
HASSANKING, M
VODKIN, MH
AF MCLAUGHLIN, GL
HOWE, DK
BIGGS, DR
SMITH, AR
LUDWINSKI, P
FOX, BC
TRIPATHY, DN
FRASCH, CE
WENGER, JD
CAREY, RB
HASSANKING, M
VODKIN, MH
TI AMPLIFICATION OF RDNA LOCI TO DETECT AND TYPE NEISSERIA-MENINGITIDIS AND
OTHER EUBACTERIA
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE POLYMERASE CHAIN REACTION; AMPLIFICATION; RIBOSOMAL DNA; NEISSERIA;
MENINGOCOCCEMIA; INTERNAL TRANSCRIBED SPACER; STRAIN IDENTIFICATION
ID POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; INTERCONTINENTAL
SPREAD; CLINICAL SPECIMENS; PERIPHERAL-BLOOD; RAPID DIAGNOSIS;
RIBOSOMAL-RNA; DNA; EPIDEMIC; IDENTIFICATION
C1 CARLE CLIN ASSOC,DEPT MICROBIOL,URBANA,IL 61801.
UNIV ILLINOIS,DEPT VET PATHOBIOL,URBANA,IL 61801.
CHAMPAIGN URBANA PUBL HLTH DIST,CHAMPAIGN,IL 61820.
CARLE CLIN ASSOC,URBANA,IL 61801.
US FDA,DIV BACTERIAL PROD,OFF BIOL RES,BETHESDA,MD 20014.
CTR DIS CONTROL,CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333.
ST FRANCIS HOSP,EVANSTON,IL 60202.
MED RES COUNCIL LAB,BANJUL,SENEGAMBIA.
RP MCLAUGHLIN, GL (reprint author), PURDUE UNIV,SCH VET MED,DEPT VET PATHOBIOL,W LAFAYETTE,IN 47907, USA.
FU NEI NIH HHS [EYO 8205]
NR 38
TC 40
Z9 40
U1 0
U2 0
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD FEB
PY 1993
VL 7
IS 1
BP 7
EP 17
DI 10.1006/mcpr.1993.1002
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Biotechnology & Applied Microbiology; Cell Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Cell Biology
GA KN199
UT WOS:A1993KN19900002
PM 8455644
ER
PT J
AU HENNEY, JE
AF HENNEY, JE
TI COMBATING MEDICAL FRAUD
SO NEW YORK STATE JOURNAL OF MEDICINE
LA English
DT Editorial Material
RP HENNEY, JE (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU MED SOC STATE OF NY
PI LAKE SUCCESS
PA 420 LAKEVILLE RD P O BOX 5404, LAKE SUCCESS, NY 11042
SN 0028-7628
J9 NEW YORK STATE J MED
PD FEB
PY 1993
VL 93
IS 2
BP 86
EP 87
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA KP617
UT WOS:A1993KP61700002
PM 8455838
ER
PT J
AU HAMMACK, TS
SHERROD, PS
BRUCE, VR
JUNE, GA
SATCHELL, FB
ANDREWS, WH
AF HAMMACK, TS
SHERROD, PS
BRUCE, VR
JUNE, GA
SATCHELL, FB
ANDREWS, WH
TI GROWTH OF SALMONELLA-ENTERITIDIS IN GRADE-A EGGS DURING PROLONGED
STORAGE
SO POULTRY SCIENCE
LA English
DT Note
DE EGGS; SALMONELLA-ENTERITIDIS; GROWTH; YOLK; DISINFECTION
ID SHELL EGGS; IMMUNOLOGIC CONTROL; TYPHOID FEVER; HENS; PATHOGENESIS;
TYPHIMURIUM; SURVIVAL
AB Migration of Salmonella enteritidis through egg albumen to the yolk and its subsequent growth in the yolk were examined. Submersion of eggs in .1% mercuric chloride solution for 1 h followed by submersion in 70% ethanol for 30 min resulted in an eggshell surface from which no Salmonella organisms were recovered. The eggs were then inoculated with S. enteritidis under the shell membrane. Although growth of S. enteritidis was negligible in eggs refrigerated up to 16 days, the population level of the organism increased by more than 8 log10 units in unrefrigerated eggs stored for the same amount of time.
RP HAMMACK, TS (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 16
TC 42
Z9 42
U1 0
U2 2
PU POULTRY SCIENCE ASSN INC
PI CHAMPAIGN
PA 309 W CLARK ST, CHAMPAIGN, IL 61802
SN 0032-5791
J9 POULTRY SCI
JI Poult. Sci.
PD FEB
PY 1993
VL 72
IS 2
BP 373
EP 377
PG 5
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA KM479
UT WOS:A1993KM47900020
PM 8441733
ER
PT J
AU YI, PN
STANLEY, WS
LEE, W
AF YI, PN
STANLEY, WS
LEE, W
TI RELATIONSHIP BETWEEN MITOTIC DELAY AND THE MINIMUM DOSE-RATE OF
X-IRRADIATION REQUIRED TO STOP CELL-PROLIFERATION
SO RADIATION RESEARCH
LA English
DT Article
ID MAMMALIAN-CELLS; CYCLE; PROGRESSION; SURVIVAL; CULTURE; LINES
C1 NEW YORK MED COLL,DEPT RADIAT MED,VALHALLA,NY 10595.
CHILDRENS NATL MED CTR,DEPT LAB MED,WASHINGTON,DC 20010.
GEORGE WASHINGTON UNIV,DEPT PEDIAT,WASHINGTON,DC 20052.
GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20052.
US FDA,CTR DEVICES & RADIOL,ROCKVILLE,MD 20857.
FU NCI NIH HHS [R01 CA 37660]
NR 23
TC 10
Z9 10
U1 0
U2 0
PU RADIATION RESEARCH SOC
PI OAK BROOK
PA 2021 SPRING RD, STE 600, OAK BROOK, IL 60521
SN 0033-7587
J9 RADIAT RES
JI Radiat. Res.
PD FEB
PY 1993
VL 133
IS 2
BP 163
EP 169
DI 10.2307/3578352
PG 7
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
Nuclear Medicine & Medical Imaging
GA KN250
UT WOS:A1993KN25000004
PM 8438056
ER
PT J
AU BOWERS, JC
AF BOWERS, JC
TI RELATIVE VERSUS ABSOLUTE RISK MODELING OF AFLATOXIN - RESPONSE
SO RISK ANALYSIS
LA English
DT Letter
RP BOWERS, JC (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MATH,HFF-118,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0272-4332
J9 RISK ANAL
JI Risk Anal.
PD FEB
PY 1993
VL 13
IS 1
BP 9
EP 10
DI 10.1111/j.1539-6924.1993.tb00720.x
PG 2
WC Public, Environmental & Occupational Health; Mathematics,
Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
Methods In Social Sciences
GA KK821
UT WOS:A1993KK82100003
PM 8451464
ER
PT J
AU REMINGTON, J
AF REMINGTON, J
TI AVAILABILITY OF SULFADIAZINE - UNITED-STATES (REPRINTED FROM MMWR, VOL
41, PG 950-951, 1992)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Reprint
C1 US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,OFF GENER DRUGS,WASHINGTON,DC 20204.
CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30333.
RP REMINGTON, J (reprint author), PALO ALTO MED FDN,RES INST,PALO ALTO,CA 94301, USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 27
PY 1993
VL 269
IS 4
BP 461
EP 461
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KH385
UT WOS:A1993KH38500008
ER
PT J
AU OBIRI, NI
HILLMAN, GG
HAAS, GP
PURI, RK
AF OBIRI, NI
HILLMAN, GG
HAAS, GP
PURI, RK
TI EXPRESSION OF FUNCTIONAL INTERLEUKIN-4 RECEPTORS (IL-4R) ON HUMAN
RENAL-CELL CARCINOMA (RCC) TUMOR-CELLS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 80
EP 80
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500283
ER
PT J
AU ANSHER, SS
THOMPSON, WC
PURI, RK
AF ANSHER, SS
THOMPSON, WC
PURI, RK
TI MODULATION OF HEPATIC DRUG-METABOLISM BY CYTOKINE ADMINISTRATION IN MICE
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,DIV BACTERIAL PROD,BETHESDA,MD 20205.
US FDA,CBER,DIV CYTOKINE BIOL,BETHESDA,MD 20205.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 85
EP 85
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500302
ER
PT J
AU MEHROTRA, P
WU, D
CRIM, JA
SIEGEL, JP
AF MEHROTRA, P
WU, D
CRIM, JA
SIEGEL, JP
TI EFFECTS OF IL-12 ON THE GENERATION OF CYTOLYTIC ACTIVITY IN HIGHLY
PURIFIED CD8+ HUMAN LYMPHOCYTES-T
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 93
EP 93
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500336
ER
PT J
AU CLOUSE, KA
HOWARD, OMZ
WEIH, KA
SMITH, C
GOODWIN, RG
FARRAR, WL
AF CLOUSE, KA
HOWARD, OMZ
WEIH, KA
SMITH, C
GOODWIN, RG
FARRAR, WL
TI INHIBITION OF HIV ACTIVATION USING SOLUBLE TUMOR-NECROSIS-FACTOR
RECEPTOR
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,BETHESDA,MD 20895.
NCI,FCRDC,BCDP,PRI DYNCORP,FREDERICK,MD 21702.
IMMUNEX CORP,SEATTLE,WA 98101.
NCI,FCRDC,BRMP,FREDERICK,MD 21702.
RI Howard, O M Zack/B-6117-2012
OI Howard, O M Zack/0000-0002-0505-7052
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 103
EP 103
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500374
ER
PT J
AU JESSOP, JJ
HENRY, S
HOFFMAN, T
AF JESSOP, JJ
HENRY, S
HOFFMAN, T
TI EFFECTS OF THE SERINE PROTEASE INHIBITOR, TAME, ON INTERLEUKIN-1-BETA IN
LIPOPOLYSACCHARIDE (LPS)-STIMULATED HUMAN MONOCYTES - THE RELATIONSHIP
BETWEEN SYNTHESIS AND RELEASE OF A 33 KDA PRECURSOR AND THE 17 KDA
BIOLOGICALLY-ACTIVE SPECIES
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 NIH,CELL BIOL LAB,DIV HEMATOL,CBER,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 105
EP 105
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500380
ER
PT J
AU TAGA, K
TOSATO, G
AF TAGA, K
TOSATO, G
TI HUMAN IL-10 DIRECTLY INHIBITS T-CELL GROWTH AND CYTOKINE PRODUCTION
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOLOG EVALUAT & RES,BETHESDA,MD 20205.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 108
EP 108
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500394
ER
PT J
AU TING, CC
LIANG, SM
CHEN, YY
HARGROVE, ME
AF TING, CC
LIANG, SM
CHEN, YY
HARGROVE, ME
TI IL-4 AND PKC REGULATION OF GENE (PERFORIN) EXPRESSION AND PROTEIN
(BLT-ESTERASE) SYNTHESIS IN T-CELL ACTIVATION
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 NCI,BETHESDA,MD 20892.
CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 121
EP 121
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500443
ER
PT J
AU DONNELLY, RP
CROFFORD, LJ
REMMERS, E
OBIRI, N
FENTON, MJ
WILDER, RL
AF DONNELLY, RP
CROFFORD, LJ
REMMERS, E
OBIRI, N
FENTON, MJ
WILDER, RL
TI TISSUE-SPECIFIC REGULATION OF IL-6 PRODUCTION BY IL-4 -
DIFFERENTIAL-EFFECTS OF IL-4 ON MONOCYTES AND FIBROBLASTS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
NIAMS,ARTHRITIS & RHEUMAT BRANCH,BETHESDA,MD 20892.
BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118.
RI Crofford, Leslie/J-8010-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 144
EP 144
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500515
ER
PT J
AU BRUNSWICK, M
JUNE, C
BURKHARDT, A
BOLEN, J
MOND, J
AF BRUNSWICK, M
JUNE, C
BURKHARDT, A
BOLEN, J
MOND, J
TI SIG MEDIATED DESENSITIZATION OF PLC DEPENDENT PATHWAYS OCCURS AT A POINT
DISTAL TO TYROSINE KINASE (TK) ACTIVATION
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,BETHESDA,MD 20014.
NMRI,BETHESDA,MD.
BRISTOL MYERS SQUIBB,PRINCETON,NJ.
USUHS,BETHESDA,MD.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 26
PY 1993
SU 17B
BP 253
EP 253
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN465
UT WOS:A1993KN46500913
ER
PT J
AU ABIAN, J
CHURCHWELL, MI
KORFMACHER, WA
AF ABIAN, J
CHURCHWELL, MI
KORFMACHER, WA
TI HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY THERMOSPRAY MASS-SPECTROMETRY OF
10 SULFONAMIDE ANTIBIOTICS - ANALYSIS IN MILK AT THE PPB LEVEL
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Article
ID SULFAMETHAZINE; RESIDUES; CONFIRMATION; EXTRACTS; BOVINE
AB Ten sulfonamide antibiotics including sulfanilamide (SNL), sulfamethazine (SMZ), sulfamethizole (SMTZ), sulfachloropyridazine and sulfaquinoxaline (SQX), were analyzed by thermospray (TSP) mass spectrometry on-line with a high-performance liquid chromatography-UV detection system. Except for the pairs SMZ-SMTZ and sulfadimethoxine-SQX, the standards were resolved in both the UV and TSP profiles. Co-eluting compounds could be differentiated in TSP by their different relative molecular masses. The [M + H]+ ion was the base peak for all the standards except SNL, which showed an [M + NH4]+ ion. Collision-induced dissociation of the [M + H]+ ions afforded daughter ion spectra characterized by common ions at m/z 92, 108 and 156, and ions derived from the amine substituent ([MH - 155]+). TSP detection limits [signal-to-noise ratio (S/N) > 3] were below 20 ng (scan mode), 2 ng (selected reaction monitoring, daughter ions from [M + H]+) and 400 pg (selected ion monitoring). UV detection limits were ca. 2 ng (S/N > 5). Results obtained from the multi-residue analysis of spiked cow milk samples at the low ng/ml level are presented.
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RI Abian, Joaquin/M-1965-2014
OI Abian, Joaquin/0000-0003-2823-5429
NR 19
TC 70
Z9 74
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PD JAN 22
PY 1993
VL 629
IS 2
BP 267
EP 276
DI 10.1016/0021-9673(93)87040-S
PG 10
WC Chemistry, Analytical
SC Chemistry
GA KJ729
UT WOS:A1993KJ72900016
PM 8429086
ER
PT J
AU OWN, ZY
WANG, SM
CHUNG, JF
MILLER, DW
FU, PP
AF OWN, ZY
WANG, SM
CHUNG, JF
MILLER, DW
FU, PP
TI SYNTHESIS OF (ETA-6-ARENE)TRICARBONYLCHROMIUM COMPLEXES - REGIOSELECTIVE
REACTION OF CHROMIUM HEXACARBONYL WITH POLYCYCLIC AROMATIC-HYDROCARBONS
SO INORGANIC CHEMISTRY
LA English
DT Article
ID SUBSTITUTION; TRICARBONYL; MECHANISMS; STABILITY
AB The reaction of chromium hexacarbonyl with 21 substituted polycyclic aromatic hydrocarbons (PAHs) was studied. The PAHs employed for study contain two to four aromatic benzo rings and include parent PAHs, mono- and dimethylated PAHs, PAHs with one or two rings saturated, and gamma-keto-hexacyclic and phenyl-substituted derivatives. In general, a partially hydrogenated ring substituent, presumably due to its electron-donating character, directs the reaction regioselectivity to the substituted aromatic ring. This suggests that steric hindrance may not be as important a factor as electron-donating ability. Further evidence for this conclusion is that a methyl substituent, also having electron-donating character, exhibits a similar effect, whereas an electron-withdrawing keto functional group directs the reaction away from the substituted aromatic ring. On the basis of the electronic effects of the substituents observed in this study, we propose that total pi-electron density, in terms of total pi-bond order, of a benzenoid ring in a PAH is a decisive factor in determining the regioselectivity of the coordination reactions between PAHs and chromium hexacarbonyl. In contrast to previous reports that a [Cr(CO)3] group always bonds to the terminal aromatic ring of a PAH, we have found that reactions between chromium hexacarbonyl and two PAHs, 9-methylanthracene and 9,10-dimethylanthracene, occur on the central aromatic ring.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP OWN, ZY (reprint author), PROVIDENCE UNIV,INST APPL CHEM,SHALU,TAIWAN.
NR 36
TC 16
Z9 16
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0020-1669
J9 INORG CHEM
JI Inorg. Chem.
PD JAN 20
PY 1993
VL 32
IS 2
BP 152
EP 159
DI 10.1021/ic00054a007
PG 8
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA KH522
UT WOS:A1993KH52200007
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI INSTRUCTIONAL VIDEOS ON FOOD SAFETY IN NURSING-HOMES
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 20
PY 1993
VL 269
IS 3
BP 328
EP 328
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KG381
UT WOS:A1993KG38100006
PM 8418328
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI PUBLIC WARNING ABOUT HERBAL PRODUCT CHAPARRAL
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 20
PY 1993
VL 269
IS 3
BP 328
EP 328
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KG381
UT WOS:A1993KG38100004
PM 8418328
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI AGENCY POLICY ON INDUSTRY-SUPPORTED CME
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 20
PY 1993
VL 269
IS 3
BP 328
EP 328
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KG381
UT WOS:A1993KG38100005
PM 8418328
ER
PT J
AU ROE, AL
SNAWDER, JE
BENSON, RW
ROBERTS, DW
CASCIANO, DA
AF ROE, AL
SNAWDER, JE
BENSON, RW
ROBERTS, DW
CASCIANO, DA
TI HEPG2 CELLS - AN INVITRO MODEL FOR P450-DEPENDENT METABOLISM OF
ACETAMINOPHEN
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID LINE; INDUCTION; ETHANOL; HEP-G2; CYTOCHROME-P-450; 1-NITROPYRENE;
OXIDATION; ENZYME; RAT
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72206.
UNIV ARKANSAS MED SCI HOSP,DEPT MOLEC BIOL & BIOCHEM,LITTLE ROCK,AR 72206.
RP ROE, AL (reprint author), NATL CTR TOXICOL RES,DIV GENET TOXICOL,JEFFERSON,AR 72079, USA.
NR 25
TC 56
Z9 57
U1 1
U2 3
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 15
PY 1993
VL 190
IS 1
BP 15
EP 19
DI 10.1006/bbrc.1993.1003
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA KH402
UT WOS:A1993KH40200003
PM 8380689
ER
PT J
AU EHRENREICH, H
COSTA, T
CLOUSE, KA
PLUTA, RM
OGINO, Y
COLIGAN, JE
BURD, PR
AF EHRENREICH, H
COSTA, T
CLOUSE, KA
PLUTA, RM
OGINO, Y
COLIGAN, JE
BURD, PR
TI THROMBIN IS A REGULATOR OF ASTROCYTIC ENDOTHELIN-1
SO BRAIN RESEARCH
LA English
DT Article
DE THROMBIN; PRIMARY ASTROCYTE; ENDOTHELIN; ENDOTHELIN RECEPTOR;
INOSITOLPHOSPHOLIPID TURNOVER; AP1; REVERSE TRANSCRIPTASE PCR
ID MESSENGER-RNA; VASOCONSTRICTOR PEPTIDE; NEURITE OUTGROWTH; PROTEASE
NEXIN-1; MESANGIAL CELLS; RAT ASTROBLASTS; UMBILICAL VEIN;
GROWTH-FACTOR; GLIAL-CELLS; EXPRESSION
AB Endothelin-1, a potent vasoconstrictor of cerebral vessels, is produced by rat primary astrocytes and is subject to autostimulatory regulation in these cells. In this study we examined the effect of thrombin on astrocytic endothelins and report that endothelin-1 is released into the culture fluid in response to thrombin treatment. However, increased production of endothelin-1 is not accompanied by a concomitant increase in steady-state levels of endothelin-1 mRNA as assessed by reverse transcriptase-polymerase chain reaction, even though thrombin stimulation leads to increased inositolphospholipid turnover and activation of the nuclear factor AP1. Thus, astrocytic production of endothelin-1 may be mainly post-transcriptionally regulated in response to thrombin stimulation. In addition, two endothelin receptor genes (ET(A) and ET(B)) were found to be transcribed simultaneously in primary astrocyte cultures, and both thrombin and endothelin-1 stimulation result in a distinct temporary decrease in ET(A) mRNA. These studies suggest a role for thrombin in the regulation of brain perfusion through astrocytic endothelin-1 expression.
C1 NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20892.
NIAID,CLIN INVEST LAB,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NICHHD,THEORET & PHYS BIOL LAB,BETHESDA,MD 20892.
NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892.
OI costa, tommaso/0000-0002-8729-3357
NR 44
TC 93
Z9 94
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JAN 15
PY 1993
VL 600
IS 2
BP 201
EP 207
DI 10.1016/0006-8993(93)91374-2
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA KG868
UT WOS:A1993KG86800004
PM 7679602
ER
PT J
AU BRAIN, KR
HADGRAFT, J
JAMES, VJ
SHAH, VP
WALTERS, KA
WATKINSON, AC
AF BRAIN, KR
HADGRAFT, J
JAMES, VJ
SHAH, VP
WALTERS, KA
WATKINSON, AC
TI INVITRO ASSESSMENT OF SKIN PERMEATION FROM A TRANSDERMAL SYSTEM FOR THE
DELIVERY OF ESTRADIOL
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Note
ID ESTRADIOL
C1 UNIV WALES COLL CARDIFF,COLL CARDIFF,WELSH SCH PHARM,REDWOOD BLDG,CARDIFF CF1 3XF,WALES.
ANEX ANALYT SERV LTD,CARDIFF CF1 3XF,WALES.
US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 5
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD JAN 15
PY 1993
VL 89
IS 2
BP R13
EP R16
DI 10.1016/0378-5173(93)90118-Y
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KK371
UT WOS:A1993KK37100010
ER
PT J
AU CONTI, A
BRANDO, C
DEBELL, KE
ALAVA, MA
HOFFMAN, T
BONVINI, E
AF CONTI, A
BRANDO, C
DEBELL, KE
ALAVA, MA
HOFFMAN, T
BONVINI, E
TI CD3-INDUCED PREFERENTIAL HYDROLYSIS OF POLYPHOSPHOINOSITIDES AND CALCIUM
REGULATION OF INOSITOL PHOSPHATE-METABOLISM IN A PERMEABILIZED MURINE
T-CELL CLONE
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROTEIN KINASE-C; ANTIGEN RECEPTOR COMPLEX; HUMAN LYMPHOCYTES-T;
1,4,5-TRISPHOSPHATE 3-KINASE; PHOSPHOLIPASE-C; PHORBOL ESTERS;
ACTIVATION; HETEROGENEITY; CALMODULIN; ION
AB Murine T helper cloned cells permeabilized with the bacterial lysin, tetanolysin, were used to investigate the role of intracellular Ca2+ in regulating myo-[2-H-3] inositol phospholipid (InsPL) hydrolysis triggered upon perturbation of the T cell receptor-CD3 complex. [Ca2+] was controlled by a calcium/magnesium/EGTA buffer. Antibody (mAb) aggregation of CD3 induced InsPL hydrolysis in the absence of added Ca2+. However, stimulated InsPL hydrolysis increased with the free [Ca2+], reaching a maximum at 100-300 nM [Ca2+]. Ca2+ increased the overall efficiency of hydrolysis without changes in EC50 of the anti-CD3 mAb. The response diminished at >300 nM [Ca2+] due to a mixed type inhibition. Ca2+ alone had no effect on inositol phosphate levels. Polyphosphoinositides were preferentially cleaved, since no accumulation of Ins(1)P/Ins(3)P was detected, indicating that direct hydrolysis of phosphatidylinositol did not occur, irrespective of the Ca2+ concentration. [Ca2+] above 300 nM shifted the relative amounts of CD3-induced inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) in favor of the latter. Unlabeled permeabilized cells exposed to greater-than-or-equal-to 100 nM [Ca2+] showed enhanced conversion of [H-3]Ins (1,4,5)P, to [H-3]Ins(1,3,4,5)P4. In conclusion, InsPL hydrolysis is optimally triggered by CD3 perturbation at intracellular Ca2+ levels approximating those observed in intact resting lymphocytes (100 nM). Ca2+ concentrations similar to those triggered by InsPL-derived metabolites may inhibit InsPL hydrolysis and promote Ins(1,3,4,5)P4 production, thus controlling the amounts of Ins(1,4,5)P3.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,CELL BIOL LAB,BLDG 29,RM 231,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 47
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 15
PY 1993
VL 268
IS 2
BP 783
EP 791
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KG077
UT WOS:A1993KG07700008
PM 8380415
ER
PT J
AU DOERGE, DR
DECKER, CJ
TAKAZAWA, RS
AF DOERGE, DR
DECKER, CJ
TAKAZAWA, RS
TI CHEMICAL AND ENZYMATIC OXIDATION OF BENZIMIDAZOLINE-2-THIONES - A
DICHOTOMY IN THE MECHANISM OF PEROXIDASE INHIBITION
SO BIOCHEMISTRY
LA English
DT Article
ID THYROID PEROXIDASE; THIOCARBAMIDE GOITROGENS; THIOUREYLENE DRUGS;
LACTOPEROXIDASE; INACTIVATION; PROPYLTHIOURACIL; IDENTIFICATION;
REACTIVITY; METABOLISM; INVITRO
AB Derivatives of imidazole-2-thiones block reactions catalyzed by thyroid peroxidase (TPX) and the closely related lactoperoxidase (LPX), and this property is used therapeutically to treat hyperthyrodism. The reactions of a series of benzimidazoline-2-thiones with chemical and enzymatic oxidants were investigated to probe systematically the mechanism of inhibition. Oxidation of benzimidazoline-2-thione (I) and 1-methylbenzimidazoline-2-thione (II) with 3-chloroperbenzoic acid (PBA) yielded reaction products and stoichiometry consistent with benzimidazole-2-sulfenic acids as reactive intermediates. The N,N'-disubstituted nature of 1,3-dimethylbenzimidazoline-2-thione (III) precludes sulfenic acid formation by tautomerization, and the oxidation of III with PBA yielded products and stoichiometry that were consistent with a benzimidazole-2-sulfonyl ylide as the reactive intermediate. I and II are suicide inhibitors of LPX and TPX, but III was found to inhibit only peroxidase-catalyzed iodination reactions by an alternate substrate mechanism. These results provide support for the hypothesis that imidazole-2-sulfenic acids are important reactive intermediates in the suicide inactivation of TPX and LPX and relate the chemical reactivity of the inhibitor with both the potency and mechanism of inhibition. These results suggest that 1,3-disubstituted thiourea derivatives represent a new class of potential antihyperthyroid drugs that block TPX-catalyzed tyrosine iodination but do not cause irreversible enzyme inactivation.
C1 BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA.
UNIV HAWAII, DEPT ENVIRONM BIOCHEM, HONOLULU, HI 96822 USA.
RP DOERGE, DR (reprint author), NATL CTR TOXICOL RES, DIV BIOCHEM TOXICOL, JEFFERSON, AR 72079 USA.
NR 29
TC 28
Z9 28
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 12
PY 1993
VL 32
IS 1
BP 58
EP 65
DI 10.1021/bi00052a009
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KG380
UT WOS:A1993KG38000009
PM 8418860
ER
PT J
AU LEWIS, RM
SCHNEIDER, MCJ
AF LEWIS, RM
SCHNEIDER, MCJ
TI INTRODUCTION OF PROCESS CHANGES IN BIOLOGICAL PRODUCTS - A REGULATORY
PERSPECTIVE
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 CTR BIOL EVALUAT & RES,BETHESDA,CA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 9
PY 1993
SU 17A
BP 42
EP 42
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN464
UT WOS:A1993KN46400136
ER
PT J
AU LIU, DT
AF LIU, DT
TI PROTEIN-PURIFICATION - SCIENTIFIC AND REGULATORY CONSIDERATION ON
GLYCOSYLATION, DEAMIDATION AND OXIDATION OF PHARMACEUTICAL PROTEINS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 CBER,FDA,DIV BIOCHEM & BIOPHYS,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 9
PY 1993
SU 17A
BP 45
EP 45
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN464
UT WOS:A1993KN46400145
ER
PT J
AU FINBLOOM, DS
WILSON, KC
FELDMAN, GM
AF FINBLOOM, DS
WILSON, KC
FELDMAN, GM
TI INTERFERON-GAMMA RAPIDLY INDUCES IN HUMAN MONOCYTES A NOVEL DNA-BINDING
FACTOR THAT RECOGNIZES THE GAMMA-RESPONSE REGION WITHIN THE PROMOTER OF
THE GENE FOR THE HIGH-AFFINITY FC-GAMMA RECEPTOR
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 9
PY 1993
SU 17A
BP 71
EP 71
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN464
UT WOS:A1993KN46400235
ER
PT J
AU WANG, JH
JONES, C
NORCROSS, M
BOHNLEIN, E
RAZZAQUE, A
AF WANG, JH
JONES, C
NORCROSS, M
BOHNLEIN, E
RAZZAQUE, A
TI SP1 BINDING-ELEMENTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROMOTER
ARE ESSENTIAL FOR TRANSACTIVATION BY A HUMAN HERPESVIRUS-6 TRANSFORMING
GENE SEGMENT
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 9
PY 1993
SU 17A
BP 132
EP 132
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN464
UT WOS:A1993KN46400477
ER
PT J
AU DIRKSEN, ML
MILLER, A
JAMRICH, M
AF DIRKSEN, ML
MILLER, A
JAMRICH, M
TI EXPRESSION OF FORK HEAD GENES DURING EARLY XENOPUS DEVELOPMENT
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 9
PY 1993
SU 17A
BP 193
EP 193
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KN464
UT WOS:A1993KN46400717
ER
PT J
AU SMITH, MJ
MAZZOLA, EP
SIMS, JJ
MIDLAND, SL
KEEN, NT
BURTON, V
STAYTON, MM
AF SMITH, MJ
MAZZOLA, EP
SIMS, JJ
MIDLAND, SL
KEEN, NT
BURTON, V
STAYTON, MM
TI THE SYRINGOLIDES - BACTERIAL C-GLYCOSYL LIPIDS THAT TRIGGER
PLANT-DISEASE RESISTANCE
SO TETRAHEDRON LETTERS
LA English
DT Article
AB The salient structural and bioorganic properties of this new class of signal molecules are reported.
C1 UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521.
UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071.
RP SMITH, MJ (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,NAT PROD & INSTRUMENTAT BRANCH,WASHINGTON,DC 20204, USA.
NR 10
TC 64
Z9 64
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD JAN 8
PY 1993
VL 34
IS 2
BP 223
EP 226
DI 10.1016/S0040-4039(00)60552-X
PG 4
WC Chemistry, Organic
SC Chemistry
GA KF932
UT WOS:A1993KF93200009
ER
PT J
AU ALTERMAN, M
CARVAN, M
SRIVASTAVA, V
LEAKEY, J
HART, R
BUSBEE, D
AF ALTERMAN, M
CARVAN, M
SRIVASTAVA, V
LEAKEY, J
HART, R
BUSBEE, D
TI EFFECTS OF AGING AND LONG-TERM CALORIC RESTRICTION ON HEPATIC-MICROSOMAL
MONOOXYGENASES IN FEMALE FISCHER 344 RATS - ALTERATIONS IN BASAL
CYTOCHROME-P-450 CATALYTIC ACTIVITIES
SO AGE
LA English
DT Article
ID DRUG-METABOLIZING-ENZYMES; AGE-RELATED-CHANGES; LIVER-MICROSOMES; UPDATE
AB The effects of aging and caloric restriction on uninduced levels of hepatic microsomal cytochrome P-450s and specific P-450-related catalytic activities were evaluated in female Fischer 344 rats. Microsomes were isolated from livers of ad libitum (AL) fed rats 1, 3, 6, 16 and 26 months of age, and from calorie-restricted (CR) rats 6, 16 and 26 months of age. The recovery of microsomal protein was higher in CR than AL rats at 6, 16 and 26 months of age. Between ages 3 and 26 months there was a gradual decline in recovered microsomal P-450, but the differences between successive age categories were not significant. A different trend was observed for total cytochrome P-450 per liver. AL rats showed a 2-fold decline in P-450/liver between 6 and 26 months of age, while P-450/liver of corresponding CR rats increased 1.7-fold. Neither cytochrome b5 nor NADPH cytochrome C reductase varied consistently as a function of increased age, with all age groups showing greater reductase activity for CR rats than for AL rats. Phenobarbital (PB) and methylcholanthrene (MC) inducible cytochrome P-450 catalytic activities (pentoxy [PROD] and ethoxy [EROD] resorufin O-deethylases) exhibited similar age-related alterations that were distinctly different from the two other enzymes examined. Both PROD and EROD showed dramatic declines in activity between 1 and 3 months of age, with a slight increase in activity at 6 months and maintenance of the activity levels through 26 months. Benzphetamine N-demethylase (BND) and aniline p-hydroxylase (APH) activities were also altered as a function of increased age, with CR rats exhibiting increased isozyme activity above that seen for aging AL rats. Calorie restriction appears to have a modulating effect, compensating for an age-related decline of hepatic microsomal monooxygenase activity in female Fischer 344 rats.
C1 TEXAS A&M UNIV SYST,COLL VET MED,DEPT ANAT & PUBL HLTH,COLL STN,TX 77843.
TEXAS A&M UNIV SYST,COLL MED,DEPT PHYSIOL,COLL STN,TX 77843.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 32
TC 12
Z9 12
U1 1
U2 3
PU AMER AGING ASSOC
PI CHESTER
PA 2129 PROVIDENCE AVENUE, CHESTER, PA 19013
SN 0161-9152
J9 AGE
JI Age
PD JAN
PY 1993
VL 16
IS 1
BP 1
EP 8
DI 10.1007/BF02436124
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA KD002
UT WOS:A1993KD00200001
ER
PT J
AU GUEST, GB
AF GUEST, GB
TI USING PROPER DRUGS AND USING THEM PROPERLY
SO AGRI-PRACTICE
LA English
DT Note
RP GUEST, GB (reprint author), US FDA,CTR VET MED,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU VETERINARY PRACTICE PUBL CO
PI SANTA BARBARA
PA 7 ASHLEY AVE SOUTH, SANTA BARBARA, CA 93103-9989
SN 0745-452X
J9 AGRI-PRACTICE
JI Agri-Pract.
PD JAN
PY 1993
VL 14
IS 1
BP 20
EP 24
PG 5
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA KM242
UT WOS:A1993KM24200004
ER
PT J
AU NITTA, AT
DOUGLAS, JM
ARAKERE, G
EBENS, JB
AF NITTA, AT
DOUGLAS, JM
ARAKERE, G
EBENS, JB
TI DISSEMINATED MENINGOCOCCAL INFECTION IN HIV-SEROPOSITIVE PATIENTS
SO AIDS
LA English
DT Note
DE NEISSERIA-MENINGITIDIS; HIV; AIDS
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME;
AIDS-RELATED COMPLEX; VIRUS-INFECTION; BACTERIAL PNEUMONIA; BACTEREMIA;
VACCINE; ADULTS; RISK
AB Objective: Although increasing numbers of infections due to various bacterial pathogens have been described in HIV-infected individuals, there have been few reports to date of disseminated Neisseria meningitidis infections in such individuals. We describe here the presentation and clinical course of systemic meningococcal infection in two HIV-1-seropositive men and the response to meningococcal vaccine in one.
Design and methods: Retrospective analysis of case reports of two patients identified in a municipal hospital in Denver, Colorado, USA, and evaluation by enzyme-linked immunosorbent assay of antibody response to quadrivalent (A, C, Y, W-135) meningococcal vaccine.
Results: A 27-year-old HIV-seropositive man with bacteremic group Y meningococcal pneumonia and a 45-year-old man with AIDS and group B meningococcal arthritis both responded to short-term antibiotic therapy without recurrence. The second patient responded to meningococcal vaccination with seroconversion to all four serogroups.
Conclusions: Disseminated meningococcal infection, although rare in HIV-infected individuals, may present with a variety of clinical manifestations and responds well to antibiotic therapy. Meningococcal vaccine appears to be immunogenic in such individuals.
C1 DENVER DIS CONTROL SERV,605 BANNOCK ST,DENVER,CO 80204.
UNIV COLORADO,HLTH SCI CTR,DIV INFECT DIS,DENVER,CO 80262.
UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262.
US FDA,BETHESDA,MD 20014.
NR 29
TC 19
Z9 20
U1 0
U2 0
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD JAN
PY 1993
VL 7
IS 1
BP 87
EP 90
DI 10.1097/00002030-199301000-00013
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA KG970
UT WOS:A1993KG97000013
PM 8442922
ER
PT B
AU SHANK, FR
AF SHANK, FR
BE Tillotson, JE
TI HEALTH MESSAGES ON FOOD LABELS
SO AMERICAS FOODS HEALTH MESSAGES AND CLAIMS: SCIENTIFIC, REGULATORY, AND
LEGAL ISSUES
SE CRC SERIES IN CONTEMPORARY FOOD SCIENCE
LA English
DT Proceedings Paper
CT Symposium on Americas Foods Health Messages and Claims: Scientific,
Regulatory, and Legal Issues
CY MAR, 1990
CL BOSTON, MA
SP TUFT UNIV, FOOD POLICY INST, US FDA, USDA, NATL FOOD PROCESSORS ASSOC, GROCERY MANUFACTURERS AMER, FLORIDA DEPT CITRUS, AMER XYROFIN, CAMPBELL SOUP, FRITO LAY, GEN MILLS
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, BOCA RATON, FL 33431
BN 0-8493-8001-4
J9 CRC CONTEMP FOOD SCI
PY 1993
BP 131
EP 136
PG 6
WC Food Science & Technology; Public, Environmental & Occupational Health
SC Food Science & Technology; Public, Environmental & Occupational Health
GA BZ62A
UT WOS:A1993BZ62A00009
ER
PT B
AU VANDERVEEN, JE
AF VANDERVEEN, JE
BE Tillotson, JE
TI FUTURE HEALTH MESSAGES
SO AMERICAS FOODS HEALTH MESSAGES AND CLAIMS: SCIENTIFIC, REGULATORY, AND
LEGAL ISSUES
SE CRC SERIES IN CONTEMPORARY FOOD SCIENCE
LA English
DT Proceedings Paper
CT Symposium on Americas Foods Health Messages and Claims: Scientific,
Regulatory, and Legal Issues
CY MAR, 1990
CL BOSTON, MA
SP TUFT UNIV, FOOD POLICY INST, US FDA, USDA, NATL FOOD PROCESSORS ASSOC, GROCERY MANUFACTURERS AMER, FLORIDA DEPT CITRUS, AMER XYROFIN, CAMPBELL SOUP, FRITO LAY, GEN MILLS
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, BOCA RATON, FL 33431
BN 0-8493-8001-4
J9 CRC CONTEMP FOOD SCI
PY 1993
BP 163
EP 166
PG 4
WC Food Science & Technology; Public, Environmental & Occupational Health
SC Food Science & Technology; Public, Environmental & Occupational Health
GA BZ62A
UT WOS:A1993BZ62A00014
ER
PT J
AU WARE, GM
FRANCIS, O
KUAN, SS
UMRIGAR, P
CARMAN, A
CARTER, L
BENNETT, GA
AF WARE, GM
FRANCIS, O
KUAN, SS
UMRIGAR, P
CARMAN, A
CARTER, L
BENNETT, GA
TI DETERMINATION OF FUMONISIN-B1 IN CORN BY HIGH-PERFORMANCE
LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
SO ANALYTICAL LETTERS
LA English
DT Article
DE FUMONISIN-B1; CORN SAMPLE; FLUORESCENCE; DETERMINATION; DERIVATIZATION;
REAGENT; NAPHTHALENE-2,3-DICARBOXALDEHYDE; HPLC
ID FUSARIUM-MONILIFORME; CARCINOGENICITY; RATS
AB A method is described for the determination of fumonisin B1 in corn. The method involves sample extraction with methanol:water (75:25) and partial purification using a solid phase extraction. Fumonisin B1 is reacted with naphthalene-2,3-dicarboxaldehyde (NDA) to produce a highly fluorescent derivative, 1-cyano-2-alkyl-benz[f]isoindole (CBI) and then separated from the sample matrix on a reverse phase C-18 column with a mobile phase of acetonitrile:water:acetic acid (55:45:1). The NDA-derivative is quantitated by fluorescence detection at 410 nm excitation and a 440 nm, long past emission filter. Recoveries of fumonisin B1 added to corn at levels of 0.25-20.0 mug/g averaged 88.1% with a coefficient of variation of 10.3%. Confirmation of fumonisin B1 in corn samples was accomplished by fast atom bombardment (FAB) spectroscopy.
C1 USDA,NCAUR,PEORIA,IL 61604.
RP WARE, GM (reprint author), US FDA,NAT TOXINS RES CTR,4298 ELYSIAN FIELDS AVE,NEW ORLEANS,LA 70122, USA.
NR 18
TC 23
Z9 23
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PY 1993
VL 26
IS 8
BP 1751
EP 1770
PG 20
WC Chemistry, Analytical
SC Chemistry
GA LL488
UT WOS:A1993LL48800015
ER
PT J
AU ZURLO, JJ
ONEILL, D
POLIS, MA
MANISCHEWITZ, J
YARCHOAN, R
BASELER, M
LANE, HC
MASUR, H
AF ZURLO, JJ
ONEILL, D
POLIS, MA
MANISCHEWITZ, J
YARCHOAN, R
BASELER, M
LANE, HC
MASUR, H
TI LACK OF CLINICAL UTILITY OF CYTOMEGALOVIRUS BLOOD AND URINE CULTURES IN
PATIENTS WITH HIV-INFECTION
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
DE CYTOMEGALOVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; VIRUS CULTIVATION;
VIREMIA; VIRURIA; ACQUIRED IMMUNODEFICIENCY SYNDROME
ID IMMUNE-DEFICIENCY SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME;
HOMOSEXUAL MEN; VIRUS INFECTION; SYNDROME AIDS; RETINITIS;
MANIFESTATION; DISEASE; GUANINE
AB Objective: To determine the clinical significance of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus (HIV) infection.
Design: Inception cohort of patients with HIV infection and CMV culture data.
Setting: Government referral-based research hospital.
Patients: A total of 322 HIV-infected patients who had a CMV blood culture and 293 HIV-infected patients who had a CMV urine culture within 7 days of a CD4 determination.
Measurements: Cytomegalovirus blood and urine culture results; circulating CD4 lymphocyte counts; pathologic or retinopathic findings of CMV disease.
Results: Nine of 26 patients (34.6%) with CMV viremia subsequently developed CMV end-organ disease compared with 11 of 74 (14.9%) patients without viremia, (difference, 19.7%; 95% CI, -0.3% to 39.7%). Fifteen of 47 patients (31.9%) with CMV viruria developed end-organ disease compared with 4 of 43 (9.3%) patients without viruria, (difference, 22.6%; CI, 6.7% to 38.5%). Cytomegalovirus culture positivity had poor predictive value for the subsequent development of end-organ disease (35% for viremia and 28% for viruria). Further, patients with proven end-organ disease were often not viremic (45%), but most were viruric (88%). Cytomegalovirus viremia did not correlate with the presence of either fever or weight loss in this patient group. Both blood culture positivity and urine culture positivity varied inversely with the CD4 count (P = 0.0001 for both associations).
Conclusions: The likelihood that a blood or urine culture will be positive in a patient with HIV infection correlates better with immunologic status than with current or future clinical status. Although the absence of CMV viruria may suggest that CMV disease is not present, CMV blood and urine cultures have poor diagnostic and predictive value and therefore should be used primarily for research purposes or drug susceptibility testing and not for making clinical decisions.
C1 NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702.
NIAID,BETHESDA,MD 20892.
NCI,BETHESDA,MD 20892.
OI Polis, Michael/0000-0002-9151-2268
FU NCI NIH HHS [N01-CO-74102]
NR 16
TC 79
Z9 82
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN 1
PY 1993
VL 118
IS 1
BP 12
EP 17
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA KE605
UT WOS:A1993KE60500003
PM 8093214
ER
PT J
AU STRAUS, SE
COHEN, JI
TOSATO, G
MEIER, J
AF STRAUS, SE
COHEN, JI
TOSATO, G
MEIER, J
TI EPSTEIN-BARR-VIRUS INFECTIONS - BIOLOGY, PATHOGENESIS, AND MANAGEMENT
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Discussion
DE EPSTEIN-BARR VIRUS; B-LYMPHOCYTES; INFECTIOUS MONONUCLEOSIS; BURKITTS
LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS
ID LINKED LYMPHOPROLIFERATIVE SYNDROME; BONE-MARROW TRANSPLANTATION; LATENT
MEMBRANE-PROTEIN; ORAL HAIRY LEUKOPLAKIA; T-CELL EPITOPE; B-CELLS;
APLASTIC-ANEMIA; EPITHELIAL-CELLS; HODGKINS-DISEASE; VIRAL LATENCY
AB Epstein-Barr virus (EBV) encodes genes that ensure its persistence in human B lymphocytes. Some of the genes encourage B-cell proliferation; others are poised to evade or defeat immune recognition. Immune restraints on the virus, however, are typically so effective that most infections are never symptomatic. In contrast, acute infectious mononucleosis, a self-limited lymphoproliferative illness, is common in adolescents and young adults. Unbridled proliferative illnesses arise when cellular immunity is grossly defective. Treatment of EBV-associated syndromes is largely supportive. Antiviral drugs have no proven role except in patients with oral hairy leukoplakia. Vaccine development is technically feasible but is not considered a high priority for developed nations.
C1 US FDA,CTR BIOL EVALUAT & RES,IMMUNOL LAB,BETHESDA,MD 20014.
RP STRAUS, SE (reprint author), NIAID,MED VIROL SECT,CLIN INVEST LAB,BLDG 10,ROOM 11N228,BETHESDA,MD 20892, USA.
NR 107
TC 270
Z9 281
U1 1
U2 6
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN 1
PY 1993
VL 118
IS 1
BP 45
EP 58
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA KE605
UT WOS:A1993KE60500009
PM 8380053
ER
PT J
AU CRESCENZO, DG
HILBERT, SL
MESSIER, RH
DOMKOWSKI, PW
BARRICK, MK
LANGE, PL
FERRANS, VJ
WALLACE, RB
HOPKINS, RA
AF CRESCENZO, DG
HILBERT, SL
MESSIER, RH
DOMKOWSKI, PW
BARRICK, MK
LANGE, PL
FERRANS, VJ
WALLACE, RB
HOPKINS, RA
TI HUMAN CRYOPRESERVED HOMOGRAFTS - ELECTRON-MICROSCOPIC ANALYSIS OF
CELLULAR INJURY
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID AORTIC-VALVE REPLACEMENT; TERM FOLLOW-UP; ALLOGRAFT
AB Twenty-five human cryopreserved valves with harvest-related warm ischemic times (WITs) ranging from 0 to 20 hours were studied using transmission electron microscopy to characterize the effects of harvesting and preservation on leaflet matrix cells. The valves were divided into seven groups on the basis of WIT and processed using standard transmission electron microscopic methods. Each cell (528 micrographs) was graded for reversible and irreversible cellular injury and subjected to a Cochran-Mantel-Haenszel trend analysis. Our results demonstrated a progression in cellular injury with increasing WIT. During the first 12 hours of warm ischemia, reversible cellular injury predominated (0.0%, 30.0%, 51.2%, 31.3%, 35.1%, 45.1%, and 40.0% at WITs of 0, 1, 2, 8, 12, 16, and 20 hours, respectively). A positive correlation (p < 0.0001) between increasing WIT and reversible cellular injury through the first 12 hours was observed. Minimal morphologic evidence of irreversible injury was noted in valves harvested with less than 12 hours of warm ischemia; however, after 12 hours there was a marked increase (0.0%, 0.0%, 4.7%, 2.4%, 2.7%, 31.4%, and 40.0% at WITs of 0, 1, 2, 8, 12, 16, and 20 hours, respectively) in irreversible cellular injury (p < 0.001 between 12 and 20 hours WIT). These data demonstrate a progression in cellular injury with increasing WIT. There was virtually no morphologic injury in valves with harvest-related WITs less than 2 hours and minimal irreversible cellular injury observed in valves exposed to 12 hours or less of warm ischemia. If cellular viability is critical to homograft durability then harvest-related warm ischemia may need to be restricted to 12 hours.
C1 GEORGETOWN UNIV,SCH MED,DEPT SURG,4PHC,3800 RESERVOIR RD NW,WASHINGTON,DC 20007.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 27
TC 14
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JAN
PY 1993
VL 55
IS 1
BP 25
EP 31
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA KF248
UT WOS:A1993KF24800005
PM 8417694
ER
PT J
AU EGAN, W
AF EGAN, W
TI THE DEVELOPMENT AND CURRENT STATUS OF GLYCOCONJUGATE VACCINES
SO ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 28
SE ANNUAL REPORTS IN MEDICINAL CHEMISTRY
LA English
DT Review
ID GROUP-B STREPTOCOCCUS; SIALIC-ACID POLYSACCHARIDE; PROTEIN CONJUGATE
VACCINE; ESCHERICHIA-COLI K1; CAPSULAR POLYSACCHARIDE;
HEMOPHILUS-INFLUENZAE; MEMBRANE-PROTEIN; BACTERIAL-MENINGITIS;
MOLECULAR-WEIGHT; YOUNG-CHILDREN
RP EGAN, W (reprint author), US FDA,CTR BIOL EVALUAT & RES,8800 ROCKVILLE PK,BETHESDA,MD 20892, USA.
NR 63
TC 9
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0065-7743
J9 ANNU REP MED CHEM
PY 1993
VL 28
BP 257
EP 265
PG 9
WC Chemistry, Applied; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA BA26B
UT WOS:A1993BA26B00027
ER
PT J
AU BLACK, PL
DOWNS, MB
LEWIS, MG
USSERY, MA
DREYER, GB
PETTEWAY, SR
LAMBERT, DM
AF BLACK, PL
DOWNS, MB
LEWIS, MG
USSERY, MA
DREYER, GB
PETTEWAY, SR
LAMBERT, DM
TI ANTIRETROVIRAL ACTIVITIES OF PROTEASE INHIBITORS AGAINST MURINE
LEUKEMIA-VIRUS AND SIMIAN IMMUNODEFICIENCY VIRUS IN TISSUE-CULTURE
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID SYNTHETIC HIV-1 PROTEASE; CRYSTAL-STRUCTURE; HTLV-III; RETROVIRAL
PROTEASES; VIRAL INFECTIVITY; ASPARTIC PROTEASE; ESCHERICHIA-COLI;
RATIONAL DESIGN; CELL LINES; MATURATION
AB Rationally designed synthetic inhibitors of retroviral proteases inhibit the processing of viral polyproteins in cultures of human immunodeficiency virus type 1 (HIV-1)-infected T lymphocytes and, as a result, inhibit the infectivity of HIV-1 for such cultures. The ability of HIV-1 protease inhibitors to suppress replication of the C-type retrovirus Rauscher murine leukemia virus (R-MuLV) and the HIV-related lentivirus simian immunodeficiency virus (SIV) was examined in plaque reduction assays and syncytium reduction assays, respectively. Three of seven compounds examined blocked production of infectious R-MuLV, with 50% inhibitory concentrations of less-than-or-equal-to 1 muM. Little or no cellular cytotoxicity was detectable at concentrations up to 100 muM. The same compounds which inhibited the infectivity of HIV-1 also produced activity against SIV and R-MuLV. Electron microscopic examination revealed the presence of many virions with atypical morphologies in cultures treated with the active compounds. Morphometric analysis demonstrated that the active compounds reduced the number of membrane-associated virus particles. These results demonstrate that synthetic peptide analog inhibitors of retroviral proteases significantly inhibit proteolytic processing of the gag polyproteins of R-MuLV and SIV and inhibit the replication of these retroviruses. These results are similar to those for inhibition of HIV-1 infectivity by these compounds, and thus, R-MuLV and SIV might be suitable models for the in vivo evaluation of the antiretroviral activities of these protease inhibitors.
C1 USA,MED RES INST INFECT DIS,DIV PATHOL,FT DETRICK,MD 21702.
US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20857.
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406.
SMITHKLINE BEECHAM PHARMACEUT,DEPT ANTIINFECT,KING OF PRUSSIA,PA 19406.
RP BLACK, PL (reprint author), SO RES INST,FREDERICK RES CTR,FREDERICK,MD 21701, USA.
FU PHS HHS [1U01A125617]
NR 36
TC 14
Z9 15
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 1993
VL 37
IS 1
BP 71
EP 77
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA KF247
UT WOS:A1993KF24700013
PM 8381640
ER
PT J
AU PITHA, J
ANAND, R
AF PITHA, J
ANAND, R
TI ALPHA-CYCLODEXTRIN SULFATE, AN ANTI-HIV AGENT, RETAINS ITS ANTIVIRAL
EFFECT IN THE PRESENCE OF HYDROCORTISOL PHOSPHATE
SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
LA English
DT Note
AB Cyclodextrin sulphates alpha (a) and beta (b) were found to be inhibitors of replication of human immunodeficiency virus (HIV-1) in phytohaemagglutinin (PHA)-stimulated human peripheral blood mononuclear cells (PBMC); the same cells were also stimulated to proliferate (Anand et al., 1990). B-Cyclodextrin sulphate was also found to stimulate another, more complex, cell proliferation-neovascularization process in rabbit cornea (Folkman et al., 1989). Since the process of neovascularization is generally associated with progression of tumour growth and other pathologies, it is obvious that its stimulation by an antiviral compound may be a serious side effect. Nevertheless endotoxin-induced neovascularization can be suppressed by simultaneous treatment with b-cyclodextrin sulphate and glucocorticoids (Folkman et al., 1989). The same co-treatment may possibly be used to improve antiviral action of cyclodextrin sulphates, but such a combination therapy may not be free of complications. Glucocorticoids also affect the stability of various cellular membranes. Treatment of cells in vitro by glucocorticoids is known to stabilize their lysozymes. Glucocorticoids affect both the proliferative capacity of the cells (Cristofalo, 1972) and cytopathic effects of rabies viral infection. Furthermore, it has been reported that the cytopathic effects of rabies and of yellow fever viruses were inhibited while those of the polio virus were only mildly affected (Hannoun et al., 1965). Consequently, in this work we evaluated effects of a glucocorticoid and of glucocorticoid-a-cyclodextrin sulphate combination on HIV-1 replication.
C1 NIA,GERONTOL RES CTR,BALTIMORE,MD 21224.
US FDA,CTR BIOL EVALUAT & RES,RETROVIROL LAB,BETHESDA,MD 20892.
NR 4
TC 1
Z9 1
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0956-3202
J9 ANTIVIR CHEM CHEMOTH
JI Antivir. Chem. Chemother.
PY 1993
VL 4
IS 1
BP 65
EP 66
PG 2
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
GA KG792
UT WOS:A1993KG79200008
ER
PT J
AU QIAN, M
SWAGLER, AR
MEHTA, M
VISHWANATHAN, CT
GALLO, JM
AF QIAN, M
SWAGLER, AR
MEHTA, M
VISHWANATHAN, CT
GALLO, JM
TI PHARMACOKINETIC EVALUATION OF ANTI-HIV DRUG-INTERACTIONS - EFFECT OF
ZIDOVUDINE ON 2'-3'-DIDEOXYINOSINE KINETICS IN MONKEYS
SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
LA English
DT Article
ID AIDS-RELATED COMPLEX; IMMUNODEFICIENCY-VIRUS TYPE-1; PLACEBO-CONTROLLED
TRIAL; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; 2',3'-DIDEOXYINOSINE;
DIDANOSINE; 3'-AZIDO-3'-DEOXYTHYMIDINE; TOXICITY; THERAPY
AB The current investigation was conducted to determine if zidovudine (AZT) altered the pharmacokinetics of dideoxyinosine (ddl) in non-human primates, an appropriate animal model for AZT and ddl pharmacokinetics in human. Each of nine animals received 20 mg kg-1 of ddl intravenously in the absence and presence of two different dosage regimens of AZT. For each combination regimen, AZT was administered as a combined i.v. bolus-constant rate infusion regimen for 30 min that produced AZT plasma concentrations of about 4 mug ml 1 in six animals (low dose group) and 11 mug ml-1 in three others (high dose group). Serial blood samples were collected, and pharmacokinetic parameters for ddl were calculated based on plasma ddl concentrations measured by HPLC techniques.
The pharmacokinetics of ddl given alone in the first phase of the low (n = 6) and high (n = 6) dose AZT groups, resulted in a mean elimination half-life 1.54 and 1.9h, a mean total clearance of 0.62 and 0.731 h-1 kg-1, and a mean steady state volume of distribution of 1.02 and 0.891 kg-1, respectively. Following combined ddl and AZT administrations, in both the low and high dose AZT groups, plasma concentration-time profiles of ddl were similar for each monkey, and no statistical differences were observed in the pharmacokinetic parameters compared to those obtained when ddl was given alone. The fact that AZT does not alter the pharmacokinetics of ddl at the range of AZT dose studied provides a basis for rational dosage design for combined ddl and AZT treatments in HIV infection.
C1 UNIV GEORGIA,COLL PHARM,DEPT PHARMACEUT,ATHENS,GA 30602.
US FDA,CTR DRUG EVALUAT & RES,DIV BIOPHARMACEUT,ROCKVILLE,MD 20857.
NR 26
TC 4
Z9 4
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0956-3202
J9 ANTIVIR CHEM CHEMOTH
JI Antivir. Chem. Chemother.
PY 1993
VL 4
IS 3
BP 155
EP 159
PG 5
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
GA LB655
UT WOS:A1993LB65500004
ER
PT J
AU DATTA, AR
MOORE, MAA
WENTZ, BA
LANE, J
AF DATTA, AR
MOORE, MAA
WENTZ, BA
LANE, J
TI IDENTIFICATION AND ENUMERATION OF LISTERIA-MONOCYTOGENES BY
NONRADIOACTIVE DNA PROBE COLONY HYBRIDIZATION
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID PHOSPHOLIPASE-C ACTIVITY; NONPATHOGENIC LISTERIA; INTRACELLULAR GROWTH;
HEMOLYSIN; VIRULENCE; PROTEIN; GENE; DISTINGUISH; DETERMINANT; IVANOVII
AB A plasmid containing the cloned listeriolysin gene of Listeria monocytogenes was used as a probe to identify Listeria strains by DNA colony hybridization. The probe DNA was labeled with horseradish peroxidase in the presence of glutaraldehyde. After the hybridization and wash procedures, the hybrid molecules were detected by luminescence, which resulted from the oxidation of luminol by a horseradish peroxidase-hydrogen peroxide-coupled reaction. Of the 150 Listeria strains and 16 non-Listeria strains examined, the probe hybridized only with L. monocytogenes. The technique was also used to enumerate L. monocytogenes in artificially contaminated foods.
RP DATTA, AR (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 42
TC 17
Z9 17
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD JAN
PY 1993
VL 59
IS 1
BP 144
EP 149
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA KF249
UT WOS:A1993KF24900024
PM 8439145
ER
PT J
AU PETTIT, GH
SAUERBREY, R
AF PETTIT, GH
SAUERBREY, R
TI PULSED ULTRAVIOLET-LASER ABLATION
SO APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING
LA English
DT Article
ID EXCIMER LASER; BIOLOGICAL TISSUE; XECL LASER; POLYIMIDE; POLYMERS;
ABSORPTION; PHOTOABLATION; SPECTRUM; FILMS; NM
AB The radiation transport involved in pulsed ultraviolet laser ablation of organic materials has been studied both theoretically and experimentally. A mathematical description of the absorption process that includes nonlinear effects such as chromophore saturation and multiphoton absorption is presented. This theoretical model accurately describes the observed polymer etch depth versus incident laser fluence relationship for various target materials, laser wavelengths, and pulse durations varying from nanoseconds to subpicoseconds. The theoretical analysis can also be used to explain observed nonlinearities in the transmission characteristics of polyimide subjected to intense KrF excimer laser irradiation.
C1 RICE UNIV,RICE QUANTUM INST,HOUSTON,TX 77251.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
RP PETTIT, GH (reprint author), RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251, USA.
NR 37
TC 120
Z9 120
U1 1
U2 12
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0947-8396
J9 APPL PHYS A-MATER
JI Appl. Phys. A-Mater. Sci. Process.
PD JAN
PY 1993
VL 56
IS 1
BP 51
EP 63
DI 10.1007/BF00351903
PG 13
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA KC880
UT WOS:A1993KC88000009
ER
PT J
AU MOREHOUSE, KM
DESROSIERS, MF
AF MOREHOUSE, KM
DESROSIERS, MF
TI ELECTRON-SPIN-RESONANCE INVESTIGATIONS OF GAMMA-IRRADIATED SHRIMP SHELL
SO APPLIED RADIATION AND ISOTOPES
LA English
DT Article; Proceedings Paper
CT 3RD INTERNATIONAL SYMP ON ESR ( ELECTRON SPIN RESONANCE ) DOSIMETRY AND
APPLICATIONS
CY OCT 14-18, 1991
CL NIST, GAITHERSBURG, MD
SP US DEPT COMMERCE, US DEF NUCL AGCY, US DOE
HO NIST
DE ELECTRON SPIN RESONANCE; ESR; GAMMA-IRRADIATION; SHRIMP SHELL; FREE
RADICALS; SHRIMP
ID FOOD
AB Gamma-irradiation of shrimp shell induces the formation of stable free radicals, which can be monitored by electron spin resonance (ESR) spectroscopy. The ESR spectrum of the free radicals is more complex than was originally reported, and was found to be species-dependent. The results presented include the effects of the following parameters on the ESR spectrum: different types of pre- and post-irradiation processing, absorbed dose, storage time, and species variations. The effects of these parameters on the ESR spectra are used to explain discrepancies between previously reported spectra for irradiated shrimp shell. Finally, the possible application of ESR spectroscopy as a tool for post-irradiation monitoring of shrimp is assessed.
C1 NATL INST STAND & TECHNOL,TECHNOL ADM DEPT COMMERCE,DIV IONIZING RADIAT,PHYS LAB,GAITHERSBURG,MD 20899.
RP MOREHOUSE, KM (reprint author), US FDA,DIV FOOD CHEM & TECHNOL,WASHINGTON,DC 20204, USA.
NR 11
TC 20
Z9 20
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0969-8043
J9 APPL RADIAT ISOTOPES
JI Appl. Radiat. Isot.
PD JAN-FEB
PY 1993
VL 44
IS 1-2
BP 429
EP 432
DI 10.1016/0969-8043(93)90261-8
PG 4
WC Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology,
Nuclear Medicine & Medical Imaging
SC Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA KP625
UT WOS:A1993KP62500076
PM 8386049
ER
PT J
AU KAZEMPOUR, MK
GRAYBILL, FA
AF KAZEMPOUR, MK
GRAYBILL, FA
TI CONFIDENCE-BOUNDS FOR RATIO OF VARIANCE-COMPONENTS IN UNBALANCED 2-WAY
CROSSED MODELS
SO ARCHIV FUR TIERZUCHT-ARCHIVES OF ANIMAL BREEDING
LA English
DT Article
DE CONFIDENCE INTERVALS FOR VARIANCE COMPONENTS; UNBALANCED 2-WAY MODELS;
EMPTY CELLS
AB Consider the two-way crossed components-of-variance model given by y(ijk) = mu + A(i) + B(j) + E(ijk) (i = 1,2, ... , a; j = 1,2, ..., b; k = 1,2, ... n(ij) greater-than-or-equal-to 0) where A(i), B(j) and E(ijk) are unobservable independent normal random variables with means zero and variances sigma(A)2, sigma(B)2 and sigma(E)2 respectively. In this paper confidence bounds on p(A) = sigma(A)2/sigma2 and p(B) = sigma(B)2/sigma2, where sigma2 = sigma(A)2 + sigma(B)2 + sigma(E)2, are derived for the above model. The balanced incomplete block model is a special case.
RP KAZEMPOUR, MK (reprint author), US FDA,5600 FISHERS LN,HFD 715,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ARCHIV FUR TIERZUCHT
PI DUMMERSTORF
PA WILHELM-STAHL-ALLEE 2, D-18196 DUMMERSTORF, GERMANY
SN 0003-9438
J9 ARCH TIERZUCHT
JI Arch. Tierz.-Arch. Anim. Breed.
PY 1993
VL 36
IS 1
BP 105
EP 114
PG 10
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA KL058
UT WOS:A1993KL05800010
ER
PT J
AU HASE, T
DUBOIS, DR
SUMMERS, PL
DOWNS, MB
USSERY, MA
AF HASE, T
DUBOIS, DR
SUMMERS, PL
DOWNS, MB
USSERY, MA
TI COMPARISON OF REPLICATION RATES AND PATHOGENICITIES BETWEEN THE SA-14
PARENT AND SA-14-14-2 VACCINE STRAINS OF JAPANESE ENCEPHALITIS-VIRUS IN
MOUSE-BRAIN NEURONS
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID CULTURED MOSQUITO CELLS; ENVELOPE PROTEIN-E; MONOCLONAL-ANTIBODIES;
PROTECTIVE IMMUNITY; ATTENUATED VACCINE; ENTRY; FLAVIVIRUSES;
GLYCOPROTEIN
AB The replication rates and pathogenicities of the SA 14 parent and SA 14-14-2 vaccine strains of Japanese encephalitis (JE) virus in neurons of the mouse brain following intracerebral inoculation were compared. All the mice inoculated with the SA 14 parent strain died within one week postinoculation (p.i.), whereas all the mice inoculated with the SA 14 - 14-2 vaccine strains survived without showing any signs of central nervous system (CNS) involvement. The virus titers of the mouse brains inoculated with the SA 14 strain reached progressively higher levels until day 5 when the animals died. On the other hand, the virus titers of the mouse brains inoculated with the SA 14- 14-2 strain persisted at low levels for several days and could not be detected after 10 days. In the routine electron microscopical study, a majority of neurons in the mouse brains inoculated with the SA 14 strain contained virions and showed characteristic cytopathological changes in connection with viral replication. In the brains inoculated with the SA 14- 14-2. strain, however, we failed to find neurons containing virions or showing characteristic cytopathological changes. In the alkaline phosphatase immunostaining of paraffin-embedded sections, a majority of neurons in the brains of mice inoculated with the SA 14 strain stained positively on day 5 p.i., but only a small number of neurons in scattered small foci stained positively in the brains inoculated with the SA 14- 14-2 strain. The immunogold staining of Vibratome sections also revealed the identical patterns; moreover, electron microscopical examination of the immunopositive foci of the brain inoculated with the vaccine strain revealed neurons that contained virions in dilated cisternae of rough endoplasmic reticulum (RER), indicating that the SA 14- 14-2 strain also replicated, albeit poorly, in neurons. The present results showed that upon intracerebral inoculation into mice the SA 14 parent strain of JE virus grew vigorously in a large number of neurons, killing the animals, while the SA 14- 14-2 vaccine strain grew poorly only in a small number of neurons without causing mortality. Possible mechanisms involved in the alteration of pathogenicity between the SA 14 parent virus and the SA 14- 14-2 vaccine virus are discussed.
C1 WALTER REED ARMY INST RES,DEPT BIOL RES,WASHINGTON,DC 20307.
USA,MED RES INST INFECT DIS,DEPT PATHOL,FT DETRICK,MD.
US FDA,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20857.
RP HASE, T (reprint author), WALTER REED ARMY INST RES,DIV PATHOL,DEPT ULTRASTRUCT PATHOL,WASHINGTON,DC 20307, USA.
NR 26
TC 18
Z9 19
U1 0
U2 0
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1993
VL 130
IS 1-2
BP 131
EP 143
DI 10.1007/BF01319002
PG 13
WC Virology
SC Virology
GA LC650
UT WOS:A1993LC65000011
PM 8503779
ER
PT J
AU ABLASHI, D
AGUT, H
BERNEMAN, Z
CAMPADELLIFIUME, G
CARRIGAN, D
CECCERININELLI, L
CHANDRAN, B
CHOU, S
COLLANDRE, H
CONE, R
DAMBAUGH, T
DEWHURST, S
DILUCA, D
FOATOMASI, L
FLECKENSTEIN, B
FRENKEL, N
GALLO, R
GOMPELS, U
HALL, C
JONES, M
LAWRENCE, G
MARTIN, M
MONTAGNIER, L
NEIPEL, F
NICHOLAS, J
PELLETT, P
RAZZAQUE, A
TORRELLI, G
THOMSON, B
SALAHUDDIN, S
WYATT, L
YAMANISHI, K
AF ABLASHI, D
AGUT, H
BERNEMAN, Z
CAMPADELLIFIUME, G
CARRIGAN, D
CECCERININELLI, L
CHANDRAN, B
CHOU, S
COLLANDRE, H
CONE, R
DAMBAUGH, T
DEWHURST, S
DILUCA, D
FOATOMASI, L
FLECKENSTEIN, B
FRENKEL, N
GALLO, R
GOMPELS, U
HALL, C
JONES, M
LAWRENCE, G
MARTIN, M
MONTAGNIER, L
NEIPEL, F
NICHOLAS, J
PELLETT, P
RAZZAQUE, A
TORRELLI, G
THOMSON, B
SALAHUDDIN, S
WYATT, L
YAMANISHI, K
TI HUMAN HERPESVIRUS-6 STRAIN GROUPS - A NOMENCLATURE
SO ARCHIVES OF VIROLOGY
LA English
DT Editorial Material
C1 NCI,BETHESDA,MD 20892.
HOP LA PITIE SALPETRIERE,PARIS,FRANCE.
CHILDRENS HOSP,SEATTLE,WA.
DUPONT MERCK PHARMACEUT CO,WILMINGTON,PA.
IST MICROBIOL,FERRARA,ITALY.
MAQUARIE UNIV,SYDNEY,NSW,AUSTRALIA.
UNIV PISA,I-56100 PISA,ITALY.
VET ADM MED CTR,PORTLAND,OR 97207.
TEL AVIV UNIV,IL-69978 TEL AVIV,ISRAEL.
JOHNS HOPKINS UNIV,BALTIMORE,MD 21218.
US FDA,BETHESDA,MD 20014.
NIH,BETHESDA,MD 20892.
UNIV BOLOGNA,I-40126 BOLOGNA,ITALY.
UNIV KANSAS,LAWRENCE,KS 66045.
UNIV ROCHESTER,ROCHESTER,NY 14627.
UNIV CAMBRIDGE,CAMBRIDGE,ENGLAND.
CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,VIRAL EXANTHEMS & HERPESVIRUS BRANCH,ATLANTA,GA 30333.
UNIV MODENA,I-41100 MODENA,ITALY.
OSAKA UNIV,OSAKA,JAPAN.
MED COLL WISCONSIN,MILWAUKEE,WI 53226.
INST PASTEUR,F-75724 PARIS 15,FRANCE.
UNIV ERLANGEN NURNBERG,W-8520 ERLANGEN,GERMANY.
HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND.
NATL INST MED RES,LONDON NW7 1AA,ENGLAND.
UNIV SO CALIF,LOS ANGELES,CA 90089.
RI Di Luca, Dario/M-9781-2014
OI Di Luca, Dario/0000-0001-9643-9170
NR 18
TC 143
Z9 145
U1 1
U2 4
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1993
VL 129
IS 1-4
BP 363
EP 366
DI 10.1007/BF01316913
PG 4
WC Virology
SC Virology
GA KT986
UT WOS:A1993KT98600034
ER
PT B
AU CHEN, M
PATNAIK, R
DIGHE, S
WILLIAMS, RL
AF CHEN, M
PATNAIK, R
DIGHE, S
WILLIAMS, RL
BE Midha, KK
Blume, HH
TI BIOEQUIVALENCE OF MARKETED FORMULATIONS - HIGHLY VARIABLE DRUGS AND
OTHER ISSUES
SO BIO-INTERNATIONAL: BIOAVAILABILITY, BIOEQUIVALENCE AND PHARMACOKINETICS
SE F.I.P. PAPERBACK
LA English
DT Proceedings Paper
CT International Conference of F I P - Bio-International 92:
Bioavailability, Bioequivalence and Pharmacokinetics
CY MAY 20-22, 1992
CL BAD HOMBURG, GERMANY
SP FEDERAT INT PHARM, AMER ASSOC PHARM SCIENTISTS, US FDA, CANADIAN HLTH PROTECT BRANCH, BUNDESGESUNDHEITSAMT, EUROPEAN FEDERAT PHARM SCI, ACAD PHARM SCI & TECHNOL JAPAN, DUTCH MED EVALUAT BOARD, ZENTRALLAB DEUT APOTHEKER
C1 US FDA,OFF GENER DRUGS,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MEDPHARM GMBH SCIENTIFIC PUBL
PI STUTTGART
PA BIRKENWALDSTRASSE 44, D-7000 STUTTGART, GERMANY
J9 F I P PAPERBACK
PY 1993
BP 125
EP 131
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BA31E
UT WOS:A1993BA31E00009
ER
PT B
AU DIGHE, SV
PATNAIK, RN
AF DIGHE, SV
PATNAIK, RN
BE Midha, KK
Blume, HH
TI NEED FOR METABOLITE ANALYSIS IN BIOEQUIVALENCE STUDIES
SO BIO-INTERNATIONAL: BIOAVAILABILITY, BIOEQUIVALENCE AND PHARMACOKINETICS
SE F.I.P. PAPERBACK
LA English
DT Proceedings Paper
CT International Conference of F I P - Bio-International 92:
Bioavailability, Bioequivalence and Pharmacokinetics
CY MAY 20-22, 1992
CL BAD HOMBURG, GERMANY
SP FEDERAT INT PHARM, AMER ASSOC PHARM SCIENTISTS, US FDA, CANADIAN HLTH PROTECT BRANCH, BUNDESGESUNDHEITSAMT, EUROPEAN FEDERAT PHARM SCI, ACAD PHARM SCI & TECHNOL JAPAN, DUTCH MED EVALUAT BOARD, ZENTRALLAB DEUT APOTHEKER
C1 US FDA,DIV BIOEQUIVALENCE,ROCKVILLE,MD 20857.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU MEDPHARM GMBH SCIENTIFIC PUBL
PI STUTTGART
PA BIRKENWALDSTRASSE 44, D-7000 STUTTGART, GERMANY
J9 F I P PAPERBACK
PY 1993
BP 149
EP 161
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BA31E
UT WOS:A1993BA31E00012
ER
PT J
AU SHAH, VP
WILLIAMS, RL
AF SHAH, VP
WILLIAMS, RL
BE Midha, KK
Blume, HH
TI BIOEQUIVALENCE OF TOPICALLY ADMINISTERED DRUGS
SO BIO-INTERNATIONAL: BIOAVAILABILITY, BIOEQUIVALENCE AND PHARMACOKINETICS
SE F.I.P. PAPERBACK
LA English
DT Proceedings Paper
CT International Conference of F I P - Bio-International 92:
Bioavailability, Bioequivalence and Pharmacokinetics
CY MAY 20-22, 1992
CL BAD HOMBURG, GERMANY
SP FEDERAT INT PHARM, AMER ASSOC PHARM SCIENTISTS, US FDA, CANADIAN HLTH PROTECT BRANCH, BUNDESGESUNDHEITSAMT, EUROPEAN FEDERAT PHARM SCI, ACAD PHARM SCI & TECHNOL JAPAN, DUTCH MED EVALUAT BOARD, ZENTRALLAB DEUT APOTHEKER
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MEDPHARM GMBH SCIENTIFIC PUBL
PI STUTTGART
PA BIRKENWALDSTRASSE 44, D-7000 STUTTGART, GERMANY
J9 F I P PAPERBACK
PY 1993
BP 267
EP 272
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BA31E
UT WOS:A1993BA31E00023
ER
PT B
AU MARLOWE, DE
AF MARLOWE, DE
BE Morrey, BF
TI REGULATION OF BIOMATERIALS AND MEDICAL DEVICES
SO BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT
SE BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC SYMPOSIUM SERIES
LA English
DT Proceedings Paper
CT 7TH ANNUAL BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC RESEARCH SYMP :
BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT
CY OCT 29-31, 1992
CL SAN ANTONIO, TX
SP BRISTOL MYERS, SQUIBB, ZIMMER
RP MARLOWE, DE (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,12200 WILKINS AVE,ROCKVILLE,MD 20852, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU RAVEN PRESS
PI NEW YORK
PA NEW YORK
BN 0-7817-0008-6
J9 BRIS MYER Z
PY 1993
BP 397
EP 404
PG 8
WC Engineering, Biomedical; Materials Science, Multidisciplinary;
Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BY98W
UT WOS:A1993BY98W00039
ER
PT B
AU MELKERSON, MN
YAHIRO, MA
MISHRA, NK
AF MELKERSON, MN
YAHIRO, MA
MISHRA, NK
BE Morrey, BF
TI REGULATORY PERSPECTIVE FOR ORTHOPEDIC DEVICES
SO BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT
SE BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC SYMPOSIUM SERIES
LA English
DT Proceedings Paper
CT 7TH ANNUAL BRISTOL-MYERS SQUIBB / ZIMMER ORTHOPAEDIC RESEARCH SYMP :
BIOLOGICAL, MATERIAL, AND MECHANICAL CONSIDERATIONS OF JOINT REPLACEMENT
CY OCT 29-31, 1992
CL SAN ANTONIO, TX
SP BRISTOL MYERS, SQUIBB, ZIMMER
RP MELKERSON, MN (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,DIV GEN & RESTORAT DEVICES,ORTHOPED BRANCH,ROCKVILLE,MD 20850, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU RAVEN PRESS
PI NEW YORK
PA NEW YORK
BN 0-7817-0008-6
J9 BRIS MYER Z
PY 1993
BP 405
EP 422
PG 18
WC Engineering, Biomedical; Materials Science, Multidisciplinary;
Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BY98W
UT WOS:A1993BY98W00040
ER
PT J
AU GARTHRIGHT, WE
AF GARTHRIGHT, WE
TI BIAS IN THE LOGARITHM OF MICROBIAL DENSITY ESTIMATES FROM SERIAL
DILUTIONS
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE BIAS; MOST PROBABLE NUMBER; MPN; DILUTION METHOD; SERIAL DILUTIONS
ID ORGANISMS
AB The bias in the most-probable-number (MPN) estimate of microbial densities derived from serial dilutions might be less important than it has appeared to be. For many purposes, bias in the logarithm of the MPN is more important than bias in the MPN, and the bias in the logarithm is much less. The lesser bias has been reduced by using the theorems of Salama, Koch, and Tolley. Formulas and tables are provided.
C1 US FDA,DIV MATH,WASHINGTON,DC 20204.
NR 9
TC 16
Z9 16
U1 1
U2 2
PU AKADEMIE VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0323-3847
J9 BIOMETRICAL J
JI Biom. J.
PY 1993
VL 35
IS 3
BP 299
EP 314
DI 10.1002/bimj.4710350306
PG 16
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA LA197
UT WOS:A1993LA19700005
ER
PT J
AU ROBERTS, CD
AF ROBERTS, CD
TI UNBIASED ESTIMATION OF ODDS RATIO BY USING NEGATIVE BINOMIAL PLANS
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE NEGATIVE BINOMIAL; ODDS RATIO; UNBIASED ESTIMATE; EXACT VARIANCE; SAMPLE
SIZE DETERMINATION
AB The use of the negative binomial distribution in both the numerator and denominator in prospective studies leads to an unbiased estimate of the odds ratio and an exact expression for its variance. Sample sizes that minimize the variance of odds ratio estimates are specified. The variance of the odds ratio estimate is shown to be close to the Cramer-Rao lower bound.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MATH,WASHINGTON,DC 20204.
NR 7
TC 4
Z9 4
U1 0
U2 0
PU AKADEMIE VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0323-3847
J9 BIOMETRICAL J
JI Biom. J.
PY 1993
VL 35
IS 5
BP 581
EP 587
DI 10.1002/bimj.4710350507
PG 7
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA LP185
UT WOS:A1993LP18500006
ER
PT J
AU CHEN, JJ
AF CHEN, JJ
TI TREND TEST FOR OVERDISPERSED PROPORTIONS
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE COCHRAN-ARMITAGE TEST; SCORE TEST; WALD TEST; TERATOLOGY; INTRALITTER
CORRELATION
ID TERATOLOGY; MODELS
AB The Cochran-Armitage test has commonly been used for a trend test in binomial proportions. The quasi-likelihood method provides a simple approach to model extra-binomial proportions. Two versions of the score and Wald tests using different parameterizations for the extra-binomial variance were investigated: one in terms of intercluster correlation, and another in terms of variance. The Monte Carlo simulation was used to evaluate the performance of the each version of the score test and the Wald test, and the Cochran-Armitage test.
The simulation shows that the Cochran-Armitage test has the proper size only for the binomial sample data, and the test is no longer valid when applied to the extra-binomial data. The Wald test is more likely to exceed the nominal level than the score test under either intercluster correlation model or variance model. Both score tests performed very well even with the binomial data; the tests control the type I error and in the meantime maintain the power of detecting the dose effects. Based on the design considered in this paper, the two scores test are comparable. The score test based on the intercluster correlations model seems better controlling the Type I error but appears less powerful than that based on the variance model. An example from a developmental toxicity experiment is given.
C1 US FDA,NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
NR 17
TC 1
Z9 1
U1 0
U2 2
PU AKADEMIE VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0323-3847
J9 BIOMETRICAL J
JI Biom. J.
PY 1993
VL 35
IS 8
BP 949
EP 958
DI 10.1002/bimj.4710350809
PG 10
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA MH319
UT WOS:A1993MH31900005
ER
PT S
AU CIARDIELLO, F
TORTORA, G
PEPE, S
BIANCO, C
BALDASSARRE, G
RUGGIERO, A
BIANCO, C
SELVAM, MP
BIANCO, AR
AF CIARDIELLO, F
TORTORA, G
PEPE, S
BIANCO, C
BALDASSARRE, G
RUGGIERO, A
BIANCO, C
SELVAM, MP
BIANCO, AR
BE Squartini, F
Bevilacqua, G
Conte, PF
Surbone, A
TI REDUCTION OF RI-ALPHA SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE
EXPRESSION INDUCES GROWTH-INHIBITION OF HUMAN MAMMARY EPITHELIAL-CELLS
TRANSFORMED BY TGF-ALPHA, C-HA-RAS, AND C-ERBB-2 GENES
SO BREAST CANCER: FROM BIOLOGY TO THERAPY
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Pisa Symposia in Oncology, to Celebrate the 650th Anniversary of the
Founding of the University of Pisa
CY OCT 19-21, 1992
CL PISA, ITALY
SP UNIV PISA, NATL INST CANC RES, SANTA CHIARA HOSP, ASSOC ITALIANA ONCOL MEDICA
C1 US FDA,BETHESDA,MD 20892.
RP CIARDIELLO, F (reprint author), UNIV NAPOLI,FAC MED & CHIRURG 2,CATTEDRA ONCOL MED,VIA S PANSINI 5,I-80131 NAPLES,ITALY.
RI Baldassarre, Gustavo/K-1350-2016
OI Baldassarre, Gustavo/0000-0002-9750-8825
NR 10
TC 4
Z9 4
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-803-0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 698
BP 102
EP 107
DI 10.1111/j.1749-6632.1993.tb17194.x
PG 6
WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences;
Pathology; Pharmacology & Pharmacy
SC Oncology; Research & Experimental Medicine; Science & Technology - Other
Topics; Pathology; Pharmacology & Pharmacy
GA BZ51X
UT WOS:A1993BZ51X00008
PM 7904135
ER
PT J
AU KADERLIK, KR
TALASKA, G
DEBORD, DG
OSORIO, AM
KADLUBAR, FF
AF KADERLIK, KR
TALASKA, G
DEBORD, DG
OSORIO, AM
KADLUBAR, FF
TI 4,4'-METHYLENE-BIS(2-CHLOROANILINE)-DNA ADDUCT ANALYSIS IN HUMAN
EXFOLIATED UROTHELIAL CELLS BY P-32 POSTLABELING
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID AROMATIC DNA ADDUCTS; WHITE BLOOD-CELLS; 4,4'-METHYLENEBIS
2-CHLOROANILINE; OCCUPATIONAL EXPOSURE; N-GLUCURONIDATION; LIVER
MICROSOMES; CARCINOGEN; RAT; WORKERS; MOCA
AB 4,4'-Methylene-bis(2-chloroaniline) (MOCA) is an aromatic amine used widely in industry, and human exposure to this compound is well documented. MOCA induces lung and liver tumors in rodents and urinary bladder tumors in dogs, and it is regarded as a suspect urinary bladder carcinogen in humans. In this pilot study, we investigated the occurrence of MOCA-DNA adducts in exfoliated urothelial cells of a MOCA-exposed worker by P-32-postlabeling analysis. Urine samples were collected from the worker at various times after accidental acute exposure to MOCA. DNA isolated from exfoliated urothelial cells collected from each urine sample was enzymatically digested and postlabeled with excess [P-32]ATP. Thin-layer chromatographic analysis of the labeled digests revealed the presence of a single, major DNA adduct that cochromatographed with the major N-hydroxy-MOCA-DNA adduct, N-(deoxyadenosin-8-yl)-4-amino-3-chlorobenzyl alcohol, formed in vitro. The MOCA-DNA adduct was detected in samples obtained between 4 and 98 h after initial exposure but not in samples collected at later times. The level of DNA adducts 4 h after exposure was determined to be 516 adducts/10(8) nucleotides. A 5-fold decrease in adduct level was observed 14 h later, followed by a gradual decrease over subsequent days. The results indicate that MOCA is potentially genotoxic to human urinary bladder in vivo and that P-32-postlabeling analysis of exfoliated urothelial cells provides a noninvasive means for biomonitoring the formation of MOCA-DNA adducts resulting from occupational exposure.
C1 NATL CTR TOXICOL RES,HFT 100,JEFFERSON,AR 72079.
UNIV CINCINNATI,MED CTR,INST ENVIRONM HLTH,CINCINNATI,OH 45267.
NIOSH,CINCINNATI,OH 45226.
CALIF DEPT HLTH SERV,BERKELEY,CA 94704.
NR 41
TC 36
Z9 36
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
PHILADELPHIA, PA 19106
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN-FEB
PY 1993
VL 2
IS 1
BP 63
EP 69
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA KF997
UT WOS:A1993KF99700012
PM 8420614
ER
PT J
AU PURI, RK
SIEGEL, JP
AF PURI, RK
SIEGEL, JP
TI INTERLEUKIN-4 AND CANCER-THERAPY
SO CANCER INVESTIGATION
LA English
DT Review
ID STIMULATORY FACTOR-I; TUMOR-NECROSIS-FACTOR; HUMAN T-CELLS; RECOMBINANT
HUMAN INTERLEUKIN-4; HUMAN-B-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN
PERIPHERAL-BLOOD; HIGH-AFFINITY; HUMAN-MONOCYTES; RECEPTOR EXPRESSION
RP PURI, RK (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,CELLULAR IMMUNOL LAB,BETHESDA,MD 20014, USA.
NR 139
TC 64
Z9 65
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0735-7907
J9 CANCER INVEST
JI Cancer Invest.
PY 1993
VL 11
IS 4
BP 473
EP 486
DI 10.3109/07357909309018879
PG 14
WC Oncology
SC Oncology
GA LN771
UT WOS:A1993LN77100013
PM 8324651
ER
PT S
AU LAMBERT, LA
WAMER, WG
WEI, RR
LAVU, S
KORNHAUSER, A
AF LAMBERT, LA
WAMER, WG
WEI, RR
LAVU, S
KORNHAUSER, A
BE Canfield, LM
Krinsky, NI
Olson, JA
TI THE ABSENCE OF A SYNERGISTIC PROTECTIVE EFFECT OF BETA-CAROTENE AND
VITAMIN-E ON SKIN TUMORIGENESIS IN MICE
SO CAROTENOIDS IN HUMAN HEALTH
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Carotenoids in Human Health
CY FEB 06-09, 1993
CL SAN DIEGO, CA
SP NEW YORK ACAD SCI
ID CANCER
RP LAMBERT, LA (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,HFS-128,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 4
TC 0
Z9 0
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-827-8
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 691
BP 259
EP 261
DI 10.1111/j.1749-6632.1993.tb26188.x
PG 3
WC Biochemistry & Molecular Biology; Engineering, Civil; Multidisciplinary
Sciences; Physiology
SC Biochemistry & Molecular Biology; Engineering; Science & Technology -
Other Topics; Physiology
GA BA01B
UT WOS:A1993BA01B00037
PM 8129306
ER
PT S
AU WAMER, WG
WEI, RR
MATUSIK, JE
KORNHAUSER, A
DUNKEL, VC
AF WAMER, WG
WEI, RR
MATUSIK, JE
KORNHAUSER, A
DUNKEL, VC
BE Canfield, LM
Krinsky, NI
Olson, JA
TI BETA-CAROTENE UPTAKE, METABOLISM, AND DISTRIBUTION IN-VITRO
SO CAROTENOIDS IN HUMAN HEALTH
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Carotenoids in Human Health
CY FEB 06-09, 1993
CL SAN DIEGO, CA
SP NEW YORK ACAD SCI
RP WAMER, WG (reprint author), CTR FOOD SAFETY & APPL NUTR,FOOD & DRUG ADM,HFS-128,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 2
TC 1
Z9 1
U1 1
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-827-8
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 691
BP 284
EP 286
DI 10.1111/j.1749-6632.1993.tb26197.x
PG 3
WC Biochemistry & Molecular Biology; Engineering, Civil; Multidisciplinary
Sciences; Physiology
SC Biochemistry & Molecular Biology; Engineering; Science & Technology -
Other Topics; Physiology
GA BA01B
UT WOS:A1993BA01B00046
PM 8129314
ER
PT J
AU MORRIS, SM
DOMON, OE
MCGARRITY, LJ
AIDOO, A
KODELL, RL
CASCIANO, DA
AF MORRIS, SM
DOMON, OE
MCGARRITY, LJ
AIDOO, A
KODELL, RL
CASCIANO, DA
TI FLOW CYTOMETRIC ANALYSIS OF THE CELL-CYCLE DISTRIBUTION OF SPLEEN
LYMPHOCYTES ISOLATED FROM FISCHER-344 RATS EXPOSED TO ETHYL NITROSOUREA
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE CELL-CYCLE ANALYSIS; COLCEMID; ENU; RAT LYMPHOCYTE DNA; FLOW CYTOMETRY
ID INDUCTION; 2-MERCAPTOETHANOL; PROLIFERATION; MODULATION; DNA
AB Current studies in our laboratory are designed to determine the frequency of genotoxic responses induced in lymphocytes isolated from Fischer 344 rats. To evaluate the effect of a model compound, N-ethyl-N-nitrosourea (ENU), on the cell-cycle distribution of spleen lymphocytes, 8-week old, female Fischer 344 rats were injected ip. with ENU and sacrificed 1, 2, 4, and 6 weeks after exposure. Four replicate cultures per dose per exposure period were established and cells were cultured for 66 hr. Colcemid, an agent which blocks cells in mitosis and induces an accumulation of cells in the G2 + M peak, was added to two of the four cultures as a positive control. After a 3 hr incubation, the cells were harvested, the nuclei stained with propidium iodide, and the DNA content of the individual nuclei was quantified by flow cytometry.
As expected, exposure to Colcemid resulted in an accumulation of cells in the G2 + M phase of the cell cycle, which was accompanied by a decrease in the G0 + G1 population. The increase in the G2 + M population was significant (p < 0.05) in cultures of lymphocytes assayed at 4 and 6 weeks after exposure. The effect of increasing ENU concentration was an increase in the percentage of S-phase cells (p = 0.05) and a decrease (p < 0.02) in the percentage of G0 + G1 cells. This finding was observed only in those lymphocytes isolated 1 week after exposure. These findings indicate that flow cytometric analysis of the distribution of cells within the cell-cycle may provide insight into the effects of toxicant exposure on mammalian cells.
RP MORRIS, SM (reprint author), US FDA,NATL CTR TOXICOL RES,DIV GENET TOXICOL,HFT-120,1 NCTR DR,JEFFERSON,AR 72079, USA.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0742-2091
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD JAN-MAR
PY 1993
VL 9
IS 1
BP 77
EP 83
DI 10.1007/BF00755141
PG 7
WC Cell Biology; Toxicology
SC Cell Biology; Toxicology
GA LC252
UT WOS:A1993LC25200006
PM 8518971
ER
PT J
AU HERRENOSAENZ, D
EVANS, FE
LAI, CC
ABIAN, J
FU, PP
DELCLOS, KB
AF HERRENOSAENZ, D
EVANS, FE
LAI, CC
ABIAN, J
FU, PP
DELCLOS, KB
TI PRODUCTS FORMED FROM THE INVITRO REACTION OF METABOLITES OF
3-AMINOCHRYSENE WITH CALF THYMUS DNA
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE AROMATIC AMINES; METABOLIC ACTIVATION; DNA ADDUCTS; P-32-POSTLABELING
ID RAT-LIVER; ADDUCT FORMATION; C8-MODIFIED DEOXYGUANOSINE;
P-32-POSTLABELING ASSAY; CARCINOGEN; 6-NITROCHRYSENE; INVIVO;
4-AMINOBIPHENYL; SENSITIVITY; MICROSOMES
AB 3-Aminochrysene, a mutagenic geometric isomer of the mutagenic and carcinogenic aromatic amine 6-aminochrysene, has been synthesized and its metabolic activation studied by characterization of the products formed from the reaction of metabolites with calf thymus DNA. DNA adducts produced by 3-aminochrysene via N-oxidation were examined by preparing 3-nitrosochrysene and incubating the nitroso derivative with calf thymus DNA in the presence of ascorbic acid (to generate the N-hydroxy derivative) at pH 5. The major adduct, as determined by H-1-NMR and thermospray-mass spectrometry of the modified nucleoside obtained after enzymatic hydrolysis of the modified DNA, was N-(deoxyguanosin-8-yl)-3-aminochrysene. Thus, the reaction of N-hydroxy-3-aminochrysene with DNA differs from that of N-hydroxy-6-aminochrysene, which had previously been shown to generate N-(deoxyguanosin-8-yl)-6-aminochrysene, 5-(deoxyguanosin-N2-yl)-6-aminochrysene and N-(deoxyinosin-8-yl)-6-aminochrysene as major adducts. P-32-Postlabeling analysis of DNA treated with 3-aminochrysene in the presence of liver microsomes from rats pretreated with phenobarbital indicated an adduct pattern identical to that seen with DNA that had been treated with 3-nitrosochrysene and ascorbic acid. However, DNA treated with 3-aminochrysene (3-AC) in the presence of liver microsomes from rats pretreated with 3-methylcholanthrene contained a major adduct that was chromatographically distinct from N-(deoxyguanosin-8-yl)-3-aminochrysene.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,HFT-110,JEFFERSON,AR 72079.
RI Abian, Joaquin/M-1965-2014
OI Abian, Joaquin/0000-0003-2823-5429
NR 37
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0009-2797
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JAN
PY 1993
VL 86
IS 1
BP 1
EP 15
DI 10.1016/0009-2797(93)90107-A
PG 15
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA KM254
UT WOS:A1993KM25400001
PM 8431961
ER
PT B
AU DePaola, A
AF DePaola, A
BE PestanadeCastro, AF
Almeida, WF
TI Vibrio cholerae in foods
SO CHOLERA ON THE AMERICAN CONTINENTS
LA English
DT Proceedings Paper
CT International Symposium on Cholera on the American Continents
CY MAY 21-23, 1992
CL SAO PAULO, BRAZIL
SP Brazilian Minist Hlth, UN, FAO, Fdn Res Support, State Sao Paulo, Int Life Sci Inst, ILSI Brazil, Pan Amer Hlth Org, Sao Paulo State Dept Hlth, State Univ Campinas, US EPA, WHO
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I L S I PRESS
PI WASHINGTON
PA INT LIFE SCIENCE INST, 1126 16TH ST NW, WASHINGTON, DC 20036
BN 0-944398-12-X
PY 1993
BP 107
EP 116
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA BF95M
UT WOS:A1993BF95M00012
ER
PT J
AU ORAEVSKY, AA
JACQUES, SL
PETTIT, GH
SAUERBREY, RA
TITTEL, FK
NGUY, JH
HENRY, PD
AF ORAEVSKY, AA
JACQUES, SL
PETTIT, GH
SAUERBREY, RA
TITTEL, FK
NGUY, JH
HENRY, PD
TI XECL LASER-INDUCED FLUORESCENCE OF ATHEROSCLEROTIC ARTERIES - SPECTRAL
SIMILARITIES BETWEEN LIPID-RICH LESIONS AND PEROXIDIZED LIPOPROTEINS
SO CIRCULATION RESEARCH
LA English
DT Article
DE ATHEROSCLEROSIS; OXIDIZED LIPOPROTEIN; FLUORESCENCE SPECTROSCOPY; XECL
LASER
ID LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-B; AUTOFLUORESCENCE; OXIDATION;
AORTA; ATHEROGENESIS; CHOLESTEROL; RELAXATION; DIAGNOSIS; DISEASE
AB Autofluorescence spectroscopy of arterial surfaces provides information about the distribution and composition of atherosclerotic plaques. The aim of the study was to determine whether accumulation of peroxidized lipoproteins in arterial walls, a process postulated to play a role in initiating atherosclerotic changes, can be demonstrated by fluorescence spectroscopy. XeCl excimer laser (308 nm)-induced fluorescence of human aortas containing early lipid-rich noncollagenous lesions exhibited marked red shifts and broadening of the fluorescence spectra compared with spectra from nonatherosclerotic aortas. Similar profiles were observed in spectra obtained from oxidatively modified low density lipoprotein but not native low density lipoprotein. In hypercholesterolemic rabbits with early foam cell lesions, spectral shifts resembled those of oxidized beta-very low density lipoprotein, the major lipoprotein accumulating in arteries of rabbits fed cholesterol. XeCl laser-fluorescence spectroscopy of arterial surfaces may be useful for the identification of arteries accumulating modified lipoproteins (oxidized low density lipoprotein), a chemical change indicative of atherosclerosis in its early and probably reversible stages.
C1 RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251.
UNIV TEXAS,MD ANDERSON CANC CTR,LASER BIOL RES LAB,HOUSTON,TX 77025.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
ACAD SCI,INST SPECT,MOSCOW,USSR.
FU NHLBI NIH HHS [R01-HL-40884, R01-HL-36894]
NR 37
TC 26
Z9 26
U1 0
U2 0
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0009-7330
J9 CIRC RES
JI Circ.Res.
PD JAN
PY 1993
VL 72
IS 1
BP 84
EP 90
PG 7
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA KC361
UT WOS:A1993KC36100010
PM 8417849
ER
PT S
AU PASTAKIA, KB
TERLE, D
PRODOUZ, KN
AF PASTAKIA, KB
TERLE, D
PRODOUZ, KN
BE Landay, AL
Ault, KT
Bauer, KD
Rabinovitch, PS
TI PENICILLIN INHIBITS AGONIST-INDUCED EXPRESSION OF PLATELET
SURFACE-MEMBRANE GLYCOPROTEINS
SO CLINICAL FLOW CYTOMETRY
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Proceedings Paper
CT CONF ON CLINICAL FLOW CYTOMETRY
CY APR 25-28, 1992
CL BALTIMORE, MD
SP NEW YORK ACAD SCI, AMAC, HOFFMANN LA ROCHE, PFIZER CENT RES, PHARMINGEN, PHOENIX FLOW SYST
RP PASTAKIA, KB (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA NEW YORK
SN 0077-8923
BN 0-89766-767-0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 677
BP 437
EP 439
DI 10.1111/j.1749-6632.1993.tb38810.x
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA BX95P
UT WOS:A1993BX95P00054
PM 8494236
ER
PT J
AU WEST, RW
KODELL, RL
AF WEST, RW
KODELL, RL
TI STATISTICAL-METHODS OF RISK ASSESSMENT FOR CONTINUOUS-VARIABLES
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE ADDITIONAL RISK; ASYMPTOTIC DISTRIBUTION; LIKELIHOOD RATIO; LINEAR
INTERPOLATION
AB Adverse health effects for continuous responses are not as easily defined as adverse health effects for binary responses. Kodell and West (1993) developed methods for defining adverse effects for continuous responses and the associated risk. Procedures were developed for finding point estimates and upper confidence limits for additional risk under the assumption of a normal distribution and quadratic mean response curve with equal variances at each dose level. In this paper, methods are developed for point estimates and upper confidence limits for additional risk at experimental doses when the equal variance assumption is relaxed. An interpolation procedure is discussed for obtaining information at doses other than the experimental doses. A small simulation study is presented to test the performance of the methods discussed.
C1 RICE UNIV,DEPT STAT,HOUSTON,TX 77251.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 11
TC 32
Z9 32
U1 1
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1993
VL 22
IS 12
BP 3363
EP 3376
DI 10.1080/03610929308831221
PG 14
WC Statistics & Probability
SC Mathematics
GA ML275
UT WOS:A1993ML27500007
ER
PT S
AU WEISSINGER, J
AF WEISSINGER, J
BE Gurny, R
Teubner, A
TI TRANSDERMAL DELIVERY OF DRUGS AND TOPICAL APPLICATION - NONCLINICAL
REGULATORY CONSIDERATIONS
SO DERMAL AND TRANSDERMAL DRUG DELIVERY: NEW INSIGHTS AND PERSPECTIVES
SE PAPERBACK APV
LA English
DT Proceedings Paper
CT 2nd International Symposium of the
International-Association-for-Pharmaceutical-Technology on Dermal and
Transdermal Drug Delivery: New Insights and Perspectives
CY NOV 11-13, 1991
CL FRANKFURT, GERMANY
SP INT ASSOC PHARM TECHNOL
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU WISSENSCHAFTLICHE verlagsgesellschaft mbh
PI STUTTGART
PA POSTFACH 40, BIRKENWALDSTRASSE 44, 70191 STUTTGART, GERMANY
SN 0720-3543
BN 3-8047-1223-1
J9 PAPERB APV
PY 1993
VL 31
BP 187
EP 193
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BZ71X
UT WOS:A1993BZ71X00011
ER
PT J
AU CHOU, MW
PEGRAM, RA
TURTURRO, A
HOLSON, R
HART, RW
AF CHOU, MW
PEGRAM, RA
TURTURRO, A
HOLSON, R
HART, RW
TI EFFECT OF CALORIC RESTRICTION ON THE INDUCTION OF HEPATIC
CYTOCHROME-P-450 AND AH RECEPTOR-BINDING IN C57BL/6N AND DBA/2J MICE
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID ARYL-HYDROCARBON HYDROXYLASE; DRUG-METABOLIZING-ENZYMES; FOOD
RESTRICTION; FISCHER-344 RAT; CORTICOSTERONE LEVELS; GENETIC EXPRESSION;
2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; MOUSE; LIVER; ASSAY
AB While it is known that caloric restriction alters activities Of certain xenobiotic metabolizing enzymes, the mechanism(s) by which this occurs have not been determined. In this study, caloric restriction (CR) increases activities of liver cytochrome P450IA1 dependent ethoxyresorufin-O-deethylase (EROD) and aryl hydrocarbon hydroxylase (AHH) and cytochrome P450IIB1 dependent pentoxyresorufin-O-dealkylase (PROD) in DBA/2J or C57BL/6N mice. However, the cytosolic Ah receptor binding in both strains of mice was not increased. The hepatic cytochrome P450IA1 activity was increased by CR in DBA/2J mice (a strain lacking normal Ah receptor binding), indicating that this induction need not be mediated by the Ah receptor. The effects of CR, sex and strain on P450IA1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) were also determined. Specific induction of cytochrome P450IA1 by TCDD was greater in females than in males of both strains, whereas the P450 isozymes induced in male DBA/2J mice had less specificity toward 7-ethoxyresorufin than those induced in C57BL/6N mice. Moreover, P450IA1 induction by TCDD was significantly potentiated by CR in the DBA/2 strain, indicating the interactive involvement of different regulartory mechanisms.
RP CHOU, MW (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 45
TC 13
Z9 13
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-0545
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PY 1993
VL 16
IS 1
BP 1
EP 19
DI 10.3109/01480549309038659
PG 19
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA KN073
UT WOS:A1993KN07300001
PM 8382149
ER
PT J
AU STEWART, SFC
BURTE, F
CLARK, RE
AF STEWART, SFC
BURTE, F
CLARK, RE
TI QUANTIFICATION OF ASYMMETRIC VALVULAR REGURGITANT JETS BY COLOR DOPPLER
ULTRASOUND INVITRO
SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED
TECHNIQUES
LA English
DT Article
DE COLOR DOPPLER ULTRASOUND; HEART VALVE REGURGITATION; MEDICAL IMAGE
ANALYSIS
AB Accurate quantification of regurgitant jets in natural and prosthetic heart valves has been a goal of health care workers and researchers for many years. One promising new method applies the law of conservation of momentum transfer to velocities measured by color Doppler ultrasound to calculate the flow rate in the jet. One complicating factor is that regurgitant jets from real heart valves may be highly asymmetric. The purpose of this investigation was to determine whether the accurate calculation of the flow rate in asymmetric jets imaged by color Doppler requires an asymmetric formulation of the conservation of momentum transfer, combined with a method for imaging the jet in three dimensions. Asymmetric jets issuing from narrow slits were imaged in an in vitro, steady flow system. The ultrasound transducer was rotated around the jet axis to image the jet in three dimensions. The three-dimensional imaging confirmed that jets from slits are indeed asymmetric, but become relatively axisymmetric far from the orifice. Images were analyzed by computer and the calculated flows compared to measured flows. The accuracy of an asymmetric formulation of the conservation of momentum transfer method was compared to a simpler, axisymmetric formulation. If axisymmetry was assumed in asymmetric jets, significant errors in the calculated flow rates occurred. In these cases, the calculated flow also varied widely with distance from the orifice. When asymmetry was taken into account, the errors were considerably reduced. The results suggests that, in asymmetric jets, the momentum transfer is convected around the jet axis.
RP STEWART, SFC (reprint author), US FDA,HYDRODYNAM & ACOUST BRANCH,5600 FISHERS LANE,HFZ-132,ROCKVILLE,MD 20857, USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU FUTURA PUBL CO
PI ARMONK
PA 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418
SN 0742-2822
J9 ECHOCARDIOGR-J CARD
JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.
PD JAN
PY 1993
VL 10
IS 1
BP 23
EP 36
DI 10.1111/j.1540-8175.1993.tb00006.x
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA KH267
UT WOS:A1993KH26700005
PM 10148114
ER
PT J
AU KATZ, R
AF KATZ, R
TI THE DOMESTIC DRUG REGULATORY PROCESS - WHY TIME IS OF THE ESSENCE
SO EPILEPSY RESEARCH
LA English
DT Article
RP KATZ, R (reprint author), US FDA,BETHESDA,MD 20014, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PY 1993
SU 10
BP 91
EP 106
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA LY572
UT WOS:A1993LY57200008
ER
PT J
AU BARTSCH, H
MALAVEILLE, C
FRIESEN, M
KADLUBAR, FF
VINEIS, P
AF BARTSCH, H
MALAVEILLE, C
FRIESEN, M
KADLUBAR, FF
VINEIS, P
TI BLACK (AIR-CURED) AND BLOND (FLUE-CURED) TOBACCO CANCER RISK .4.
MOLECULAR DOSIMETRY STUDIES IMPLICATE AROMATIC-AMINES AS BLADDER
CARCINOGENS
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
ID CIGARETTE-SMOKE CONDENSATE; HUMAN-LIVER-MICROSOMES; HEMOGLOBIN ADDUCTS;
2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; HETEROCYCLIC
AMINES; ALPHA-CARBOLINES; MAINSTREAM SMOKE; LIQUID-CHROMATOGRAPHY;
COPPER-PHTHALOCYANINE; METABOLIC-ACTIVATION
AB Tobacco smoking causes a major fraction of male urinary bladder cancers and the relative risk of bladder cancer is reported to be two to three times higher for smoking of black (air-cured) than for smoking of blond (flue-cured) tobacco. In molecular dosimetry studies to examine the hypothesis that aromatic amines in tobacco smoke are primarily responsible for bladder cancer, the higher bladder cancer risk in smokers of black tobacco was correlated with two to five times higher exposure to carcinogenic aromatic amines present in black tobacco smoke, notably 4-aminobiphenyl (ABP). For the same amount of smoking, black tobacco smokers had levels of ABP-haemoglobin (Hb) adducts 1.5 times higher and excreted a 1.8-fold higher level of urinary mutagens. These mutagens were characterised as aromatic amines, and included the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a known mutagen and multiorgan/species carcinogen. In smoking volunteers, the ABP-Hb adduct level depended significantly on the acetylator and P-450IA2 phenotypes, being 1.3- to 1.5-fold lower in fast acetylators, slow/intermediate P-450IA2 individuals. The N-(deoxyguanosin-8-yl)-ABP adduct was a major smoking-related DNA adduct in bladder biopsies from surgical patients. It was also tentatively identified in exfoliated urothelial cells of smoking volunteers, who showed a significant and linear correlation between adduct levels of ABP with Hb and with deoxyguanosine in urothelial DNA; both were related to number of cigarettes smoked per day. Levels of several smoking-related DNA adducts in urothelial cells were 2-20 times elevated in smokers. Similar convex dose-response relationships have been found between the number of cigarettes smoked and the relative risk for bladder cancer and between the levels of ABP-Hb adducts and markers of recent smoking. A possible explanation is that fast and slow acetylators have different susceptibility to aromatic amine carcinogens. Case-control studies have consistently revealed an excess of variable magnitude of slow acetylators in subgroups exposed occupationally to carcinogenic aromatic amines. Altogether, results from these studies reinforce the association between cigarette smoking, carcinogen-DNA adducts in urothelial cells, and implicate primary aromatic and possibly heterocyclic amines as bladder carcinogens.
C1 DIPARTIMENTO SCI BIOMED & ONCOL UMANA,TURIN,ITALY.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP BARTSCH, H (reprint author), INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.
NR 79
TC 107
Z9 110
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PY 1993
VL 29A
IS 8
BP 1199
EP 1207
DI 10.1016/S0959-8049(05)80315-6
PG 9
WC Oncology
SC Oncology
GA LC546
UT WOS:A1993LC54600027
PM 8518034
ER
PT J
AU SKELLY, JP
SHIU, GF
AF SKELLY, JP
SHIU, GF
TI INVITRO INVIVO CORRELATIONS IN BIOPHARMACEUTICS - SCIENTIFIC AND
REGULATORY IMPLICATIONS
SO EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article
DE INVIVO INVITRO CORRELATION; BIOEQUIVALENCE MAPPING; CONVOLUTION
DECONVOLUTION
ID RELEASE DOSAGE FORMS
AB This paper explains the regulatory and scientific reasons for the regulatory authorities employing dissolution as a key variable for regulatory approval of batch to batch bioequivalence assurance, site of manufacture change, formulation changes, and batch size scale-up for immediate release dosage forms. It also explains the scientific and regulatory reasons why either an in vivo/in vitro correlation using USP's Level 'A'. 'B' or 'C', or a newly proposed 'mapping' approach will be required for allowing such changes for controlled-release dosage forms.
C1 US FDA,OFF RES RESOURCES,WASHINGTON,DC 20204.
US FDA,BIOPHARMACEUT RES BRANCH,WASHINGTON,DC 20204.
NR 15
TC 33
Z9 37
U1 0
U2 0
PU MEDECINE ET HYGIENE
PI GENEVA 4
PA 78 AVE ROSERALE, 1211 GENEVA 4, SWITZERLAND
SN 0378-7966
J9 EUR J DRUG METAB PH
JI Eur. J. Drug Metabol. Pharmacokinet.
PD JAN-MAR
PY 1993
VL 18
IS 1
BP 121
EP 129
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LE434
UT WOS:A1993LE43400013
PM 8335035
ER
PT J
AU LEININGER, E
PROBST, PG
BRENNAN, MJ
KENIMER, JG
AF LEININGER, E
PROBST, PG
BRENNAN, MJ
KENIMER, JG
TI INHIBITION OF BORDETELLA-PERTUSSIS FILAMENTOUS HEMAGGLUTININ-MEDIATED
CELL ADHERENCE WITH MONOCLONAL-ANTIBODIES
SO FEMS MICROBIOLOGY LETTERS
LA English
DT Article
DE BORDETELLA-PERTUSSIS; MONOCLONAL ANTIBODIES; ADHERENCE
ID ARG-GLY-ASP; PROMOTING FACTOR; INFECTION; PROTEIN; RECOGNITION;
RESPONSES; ANTIGENS; SEQUENCE; SYSTEM; TOXIN
AB Filamentous hemagglutinin (FHA), a 220-kDa protein located on the surface of Bordetella pertussis, is one of the major cell adhesins of this bacterium. We have produced three hybridoma cell lines that express monoclonal antibodies (mAbs) against FHA: X3C, X3E and X4B. The anti-FHA mAbs X3C and X3E reacted with 220-kDa and 98-kDa FHA protein bands on Western blots. The mAb X4B, which reacted with FHA in ELISA, did not bind to FHA in a Western blot assay. All three mAbs seemed to be directed to the same epitope or to epitopes in close proximity as suggested by competition ELISAs. All three mAbs were able to inhibit the adherence of Chinese hamster ovary cells to purified FHA, and they could also inhibit the FHA-mediated agglutination of goose red blood cells. The attachment of B. pertussis to epithelial cell monolayers was inhibited by the mAb X3C. These antibodies are very useful probes to identify the presence of FHA in bordetellae species and in clinical reagents such as pertussis vaccines, and to characterize the functional domains of this important bacterial adhesin.
RP LEININGER, E (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 25
TC 19
Z9 19
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1097
J9 FEMS MICROBIOL LETT
JI FEMS Microbiol. Lett.
PD JAN 1
PY 1993
VL 106
IS 1
BP 31
EP 38
DI 10.1111/j.1574-6968.1993.tb05931.x
PG 8
WC Microbiology
SC Microbiology
GA KH858
UT WOS:A1993KH85800005
PM 8440465
ER
PT J
AU POHLAND, AE
AF POHLAND, AE
TI MYCOTOXINS IN REVIEW
SO FOOD ADDITIVES AND CONTAMINANTS
LA English
DT Article; Proceedings Paper
CT INTERNATIONAL SYMP ON WORKSHOP ON FOOD CONTAMINATION, MYCOTOXINS AND
PHYCOTOXINS
CY NOV 04-15, 1990
CL CAIRO, EGYPT
DE AFLATOXIN; AMATOXIN; CARCINOGENICITY; CITREOVIRIDIN; ERGOT ALKALOIDS;
FUMONISIN; FUSARIUM; GLIOTOXIN; MONILIFORMIN; PATULIN; PENICILLIC ACID;
TENUAZONIC ACID; TRICHOTHECENES; ZEARALENONE
AB The putative involvement of mycotoxins in human diseases, including cancer, is reviewed with reference to ergotism, citreoviridin toxicosis, alimentary toxic aleukia, stachybotryotoxicosis, Balkan endemic nephropathy and aflatoxicoses. Analytical and sampling problems in determining the occurrence of and exposure to mycotoxins are discussed against the background that over 300 mycotoxins have been identified, produced by some 350 fungal species, and that the potency of some of them demands the quantitation of extremely small quantities of analyte.
Mycotoxins associated with food and originating from Alternaria, Aspergillus, Fusaria, Penicillia and Claviceps spp. are reviewed with reference to the toxicological, regulatory and economic issues arising.
It is concluded that continued efforts are needed to: identify and quantify human/animal exposure; estimate health risks and make defensible risk-benefit judgements; develop sampling plans based on experimental observation; arrive at agreed regulatory levels based on legitimate sampling plans, analytical capabilities and economic considerations; develop procedures for disposal of contaminated lots; and develop plant varieties resistant to fungal invasion.
RP POHLAND, AE (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 67
Z9 75
U1 1
U2 16
PU TAYLOR & FRANCIS LTD
PI LONDON
PA ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE
SN 0265-203X
J9 FOOD ADDIT CONTAM
JI Food Addit. Contam.
PD JAN-FEB
PY 1993
VL 10
IS 1
BP 17
EP 28
PG 12
WC Chemistry, Applied; Food Science & Technology; Toxicology
SC Chemistry; Food Science & Technology; Toxicology
GA KX620
UT WOS:A1993KX62000004
PM 8504870
ER
PT J
AU HORWITZ, W
AF HORWITZ, W
TI INTERNATIONAL COORDINATION AND VALIDATION OF ANALYTICAL METHODS
SO FOOD ADDITIVES AND CONTAMINANTS
LA English
DT Article; Proceedings Paper
CT INTERNATIONAL SYMP ON WORKSHOP ON FOOD CONTAMINATION, MYCOTOXINS AND
PHYCOTOXINS
CY NOV 04-15, 1990
CL CAIRO, EGYPT
DE RELIABILITY; ANALYTICAL ERROR; QUALITY CONTROL
AB Most experimentation dealing with analytical methodology in the physical and biological sciences has been conducted within a single laboratory. Method validation by other laboratories was considered not only unnecessary but also detrimental because, in the words of one commentator, 'the results arc too variable'. Within the last two decades, however, largely as a result of the requirements of international environmental and food standards programmes, it has become increasingly apparent that a collaborative interlaboratory study is the only way to estimate the variability characteristics of methods of analysis as performed by the typical population of laboratories using the methods. To obtain a common basis for measuring the statistical characteristics of analytical methods, representatives of almost two dozen international organizations meeting in Geneva, in May 1987, approved by consensus a protocol for the design and interpretation of data from collaborative studies of chemical methods of analysis.
RP HORWITZ, W (reprint author), US FDA,HFF-7,WASHINGTON,DC 20204, USA.
NR 0
TC 8
Z9 9
U1 1
U2 3
PU TAYLOR & FRANCIS LTD
PI LONDON
PA ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE
SN 0265-203X
J9 FOOD ADDIT CONTAM
JI Food Addit. Contam.
PD JAN-FEB
PY 1993
VL 10
IS 1
BP 61
EP 69
PG 9
WC Chemistry, Applied; Food Science & Technology; Toxicology
SC Chemistry; Food Science & Technology; Toxicology
GA KX620
UT WOS:A1993KX62000008
PM 8504875
ER
PT J
AU HOOKER, TL
AF HOOKER, TL
TI GREETINGS FROM YOUR DISTRICT OFFICE - NOW WHAT
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT MEETING OF FOOD AND DRUG LAW INST AND FDA - WOMEN IN CLINICAL TRIALS OF
FDA-REGULATED PRODUCTS : WHO PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FDA 2, FOOD & DRUG INST
RP HOOKER, TL (reprint author), US FDA,MID ATLANTIC REG OFF,BALTIMORE,MD 21240, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 1
BP 29
EP 34
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LE875
UT WOS:A1993LE87500005
ER
PT J
AU MEYER, GF
AF MEYER, GF
TI CDERS ORGANIZATIONAL CHANGES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT MEETING OF FOOD AND DRUG LAW INST AND FDA - WOMEN IN CLINICAL TRIALS OF
FDA-REGULATED PRODUCTS : WHO PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FDA 2, FOOD & DRUG INST
RP MEYER, GF (reprint author), US FDA,CTR DRUG EVALUAT & RES,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 1
BP 43
EP 46
PG 4
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LE875
UT WOS:A1993LE87500008
ER
PT J
AU RULIS, AM
TARANTINO, LM
AF RULIS, AM
TARANTINO, LM
TI THE FOOD ADDITIVE PETITION PROCESS - RECENT DATA
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP RULIS, AM (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,OFF PREMARKET APPROVAL,WASHINGTON,DC 20204, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 1
BP 137
EP 151
PG 15
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LE875
UT WOS:A1993LE87500016
ER
PT J
AU MERKATZ, RB
AF MERKATZ, RB
TI WOMEN IN CLINICAL-TRIALS - AN INTRODUCTION
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT SEMINAR ON WOMEN IN CLINICAL TRIAL OF FDA-REGULATED PRODUCTS : WHO
PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP MERKATZ, RB (reprint author), US FDA,WOMENS HLTH ISSUES,WASHINGTON,DC 20204, USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 2
BP 161
EP 166
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LQ865
UT WOS:A1993LQ86500001
PM 11653138
ER
PT J
AU SCHEMAN, CR
AF SCHEMAN, CR
TI REMARKS OF THE DEPUTY COMMISSIONER FOR EXTERNAL AFFAIRS
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT SEMINAR ON WOMEN IN CLINICAL TRIAL OF FDA-REGULATED PRODUCTS : WHO
PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP SCHEMAN, CR (reprint author), US FDA,EXTERNAL AFFAIRS,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 2
BP 167
EP 168
PG 2
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LQ865
UT WOS:A1993LQ86500002
ER
PT J
AU MURPHY, D
AF MURPHY, D
TI WOMEN IN CLINICAL-TRIALS - HIV-INFECTED WOMEN
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT SEMINAR ON WOMEN IN CLINICAL TRIAL OF FDA-REGULATED PRODUCTS : WHO
PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP MURPHY, D (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,WASHINGTON,DC 20204, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 2
BP 175
EP 179
PG 5
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LQ865
UT WOS:A1993LQ86500004
PM 11653140
ER
PT J
AU BAGLEY, G
AF BAGLEY, G
TI INFORMED CONSENT - THE FDAS PERSPECTIVE
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT SEMINAR ON WOMEN IN CLINICAL TRIAL OF FDA-REGULATED PRODUCTS : WHO
PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP BAGLEY, G (reprint author), US FDA,OFF HLTH AFFAIRS,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 2
BP 181
EP 186
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LQ865
UT WOS:A1993LQ86500005
PM 11653141
ER
PT J
AU HAFFNER, ME
AF HAFFNER, ME
TI STUDIES INVOLVING ORPHAN PRODUCTS FOR TREATING DIAGNOSING WOMENS
DISEASES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT SEMINAR ON WOMEN IN CLINICAL TRIAL OF FDA-REGULATED PRODUCTS : WHO
PARTICIPATES AND WHO DECIDES
CY OCT 05, 1992
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP HAFFNER, ME (reprint author), US FDA,OFF ORPHAN PROD DEV,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 2
BP 205
EP 211
PG 7
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA LQ865
UT WOS:A1993LQ86500008
PM 11653144
ER
PT J
AU JOHNSON, RM
AF JOHNSON, RM
TI GMPS AND THE PRODUCT REVIEW PROCESS
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
CY DEC 08-09, 1992
CL WASHINGTON, DC
SP FOOD & DRUG INST
RP JOHNSON, RM (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF COMPLIANCE,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 299
EP 304
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200002
ER
PT J
AU HENNEY, JE
AF HENNEY, JE
TI FOOD SAFETY CHALLENGES AND THE NEW CENTER
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
CY DEC 08-09, 1992
CL WASHINGTON, DC
SP FOOD & DRUG INST
RP HENNEY, JE (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 473
EP 477
PG 5
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200010
ER
PT J
AU SHANK, FR
DEROEVER, CM
AF SHANK, FR
DEROEVER, CM
TI DESIGNING THE NEW CFSAN
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
CY DEC 08-09, 1992
CL WASHINGTON, DC
SP FOOD & DRUG INST
RP SHANK, FR (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 479
EP 486
PG 8
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200011
ER
PT J
AU ARCHER, DL
DEROEVER, CM
AF ARCHER, DL
DEROEVER, CM
TI CFSANS PROGRAM OFFICES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
CY DEC 08-09, 1992
CL WASHINGTON, DC
SP FOOD & DRUG INST
RP ARCHER, DL (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 487
EP 490
PG 4
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200012
ER
PT J
AU LAKE, LR
AF LAKE, LR
TI THE FUNCTIONS OF THE OFFICE-OF-POLICY-PLANNING-AND-STRATEGIC-INITIATIVES
IN THE FDAS CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
RP LAKE, LR (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 491
EP 494
PG 4
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200013
ER
PT J
AU BURKE, JA
AF BURKE, JA
TI CENTER-FOR-FOOD-SAFETY-AND-APPLIED-NUTRITIONS OFFICE OF SYSTEMS AND
SUPPORT
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 36TH ANNUAL EDUCATIONAL CONF OF THE FOOD-AND-DRUG-INST
CY DEC 08-09, 1992
CL WASHINGTON, DC
SP FOOD & DRUG INST
RP BURKE, JA (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 3
BP 495
EP 499
PG 5
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA MH932
UT WOS:A1993MH93200014
ER
PT J
AU LEVITT, JA
KELSEY, JV
AF LEVITT, JA
KELSEY, JV
TI THE ORPHAN DRUG REGULATIONS AND RELATED ISSUES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP LEVITT, JA (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,WASHINGTON,DC 20204, USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 525
EP 532
PG 8
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400002
ER
PT J
AU ELLSWORTH, DI
AF ELLSWORTH, DI
TI CURRENT DEVELOPMENTS IN IMPLEMENTING THE GENERIC DRUG ENFORCEMENT ACT
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP ELLSWORTH, DI (reprint author), US FDA,CTR DRUG EVALUAT & RES,OFF COMPLIANCE,DIV REGULATORY AFFAIRS,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 537
EP 544
PG 8
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400004
ER
PT J
AU HORTON, LR
AF HORTON, LR
TI OVER-THE-COUNTER DRUG AUTHORITY ISSUES - SELECTED TOPICS
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP HORTON, LR (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 545
EP 562
PG 18
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400005
ER
PT J
AU KATZ, LM
AF KATZ, LM
TI PRESCRIPTION TO OVER-THE-COUNTER DRUG SWITCHES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP KATZ, LM (reprint author), US FDA,CTR DRUG EVALUAT & RES,PILOT DRUG EVALUAT STAFF,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 567
EP 570
PG 4
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400007
ER
PT J
AU HENNEY, JE
AF HENNEY, JE
TI DIRECTIONS IN DEVICE REGULATION - PAST, PRESENT, AND FUTURE
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP HENNEY, JE (reprint author), US FDA,OFF COMMISSIONER,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 697
EP 702
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400014
ER
PT J
AU JOHNSON, RM
AF JOHNSON, RM
TI ENFORCEMENT OVERVIEW
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP JOHNSON, RM (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF COMPLIANCE,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1993
VL 48
IS 4
BP 703
EP 707
PG 5
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA NG844
UT WOS:A1993NG84400015
ER
PT J
AU BARATTA, EJ
AF BARATTA, EJ
TI FDA QUALITY ASSURANCE FOR RADIOACTIVITY IN FOODS AND
RADIOPHARMACEUTICALS
SO FRESENIUS JOURNAL OF ANALYTICAL CHEMISTRY
LA English
DT Article; Proceedings Paper
CT 5TH INTERNATIONAL SYMP ON BIOLOGICAL AND ENVIRONMENTAL REFERENCE
MATERIALS ( BERM-5 )
CY MAY 11-14, 1992
CL AACHEN, GERMANY
SP DEUT FORSCHUNGSGEMEINSCH, UNEP, FORSCHUNGSZENTRUM KFA JULICH, MINIST WISSENSCH & FORSCH LANDES NORDRHEIN WEST FALEN, INT UNION PURE & APPL CHEM, COMMISS EUROPEAN COMMUNITIES, USDA, NIST, US FDA, INT ATOMIC ENERGY AGCY
AB The Food and Drug Administration (FDA) has regulatory responsibility for radionuclides in foods and radiopharmaceuticals and must maintain an ongoing Quality Assurance Program. These Quality Control Programs involve the U.S. Environmental Protection Agency (EPA) [1, 2] and the National Institute of Standards and Technology (NIST) [31, who supply the necessary reference materials and standards to ensure that the measurements are accurate and reproduceable. Data from EPA (1987 to 1991) and from a NIST ''Blind'' Source study (1985 to 1991) show the results are accurate with an average variation from NIST values of 1.8% [4-10]. The use of standard materials with the same matrices as the samples being analyzed provides credibility to the measurements.
RP BARATTA, EJ (reprint author), US FDA,109 HOLTON ST,WINCHESTER,MA 01890, USA.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0937-0633
J9 FRESEN J ANAL CHEM
JI Fresenius J. Anal. Chem.
PD JAN-FEB
PY 1993
VL 345
IS 2-4
BP 152
EP 155
DI 10.1007/BF00322576
PG 4
WC Chemistry, Analytical
SC Chemistry
GA KM830
UT WOS:A1993KM83000020
ER
PT S
AU HARRIS, GR
PATTON, CA
AF HARRIS, GR
PATTON, CA
BE Levy, M
McAvoy, BR
TI COMPUTATION OF WORST-CASE BIOEFFECTS INDEXES AND PULSE-AVERAGE INTENSITY
VALUES BASED ON ACOUSTIC OUTPUT DATA SUBMITTED TO THE FDA
SO IEEE 1993 ULTRASONICS SYMPOSIUM PROCEEDINGS, VOLS 1 AND 2
SE ULTRASONICS SYMPOSIUM
LA English
DT Proceedings Paper
CT IEEE 1993 Ultrasonics Symposium
CY OCT 31-NOV 03, 1993
CL BALTIMORE, MD
SP ULTRASON FERROELECT & FREQUENCY CONTROL SOC
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
SN 1051-0117
BN 0-7803-1278-3
J9 ULTRASON
PY 1993
BP 935
EP 938
PG 4
WC Acoustics; Engineering, Electrical & Electronic
SC Acoustics; Engineering
GA BA31N
UT WOS:A1993BA31N00182
ER
PT J
AU WEAR, KA
WAGNER, RF
INSANA, MF
HALL, TJ
AF WEAR, KA
WAGNER, RF
INSANA, MF
HALL, TJ
TI APPLICATION OF AUTOREGRESSIVE SPECTRAL-ANALYSIS TO CEPSTRAL ESTIMATION
OF MEAN SCATTERER SPACING
SO IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
LA English
DT Article
ID DOPPLER ULTRASOUND; LIVER
AB The problem of estimation of mean scatterer spacing in an object containing regularly spaced structures is addressed. An autoregressive (AR) spectral estimation method (based on Burg's algorithm) is compared with a conventional fast Fourier transform (FFT) based approach for this task. Regularly spaced structures produce a periodicity in the power spectrum of ultrasonic backscatter. This periodicity is manifested as a peak in the cepstrum. A phantom was constructed for comparison of the two methods. This phantom contained regularly spaced nylon filaments. In addition, it contained randomly positioned glass spheres that produced incoherent backscatter. In an experiment in which this target was interrogated using broadband ultrasound, the AR spectral estimate offered considerable improvement over the FFT when the analysis gate length was on the order of the structural dimension. Advantages included improved resolution, reduction in bias and variance of scatterer spacing estimates, and greater resistance to ringing artifacts. Data was also acquired from human liver in vivo. AR spectral estimates on human data exhibited a decreased dependence on gate length. These results offer promise for enhanced spatial resolution and accuracy in ultrasonic tissue characterization and nondestructive evaluation of materials.
C1 UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103.
RP WEAR, KA (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,HFZ-142,1270 TWINBROOK PKWY,ROCKVILLE,MD 20852, USA.
RI Hall, Timothy/K-3632-2012
NR 19
TC 79
Z9 93
U1 1
U2 3
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017-2394
SN 0885-3010
J9 IEEE T ULTRASON FERR
JI IEEE Trans. Ultrason. Ferroelectr. Freq. Control
PD JAN
PY 1993
VL 40
IS 1
BP 50
EP 58
DI 10.1109/58.184998
PG 9
WC Acoustics; Engineering, Electrical & Electronic
SC Acoustics; Engineering
GA KL024
UT WOS:A1993KL02400007
PM 18263156
ER
PT S
AU BLACK, PL
MCKINNON, KM
WOODEN, SL
USSERY, MA
AF BLACK, PL
MCKINNON, KM
WOODEN, SL
USSERY, MA
BE Georgiev, VS
Yamaguchi, H
TI ANTIVIRAL ACTIVITY OF A SYNTHETIC DOUBLE-STRANDED POLYRIBONUCLEOTIDE
INTERFERON INDUCER IN A MURINE AIDS RETROVIRUS MODEL - ROLE OF
AUGMENTATION OF NATURAL-KILLER-CELL ACTIVITY AND SYNERGY WITH ORAL AZT
SO IMMUNOMODULATING DRUGS
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Proceedings Paper
CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS
DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL
EVALUATION
CY FEB 27-JUL 01, 1992
CL WASHINGTON, DC
SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO
RP BLACK, PL (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20857, USA.
RI Messier, Claude/A-2322-2008
OI Messier, Claude/0000-0002-4791-1763
FU NIAID NIH HHS [NIAID (1U01AI2567)]
NR 0
TC 3
Z9 3
U1 0
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA NEW YORK
SN 0077-8923
BN 0-89766-771-9
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 685
BP 467
EP 470
DI 10.1111/j.1749-6632.1993.tb35908.x
PG 4
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA BY53M
UT WOS:A1993BY53M00061
PM 8363255
ER
PT S
AU KUNDER, SC
MORAHAN, PS
AF KUNDER, SC
MORAHAN, PS
BE Georgiev, VS
Yamaguchi, H
TI NK CELLS AND INTERFERON AS MEDIATORS OF BIOLOGICAL RESPONSE
MODIFIER-MEDIATED PROTECTION AGAINST MCMV AND HSV-2 INFECTION IN NORMAL
AND IMMUNOCOMPROMISED MICE
SO IMMUNOMODULATING DRUGS
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Proceedings Paper
CT 3RD INTERNATIONAL CONF ON DRUG RESEARCH IN IMMUNOLOGIC AND INFECTIOUS
DISEASES - IMMUNOMODULATING DRUGS : SYNTHESIS, PRECLINICAL AND CLINICAL
EVALUATION
CY FEB 27-JUL 01, 1992
CL WASHINGTON, DC
SP NEW YORK ACAD SCI, BAYER, AMGEN, BRISTOL MYERS SQUIBB PHARM RES INST, BURROUGHS WELLCOME, JANSSEN RES FDN, MERCK SHARP & DOHME RES LABS, SANDOZ RES IST, SMITHKLINE BEECHAM PHARM, TSUMURA & CO
RP KUNDER, SC (reprint author), US FDA,DIV ANTIVIRAL DRUG PROD,HFD-530,5600 FISHER LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA NEW YORK
SN 0077-8923
BN 0-89766-771-9
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 685
BP 618
EP 619
DI 10.1111/j.1749-6632.1993.tb35926.x
PG 2
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA BY53M
UT WOS:A1993BY53M00079
PM 7689813
ER
PT B
AU GUEST, GB
AF GUEST, GB
BE Goldberg, AM
TI A 10-YEAR PROGRESS REPORT OF THE
CENTER-FOR-ALTERNATIVES-TO-ANIMAL-TESTING - A GOVERNMENTAL PERSPECTIVE
SO IN VITRO TOXICOLOGY: TENTH ANNIVERSARY SYMPOSIUM OF CAAT
SE ALTERNATIVE METHODS IN TOXICOLOGY SERIES
LA English
DT Proceedings Paper
CT 10th Anniversary Symposium of CAAT - In Vitro Toxicology
CY APR 14-16, 1992
CL JOHNS HOPKINS HLTH INST, BALTIMORE, MD
SP US EPA, NIH, HLTH EFFECTS RES LAB, 3M, ALBERTO CULVER CO, ARCO, AVAON PROD INC, BERNICE BARBOUR FDN INC, BRISTOL MYERS SQUIBB CO, CHARLES RIVER LABS INC, CIBA GEIGY CORP, COSMET TOILETRY & FRAGRANCE ASSOC, GERALDINE R DODGE FDN, EXXON CORP, HOFFMANN LA ROCHE INC, IBM CORP, JOHNSON & JOHNSON, L OREAL, MARY KAY COSMET INC
HO JOHNS HOPKINS HLTH INST
C1 US FDA,CTR VET MED,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
BN 0-913113-60-3
J9 ALTERN METH
PY 1993
VL 9
BP 151
EP 154
PG 4
WC Toxicology
SC Toxicology
GA BB48D
UT WOS:A1993BB48D00014
ER
PT J
AU HAUSMAN, SZ
BURNS, DL
AF HAUSMAN, SZ
BURNS, DL
TI BINDING OF PERTUSSIS TOXIN TO LIPID VESICLES CONTAINING GLYCOLIPIDS
SO INFECTION AND IMMUNITY
LA English
DT Note
ID RECEPTOR; CELLS
AB The binding of pertussis toxin and its B oligomer to lipid vesicles containing glycosphingolipids was studied. Both pertussis toxin and the B oligomer bound to lipid vesicles containing ganglioside G(D1a). Binding of pertussis toxin to these vesicles decreased upon treatment of the vesicles with neuraminidase, suggesting that sialic acid residues are important for efficient binding of the toxin to G(D1a).
C1 US FDA,CTR BIOLOGICS EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20014.
NR 12
TC 24
Z9 24
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JAN
PY 1993
VL 61
IS 1
BP 335
EP 337
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KF636
UT WOS:A1993KF63600046
PM 8418057
ER
PT J
AU CREASIA, DA
THURMAN, JD
AF CREASIA, DA
THURMAN, JD
TI COMPARATIVE ACUTE INHALATION TOXICITY OF A SALINE SUSPENSION AND AN
ETHANOL SOLUTION OF T-2 MYCOTOXIN IN MICE
SO INHALATION TOXICOLOGY
LA English
DT Article
AB We compared retention, distribution, toxicity, and histopathological change in mice after exposure to aerosols of T-2 suspended in saline or dissolved in ethanol. We found that the LC50 for mice exposed for 10 min to an aerosol of a saline suspension of T-2 was 0.035 +/- 0.02 mg T-2 per liter air, which was lower than the LC50 (0.380 +/-0.08 mg T-2 per liter air) for an aerosol of T-2 dissolved in ethanol. However, within about 15 min postexposure, most of the T-2 deposited in the respiratory tract was translocated from the respiratory tract regardless of whether the T-2 aerosol was from a saline suspension or ethanol solution. Also, although T-2 is an inflammatory agent to dermis and gastrointestinal epithelium, T-2 from either aerosol did not produce any histological evidence of inflammation in the respiratory tract.
C1 NATL CTR TOXICOL RES,PATHOL ASSOCIATES INC,JEFFERSON,AR 72079.
USA,MED RES INST INFECT DIS,DIV TOXICOL,FREDERICK,MD 21701.
NR 12
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS
PI BRISTOL
PA 1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598
SN 0895-8378
J9 INHAL TOXICOL
JI Inhal. Toxicol.
PD JAN-MAR
PY 1993
VL 5
IS 1
BP 33
EP 41
DI 10.3109/08958379309034492
PG 9
WC Toxicology
SC Toxicology
GA KQ828
UT WOS:A1993KQ82800002
ER
PT B
AU PECK, CC
AF PECK, CC
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI RATIONALE FOR THE EFFECTIVE USE OF PHARMACOKINETICS AND PHARMACODYNAMICS
IN EARLY DRUG DEVELOPMENT
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP PECK, CC (reprint author), US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 5
Z9 5
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 1
EP 5
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00001
ER
PT B
AU FITZGERALD, GG
AF FITZGERALD, GG
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI PHARMACOKINETICS AND DRUG-METABOLISM IN ANIMAL STUDIES (ADME,
PROTEIN-BINDING, MASS BALANCE, ANIMAL-MODELS)
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP FITZGERALD, GG (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV NEUROPHARMACOL DRUG PROD,ROCKVILLE,MD 20857, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 23
EP 31
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00004
ER
PT B
AU GREEN, MD
AF GREEN, MD
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI NONCLINICAL CONSIDERATIONS - DISPOSITION OF DRUGS
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP GREEN, MD (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,OFF DRUG EVALUAT 2,KENSINGTON,MD 20895, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 1
Z9 1
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 33
EP 37
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00005
ER
PT B
AU COLLINS, JM
AF COLLINS, JM
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI USE OF PHARMACOKINETICS AND PHARMACODYNAMICS IN PRECLINICAL STUDIES TO
GUIDE DOSAGE ESCALATION SCHEMES IN PHASE-I STUDIES OF ANTICANCER DRUGS
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP COLLINS, JM (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV CLIN PHARMACOL,OFF RES RESOURCES,ROCKVILLE,MD 20857, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 2
Z9 2
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 49
EP 53
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00007
ER
PT B
AU MUKHERJEE, A
CHEN, C
JEAN, L
COUTINHO, CB
AF MUKHERJEE, A
CHEN, C
JEAN, L
COUTINHO, CB
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI PRECLINICAL PHARMACODYNAMICS OF ANTIINFLAMMATORY DRUGS
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP MUKHERJEE, A (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV PILOT DRUG EVALUAT,ROCKVILLE,MD 20857, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 105
EP 113
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00013
ER
PT B
AU PECK, CC
BARR, WH
BENET, LZ
COLLINS, J
DESJARDINS, RE
FURST, DE
HARTER, JG
LEVY, G
LUDDEN, T
RODMAN, JH
SANATHANAN, L
SCHENTAG, JJ
SHAH, VP
SHEINER, LB
SKELLY, JP
STANSKI, DR
TEMPLE, RJ
VISWANATHAN, CT
WEISSINGER, J
YACOBI, A
AF PECK, CC
BARR, WH
BENET, LZ
COLLINS, J
DESJARDINS, RE
FURST, DE
HARTER, JG
LEVY, G
LUDDEN, T
RODMAN, JH
SANATHANAN, L
SCHENTAG, JJ
SHAH, VP
SHEINER, LB
SKELLY, JP
STANSKI, DR
TEMPLE, RJ
VISWANATHAN, CT
WEISSINGER, J
YACOBI, A
BE Yacobi, A
Skelly, JP
Shah, VP
Benet, LZ
TI OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS AND
TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT
SO INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN
RATIONAL DRUG DEVELOPMENT
LA English
DT Proceedings Paper
CT CONF ON THE INTEGRATION OF PHARMACOKINETIC, PHARMACODYNAMIC AND
TOXICOKINETIC PRINCIPLES IN RATIONAL DRUG DEVELOPMENT
CY APR 24-26, 1991
CL ARLINGTON, VA
SP AMER ASSOC PHARM SCIENTISTS, US FDA, AMER SOC CLIN PHARM & THERAPEUT
RP PECK, CC (reprint author), US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857, USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 1
Z9 1
U1 0
U2 1
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA NEW YORK
BN 0-306-44356-2
PY 1993
BP 249
EP 263
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BX44L
UT WOS:A1993BX44L00026
ER
PT J
AU UMEHARA, H
TAKASHIMA, A
MINAMI, Y
BLOOM, ET
AF UMEHARA, H
TAKASHIMA, A
MINAMI, Y
BLOOM, ET
TI SIGNAL TRANSDUCTION VIA PHOSPHORYLATED ADHESION MOLECULE, LFA-1-BETA
(CD18), IS INCREASED BY CULTURE OF NATURAL-KILLER-CELLS WITH IL-2 IN THE
GENERATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE ADHESION MOLECULE; CYTOTOXICITY; HUMAN; INTEGRIN; LYMPHOKINE ACTIVATED
KILLER CELLS; NATURAL KILLER CELLS; PHOSPHORYLATION
ID P70-75 BETA-SUBUNIT; PROTEIN-KINASE-C; LYMPHOCYTES-T; TYROSINE
PHOSPHORYLATION; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; MEDIATED
CYTOLYSIS; LEUKOCYTE ADHESION; SERINE ESTERASE; PLASMA-MEMBRANE
AB It is well known that IL-2 stimulates natural killer (NK) cells to express lymphokine activated killer (LAK) activity and that this stimulation prompts the acquisition of the ability to lyse previously insensitive target cells. The possible role of adhesion molecules in the IL-2 activation process was probed by focussing on a lymphocyte function-associated antigen (LFA)-1-dependent model system. A mAb to the LFA-1beta chain abrogated LAK activity, but only moderately suppressed NK activity, suggesting a differential role for LFA-1beta in LAK compared with NK mediated lysis. Orthophosphate labeling demonstrated that the LFA-1beta chain was strongly phosphorylated in LAK but not NK cells; in contrast, the alpha chain was phosphorylated similarly in both effector cell types. At least a portion of the phosphorylation of the beta chain was on tyrosine residues, as shown by Western blotting with anti-phosphotyrosine antibody of LFA-1beta immunoprecipitates. Crosslinking of the LFA-1beta chain with plastic-adhered antibody stimulated Ca2+-dependent release of cytoplasmic lytic granules and induced phosphatidyl inositol turnover in LAK but not NK cells. We conclude that the IL-2-induced phosphorylation of the beta chain of the LFA-1 adhesion molecule in LAK cells and associated alteration in signal transduction may be important in the stimulation of LAK cell activity in NK cells.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892.
NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892.
FU NCI NIH HHS [CA30187]
NR 63
TC 25
Z9 26
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD JAN
PY 1993
VL 5
IS 1
BP 19
EP 27
DI 10.1093/intimm/5.1.19
PG 9
WC Immunology
SC Immunology
GA KJ347
UT WOS:A1993KJ34700003
PM 8095153
ER
PT J
AU GRASSI, J
MICHEL, C
ANDERSON, MC
GUERIN, B
AF GRASSI, J
MICHEL, C
ANDERSON, MC
GUERIN, B
TI IMMUNOENZYMATIC MEASUREMENT OF FEL-DI
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 CTR ETUDE SACLAY,SPI DRIPP,F-91191 GIF SUR YVETTE,FRANCE.
ALLERBIO,F-55270 VARENNES ARGONNE,FRANCE.
US FDA,ALLERGY & IMMUNOCHEM LAB,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 1993
VL 91
IS 1
BP 373
EP 373
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA KK431
UT WOS:A1993KK43100926
ER
PT J
AU BERKOWITZ, DB
AF BERKOWITZ, DB
TI THE FOOD SAFETY OF TRANSGENIC ANIMALS - IMPLICATIONS FROM TRADITIONAL
BREEDING
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article
DE TRANSGENICS; FOOD SAFETY; ANIMAL BREEDING; QUANTITATIVE TRAITS;
RESTRICTION FRAGMENT LENGTH POLYMORPHISMS
ID MUTATION; GENE; MICE; PROLACTIN; HORMONE
AB The genetic events associated with traditional selection have implications for the food safety of transgenic animals. Selection has been empirical, relying on the use of the best animals for breeding. Molecular techniques are now being used to identify the genes selected and to describe the differences between alleles that are important in selection to improve quantitative traits. The results of such analyses provide background details of the genetic and physiological effects of the traditional selection of animal lines. Examples of the kinds of genes that may be subject to selection are those coding for peptide hormones, steroid metabolic enzymes, the calcium-channel gating protein, and genes of the major histocompatibility complex. Unselected genes, sometimes with undesirable alleles, may be carried along as ''hitchhikers'' if they are closely linked to the selected gene. In spite of this potential for physiologically dangerous genetic changes in selected animals, hereditary food toxicity has never been associated with a selected line of the common food animals. This is probably because the allowable physiological range of results of selection is limited by the requirement for healthy, productive animals. Based on these limitations, foods from healthy transgenic animals produced for the purpose of herd improvement are likely to be as safe as the foods from the untransformed parental line. Animals are important indicators of their own food safety.
RP BERKOWITZ, DB (reprint author), US FDA, OFF BIOTECHNOL HF-6, ROCKVILLE, MD 20857 USA.
NR 18
TC 3
Z9 3
U1 1
U2 2
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA
SN 0021-8812
J9 J ANIM SCI
JI J. Anim. Sci.
PY 1993
VL 71
SU S3
BP 43
EP 46
PG 4
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA LB507
UT WOS:A1993LB50700008
PM 8099351
ER
PT J
AU YESS, NJ
AF YESS, NJ
TI UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION SURVEY OF METHYL MERCURY IN
CANNED TUNA
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB Methyl mercury was determined by the U.S. Food and Drug Administration (FDA) in 220 samples of canned tuna collected in 1991. Samples were chosen to represent different styles, colors, and packs as available. Emphasis was placed on water-packed tuna, small can size, and the highest-volume brand names. The average methyl mercury (expressed as Hg) found for the 220 samples was 0.17 ppm; the range was <0.10-0.75 ppm. Statistically, a significantly higher level of methyl mercury was found in solid white and chunk white tuna than was found in chunk light and chunk tuna. Methyl mercury level was not related to can size. None of the 220 samples had methyl mercury levels that exceeded the 1 ppm FDA action level.
RP YESS, NJ (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 10
TC 35
Z9 35
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 36
EP 38
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100007
PM 8448441
ER
PT J
AU GLAZE, LE
AF GLAZE, LE
TI EXTRACTION OF LIGHT FILTH FROM ORIENTAL FISH PRODUCTS CONTAINING SPICE -
COLLABORATIVE STUDY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A collaborative study was conducted to validate a new method for the extraction of light filth from oriental fish products containing spice. A 100 g test portion is digested by boiling in a mixture of HCl, Igepal DM-710, and CO-730. Light fifth is isolated by wet-sieving on a No. 230 plain-weave sieve with Tergitol, deaeration boiling in 40% isopropanol, and extracting with mineral oil-heptane (85 + 15) and 40% isopropanol in a Wildman trap flask. Three spiking levels for rat hairs and insect fragments were used in the study. For rat hairs, recoveries at the low, medium, and high levels averaged 80.0, 71.6, and 88.0%, respectively. Recoveries of insect fragments for low, medium, and high levels averaged 87.8,83.7, and 89.4%, respectively. The method was adopted first action by AOAC International.
RP GLAZE, LE (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 44
EP 46
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100009
PM 8448443
ER
PT J
AU NAKASHIMA, MJ
AF NAKASHIMA, MJ
TI EXTRACTION OF LIGHT FILTH FROM ORIENTAL SAUCES CONTAINING SOY-SAUCE,
THICKENERS, AND SPICES - COLLABORATIVE STUDY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB Results are reported for a collaborative study of a method for the extraction of light filth from oriental sauces containing soy sauce, thickeners, and spices. A 100 g test portion is pretreated in a 2% solution of Tergitol Anionic 4 over a steam bath, and oils are removed by wet-sieving on No. 230 sieve. Filth is isolated from 40% isopropanol by using Na4EDTA and mineral oil. Average recoveries by 9 collaborators for 3 spike levels of rat hairs (5, 10, and 15) were 84, 78, and 79%, respectively; for insect fragments (5,15, and 30), recoveries were 92, 95, and 96%, respectively. The method was adopted first action by AOAC International.
RP NAKASHIMA, MJ (reprint author), US FDA,DIV MICROBIOL,HFF-237,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 47
EP 49
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100010
PM 8448444
ER
PT J
AU NAKASHIMA, MJ
AF NAKASHIMA, MJ
TI EXTRACTION OF LIGHT FILTH FROM TOFU - COLLABORATIVE STUDY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB Results are reported for a collaborative study of a method for the extraction of light filth from tofu. A 100 g test portion is digested in HCl solution with Igepal CO-730 and Igepal DM-710. Hairs and insect fragments are isolated by wet-sieving on a No. 230 sieve, dispersing remaining residual product with Aerosol OT 75%, and filtering. Average recoveries by 9 collaborators for 3 spike levels of rat hairs (5, 10, 15) were 80, 78, and 84%, respectively; for 3 spike levels of insect fragments (5,15, 30), recoveries were 97, 99, and 99%, respectively. The method was adopted first action by AOAC International.
RP NAKASHIMA, MJ (reprint author), US FDA,DIV MICROBIOL,HFF-237,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 50
EP 52
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100011
PM 8448445
ER
PT J
AU BARNES, CJ
AF BARNES, CJ
TI DRUG RESIDUES IN ANIMAL-TISSUES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BARNES, CJ (reprint author), US FDA,DIV VET MED RES,BELTSVILLE,MD 20705, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 102
EP 102
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100026
ER
PT J
AU SMITH, E
AF SMITH, E
TI DRUGS-II
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP SMITH, E (reprint author), US FDA,CTR DRUG EVALUAT & RES,WASHINGTON,DC 20204, USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 102
EP 103
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100028
ER
PT J
AU ALEXANDER, TG
AF ALEXANDER, TG
TI DRUGS-V
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP ALEXANDER, TG (reprint author), US FDA,CTR DRUG EVALUAT & RES,HFD-473,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 104
EP 105
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100031
ER
PT J
AU NG, LL
AF NG, LL
TI DRUGS-IV
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP NG, LL (reprint author), US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 104
EP 104
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100030
ER
PT J
AU CICHOWICZ, SM
AF CICHOWICZ, SM
TI FORENSIC SCIENCES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP CICHOWICZ, SM (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 105
EP 105
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100032
ER
PT J
AU FAZIO, T
AF FAZIO, T
TI FOOD-ADDITIVES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP FAZIO, T (reprint author), US FDA,OFF PHYS SCI,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 108
EP 111
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100035
ER
PT J
AU PAGE, SW
AF PAGE, SW
TI PLANT TOXINS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID CHROMATOGRAPHIC DETERMINATION
RP PAGE, SW (reprint author), US FDA,NAT PROD & INSTRUMENTAT BRANCH,WASHINGTON,DC 20204, USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 119
EP 120
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100038
ER
PT J
AU HUNGERFORD, JM
AF HUNGERFORD, JM
TI SEAFOOD TOXINS AND SEAFOOD PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; FLOW-INJECTION ANALYSIS; FISH SPECIES
IDENTIFICATION; MONKEYS MACACA-FASCICULARIS; POISON EXTRACTION
PROCEDURE; MUSSEL MYTILUS-EDULIS; DOMOIC ACID; OKADAIC ACID;
PROTEIN-PHOSPHORYLATION; LUMINESCENCE DETECTION
RP HUNGERFORD, JM (reprint author), US FDA,22201 23RD DR SE,POB 3012,BOTHELL,WA 98041, USA.
NR 126
TC 9
Z9 9
U1 1
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 120
EP 130
PG 11
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100039
ER
PT J
AU PROSKY, L
AF PROSKY, L
TI DIETARY FIBER
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP PROSKY, L (reprint author), US FDA,DIV NUTR,LAUREL,MD 20708, USA.
NR 0
TC 1
Z9 2
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 132
EP 133
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100042
ER
PT J
AU FIRESTONE, D
AF FIRESTONE, D
TI FATS AND OILS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; INFRARED SPECTROPHOTOMETRY; ACIDS;
MARGARINES; CIS
RP FIRESTONE, D (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 27
TC 4
Z9 4
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 133
EP 136
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100043
ER
PT J
AU BOLAND, FE
AF BOLAND, FE
TI FRUITS AND FRUIT PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BOLAND, FE (reprint author), US FDA,DIV FOOD CHEM & TECHNOL,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 136
EP 138
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100044
ER
PT J
AU MULVANEY, TR
AF MULVANEY, TR
TI PROCESSED VEGETABLE PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP MULVANEY, TR (reprint author), US FDA,DIV FOOD CHEM & TECHNOL,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 138
EP 139
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100046
ER
PT J
AU NEWTON, JM
AF NEWTON, JM
TI NONALCOHOLIC BEVERAGES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP NEWTON, JM (reprint author), US FDA,50 UNITED NATIONS PLAZA,SAN FRANCISCO,CA 94102, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 138
EP 138
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100045
ER
PT J
AU DEUTSCH, MJ
AF DEUTSCH, MJ
TI VITAMINS AND OTHER NUTRIENTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP DEUTSCH, MJ (reprint author), US FDA,DIV NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 141
EP 141
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100049
ER
PT J
AU CAPAR, SG
AF CAPAR, SG
TI METALS AND OTHER ELEMENTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP CAPAR, SG (reprint author), US FDA,DIV CONTAMINANTS CHEM,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 142
EP 144
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100050
ER
PT J
AU SAWYER, LD
AF SAWYER, LD
TI MULTIRESIDUE METHODS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP SAWYER, LD (reprint author), US FDA,DIV CONTAMINANTS CHEM,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 144
EP 147
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100051
ER
PT J
AU MCMAHON, BM
AF MCMAHON, BM
TI ORGANOHALOGEN PESTICIDES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP MCMAHON, BM (reprint author), US FDA,DIV PESTICIDES & IND CHEM,WASHINGTON,DC 20204, USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 147
EP 148
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100052
ER
PT J
AU BARATTA, EJ
AF BARATTA, EJ
TI RADIOACTIVITY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BARATTA, EJ (reprint author), US FDA,WINCHESTER ENGN & ANALYT CTR,WINCHESTER,MA 01890, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 149
EP 149
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100054
ER
PT J
AU HITCHINS, AD
AF HITCHINS, AD
TI COSMETIC MICROBIOLOGY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP HITCHINS, AD (reprint author), US FDA,DIV MICROBIOL,HFF 234,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 150
EP 151
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100055
ER
PT J
AU PLACENCIA, AM
AF PLACENCIA, AM
TI DRUG-RELATED AND DEVICE-RELATED MICROBIOLOGY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP PLACENCIA, AM (reprint author), US FDA,MINNEAPOLIS,MN, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 151
EP 151
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100056
ER
PT J
AU BOESE, JI
AF BOESE, JI
TI FILTH AND EXTRANEOUS MATERIALS IN FOODS AND DRUGS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BOESE, JI (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 152
EP 153
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100057
ER
PT J
AU ANDREWS, WH
AF ANDREWS, WH
TI FOOD MICROBIOLOGY - NONDAIRY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP ANDREWS, WH (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 2
TC 5
Z9 6
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1993
VL 76
IS 1
BP 154
EP 159
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA KG911
UT WOS:A1993KG91100059
ER
PT J
AU STERN, SJ
DEGAWA, M
MARTIN, MV
GUENGERICH, FP
KADERLIK, RK
ILETT, KF
BREAU, R
MCGHEE, M
MONTAGUE, D
LYNCOOK, B
KADLUBAR, FF
AF STERN, SJ
DEGAWA, M
MARTIN, MV
GUENGERICH, FP
KADERLIK, RK
ILETT, KF
BREAU, R
MCGHEE, M
MONTAGUE, D
LYNCOOK, B
KADLUBAR, FF
TI METABOLIC-ACTIVATION, DNA-ADDUCTS, AND H-RAS MUTATIONS IN HUMAN
NEOPLASTIC AND NONNEOPLASTIC LARYNGEAL TISSUE
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE CYTOCHROME P-450; N-ACETYLTRANSFERASE; P-32-POSTLABELING; H-RAS
MUTATIONS; LARYNX
ID HUMAN-LIVER; ACETYLTRANSFERASE; PURIFICATION; BLADDER
AB Metabolic activation, DNA adducts, and H-ras mutations were examined in human laryngeal tissue (n = 16) from both smoker and non/ex-smoker patients with laryngeal cancer. DNA adducts detected by P-32-postlabelling were evident only in smokers (n = 13); in fact, smoking cessation for as little as 10 months resulted in no DNA adducts detected (n = 3). Total DNA adduct levels in these samples were significantly correlated with levels of cytochromes P-4502C and 1A1 in laryngeal microsomes. Moreover, the P-4501A1 levels represent the highest yet found in human tissues. In contrast, laryngeal microsomes did not have detectable P-4501A2 activity, while laryngeal cytosols showed appreciable N-acetyltransferase activity for p-aminobenzoic acid (NAT1) but not sulfamethazine (NAT2).
DNA was extracted from laryngeal specimens and amplified by PCR. Nylon filter dot or slot blots were hybridized with P-32-labelled probes for codons 12, 13, and 61 of the H-ras gene. Sixty percent of specimens demonstrated mutations in either codon 12, 13, or 61; a single common and specific mutation was a Gln --> Glu transversion in codon 61. This mutation appeared in 5 laryngeal specimens, all from smokers.
These results implicate cigarette smoke components, bioactivated by CYP1A1 and/or CYP2C, in DNA adduct formation. These results also demonstrate a probable smoking-related H-ras Gln --> Glu transversion in codon 61. (C) 1993 Wiley-Liss, Inc.
C1 VANDERBILT UNIV,NASHVILLE,TN 37232.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP STERN, SJ (reprint author), UNIV ARKANSAS MED SCI HOSP,DEPT OTOLARYNGOL HEAD & NECK SURG,4301 W MARKHAM,SLOT 543,LITTLE ROCK,AR 72205, USA.
RI Degawa, Masakuni/F-5702-2010
NR 20
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1993
SU 17F
BP 129
EP 137
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LT580
UT WOS:A1993LT58000017
ER
PT J
AU PERICO, A
PRATOLONGO, R
FREED, KF
PASTOR, RW
SZABO, A
AF PERICO, A
PRATOLONGO, R
FREED, KF
PASTOR, RW
SZABO, A
TI POSITIONAL TIME CORRELATION-FUNCTION FOR ONE-DIMENSIONAL SYSTEMS WITH
BARRIER CROSSING - MEMORY FUNCTION CORRECTIONS TO THE OPTIMIZED
ROUSE-ZIMM APPROXIMATION
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID ACTIVATED RATE-PROCESSES; NON-MARKOVIAN THEORY; CONFORMATIONAL
TRANSITIONS; ISOMERIZATION DYNAMICS; POLYPEPTIDE DYNAMICS; BROWNIAN
DYNAMICS; CHAIN MOLECULES; RATE CONSTANTS; POLYMERS; RELAXATION
AB The one-variable Smoluchowski equation is used to study the influence of barrier crossing processes on the positional time correlation function. The memory function of this correlation function is evaluated for a 2-4 potential as a function of the barrier height using the Mori continued fraction expansion and an equivalent but more efficient matrix formulation. Higher orders in the expansions are required to obtain numerical convergence as the barrier height increases. An exact integral solution for the correlation time is derived and is compared with the approximations. A biexponential approximation, which describes the independent motion in a potential well and the transition between wells, is found to be very accurate for high barriers. Numerical simulations provide checks on the approximations to the correlation function for a barrier height of 2 k(B)T. The possibility of including the influence of more rapid barrier crossing processes into the many variable Smoluchowski description of long time polymer and protein dynamics is discussed.
C1 UNIV CHICAGO,JAMES FRANCK INST,CHICAGO,IL 60637.
UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637.
US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
NIADDKD,CHEM PHYS LAB,BETHESDA,MD 20892.
RP PERICO, A (reprint author), CTR STUDI CHIMICOFIS MACROMOLEC SINTETICHE & NAT,CNR,CORSO EUROPA 30,I-16132 GENOA,ITALY.
RI Szabo, Attila/H-3867-2012
NR 41
TC 49
Z9 49
U1 0
U2 2
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD JAN 1
PY 1993
VL 98
IS 1
BP 564
EP 573
DI 10.1063/1.464598
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA KF406
UT WOS:A1993KF40600064
ER
PT J
AU OBIRI, NI
HILLMAN, GG
HAAS, GP
SUD, S
PURI, RK
AF OBIRI, NI
HILLMAN, GG
HAAS, GP
SUD, S
PURI, RK
TI EXPRESSION OF HIGH-AFFINITY INTERLEUKIN-4 RECEPTORS ON HUMAN RENAL-CELL
CARCINOMA-CELLS AND INHIBITION OF TUMOR-CELL GROWTH-INVITRO BY
INTERLEUKIN-4
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE IL-4 RECEPTORS ON RENAL CELL CARCINOMA; MODULATION OF IL-4 RECEPTORS;
TUMOR CELL GROWTH INHIBITION
ID FACTOR-I RECEPTOR; NECROSIS-FACTOR; GAMMA-INTERFERON; UP-REGULATION;
ALPHA; IDENTIFICATION; LYMPHOCYTES; LYMPHOKINE
AB Previously, Puri et al. (Puri, R. K., M. Ogata, P. Leland, G. M. Feldman, D. Fitzgerald, and I. Pastan. 1991. Cancer Res. 51:3011-3017) have demonstrated that murine sarcoma and colon adenocarcinoma cells express high affinity interleukin-4 receptors (IL4R) which are internalized after binding to a chimeric ligand consisting of IL4 and Pseudomonas exotoxin. In the present study, we have tested primary cultures of human renal cell carcinoma (RCC) cells, generated from tumor specimens obtained after nephrectomy, for the expression of IL-4R and their modulation by IL4. By using iodinated IL-4 in a receptor binding assay, we observed that renal cell carcinoma cells expressed a single class of high affinity IL-4R ranging from 1,425 +/- 207 (mean +/- SEM) to 3,831 +/- 299 (mean +/- SEM) IL-4R molecules/cell with a K(d) ranging from 112 +/- 11 pM to 283 +/- 71 pM. Northern blot analysis for 1L-4R gene expression, performed with a cDNA probe to IL-4R, revealed that all RCC cells exhibited a single mRNA species of 4 kb. IL4 downregulated the surface expression of IL-4R on one RCC tumor cell line. The function of IL-4R expression on RCC tumor cells was further determined by investigating the effect of 11.4 on tumor cell growth in vitro and comparing it with IL-4 effect on growth of normal fibroblast and endothelial cell lines. Tumor cell growth, as measured by [H-3]thymidine incorporation, was inhibited by IL-4 from 20 to 68% in a dose-dependent manner. A neutralizing antibody to human IL-4 was able to reverse the growth inhibitory effect of IL-4. Normal human fibroblast and endothelial cell lines also expressed high affinity IL-4R, however, IL=4 did not inhibit their growth in vitro. In fact, IL-4 caused modest stimulation of their growth. Taken together, our findings can help develop strategies for the treatment of RCC in which IL-4R may be used as a target for IL-4 itself, for IL-4 toxin therapy or, alternatively, in gene therapy.
C1 WAYNE STATE UNIV,SCH MED,DEPT UROL,DETROIT,MI 48201.
RP OBIRI, NI (reprint author), US FDA,CELLULAR BIOL LAB,DIV CYTOKINE BIOL,CTR BIOL EVALUAT & RES,BLDG 29A,ROOM 2B20,BETHESDA,MD 20892, USA.
NR 32
TC 167
Z9 168
U1 0
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 1993
VL 91
IS 1
BP 88
EP 93
DI 10.1172/JCI116205
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KK042
UT WOS:A1993KK04200015
PM 8423237
ER
PT J
AU CALDERWOOD, JA
JOHNSON, JM
AF CALDERWOOD, JA
JOHNSON, JM
TI A LEGAL CURRICULUM FOR THE CLINICAL PHARMACOLOGIST .2. THE COURT SYSTEM
AND GRANTS AND CONTRACTS
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
C1 CTR DRUG EVALUAT & RES,DIV EPIDEMIOL & SURVEILLANCE,ROCKVILLE,MD.
RP CALDERWOOD, JA (reprint author), ZUCKERT SCOUTT & RASENBERGER,888 17TH ST NW,SUITE 600,WASHINGTON,DC 20006, USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD JAN
PY 1993
VL 33
IS 1
BP 22
EP 28
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KG670
UT WOS:A1993KG67000004
PM 8429109
ER
PT J
AU FERREIRA, JL
BAUMSTARK, BR
HAMDY, MK
MCCAY, SG
AF FERREIRA, JL
BAUMSTARK, BR
HAMDY, MK
MCCAY, SG
TI POLYMERASE CHAIN-REACTION FOR DETECTION OF TYPE-A CLOSTRIDIUM-BOTULINUM
IN FOODS
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID NEUROTOXIN; SEQUENCE; DNA
AB A DNA fragment of the type A Clostridium botulinum neurotoxin gene was demonstrated in canned food products with the polymerase chain reaction (PCR). The fragment, 1340-bp in size, was amplified from green peas, whole kernel com, green beans, lima beans, black-eyed peas, and turnip greens previously inoculated with type A C. botulinum. The PCR products were identified by agarose gel electrophoresis and also confirmed by dot blot DNA hybridization with a type A specific gene probe. Some inoculated foods were PCR negative but became PCR positive after subculture and overnight incubation in brain heart infusion broth. No PCR amplification products were obtained from uninoculated foods. The procedure was highly sensitive and detected as few as 100 vegetative cells per ml brain heart infusion broth culture.
C1 GEORGIA STATE UNIV,DEPT FOOD SCI,ATLANTA,GA 30303.
US FDA,ATLANTA,GA.
RP FERREIRA, JL (reprint author), GEORGIA STATE UNIV,DEPT BIOL,ATLANTA,GA 30303, USA.
NR 12
TC 18
Z9 18
U1 0
U2 0
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD JAN
PY 1993
VL 56
IS 1
BP 18
EP 20
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA KK749
UT WOS:A1993KK74900004
ER
PT J
AU DEBELL, KE
HODES, R
GRAHAM, L
YUAN, D
HOFFMAN, T
BONVINI, E
AF DEBELL, KE
HODES, R
GRAHAM, L
YUAN, D
HOFFMAN, T
BONVINI, E
TI SIGNALING PATHWAYS IN MURINE TH1 AND TH2 CLONES
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Meeting Abstract
C1 NIH,CBER,DMA,CELL BIOL LAB,BETHESDA,MD 20892.
NIA,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PY 1993
SU S
BP 57
EP 57
PG 1
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA ME185
UT WOS:A1993ME18500146
ER
PT J
AU DHAWAN, S
HEWLETT, I
UHING, R
WHITE, J
WONG, H
CIANCIOLO, G
ARONOVITZ, J
MELTZER, M
AF DHAWAN, S
HEWLETT, I
UHING, R
WHITE, J
WONG, H
CIANCIOLO, G
ARONOVITZ, J
MELTZER, M
TI SYNTHETIC PEPTIDE DERIVED FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV)
GP41 INHIBITS HIV-INFECTION OF MONOCYTES
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Meeting Abstract
C1 US FDA,DIV TRANSFUS TRANSMITTED DIS,MOLEC VIROL LAB,ROCKVILLE,MD 20895.
MACRONEX INC,MORRISVILLE,NC 27560.
WALTER REED ARMY INST RES,WASHINGTON,DC 20307.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PY 1993
SU S
BP 74
EP 74
PG 1
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA ME185
UT WOS:A1993ME18500241
ER
PT J
AU RUSSELL, SM
HARADA, N
NAKAMURA, Y
NOGUCHI, M
LELAND, P
MIYAJIMA, A
PURI, RK
LEONARD, WJ
AF RUSSELL, SM
HARADA, N
NAKAMURA, Y
NOGUCHI, M
LELAND, P
MIYAJIMA, A
PURI, RK
LEONARD, WJ
TI THE INTERLEUKIN-2 RECEPTOR-GAMMA CHAIN IS A COMPONENT OF THE
INTERLEUKIN-4 RECEPTOR
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Meeting Abstract
C1 NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892.
DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304.
US FDA,CBER,DIV CELLULAR & GENE THERAPY,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PY 1993
SU S
BP 107
EP 107
PG 1
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA ME185
UT WOS:A1993ME18500443
ER
PT J
AU SCHENCK, FJ
WAGNER, R
BARGO, W
AF SCHENCK, FJ
WAGNER, R
BARGO, W
TI DETERMINATION OF CLORSULON RESIDUES IN MILK USING A SOLID-PHASE
EXTRACTION CLEANUP AND LIQUID-CHROMATOGRAPHIC DETERMINATION
SO JOURNAL OF LIQUID CHROMATOGRAPHY
LA English
DT Article
AB A method for the isolation and liquid chromatographic determination of the antiparasitic drug clorsulon in milk is presented. Milk samples are deproteinized and the supernatant is purified by solid-phase extraction (SPE). The purified extracts are quantified by HPLC analysis with UV detection. The overall recovery of clorsulon from 30 control milk samples spiked at 25-200 ppb was 77.0% (C.V.- 5.3%). This method, a liquid-liquid extraction method, and a matrix solid phase dispersion (MSPD) method for the determination of clorsulon in milk gave comparable values for milk samples with incurred clorsulon residues. However, the SPE method uses less solvent and is more rapid than the liquid-liquid extraction method and is more sensitive than the MSPD method.
RP SCHENCK, FJ (reprint author), US FDA,900 MADISON AVE,BALTIMORE,MD 21201, USA.
NR 6
TC 8
Z9 9
U1 1
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-3919
J9 J LIQ CHROMATOGR
JI J. Liq. Chromatogr.
PY 1993
VL 16
IS 2
BP 513
EP 520
DI 10.1080/10826079308020928
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA KG869
UT WOS:A1993KG86900016
ER
PT J
AU SCHENCK, FJ
HENNESSY, MK
AF SCHENCK, FJ
HENNESSY, MK
TI DETERMINATION OF DINOCAP IN APPLES, GRAPES, AND PEARS USING A
SOLID-PHASE EXTRACTION CLEANUP AND HPLC-UV DETECTION
SO JOURNAL OF LIQUID CHROMATOGRAPHY
LA English
DT Article
ID GAS-CHROMATOGRAPHIC DETERMINATION
AB A solid phase extraction (SPE) technique for the isolation and HPLC-UV determination of the pesticide dinocap in apples, grapes and pears is described. samples are extracted with acetone; the acetone extract is subjected to cleanup on both C-18 and silica SPE columns. The residues are determined using HPLC with a UV detector. The average recovery from crop samples spiked at tolerance, 0.1 ppm dinocap, was 85.9%.
RP SCHENCK, FJ (reprint author), US FDA,BALTIMORE DIST,900 MADISON AVE,BALTIMORE,MD 21201, USA.
NR 8
TC 8
Z9 10
U1 1
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-3919
J9 J LIQ CHROMATOGR
JI J. Liq. Chromatogr.
PY 1993
VL 16
IS 3
BP 755
EP 766
DI 10.1080/10826079308019562
PG 12
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA KK617
UT WOS:A1993KK61700013
ER
PT J
AU SCIACCHITANO, CJ
MOPPER, B
AF SCIACCHITANO, CJ
MOPPER, B
TI ANALYSIS OF PARALYTIC SHELLFISH TOXIN (SAXITOXIN) IN MOLLUSKS BY
CAPILLARY ZONE ELECTROPHORESIS
SO JOURNAL OF LIQUID CHROMATOGRAPHY
LA English
DT Article; Proceedings Paper
CT 3RD ANNUAL FREDERICK CONF ON CAPILLARY ELECTROPHORESIS
CY OCT 20-21, 1992
CL FREDERICK, MD
AB Contamination of seafood by paralytic shellfish toxins is considered a public health hazard by the U.S. Food and DrUg Administration. Human consumption of bivalves including clams, oysters, and mussels which have accumulated significant levels of saxitoxins (STXs) is known as paralytic shellfish poisoning (PSP). The STXs are a group of structurally related purines which inhibit neurological transmission to nerves and muscles by reversibly binding to sodium channels. The major sources of saxitoxins are the dinoflagellates Alexandrium spp., Pyrodium bahamense var. compressa, and Gymnodinium catenatum. The official method for the detection of the saxitoxins is a non-specific mouse bioassay. Recently, HPLC procedures have been reported to separate and quantify the saxitoxins. TheSe methods, however involve extensive sample clean-up and derivatizations. A simple and selective analysis of a saxitoxin (STX) in mollusks by capillary zone electrophoresis (CZE) utilizing UV detection, was developed. Detection of saxitoxin was linear over a wide range of STX concentrations, ranging from 0.75ppm to 50ppm (correlation coeffiecient r=0.999), and the coefficient of variation (n=5) for migration and peak area response were less than 1% and 3%, respectively.
RP SCIACCHITANO, CJ (reprint author), US FDA,NEW YORK REG LAB,850 3RD AVE,BROOKLYN,NY 11232, USA.
NR 12
TC 7
Z9 7
U1 0
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-3919
J9 J LIQ CHROMATOGR
JI J. Liq. Chromatogr.
PY 1993
VL 16
IS 9-10
BP 2081
EP 2088
DI 10.1080/10826079308019916
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA LD281
UT WOS:A1993LD28100015
ER
PT J
AU BRIGHT, RA
JENG, LL
MOORE, RM
AF BRIGHT, RA
JENG, LL
MOORE, RM
TI NATIONAL SURVEY OF SELF-REPORTED BREAST IMPLANTS - 1988 ESTIMATES
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE BREAST; ARTIFICIAL IMPLANTS; SILICONE; EPIDEMIOLOGY; STATISTICS
ID ELECTRON-MICROSCOPY; RECONSTRUCTION; TISSUE; PROSTHESES; MASTECTOMY;
CANCER
AB This report provides the first population-based national estimates of the prevalence of adult women with breast implants in the U.S. These findings are based on the Medical Device Implant Supplement to the 1988 National Health Interview Survey.
The overall prevalence was 33 implant recipients (95% confidence limits [CL]: 26 to 40) per 10,000 women. Almost three-fourths had two implants; prevalence peaked at 85 (59 to 110) per 10,000 for women aged 35 to 44 years. Implant prevalence was statistically significantly greater among women who were white, residents of the south and west, had higher family income, and had more education, who worked, or were slim. Among current implants, 87% were original. Complications were reported for 24% of the implants.
C1 US DEPT HHS,PUBL HLTH SERV REG 6,OFF ASSISTANT SECRETARY HLTH,DALLAS,TX 75202.
US DEPT HHS,OFF INT AFFAIRS,OFF ASSISTANT SECRETARY HLTH,ROCKVILLE,MD 20857.
RP BRIGHT, RA (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,HFZ-161,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
RI Bright, Roselie/D-2240-2016
NR 21
TC 35
Z9 35
U1 0
U2 1
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1993
VL 3
IS 1
BP 81
EP 89
PG 9
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA KZ655
UT WOS:A1993KZ65500006
PM 10171654
ER
PT J
AU SHARKNESS, CM
ACOSTA, SK
MOORE, RM
HAMBURGER, S
GROSS, TP
AF SHARKNESS, CM
ACOSTA, SK
MOORE, RM
HAMBURGER, S
GROSS, TP
TI METALLIC ORTHOPEDIC IMPLANTS AND THEIR POSSIBLE ASSOCIATION WITH CANCER
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE IMPLANTATION; ORTHOPEDICS; CANCER
ID MALIGNANT FIBROUS HISTIOCYTOMA; TOTAL HIP-REPLACEMENT; TOTAL KNEE
REPLACEMENT; JOINT REPLACEMENT; SITE; SARCOMA; HEMANGIOENDOTHELIOMA;
ARTHROPLASTY; PROSTHESIS; VITALLIUM
AB In recent years the use of metallic orthopedic implants has increased greatly. The long-term effects of these artificial joints and fixation devices on surrounding and distant body tissues are uncertain. This review paper examines the possible association of cancer with metallic orthopedic implants. Biochemical processes stemming from formation of wear particles and corrosion and iophysical processes related to surface characteristics of implants are discussed as possible initiators and promoters of carcinogenic responses, locally as well as in remote sites. Animal data and human case reports are summarized. Approaches to further studying the issue, including epidemiologic studies, use of registries, and in vitro assays, are presented.
C1 US FDA,CDRH,OST,DBS,EB,HFZ-161,5600 FISHERS LANE,ROCKVILLE,MD 20857.
NR 43
TC 3
Z9 3
U1 0
U2 0
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1993
VL 3
IS 3
BP 237
EP 249
PG 13
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA MA972
UT WOS:A1993MA97200007
ER
PT J
AU BURLINGTON, DB
AF BURLINGTON, DB
TI NEW DIRECTIONS AT FDAS CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Note
RP BURLINGTON, DB (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1993
VL 3
IS 4
BP 265
EP 267
PG 3
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA MR230
UT WOS:A1993MR23000002
ER
PT J
AU CALLAHAN, TJ
MARLOWE, DE
AF CALLAHAN, TJ
MARLOWE, DE
TI RISK ASSESSMENT AND MANAGEMENT AS RELATED TO EVALUATION OF MEDICAL
DEVICES - A VIEW FROM THE FDA
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE RISK MANAGEMENT; MEDICAL DEVICES; IMPLANTS; MATERIALS; FDA; FOOD AND
DRUG ADMINISTRATION
AB The regulatory management by the FDA of medical products should be thought of as a form of risk assessment and risk management. This is a new approach, a new way of thinking about product review and postmarket management processes. This paper outlines several aspects of risk assessment and management that have recently been incorporated into the FDA processes that will simplify reviews and lower the risks involved with the use of medical devices. These aspects include development of a new process for selecting the appropriate resources to dedicate to individual device applications, an increased emphasis on good experimental design for clinical studies, and continued development of a biomaterials database (Biomaterials Compendium).
C1 US FDA,CTR DEVICES & RADIOL HLTH,DIV MECH & MAT SCI,OFF SCI & TECHNOL,12200 WILKINS AVE,ROCKVILLE,MD 20852.
US FDA,CTR DEVICES & RADIOL HLTH,DIV CARDIOVASC RESP & NEUROL DEVICES,ROCKVILLE,MD 20850.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1993
VL 3
IS 4
BP 269
EP 276
PG 8
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA MR230
UT WOS:A1993MR23000003
PM 10172029
ER
PT J
AU ALI, SF
HOLSON, RR
NEWPORT, GD
SLIKKER, W
BOWYER, JE
AF ALI, SF
HOLSON, RR
NEWPORT, GD
SLIKKER, W
BOWYER, JE
TI METHAMPHETAMINE TOXICITY IS INHIBITED BY PHARMACOLOGICAL MANIPULATION
AND REDUCED ENVIRONMENTAL TEMPERATURES IN MICE
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PY 1993
VL 61
SU S
BP S206
EP S206
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA LM565
UT WOS:A1993LM56500815
ER
PT J
AU GALLO, JM
SWAGLER, AR
MEHTA, M
QIAN, MX
AF GALLO, JM
SWAGLER, AR
MEHTA, M
QIAN, MX
TI PHARMACOKINETIC EVALUATION OF DRUG-INTERACTIONS WITH
ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS DRUGS .6. EFFECT OF THE
CALCIUM-CHANNEL BLOCKER NIMODIPINE ON ZIDOVUDINE KINETICS IN MONKEYS
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID CEREBROSPINAL-FLUID; 3'-AZIDO-3'-DEOXYTHYMIDINE; ANTAGONISTS;
METABOLISM; NUCLEOSIDE; PROTEIN; INHIBITION; TRANSPORT; VERAPAMIL;
MEMBRANE
AB Coadministration of zidovudine (AZT) and nimodipine, a calcium-channel blocker, is a potential therapeutic regimen in acquired immunodeficiency syndrome patients based on the report that nimodipine can prevent human immunodeficiency virus-induced neurotoxicity in vitro. An evaluation of the pharmacokinetics of AZT and its glucuronide metabolite 3'-azido-3'-deoxy-5'-O-beta-D-glucopyranurosylthymidine (GAZT) in the presence and absence of nimodipine in monkeys was undertaken. After 20 mg/kg of AZT given i.v. in the presence and absence of nimodipine, nimodipine caused a significant reduction (41%) in the volume of distribution of AZT at steady state and a 22% decrease in total clearance. The disposition of GAZT was also influenced by nimodipine, causing a large increase in its area under the plasma concentration-time curve. Renal excretion data for AZT and GAZT, although inconclusive, suggested nimodipine caused a decrease in the renal clearance of AZT with a minimal change in the renal clearance of GAZT. The combined effects of nimodipine on the clearance of AZT and volume of distribution at steady state produced no change in its elimination half-life.
C1 US FDA,CTR DRUG EVALUAT & RES,DIV BIOPHARMACEUT,ROCKVILLE,MD 20857.
UNIV GEORGIA,COLL PHARM,DEPT PHARMACEUT,ATHENS,GA 30602.
FU PHS HHS [223-89-3806]
NR 25
TC 4
Z9 4
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JAN
PY 1993
VL 264
IS 1
BP 315
EP 320
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KG484
UT WOS:A1993KG48400046
PM 8423534
ER
PT J
AU LINDSTROM, RM
ZEISLER, R
VINCENT, DH
GREENBERG, RR
STONE, CA
MACKEY, EA
ANDERSON, DL
CLARK, DD
AF LINDSTROM, RM
ZEISLER, R
VINCENT, DH
GREENBERG, RR
STONE, CA
MACKEY, EA
ANDERSON, DL
CLARK, DD
TI NEUTRON-CAPTURE PROMPT GAMMA-RAY ACTIVATION-ANALYSIS AT THE NIST COLD
NEUTRON RESEARCH FACILITY
SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES
LA English
DT Article; Proceedings Paper
CT 8TH INTERNATIONAL CONF ON MODERN TRENDS IN ACTIVATION ANALYSIS ( MTAA 8
)
CY SEP 16-20, 1991
CL VIENNA, AUSTRIA
ID SCATTERING; RATES
AB An instrument for neutron capture prompt gamma-ray activation analysis (PGAA) has been constructed as part of the Cold Neutron Research Facility at the 20 MW National Institute of Standards and Technology Research Reactor. The neutron fluence rate (thermal equivalent) is 1.5 . 10(8) n . cm-2 . s-1, with negligible fast neutrons and gamma-rays. With compact geometry and hydrogen-free construction, the sensitivity is sevenfold better than an existing thermal instrument. Hydrogen background is thirtyfold lower.
C1 US FDA,WASHINGTON,DC 20204.
CORNELL UNIV,ITHACA,NY 14853.
RP LINDSTROM, RM (reprint author), NATL INST STAND & TECHNOL,GAITHERSBURG,MD 20899, USA.
NR 17
TC 30
Z9 31
U1 1
U2 1
PU AKADEMIAI KIADO
PI BUDAPEST
PA PO BOX 245, H-1519 BUDAPEST, HUNGARY
SN 0236-5731
J9 J RADIOAN NUCL CH AR
JI J. Radioanal. Nucl. Chem.-Artic.
PD JAN
PY 1993
VL 167
IS 1
BP 121
EP 126
DI 10.1007/BF02035470
PG 6
WC Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science &
Technology
SC Chemistry; Nuclear Science & Technology
GA KJ310
UT WOS:A1993KJ31000015
ER
PT J
AU ANDERSON, DL
CUNNINGHAM, WC
ALVAREZ, GH
AF ANDERSON, DL
CUNNINGHAM, WC
ALVAREZ, GH
TI MULTIELEMENT ANALYSIS OF FOODS BY NEUTRON-CAPTURE PROMPT GAMMA-RAY
ACTIVATION-ANALYSIS
SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES
LA English
DT Article; Proceedings Paper
CT 8TH INTERNATIONAL CONF ON MODERN TRENDS IN ACTIVATION ANALYSIS ( MTAA 8
)
CY SEP 16-20, 1991
CL VIENNA, AUSTRIA
AB A method is described for the determination of H, B, Cl, K, Na, S, Ca, and Cd in foods using in-beam neutron capture prompt gamma-ray activation analysis. Special calibration procedures were necessary because of matrix-related thermal neutron scattering-induced sensitivity and background enhancements. Detection limits and sensitivities are presented for best-case and worst-case irradiation conditions. The method was applied to multielement analysis of 41 foods and to B, Cl, and K analysis of 13 orange juice produts in conjunction with analysis by inductively coupled plasma atomic emission spectrometry. The purpose of the latter application was to study B losses during acid digestion.
RP ANDERSON, DL (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 9
TC 27
Z9 27
U1 0
U2 0
PU AKADEMIAI KIADO
PI BUDAPEST
PA PO BOX 245, H-1519 BUDAPEST, HUNGARY
SN 0236-5731
J9 J RADIOAN NUCL CH AR
JI J. Radioanal. Nucl. Chem.-Artic.
PD JAN
PY 1993
VL 167
IS 1
BP 139
EP 144
DI 10.1007/BF02035473
PG 6
WC Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science &
Technology
SC Chemistry; Nuclear Science & Technology
GA KJ310
UT WOS:A1993KJ31000018
ER
PT J
AU ANDERSON, DL
MACKEY, EA
AF ANDERSON, DL
MACKEY, EA
TI NEUTRON SCATTERING-INDUCED BACKGROUND ENHANCEMENT IN PROMPT GAMMA-RAY
ACTIVATION-ANALYSIS
SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES
LA English
DT Article; Proceedings Paper
CT 8TH INTERNATIONAL CONF ON MODERN TRENDS IN ACTIVATION ANALYSIS ( MTAA 8
)
CY SEP 16-20, 1991
CL VIENNA, AUSTRIA
AB Background enhancements in neutron capture prompt gamma-ray activation analysis were determined over a large range of total scattering cross sections by irradiating graphite, S, Be, paraffin, urea and H2O targets. Relative to irradiations using Do target, B, Na, Cl, Al, and Pb backgrounds were 7-12 times greater with 2 ml of H2O, but N and Fe backgrounds were only 1.2 and 1.75 times greater, respectively. For biological targets, background count rates can be determined as functions of the 2223 keV H photopeak count rate.
C1 UNIV MARYLAND,COLL PK,MD 20742.
RP ANDERSON, DL (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 7
TC 19
Z9 19
U1 0
U2 2
PU AKADEMIAI KIADO
PI BUDAPEST
PA PO BOX 245, H-1519 BUDAPEST, HUNGARY
SN 0236-5731
J9 J RADIOAN NUCL CH AR
JI J. Radioanal. Nucl. Chem.-Artic.
PD JAN
PY 1993
VL 167
IS 1
BP 145
EP 151
DI 10.1007/BF02035474
PG 7
WC Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science &
Technology
SC Chemistry; Nuclear Science & Technology
GA KJ310
UT WOS:A1993KJ31000019
ER
PT J
AU MATCHETTE, LS
VEGELLA, TJ
FAALAND, RW
AF MATCHETTE, LS
VEGELLA, TJ
FAALAND, RW
TI VIABLE BACTERIOPHAGE IN CO2-LASER PLUME - AERODYNAMIC SIZE DISTRIBUTION
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE ABLATION; LASER SURGERY; PARTICLE DISPERSION; VIRUS AEROSOL
ID CARBON-DIOXIDE LASER; INVITRO PRODUCTION; PAPILLOMAVIRUS; VAPOR; DNA
AB The size of CO2 laser generated plume particles containing viable bacteriophage, PHIX174, was determined with 2 models (10-830 and 15-500) of Andersen bioaerosol cascade impactors. Samples were collected during 100 one-second laser exposures (approximately 68 W/cm2) of a bacteriophage-agar substrate with and without a space-confining hood. The hood appeared to facilitate collection of the largest particles (P < 0.1). In addition, Andersen model 15-500 was a more efficient collector of the largest particles, a phenomenon which is likely a function of the dynamic nature of the laser plume as well as impactor design. We found that laser plume particles containing viable bacteriophage are very large, in one instance exhibiting a count median aerodynamic diameter (CMAD) and mass median aerodynamic diameter (MMAD) of 23 and 55 mum, respectively. Furthermore, the appearance of viable bacteriophage in these plume particles constitutes an extremely rare event. The limitations of cascade impactor design when used to analyze particles with high water concentrations generated in a laser plume are discussed.
C1 CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 11
TC 5
Z9 5
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 1
BP 18
EP 22
DI 10.1002/lsm.1900130106
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA KJ791
UT WOS:A1993KJ79100003
PM 8426522
ER
PT J
AU ORAEVSKY, AA
JACQUES, SL
PETTIT, GH
TITTEL, FK
HENRY, PD
AF ORAEVSKY, AA
JACQUES, SL
PETTIT, GH
TITTEL, FK
HENRY, PD
TI XECL LASER ABLATION OF ATHEROSCLEROTIC AORTA - LUMINESCENCE SPECTROSCOPY
OF ABLATION PRODUCTS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE XECL LASER; TISSUE ABLATION; PLUME LUMINESCENCE
ID ULTRAVIOLET-LASERS; TISSUE ABLATION; PULSE DURATION; EXCIMER LASER;
PLAQUE; ANGIOPLASTY
AB XeCl laser ablation of atherosclerotic aorta tissue was investigated. Luminescence spectra of ablation products were measured for soft and hard arterial tissues. A pronounced difference observed between plume luminescence for various plaques and normal vessel wall correlates with the chemical composition of the tissue. The mechanism of plume luminescence appeared to be thermochemical excitation of ablation products (particles, atoms, molecules, etc.) in the air. The process of soft tissue ablation was delayed with respect to the exciting laser pulse at relatively low laser fluences close to the ablation threshold. The kinetics of the ablation process as a function of laser-pulse energy fluence is reported. The data indicate that tissue ejection mechanism, which involves vapor bubbles formation, expansion and explosion, is suitable for the description of the XeCl excimer laser ablation of soft tissues.
C1 RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251.
BAYLOR COLL MED,DIV CARDIOL,HOUSTON,TX 77030.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
USSR ACAD SCI,INST SPECTROSCOPY,TROITSK 142092,RUSSIA.
RP ORAEVSKY, AA (reprint author), UNIV TEXAS,MD ANDERSON CANC CTR,LASER BIOL LAB 17,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.
FU NHLBI NIH HHS [R29-HL4504501, R01-HL40884, R01-HL36894]
NR 29
TC 13
Z9 13
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 2
BP 168
EP 178
DI 10.1002/lsm.1900130204
PG 11
WC Dermatology; Surgery
SC Dermatology; Surgery
GA KU389
UT WOS:A1993KU38900003
PM 8464302
ER
PT J
AU EDIGER, MN
PETTIT, GH
WEIBLINGER, RP
CHEN, CH
AF EDIGER, MN
PETTIT, GH
WEIBLINGER, RP
CHEN, CH
TI TRANSMISSION OF CORNEAL COLLAGEN DURING ARF EXCIMER LASER ABLATION
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE PHOTOABLATION; PHOTOREFRACTIVE KERATOPLASTY; ULTRAVIOLET
ID ORGANIC POLYMERS; LENS
AB The time-resolved transmission of collagen films and 10-mum sections of bovine cornea during ArF laser ablation has been investigated. The film studies were performed on thin layers of extracted bovine corneal collagen, the principal chromophore in 193 nm photoablation. Transmission measurements were made on both dry and water-saturated films to assess the sensitivity of the ablation process to hydration. Distinct transient optical changes were observed in both fully desiccated and rehydrated films. Dehydrated films exhibit rapid reduction in film absorption over the time-course of the ablating laser pulse, presumably due to chromophore bleaching or annihilation. In contrast, rehydrated films demonstrate a short-lived enhancement of the attenuation. In either case, a single ablative laser pulse increased the long-term transmission of the film, although this increase was a factor of five greater for dehydrated films than for rehydrated samples. Results obtained from corneal tissue sections were essentially identical to those derived from hydrated collagen films.
C1 JOHNS HOPKINS UNIV,SCH MED,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205.
RP EDIGER, MN (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,1901 CHAPMAN AVE,HFZ-134,ROCKVILLE,MD 20857, USA.
NR 17
TC 24
Z9 24
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 2
BP 204
EP 210
DI 10.1002/lsm.1900130208
PG 7
WC Dermatology; Surgery
SC Dermatology; Surgery
GA KU389
UT WOS:A1993KU38900007
PM 8464306
ER
PT J
AU PETTIT, GH
SAUERBREY, R
TITTEL, FK
WEILBACHER, D
HENRY, PD
AF PETTIT, GH
SAUERBREY, R
TITTEL, FK
WEILBACHER, D
HENRY, PD
TI ATHEROSCLEROTIC TISSUE-ANALYSIS BY TIME-RESOLVED XECL EXCIMER-LASER
REFLECTOMETRY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE ABLATION; ANGIOPLASTY; DYNAMIC REFLECTIVITY
ID FLUORESCENCE; ABLATION; REFLECTIVITY; ANGIOPLASTY; DIAGNOSIS; DYNAMICS
AB The temporal modification of XeCl laser pulses reflected from human aorta tissue immersed in saline has been studied. Dynamic tissue reflectivity of both normal and atherosclerotic tissues has been examined for various incident pulse fluences between 0.7 and 6.5 J/cm2. Changes in reflected pulse duration are observed for fluences at or above 2.6 J/cm2 with normal tissue targets and 3.0 J/cm2 With calcified plaque. Such reflected pulse analysis may prove useful in identifying tissue targets for ablation during laser angioplasty.
C1 BAYLOR COLL MED,HOUSTON,TX 77030.
RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251.
RP PETTIT, GH (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,MAIL STOP HFZ-134,ROCKVILLE,MD 20857, USA.
FU NHLBI NIH HHS [5R01 HL36894]
NR 13
TC 2
Z9 2
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 3
BP 279
EP 283
DI 10.1002/lsm.1900130304
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA LE065
UT WOS:A1993LE06500003
PM 8515667
ER
PT J
AU PETTIT, GH
EDIGER, MN
AF PETTIT, GH
EDIGER, MN
TI PUMP-PROBE TRANSMISSION MEASUREMENTS OF CORNEAL TISSUE DURING
EXCIMER-LASER ABLATION
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE CORNEAL TISSUE; COLLIMATED TRANSMISSION; SCATTERING; PHOTOABLATION
AB Transient changes in the transmission of a 355 nm probe pulse through corneal tissue during 193 nm ArF laser ablation have been examined. A significant decrease in collimated transmission of the probe beam was observed for time delays between 10 ns and 1 ms after the 193 nm laser pulse. At 10 ns delay the collimated probe transmission was 70% of the preablation level. Minimum collimated transmission (40%) was observed at 30 mus delay. Transmitted probe examination by both diode array and integrating sphere measurements indicate the observed attenuation is due to scattering of the incident probe beam and not due to absorption. The significant scattering at nanosecond delay times suggests onset of the ablation process during the ArF pulse. Scattering therefore may affect the deposition of the 193 nm radiation in the ablation target.
RP PETTIT, GH (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,MAIL STOP HFZ-134,1901 CHAPMAN AVE,ROCKVILLE,MD 20857, USA.
NR 10
TC 13
Z9 13
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 3
BP 363
EP 367
DI 10.1002/lsm.1900130313
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA LE065
UT WOS:A1993LE06500012
PM 8515675
ER
PT J
AU MERBERG, GN
AF MERBERG, GN
TI CURRENT STATUS OF INFRARED FIBER OPTICS FOR MEDICAL LASER POWER DELIVERY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Review
DE CHALCOGENIDE; FLUORIDE GLASS; HOLLOW WAVE-GUIDE; SAPPHIRE; SILVER HALIDE
ID SAPPHIRE FIBERS; HOLLOW SAPPHIRE; WAVE-GUIDES; TRANSMISSION; SYSTEMS
AB There are a host of fiber-optic delivery devices available for use with the Er:YAG, HF, CO, and CO2 lasers at 2.9, 2.8, 5.3, and 10.6 mum wavelengths, respectively. While many of these fibers are not as convenient to use as conventional silica fibers, they offer the ability to deliver infrared laser energy for a wide variety of medical applications. The fundamental attributes of fluoride glass, chalcogenide glass, single-crystal sapphire, and polycrystalline silver halide optical fibers are reviewed and their practical properties tabulated. (C) 1993 Wiley-Liss, Inc.
RP MERBERG, GN (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL HFZ-134,ROCKVILLE,MD 20857, USA.
NR 27
TC 40
Z9 40
U1 0
U2 4
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1993
VL 13
IS 5
BP 572
EP 576
DI 10.1002/lsm.1900130513
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA LZ529
UT WOS:A1993LZ52900012
PM 8264330
ER
PT J
AU KESSLER, DA
TAYLOR, MR
MARYANSKI, JH
FLAMM, EL
KAHL, LS
AF KESSLER, DA
TAYLOR, MR
MARYANSKI, JH
FLAMM, EL
KAHL, LS
GP SUFFOLK UNIVERSITY LAW SCHOOL
TI THE SAFETY OF FOODS DEVELOPED BY BIOTECHNOLOGY
SO LAW AND SCIENCE AT THE CROSSROADS: BIOMEDICAL TECHNOLOGY, ETHICS, PUBLIC
POLICY AND THE LAW
LA English
DT Proceedings Paper
CT Conference on Law and Science at the Crossroads: Biomedical Technology,
Ethics, Public Policy and the Law
CY OCT 21-22, 1993
CL BOSTON, MA
SP SUFFOLK UNIV LAW SCH, UNIV MASSACHUSETTS MED CTR, OFF CONTINUING EDUC
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SUFFOLK UNIV LAW SCHOOL
PI BOSTON
PA ADVANCED LEGAL STUDIES, 41 TEMPLE STREET, BOSTON, MA 02114
PY 1993
BP 411
EP 414
PG 4
WC Law; Social Sciences, Biomedical
SC Government & Law; Biomedical Social Sciences
GA BZ93T
UT WOS:A1993BZ93T00051
ER
PT B
AU WAYNANT, RW
MERBERG, GN
AF WAYNANT, RW
MERBERG, GN
GP IEEE
TI FIBER OPTICS FOR FREE-ELECTRON LASER MEDICAL APPLICATIONS
SO LEOS '93 CONFERENCE PROCEEDINGS: IEEE LASERS AND ELECTRO-OPTICS SOCIETY
1993 ANNUAL MEETING
LA English
DT Proceedings Paper
CT 6th Annual Meeting of the IEEE Lasers-and-Electro-Optics-Society (LEOS
93)
CY NOV 15-18, 1993
CL SAN JOSE CONVENT CTR, SAN JOSE, CA
SP IEEE, LASERS & ELECTRO OPT SOC
HO SAN JOSE CONVENT CTR
C1 US FDA,CDRH,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-1263-5
J9 IEEE LEOS ANN MTG
PY 1993
BP 227
EP 227
PG 1
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA BA47C
UT WOS:A1993BA47C00103
ER
PT J
AU FARRIS, FF
DEDRICK, RL
AF FARRIS, FF
DEDRICK, RL
TI ABSORPTION OF METHYLMERCURY FROM HAIR INGESTED BY RATS
SO LIFE SCIENCES
LA English
DT Article
ID MAMMALIAN PREY DIGESTIBILITY; INORGANIC MERCURY; TRANSPORT
AB Hair taken from rats dosed with Hg-203-labeled methylmercury was fed to previously untreated rats in order to determine if the organo-mercurial was available for release from the hair matrix within the gut lumen and for subsequent systemic absorption. Cumulative fecal excretion data were consistent with an absorption of about 80% of the ingested methylmercury. The relative amounts of methylmercury and of its metabolite, inorganic mercury, in the feces indicated that the percentage of the parent compound released from hair within the intestine equaled or exceeded the estimated bioavailability. Radioactivity in tissues of animals killed 42 hr following hair consumption confirmed that mercury absorption had occurred.
C1 NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892.
RP FARRIS, FF (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV CLIN PHARMACOL,4 RES COURT,ROOM 314,ROCKVILLE,MD 20850, USA.
NR 30
TC 2
Z9 2
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PY 1993
VL 53
IS 12
BP 1023
EP 1029
DI 10.1016/0024-3205(93)90125-M
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LT666
UT WOS:A1993LT66600007
PM 8361326
ER
PT J
AU SNAWDER, JE
BENSON, RW
LEAKEY, JEA
ROBERTS, DW
AF SNAWDER, JE
BENSON, RW
LEAKEY, JEA
ROBERTS, DW
TI THE EFFECT OF PROPYLENE-GLYCOL ON THE P450-DEPENDENT METABOLISM OF
ACETAMINOPHEN AND OTHER CHEMICALS IN SUBCELLULAR-FRACTIONS OF
MOUSE-LIVER
SO LIFE SCIENCES
LA English
DT Article
ID CYTOCHROME-P-450 ISOZYMES; PROTEIN; PARACETAMOL; MICROSOMES; SYSTEM;
ASSAY; HEPATOTOXICITY; HYDROXYLATION; DEMETHYLASE; ACTIVATION
AB Propylene glycol (PG) decreases the hepatotoxicity of acetaminophen (APAP). To elucidate the mechanism for this response, we measured the effect of PG on the in vitro metabolism of APAP by subcellular liver fractions from 6-10 week-old male B6C3F1 mice. The, fractions were assayed for their ability to bioactivate APAP to N-acetyl-p-benzoquinone imine, which was trapped as APAP-glutathione conjugates or APAP-protein adducts, and for dimethyl-nitrosamine-N-demethylase (DMN), 4-nitrophenol hydroxylase (4-NPOH), and phenacetin-0-deethylase (PAD) activities. Activity in the crude mitochondrial-rich (10,000 x g pellet) fraction was low and PG had no effect. PG inhibited DMN and 4-NPOH, indicators of IIE1-dependent activity, and the formation of APAP-glutathione conjugates and APAP-protein adducts in both heavy (15,000 xg pellet) and light (100,000 xg pellet) microsomes. PAD, a measure of IA2-dependent activity, was not inhibited. These data demonstrate that PG selectively inhibits IIE1 activity, including the bioactivation of APAP, and implicates this as the mechanism for PG-mediated protection of APAP hepatotoxicity in mice.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
RP SNAWDER, JE (reprint author), NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079, USA.
NR 27
TC 11
Z9 11
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PY 1993
VL 52
IS 2
BP 183
EP 189
DI 10.1016/0024-3205(93)90138-S
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KC066
UT WOS:A1993KC06600008
PM 8355558
ER
PT J
AU HANSEN, DK
KNOWLES, BJ
FULLERTON, FR
POIRIER, LA
AF HANSEN, DK
KNOWLES, BJ
FULLERTON, FR
POIRIER, LA
TI EFFECT OF NITROUS-OXIDE EXPOSURE ON MATERNAL AND EMBRYONIC
S-ADENOSYLMETHIONINE LEVELS AND ORNITHINE DECARBOXYLASE ACTIVITY
SO LIFE SCIENCES
LA English
DT Article
ID RAT-LIVER; METHIONINE; ANESTHETISTS; METABOLISM; ADENOSYLHOMOCYSTEINE;
INACTIVATION; PREGNANCY; OXIDATION; TISSUES; ACID
AB Nitrous oxide is suspected to be a developmental toxicant in humans. The anesthetic does produce increases in the resorption and malformation frequencies in rodents. The mechanism for the drug's developmental toxicant effects is unknown. Embryonic DNA synthesis is decreased; however, this decrease does not appear to be due to depressed levels of adenine or guanine. In this investigation, we examined the effect of N2O on maternal and embryonic S-adenosylmethionine (AdoMet) levels and ornithine decarboxylase (ODC) activity, and the effect of exogenous methionine (Met) on these parameters was also examined. AdoMet and ODC are involved in polyamine synthesis, and polyamines are involved in regulation of macromolecular synthesis. Pregnant rats were treated with N2O for 24 hours beginning on the morning of day 10 of gestation. There was no effect of N2O on maternal hepatic AdoMet or S-adenosylhomocysteine (AdoHcy) levels; there was also no effect on embryonic AdoMet. Embryonic AdoHcy could not be detected in many of the samples; however, N2O treatment did significantly increase the number of embryonic samples in which AdoHcy was detectable. ODC activity was not affected by either treatment in dams but was increased by N2O in embryos. It is possible that the embryotoxic effect of this anesthetic is mediated by alterations in the AdoMet to AdoHcy ratio or to changes in ODC activity and polyamine synthesis.
C1 US FDA,NATL CTR TOXICOL RES,DIV MICROBIOL,JEFFERSON,AR 72079.
US FDA,NATL CTR TOXICOL RES,DIV NUTR TOXICOL,JEFFERSON,AR 72079.
RP HANSEN, DK (reprint author), US FDA,NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079, USA.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PY 1993
VL 52
IS 21
BP 1669
EP 1675
DI 10.1016/0024-3205(93)90474-H
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KY625
UT WOS:A1993KY62500001
PM 8502112
ER
PT B
AU MYERS, KJ
WAGNER, RF
HANSON, KM
AF MYERS, KJ
WAGNER, RF
HANSON, KM
BE MohammadDjafari, A
Demoment, G
TI BINARY TASK-PERFORMANCE ON IMAGES RECONSTRUCTED USING MEMSYS-3 -
COMPARISON OF MACHINE AND HUMAN OBSERVERS
SO MAXIMUM ENTROPY AND BAYESIAN METHODS
SE FUNDAMENTAL THEORIES OF PHYSICS
LA English
DT Proceedings Paper
CT 12th International Workshop on Maximum Entropy and Bayesian Methods
(MaxEnt 92)
CY JUL 19-24, 1992
CL CNRS, PARIS, FRANCE
SP CNRS, DEF MINIST, DIRECT RECH & DEV, SHOUNAN INST TECHNOL, CTR NATL ETUDES TELECOMMUN, CNRS, GRP RES GDR 134, LAB SIGNAUX & SYST, KLUWER ED
HO CNRS
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-2280-0
J9 FUND THEOR
PY 1993
VL 53
BP 415
EP 421
PG 7
WC Physics, Mathematical; Statistics & Probability
SC Physics; Mathematics
GA BA12B
UT WOS:A1993BA12B00051
ER
PT J
AU SCHEUERMANN, RH
BAUER, SR
AF SCHEUERMANN, RH
BAUER, SR
TI POLYMERASE CHAIN REACTION-BASED MESSENGER-RNA QUANTIFICATION USING AN
INTERNAL STANDARD - ANALYSIS OF ONCOGENE EXPRESSION
SO METHODS IN ENZYMOLOGY
LA English
DT Review
ID NUCLEOTIDE-SEQUENCE; CHROMOSOME-TRANSLOCATION; ENZYMATIC AMPLIFICATION;
INSITU HYBRIDIZATION; CDNA SEQUENCE; GROWTH-FACTOR; GENE; DNA; PROTEIN;
MURINE
C1 US FDA,MOLEC IMMUNOL LAB,BETHESDA,MD 20892.
RP SCHEUERMANN, RH (reprint author), UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235, USA.
RI Bauer, Steven/G-5559-2012;
OI Scheuermann, Richard/0000-0003-1355-892X
NR 36
TC 56
Z9 56
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Method Enzymol.
PY 1993
VL 218
BP 446
EP 473
PG 28
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LU441
UT WOS:A1993LU44100033
PM 7685470
ER
PT J
AU NEFT, RE
ROE, AL
SMITH, BA
BELAND, FA
AF NEFT, RE
ROE, AL
SMITH, BA
BELAND, FA
TI DINITROPYRENE METABOLISM, DNA ADDUCT FORMATION, AND DNA AMPLIFICATION IN
AN SV40-TRANSFORMED CHINESE-HAMSTER EMBRYO CELL-LINE
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE C-FOS; P-32-POSTLABELING; CO-60 CELLS
ID OVARY CELLS; ONCOGENE AMPLIFICATION; 1,6-DINITROPYRENE; INDUCTION;
1,8-DINITROPYRENE; CARCINOGENICITY; MUTAGENICITY; NITROARENES; INVITRO;
RATS
AB The environmental pollutants 1,6-dinitropyrene (1,6-DNP) and 1,8-dinitropyrene (1,8-DNP) are strongly carcinogenic in a number of animal models. These DNPs are metabolized by nitroreduction to N-hydroxy arylamine derivatives that either directly or after acetylation bind to cellular DNA. In the experiments reported here, we examined whether DNA adduct formation by 1,6-DNP and 1,8-DNP was associated with amplification of specific DNA sequences, a process that may be causally related to tumorigenesis. CO60 cells, an SV40-transformed Chinese hamster embryo cell line, were incubated with 2.5 or 50 ng/mL [4,5,9,10-H-3]1,6-DNP for 5 h. High-pressure liquid chromatographic analysis of organic extracts of the medium indicated the presence of 1-acetylamino-6-nitropyrene, suggesting that these cells are capable of nitroreduction and acetylation. P-32-Postlabeling analysis of DNA isolated from cells exposed to 1.0 or 2.5 ng/mL 1,6-DNP revealed dose-related formation of N-(deoxyguanosin-8-yl)-1-amino-6-nitropyrene. A similar adduct, presumably N-(deoxyguanosin-8-yl)-1-amino-8-nitropyrene, was detected after incubations with 1,8-DNP. DNA isolated from analogous experiments was slot-blotted onto nylon membranes and hybridized with P-32 labeled SV40, c-fos, or beta-actin DNA probes. beta-Actin was not amplified and c-fos was amplified only a small amount; however, there was dose-related amplification of SV40 sequences, whose levels were in some instances approximately 20 times that observed in solvent-treated controls. These data indicate that DNA adduct formation by 1,6-DNP and 1,8-DNP is associated with the amplification of certain DNA sequences, a response that may be related to the tumorigenic potential of these compounds. (C) 1993 Wiley-Liss, Inc.*
C1 NATL CTR TOXICOL RES,DIV GENET TOXICOL,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PY 1993
VL 7
IS 4
BP 221
EP 227
DI 10.1002/mc.2940070404
PG 7
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA LK596
UT WOS:A1993LK59600003
PM 8394716
ER
PT J
AU GAO, WY
STORM, C
EGAN, W
CHENG, YC
AF GAO, WY
STORM, C
EGAN, W
CHENG, YC
TI CELLULAR PHARMACOLOGY OF PHOSPHOROTHIOATE HOMOOLIGODEOXYNUCLEOTIDES IN
HUMAN-CELLS
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID C-MYC; ANTISENSE OLIGONUCLEOTIDES; COMPARATIVE INHIBITION; EXPRESSION;
PINOCYTOSIS; OLIGODEOXYNUCLEOTIDES; MECHANISMS; TRANSPORT; ENDOSOMES;
LYSOSOMES
AB The uptake and distribution of phosphorothioate oligodeoxynucleotides by human cells were studied using S-35-labeled 28-mer phosphorothioate oligodeoxycytidine [S-(dC)28]. Accumulation of intracellular S-(dC)28 was found to be higher in the carcinoma cells (grown in monolayers) than in the leukemia cells (grown in suspension culture). A hepatoma cell line transfected with hepatitis B virus, 2215, was chosen for further studies. The uptake of S-(dC)28 was partially dependent on temperature and energy. The intracellular concentration was significantly higher than that in the medium and the amount accumulated was dependent on the extracellular concentration. It appears that the uptake of S-(dC)28 involves mechanisms of both fluid-phase pinocytosis and adsorptive endocytosis. Neither oligonucleotides nor 5'-phosphorylated nucleotides inhibited S-(dC)28 uptake. Unlike horseradish peroxidase, which was primarily associated with endosomes once it was taken into the cell, S-(dC)28 was found to be present in both nuclear and cytoplasmic fractions. Efflux of S-(dC)28 from the cell was multiphasic; a trapping mechanism that could be due to a potent interaction of S-(dC)28 with cellular proteins was implicated. This trapping mechanism could be responsible for the lack of biological activity such as cytotoxicity and antisense activity of phosphorothioate oligodeoxynucleotides in some human cells.
C1 YALE UNIV,SCH MED,DEPT PHARMACOL,POB 3333,STERLING HALL MED,333 CEDAR ST,NEW HAVEN,CT 06510.
US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
FU NCI NIH HHS [CA-44358]
NR 21
TC 87
Z9 87
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD JAN
PY 1993
VL 43
IS 1
BP 45
EP 50
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KH565
UT WOS:A1993KH56500008
PM 8423768
ER
PT B
AU KODELL, RL
GEORGE, EO
AF KODELL, RL
GEORGE, EO
BE Patil, GP
Rao, CR
TI CARCINOGENICITY TESTS INVOLVING MULTIPLE TUMOR SITES
SO MULTIVARIATE ENVIRONMENTAL STATISTICS
SE NORTH-HOLLAND SERIES IN STATISTICS AND PROBABILITY
LA English
DT Proceedings Paper
CT 7th International Conference on Multivariate Analysis
CY MAY, 1992
CL PENN STATE, UNIV PK, PA
HO PENN STATE
DE BIOASSAY; P-VALUE; EXPERIMENTWISE ERROR; BONFERRONI-STYLE ADJUSTMENTS
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE PUBL B V
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
BN 0-444-89804-2
J9 N-HOLLAND STAT PROB
PY 1993
VL 6
BP 215
EP 225
PG 11
WC Environmental Sciences; Statistics & Probability
SC Environmental Sciences & Ecology; Mathematics
GA BZ95N
UT WOS:A1993BZ95N00011
ER
PT J
AU AIDOO, A
LYNCOOK, LE
HEFLICH, RH
GEORGE, EC
CASCIANO, DA
AF AIDOO, A
LYNCOOK, LE
HEFLICH, RH
GEORGE, EC
CASCIANO, DA
TI THE EFFECT OF TIME AFTER TREATMENT, TREATMENT SCHEDULE AND ANIMAL AGE ON
THE FREQUENCY OF 6-THIOGUANINE-RESISTANT LYMPHOCYTE-T INDUCED IN
FISCHER-344 RATS BY N-ETHYL-N-NITROSOUREA
SO MUTATION RESEARCH
LA English
DT Article
DE DOSES, SINGLE AND SPLIT; LYMPHOCYTES, RAT; 6-THIOGUANINE-RESISTANT
T-LYMPHOCYTES; N-ETHYL-N-NITROSOUREA
ID DRUG-METABOLIZING ENZYMES; CALORIC RESTRICTION; PERIPHERAL-BLOOD; MUTANT
FREQUENCY; CELL; INVIVO; MICE; MUTATIONS; INDUCTION; EXPOSURE
AB The persistence of 6-thioguanine-resistant (TG(r)) T-lymphocytes was investigated in Fischer 344 rats treated with N-ethyl-N-nitrosourea (ENU) using two schedules. Male rats, aged 3 months, were given i.p. injections containing a total of 0, 50 or 100 mg ENU/kg either as a single treatment (single-dose group) or divided among 10 weekly treatments (split-dose group). At 1, 3, 5, 10, 20, 30 and 50 weeks after the single-dose treatment, and 10, 20, 30 and 50 weeks after beginning the split-dose regimen, animals were assayed for the frequency of TG(r) spleen lymphocytes. ENU produced significant dose- and time-dependent responses in the single- and the split-dose treatment groups. Although a few of the 50 mg/kg split-dose treatments were significantly higher than the comparative single-dose groups, the number of TG(r) lymphocytes produced by the two dosing regimens were generally similar. The frequency of TG(r) cells for control animals increased with the age of the animals. The mode of ENU administration did not greatly influence the percent cloning efficiency (%CE) of the non-selection cultures, although the %CE declined in animals over 10 months of age. To investigate the relationship between the frequency of TG(r) cells and the age of the animals at the time of ENU administration, additional rats aged 17 months were treated with a single dose of ENU and at 1, 5 and 10 weeks following exposure, the frequencies of TG(r) cells were determined from the isolated lymphocytes. No difference in mutagen sensitivity between rats treated at 3 months of age and those treated at 17 months of age was detected at the time points evaluated. The data demonstrate the persistence of ENU-induced TG(r) T-lymphocytes in the rat and suggest that the dose and possibly the treatment schedule, but not the age of the animal at the time of treatment, affect the response.
RP AIDOO, A (reprint author), US FDA,NATL CTR TOXICOL RES,DEPT HLTH & HUMAN SERV,JEFFERSON,AR 72079, USA.
NR 26
TC 49
Z9 49
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD JAN
PY 1993
VL 298
IS 3
BP 169
EP 178
DI 10.1016/0165-1218(93)90038-F
PG 10
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA KG888
UT WOS:A1993KG88800004
PM 7678151
ER
PT J
AU MARAGOS, CM
ANDREWS, AW
KEEFER, LK
ELESPURU, RK
AF MARAGOS, CM
ANDREWS, AW
KEEFER, LK
ELESPURU, RK
TI MUTAGENICITY OF GLYCERYL TRINITRATE (NITROGLYCERIN) IN
SALMONELLA-TYPHIMURIUM
SO MUTATION RESEARCH
LA English
DT Article
DE GLYCERYL TRINITRATE; NITROGLYCERIN; NITRIC OXIDE; SEQUENCE ANALYSIS;
SALMONELLA-TYPHIMURIUM
ID NITRIC-OXIDE; TARGET SEQUENCES; RATS; DNA; NITROARENES; INDUCTION;
MUTATIONS; NITRATE; STRAINS; AGENTS
AB The recent finding that the clinical nitrovasodilator, glyceryl trinitrate (GTN), is mutagenic in Salmonella typhimurium strain TA1535 has been examined in closer detail, with emphasis on its mechanism of action. GTN increased the number of His+ revertants to a maximum of 4 times over background at a GTN dose of 5 mumol/plate. Hamster liver S9 depressed the toxicity of high GTN doses and increased the maximum number of revertants to 5 times over background at 10 mumol/plate. GTN did not cause significant reversion in any of the six other S. typhimurium strains tested (TA1975, TA102, TA1538, TA100, TA100NR, YG1026), although signs of toxicity were observed. Therefore, the mutagenicity of GTN was manifest only in the repair-deficient (uvrB and lacking in pKM101) strain which is responsive to single base changes. Oligonucleotide probe hybridization of TA1535 revertants showed that virtually all of the GTN-induced mutants contained C --> T transitions in either the first or second base of the hisG46 (CCC) target codon, with a preference for the latter. A similar mutational spectrum was seen previously with a complex of spermine and nitric oxide (NO) which releases nitric oxide. This suggests that NO, which can be derived from GTN via metabolic reduction, may be responsible for GTN's mutagenic action. The known NO scavenger oxymyoglobin did not substantially alter the dose response of GTN, indicating that extracellular NO was not mediating reversion. The data are consistent with the hypothesis that intracellular nitric oxide is responsible for the observed mutations.
C1 NCI,FREDERICK CANC RES & DEV CTR,CHEM SECT,COMPARAT CARCINOGENESIS LAB,BLDG 538,ROOM 205E,FREDERICK,MD 21702.
NCI,FREDERICK CANC RES & DEV CTR,PRI DYN CORP,FREDERICK,MD 21702.
US FDA,ROCKVILLE,MD 20857.
RI Keefer, Larry/N-3247-2014
OI Keefer, Larry/0000-0001-7489-9555
FU NCI NIH HHS [N01-CO-74102]
NR 23
TC 26
Z9 28
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD JAN
PY 1993
VL 298
IS 3
BP 187
EP 195
DI 10.1016/0165-1218(93)90040-K
PG 9
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA KG888
UT WOS:A1993KG88800006
PM 7678153
ER
PT J
AU SHADDOCK, JG
FEUERS, RJ
CHOU, MW
PEGRAM, RA
CASCIANO, DA
AF SHADDOCK, JG
FEUERS, RJ
CHOU, MW
PEGRAM, RA
CASCIANO, DA
TI EFFECTS OF AGING AND CALORIC RESTRICTION ON THE GENOTOXICITY OF 4
CARCINOGENS IN THE INVITRO RAT HEPATOCYTE DNA-REPAIR ASSAY
SO MUTATION RESEARCH
LA English
DT Article
DE CALORIC RESTRICTION; DNA REPAIR; HEPATOCYTES, RAT; 2-AAF; AFB1; DMBA;
DMN; CYTOCHROME-P450 ENZYMES
ID DRUG-METABOLIZING-ENZYMES; LIFE-SPAN; CHEMICAL CARCINOGENS; DIETARY
RESTRICTION; LIVER-MICROSOMES; FOOD RESTRICTION; EXCISION-REPAIR;
FISCHER-344 RAT; AGE; CYTOCHROME-P-450
AB The effects of aging and chronic caloric restriction (CR) on the genotoxicity of four carcinogens, representing four different classes of chemicals, in the in vitro rat hepatocyte/DNA repair assay were investigated. Hepatocyte cultures were isolated from young, middle-aged, and old male Fischer (F344) rats which were maintained on either an ad libitum (AL) or a CR diet (60% of AL). Hepatocyte cultures from old AL rats, treated with 2-acetylaminofluorene (2-AAF), aflatoxin B1 (AFB1), 7,12-dimethylbenz[a]anthracene (DMBA) and dimethylnitrosamine (DMN), exhibited age-related decreases in DNA repair as compared to young AL rats. By contrast, cultures from young CR rats exhibited significant diet-related decreases in DNA repair with 2-AAF, AFB1, DMBA and DMN, when compared to results from young AL diet-fed rats. Old CR F344 rat derived cultures exhibited no significant age-related dose-dependent decrease in the DNA repair response with any of the chemicals tested. However, in cultures from old CR rats 10.0 muM AFB1 produced an age-related decrease in DNA repair from the response observed in young CR rats. When hepatocytes were isolated from Aroclor 1254-induced rats, increases in DNA repair were observed. These data indicate an age- and diet-related decrease in DNA repair and/or DNA damage and suggest that this decrease is due to a decrease in metabolic activation of these carcinogens to genotoxic species.
C1 NATL CTR TOXICOL RES,DIV COMPARAT TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT TOXICOL,LITTLE ROCK,AR 72205.
RP SHADDOCK, JG (reprint author), NATL CTR TOXICOL RES,DIV GENET TOXICOL,HFT 120,NCTR DR,JEFFERSON,AR 72079, USA.
NR 56
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD JAN
PY 1993
VL 295
IS 1
BP 19
EP 30
DI 10.1016/0921-8734(93)90008-Q
PG 12
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA JZ619
UT WOS:A1993JZ61900003
PM 7677926
ER
PT J
AU RANDERATH, K
HART, RW
ZHOU, GD
REDDY, R
DANNA, TF
RANDERATH, E
AF RANDERATH, K
HART, RW
ZHOU, GD
REDDY, R
DANNA, TF
RANDERATH, E
TI ENHANCEMENT OF AGE-RELATED INCREASES IN DNA I-COMPOUND LEVELS BY CALORIE
RESTRICTION - COMPARISON OF MALE B-N AND F-344-RATS
SO MUTATION RESEARCH
LA English
DT Article
DE DNA ADDUCTS; I-COMPOUNDS; (RAT); LIVER; KIDNEY; CALORIC RESTRICTION;
STRAIN COMPARISON; P-32 POSTLABELING
ID SPRAGUE-DAWLEY RATS; LIVER DNA; FISCHER RATS;
2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; METABOLISM; MODULATION;
REDUCTION; HEPATOMAS; INDUCTION; PROTEIN
AB Caloric restriction (CR), known to extend median and maximum life spans, improve resistance to carcinogenesis, and significantly retard age-associated degenerative diseases in rodents, was previously reported to modulate levels of indigenous, age-dependent DNA modifications, called I-compounds, in male Brown-Norway (B-N) rats. Since profiles of these adduct-like derivatives are species-, strain-, sex-, and tissue-specific, we explored this apparent CR/I-compound relationship in a comparative study between male B-N and male Fischer 344 (F-344) rats, the latter having a shorter life expectancy and high incidence of renal disease. Control animals were fed NIH-31 diet ad libitum (AL), while the caloric intake of CR animals was limited to 60% of AL, starting at 3.5 months. Liver and kidney DNA from 1, 8, 12, 16, 24 (AL, CR), and 30 (CR only) month old rats was analyzed by P-32-postlabeling. Corresponding tissues from the two strains yielded similar DNA profiles. Total liver I-compound levels displayed 2.3-4.6-fold age-dependent increases from 1 to 24 months, and kidney values at 24 months were 5.2-8 times higher than those at 1 month. In both strains, I-compound levels of CR animals were higher, up to 2-fold, than in age-matched AL rats. Regression analyses indicated linear relationships between most CR relative adduct labeling values (both total and individual fractions) and age, whereas many AL values exhibited this type of link with log age. These findings confirm that a correlation exists between CR and I-compound levels, and, given the above physiological benefits of CR, indicate that I-compounds represent biomarkers of aging with potential utility in intervention studies.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP RANDERATH, K (reprint author), BAYLOR COLL MED,DEPT PHARMACOL,DIV TOXICOL,HOUSTON,TX 77030, USA.
FU NIA NIH HHS [R01 AG 07750]
NR 37
TC 20
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD JAN
PY 1993
VL 295
IS 1
BP 31
EP 46
DI 10.1016/0921-8734(93)90009-R
PG 16
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA JZ619
UT WOS:A1993JZ61900004
PM 7677927
ER
PT J
AU BENNETT, RW
MURTHY, G
KAYLOR, L
COX, S
HARMON, SM
AF BENNETT, RW
MURTHY, G
KAYLOR, L
COX, S
HARMON, SM
TI BIOLOGICAL CHARACTERIZATION AND SEROLOGICAL IDENTIFICATION OF
BACILLUS-CEREUS DIARRHEAL FACTOR
SO NETHERLANDS MILK AND DAIRY JOURNAL
LA English
DT Article
DE BACILLUS CEREUS; ENTEROTOXIN; TOXIN; HUMAN DIARRHEA
ID ENTERO-TOXIN
AB Bacillus cereus is associated with two distinct types of foodborne illness, diarrhoeal and emetic, which are caused by two toxins produced by the bacterium. Because the symptoms of these toxins are like those of other foodborne toxins, they must be identified in suspect foods. We attempted to identify and characterize the bacterial antigen associated with toxic diarrhoea. Selected extracellular proteins of the bacterium (antigens 573, 577 and 580, cereolysin and secondary haemolysins from several strains of B. cereus, including B4ac) were identified serologically and given by mouth to monkeys (Macaca fascicularis) in crude form or partially purified through Amberlite resin CG400. Monkeys fed on crude or partially purified preparations of antigen 577 suffered diarrhoea (crude, 13 out of 15; partially purified, 4 out of 5) after receiving at least 250 arbitary units (1 u corresponds to 1 mL of preparation with a titre of 1 or, for instance, 1 muL of titre 1000). However comparable preparations chromatographed on diethylaminoethyl-cellulose (DEAE) caused no diarrhoea (0/9). So the DEAE must have destabilized or inactivated the toxin. Preparations lacking antigen 577 but containing the other antigens caused no diarrhoea. Crude or partially purified antigen 577 neutralized with a serum against 577 caused no significant diarrhoea (1 out of 12). A monospecific serum against 577 has been prepared for identification of the diarrhoeal toxin produced by B. species including B. cereus in culture fluids and foods.
C1 US FDA,DIV MICROBIOL,WASHINGTON,DC 20204.
RP BENNETT, RW (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 21
TC 9
Z9 9
U1 0
U2 0
PU PUDOC
PI WAGENINGEN
PA P O BOX 4, 6700 WAGENINGEN, NETHERLANDS
SN 0028-209X
J9 NETH MILK DAIRY J
JI Neth. Milk Dairy J.
PY 1993
VL 47
IS 2
BP 105
EP 120
PG 16
WC Food Science & Technology
SC Food Science & Technology
GA LQ415
UT WOS:A1993LQ41500006
ER
PT J
AU BOAL, JH
IYER, RP
EGAN, W
AF BOAL, JH
IYER, RP
EGAN, W
TI THE 5'-HYDROGEN PHOSPHONATE ANALOG AS A POTENTIAL PRODRUG OF
3'-AZIDO-2',3'-DIDEOXYTHYMIDINE (AZT)
SO NUCLEOSIDES & NUCLEOTIDES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX;
REVERSE-TRANSCRIPTASE; 3'-AZIDO-3'-DEOXYTHYMIDINE; REPLICATION;
ZIDOVUDINE; INHIBITOR; THERAPY; HIV
AB A novel synthesis of AZT-5'-H-phosphonate 2, involving decarboxylation of the phosphonoformate intermediate 7, is reported herein. Studies of the metabolism of 2 in U937 cells indicate that 2 is readily converted to AZT-5'-monophosphate.
C1 CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
NR 19
TC 16
Z9 16
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0732-8311
J9 NUCLEOS NUCLEOT
JI Nucleosides Nucleotides
PY 1993
VL 12
IS 10
BP 1075
EP 1084
DI 10.1080/07328319308016205
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MM884
UT WOS:A1993MM88400006
ER
PT J
AU DAUSCH, JG
FULLERTON, FR
AF DAUSCH, JG
FULLERTON, FR
TI INCREASED LEVELS OF S-ADENOSYLMETHIONINE IN THE LIVERS OF RATS FED
VARIOUS FORMS OF SELENIUM
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID AZO-DYE HEPATOCARCINOGENESIS; DNA METHYLATION; CANCER;
2-ACETYLAMINOFLUORENE; PROTECTION; METHIONINE; TOXICITY
AB The levels of S-adenosylmethionine (SAM) were determined in the livers of male weanling rats fed six different forms of selenium for five weeks. The following forms of selenium were administrated in the diet in logarithmic doses: sodium selenite, sodium selenate, sodium selenide, selenomethionine, selenocystine, and selenium sulfide. An overall increase in hepatic SAM was observed, and all compounds resulted in at least one observation where SAM was significantly, elevated (p < 0.01). No dose-response relationship was found to exist, however. A comparison of the relative toxicity of each of the selenicals was based on a dose of 10 ppm dietary selenium for each chemical form. The elevation of SAM resulting from the subchronic administration of selenium may be one mechanism involved in the well-known chemopreventive effects in experimental models.
C1 CTR DIS CONTROL,NATL CTR HLTH STAT,HYATTSVILLE,MD.
US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702.
NR 34
TC 3
Z9 3
U1 1
U2 2
PU LAWRENCE ERLBAUM ASSOC INC
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 1993
VL 20
IS 1
BP 31
EP 39
PG 9
WC Oncology; Nutrition & Dietetics
SC Oncology; Nutrition & Dietetics
GA LQ540
UT WOS:A1993LQ54000004
PM 8415128
ER
PT J
AU WAMER, WG
WEI, RR
MATUSIK, JE
KORNHAUSER, A
DUNKEL, VC
AF WAMER, WG
WEI, RR
MATUSIK, JE
KORNHAUSER, A
DUNKEL, VC
TI BETA-CAROTENE UPTAKE, METABOLISM, AND DISTRIBUTION IN BALB/C 3T3 CELLS
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID RETINOIC ACID; 10T1/2 CELLS; VITAMIN-A; INVITRO; CANCER; TRANSFORMATION;
CANTHAXANTHIN
AB Although a growing number of epidemiological studies indicate that dietary beta-carotene has anticarcinogenic activity, the mechanism(s) of beta-carotene protection remains to be definitively established. In this context, in vitro studies of beta-carotene have been, and continue to be, valuable. We examined the following critical features in designing an in vitro system for studying the protective action of beta-carotene: 1) form of beta-carotene used for cellular uptake, 2) cellular metabolism of beta-carotene, and 3) subcellular distribution of beta-carotene. It was determined that beta-carotene added to medium in a water-dispersible formulation is readily taken up by BALB/c 3T3 cells and is located predominantly in cellular membranes. Cellular uptake of beta-carotene added to medium in an organic solvent is greatly reduced. It was also found that intracellular retinol increased significantly after a three-day exposure of BALB/c 3T3 cells to media containing beta-carotene. This result suggests that the ability to metabolize beta-carotene to retinoids is not limited to cells of intestinal origin. The results and methodology described here will be useful in the rational design of in vitro assays for elucidating the mechanism (s) of beta-carotene protective effects at the cellular level.
RP WAMER, WG (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,HFF-164,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 40
TC 23
Z9 23
U1 0
U2 0
PU LAWRENCE ERLBAUM ASSOC INC
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 1993
VL 19
IS 1
BP 31
EP 41
PG 11
WC Oncology; Nutrition & Dietetics
SC Oncology; Nutrition & Dietetics
GA KU904
UT WOS:A1993KU90400004
PM 8446513
ER
PT J
AU JENKINS, MY
SHEIKH, NM
MITCHELL, GV
GRUNDEL, E
BLAKELY, SR
CARTER, CJ
AF JENKINS, MY
SHEIKH, NM
MITCHELL, GV
GRUNDEL, E
BLAKELY, SR
CARTER, CJ
TI DIETARY CAROTENOIDS INFLUENCED BIOCHEMICAL BUT NOT MORPHOLOGICAL-CHANGES
IN ADULT MALE-RATS FED A CHOLINE-DEFICIENT DIET
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID TRANS-BETA-CAROTENE; VITAMIN-E; DUNALIELLA-BARDAWIL; LIPID-PEROXIDATION;
ALPHA-TOCOPHEROL; CANCER; CANTHAXANTHIN; METHIONINE; INHIBITION;
SELENIUM
AB In a study of the effects of carotenoids, canthaxanthin (CA), beta-apo-8'-carotenal (BA), or beta-carotene in an extract of Spirulina-Dunaliella algae (AE) was fed at 0%, 0.1%, or 0.2% in a choline-deficient (CD) diet. In each of eight groups, 10 adult male Fischer 344 rats were fed diets with designated carotenoid sources and levels or a choline-sufficient diet for 12 weeks. Carotenoids altered some of the changes induced by the CD diet. Increases in enlargement of fatty livers and low plasma cholesterol levels occurred in rats fed 0.2% BA. Plasma retinol was further reduced 35% by BA or AE BA and AE increased liver total vitamin A about 80% and 305%, respectively. Liver lipid peroxidation was enhanced and plasma alpha-tocopherol was reduced further by 1.0% AE. AE, BA, and CA (mg/g fat) depressed liver alpha-tocopherol about 49%, 67%, and 78%, respectively. The decreased liver alpha-tocopherol was concurrent with an increase in carotenoid stores of CA > BA > AE Histopathological examination of sections of liver tissue by light microscopy showed fatty and cirrhotic changes in all rats fed CD diets. Histochemical evaluation based on a semiquantitative assay revealed a marked increase in peroxisome enzyme activity in the livers of all CD rats. None of the carotenoids appeared to have any effect on the development of morphological changes in the liver. Although carotenoids can function as antioxidants, they did not prevent changes observed in rats fed CD diets.
C1 US FDA, DIV NUTR, WASHINGTON, DC 20204 USA.
US FDA, CTR FOOD SAFETY & APPL NUTR, DIV PATHOL, WASHINGTON, DC 20204 USA.
NR 48
TC 10
Z9 10
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PY 1993
VL 19
IS 1
BP 55
EP 65
PG 11
WC Oncology; Nutrition & Dietetics
SC Oncology; Nutrition & Dietetics
GA KU904
UT WOS:A1993KU90400006
PM 8446515
ER
PT S
AU HEWLETT, IK
JOSHI, B
RIORDAN, G
POLLOCK, L
EPSTEIN, JS
AF HEWLETT, IK
JOSHI, B
RIORDAN, G
POLLOCK, L
EPSTEIN, JS
BE Lyman, WD
Rubinstein, A
TI A RAPID, SENSITIVE, PCR-BASED METHOD FOR DETECTION OF HIV-1 SPECIFIC
NUCLEIC-ACID IN THE CULTURE SUPERNATANT OF INFECTED-CELLS
SO PEDIATRIC AIDS: CLINICAL, PATHOLOGIC, AND BASIC SCIENCE PERSPECTIVES
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Pediatric Aids: Clinical, Pathologic, and Basic Science
Perspectives
CY NOV 18-21, 1992
CL WASHINGTON, DC
SP NEW YORK ACAD SCI
RP HEWLETT, IK (reprint author), US FDA,CTR BIOL EVALUAT & RES,RETROVIROL LAB,BETHESDA,MD 20892, USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-791-3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 693
BP 264
EP 267
DI 10.1111/j.1749-6632.1993.tb26278.x
PG 4
WC Immunology; Multidisciplinary Sciences; Pathology; Pediatrics; Virology
SC Immunology; Science & Technology - Other Topics; Pathology; Pediatrics;
Virology
GA BZ45X
UT WOS:A1993BZ45X00029
PM 8267274
ER
PT S
AU JOSHI, B
EPSTEIN, J
LEE, SF
MAYNER, R
HEWLETT, IK
AF JOSHI, B
EPSTEIN, J
LEE, SF
MAYNER, R
HEWLETT, IK
BE Lyman, WD
Rubinstein, A
TI EVALUATION OF ANTI-HIV AGENTS IN-VITRO BY QUANTITATIVE PCR
SO PEDIATRIC AIDS: CLINICAL, PATHOLOGIC, AND BASIC SCIENCE PERSPECTIVES
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Pediatric Aids: Clinical, Pathologic, and Basic Science
Perspectives
CY NOV 18-21, 1992
CL WASHINGTON, DC
SP NEW YORK ACAD SCI
C1 US FDA,CTR BIOL EVALUAT & RES,DIV TRANSFUS SCI,RETROVIROL LAB,BETHESDA,MD 20892.
NR 2
TC 0
Z9 0
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-791-3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1993
VL 693
BP 306
EP 308
DI 10.1111/j.1749-6632.1993.tb26292.x
PG 3
WC Immunology; Multidisciplinary Sciences; Pathology; Pediatrics; Virology
SC Immunology; Science & Technology - Other Topics; Pathology; Pediatrics;
Virology
GA BZ45X
UT WOS:A1993BZ45X00043
PM 8267287
ER
PT J
AU BOWYER, JF
GOUGH, B
SLIKKER, W
LIPE, GW
NEWPORT, GD
HOLSON, RR
AF BOWYER, JF
GOUGH, B
SLIKKER, W
LIPE, GW
NEWPORT, GD
HOLSON, RR
TI EFFECTS OF A COLD ENVIRONMENT OR AGE ON METHAMPHETAMINE-INDUCED DOPAMINE
RELEASE IN THE CAUDATE PUTAMEN OF FEMALE RATS
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE METHAMPHETAMINE; MICRODIALYSIS; CAUDATE PUTAMEN; DOPAMINE; AMINO ACIDS;
NEUROTOXICITY; AGING
ID STRIATAL DOPAMINE; INTRACEREBRAL DIALYSIS; AMINO-ACIDS; BRAIN;
AMPHETAMINE; MICRODIALYSIS; GLUTAMATE; NUCLEUS; ANTAGONISTS; METABOLISM
AB Extracellular levels of dopamine (DA) and metabolites as well as serotonin [5-hydroxytryptamine (5-HT)] and 5-hydroxyindoleacetic acid (5-HIAA) were determined in the caudate putamen (CPU) of either 6- or 12-month-old female rats using microdialysis and high-performance liquid chromatography with electrochemical detection (HPLC-ED) before, during, and after four consecutive injections (given at 2-h intervals) of methamphetamine (METH). In 6-month-old rats administered 4 x 5 mg/kg METH at an environmental temperature (ET) of 23-degrees-C, peak extracellular DA levels (between 50 and 150 pg/10 mul) were attained 30-45 min after each dose of METH while dihydroxyphenylacetic acid (DOPAC) decreased steadily after the first doses of METH until it reached a plateau at 50% of control (550-700 pg/10 mul) levels. Increases in 5-HT levels during METH administrations paralleled DA increases while 5-HIAA decreases paralleled DOPAC decreases. The total CPU DA and 5-HT content of these rats was about 65% of control at 3 days post-METH. Reducing the ET to 4-degrees-C during dosing decreased the peak and average DA levels attained during the 4 x 5 mg/kg METH administration to about 50% of that observed at a 23-degrees-C ET. Increasing the dose to 4 x 10 mg/kg METH (4-degrees-C ET) increased peak and average CPU DA levels to 200% that observed during 4 x 5 mg/kg METH at a 23-degrees-C ET. However, no significant decreases in total CPU DA content of any rats dosed with METH at a 4-degrees-C ET were observed 3 days post-METH. In 12-month-old rats dosed with 4 x 5 mg/kg METH (23-degrees-C ET), the peak and average extracellular DA levels were only 30-60% that of 6-month-old rats. However, the CPU DA content of older rats was significantly decreased both 3 (30% control) and 14 (60% control) days post-METH. In summary, METH toxicity may not be predicted solely by the extracellular levels of DA attained during METH administration; age and ET also greatly influence METH neurotoxicity.
C1 NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
RP BOWYER, JF (reprint author), NATL CTR TOXICOL RES,DIF NEUROTOXICOL,HFT-132,JEFFERSON,AR 72079, USA.
NR 39
TC 90
Z9 91
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD JAN
PY 1993
VL 44
IS 1
BP 87
EP 98
DI 10.1016/0091-3057(93)90284-Z
PG 12
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA KG426
UT WOS:A1993KG42600011
PM 8094252
ER
PT J
AU TAPIOVAARA, MJ
WAGNER, RF
AF TAPIOVAARA, MJ
WAGNER, RF
TI SNR AND NOISE MEASUREMENTS FOR MEDICAL IMAGING - IA PRACTICAL APPROACH
BASED ON STATISTICAL DECISION-THEORY
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID HOTELLING TRACE CRITERION; VISUAL SIGNAL-DETECTION; DIGITAL RADIOGRAPHY;
OBSERVER PERFORMANCE; IDEAL-OBSERVER; QUALITY; SYSTEMS; OPTIMIZATION;
EFFICIENCY; CONTRAST
AB A method of measuring the image quality of medical imaging equipment is considered within the framework of statistical decision theory. In this approach, images are regarded as random vectors and image quality is defined in the context of the image information available for performing a specified detection or discrimination task. The approach provides a means of measuring image quality, as related to the detection of an image detail of interest, without reference to the actual physical mechanisms involved in image formation and without separate measurements of signal transfer characteristics or image noise. The measurement does not, however, consider deterministic errors in the image; they need a separate evaluation for imaging modalities where they am of concern. The detectability of an image detail can be expressed in terms of the ideal observer's signal-to-noise ratio (SNR) at the decision level. Often a good approximation to this SNR can be obtained by employing sub-optimal observers, whose performance correlates well with the performance of human observers as well. In this paper the measurement Of SNR is based on implementing algorithmic realizations of specified observers and analysing their responses while actually performing a specified detection task of interest. Three observers are considered: the ideal prewhitening matched filter, the non-prewhitening matched filter, and the DC-suppressing non-prewhitening matched filter. The construction of the ideal observer requires an impractical amount of data and computing, except for the most simple imaging situations, Therefore, the utilization of sub-optimal observers is advised and their performance in detecting a specified signal is discussed. Measurement of noise and SNR has been extended to include temporally varying images and dynamic imaging systems.
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
RP TAPIOVAARA, MJ (reprint author), FINNISH CTR RADIAT & NUCL SAFETY,POB 268,SF-00101 HELSINKI,FINLAND.
NR 78
TC 66
Z9 66
U1 2
U2 5
PU IOP PUBLISHING LTD
PI BRISTOL
PA TECHNO HOUSE, REDCLIFFE WAY, BRISTOL, ENGLAND BS1 6NX
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JAN
PY 1993
VL 38
IS 1
BP 71
EP 92
DI 10.1088/0031-9155/38/1/006
PG 22
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA KH176
UT WOS:A1993KH17600006
PM 8426870
ER
PT J
AU LUU, HMD
WHITE, KD
AF LUU, HMD
WHITE, KD
TI IN-VITRO DETECTION OF 2,4-TDA AND 2,6-TDA AS DEGRADATION PRODUCTS OF A
POLYESTERURETHANE FOAM
SO POLYMER DEGRADATION AND STABILITY
LA English
DT Article
ID COVERED BREAST IMPLANTS; POLYURETHANE; TOLUENEDIAMINES; PATIENT
AB The polyesterurethane (PU) foam, also known as Scotfoam or Microthane foam, was found to produce 2,4- and 2,6-toluene diamine (TDA) in the aqueous extracts following approximately 3.5 months of incubation in phosphate buffer pH 7.4 at 37-degrees-C. PU foams were first exhaustively extracted in methylene chloride at 37-degrees-C and subsequently subjected to mild hydrolysis in phosphate buffer pH 7.4 at 37-degrees-C. The amount of 2,4- and 2,6-TD at 37-degrees-C at different time intervals were determined using high pressure liquid chromatography (HPLC) with UV photodiode array detector and gas chromatography/mass spectroscopy (GC/MS). Following exhaustive washing of the foam, measurement of 2,4- and 2,6-TDA showed total cumulative levels of 2.81 +/-0.85mug/g of 2,4-TDA and 2.0 +/- 0.47mug/g of 2,6-TDA in the foam buffer extracts over 3.5 months of incubation at 37-degrees-C. The linear kinetics obtained for TDA formation with time (R(2, 4) = 0.964 and R(2, 6) = 0.982) indicates hydrolysis of the PU foam, not contamination from manufacturing process or analytical procedure used.
C1 US FDA,CTR FOOD SATEFY & APPL NUTR,DIV CONTAMINANT CHEM,WASHINGTON,DC 20204.
RP LUU, HMD (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV MECH & MAT SCI,12200 WILKINS AVE,ROCKVILLE,MD 20852, USA.
NR 20
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0141-3910
J9 POLYM DEGRAD STABIL
JI Polym. Degrad. Stabil.
PY 1993
VL 42
IS 3
BP 245
EP 251
PG 7
WC Polymer Science
SC Polymer Science
GA ME224
UT WOS:A1993ME22400003
ER
PT J
AU GOGOLEWSKI, S
JOVANOVIC, M
PERREN, SM
DILLON, JG
HUGHES, MK
AF GOGOLEWSKI, S
JOVANOVIC, M
PERREN, SM
DILLON, JG
HUGHES, MK
TI THE EFFECT OF MELT-PROCESSING ON THE DEGRADATION OF SELECTED
POLYHYDROXYACIDS - POLYLACTIDES, POLYHYDROXYBUTYRATE, AND
POLYHYDROXYBUTYRATE-CO-VALERATES
SO POLYMER DEGRADATION AND STABILITY
LA English
DT Article
ID THERMAL-DEGRADATION; POLY(-(D)-BETA-HYDROXYBUTYRIC ACID);
MECHANICAL-PROPERTIES; BETA-HYDROXYBUTYRATE; MOLECULAR-WEIGHT;
HYDROXYVALERATE; POLYMERS; POLY(3-HYDROXYBUTYRATE-CO-3-HYDROXYVALERATE);
POLY(3-HYDROXYBUTYRATE-CO-4-HYDROXYBUTYRATE); COPOLYESTERS
AB A series of resorbable polyhydroxyacids were studied by size exclusion chromatography (SEC), viscosity measurements, and differential scanning calorimetry (DSC) for the effect of the injection moulding process on the molecular weight and thermal properties of the polymers. The polymers studied were polylactides (PLA), polyhydroxybutyrate (PHB) and polyhydroxybutyrate-co-valerate (PHB/VA) (5-22% VA content). All polylactides underwent extensive degradation, in the range of 50-88%, and an increase in molecular weight distribution (MWD) following injection moulding at temperatures ranging from 130 to 215-degrees-C. In contrast to the polylactides, the decrease in molecular weight of the PHB and PHB/VA polymers after injection moulding at temperatures from 135 to 160-degrees-C was less dramatic, in the range of 4-53%. This was accompanied by a decrease of the MWD. No evidence for low molecular weight non-volatile degradation products was observed. Injection moulding led to a decrease in the melting temperature (T(m)) and the heat of melting (DELTAH(m)) of PLA. Conversely, the moulding process did not significantly affect the melting temperature and heat of melting of polyhydroxybutyrate/valerates.
C1 US FDA,DIV MECH & MAT SCI,ROCKVILLE,MD 20852.
RP GOGOLEWSKI, S (reprint author), AO ASIF,RES INST,DEPT POLYMERS,CLAVADELERSTR,CH-7270 DAVOS,SWITZERLAND.
NR 22
TC 106
Z9 107
U1 3
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0141-3910
J9 POLYM DEGRAD STABIL
JI Polym. Degrad. Stabil.
PY 1993
VL 40
IS 3
BP 313
EP 322
DI 10.1016/0141-3910(93)90137-8
PG 10
WC Polymer Science
SC Polymer Science
GA LD437
UT WOS:A1993LD43700004
ER
PT J
AU SAMUDZI, CT
NGUYEN, NY
RUBIN, JR
AF SAMUDZI, CT
NGUYEN, NY
RUBIN, JR
TI CRYSTALLIZATION AND PRELIMINARY-X-RAY DIFFRACTION STUDIES OF DOGFISH
C-REACTIVE PROTEIN
SO PROTEINS-STRUCTURE FUNCTION AND GENETICS
LA English
DT Article
DE DOGFISH C-REACTIVE PROTEIN; VAPOR PHASE EQUILIBRATION; AMMONIUM SULFATE;
SITTING DROP TECHNIQUE; HEXAMERS
ID POLYSACCHARIDE
AB Crystals of dogfish (Mustelus canis) C-reactive protein were obtained through vapor phase equilibration using the sitting drop rod technique with ammonium sulfate as the precipitating agent. The space group was determined to be P1 (triclinic lattice) with unit cell dimensions of a = 82.91, b = 92.25 and c = 103.40 angstrom; alpha = 83.36-degrees, beta = 89.76-degrees, and gamma = 81.30-degrees. These crystals diffract to about 2.6 angstrom resolution and contain two hexamers in the asymmetric unit.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
RP SAMUDZI, CT (reprint author), NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.
FU NCI NIH HHS [N01-CO-74101]
NR 20
TC 1
Z9 1
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0887-3585
J9 PROTEINS
JI Proteins
PD JAN
PY 1993
VL 15
IS 1
BP 100
EP 102
DI 10.1002/prot.340150112
PG 3
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA KC061
UT WOS:A1993KC06100011
PM 8451236
ER
PT J
AU WEIDEN, P
SCHOOLER, NR
SEVERE, JB
LEE, JH
SCHULZ, SC
AF WEIDEN, P
SCHOOLER, NR
SEVERE, JB
LEE, JH
SCHULZ, SC
TI STABILIZATION AND DEPOT NEUROLEPTIC DOSAGES
SO PSYCHOPHARMACOLOGY BULLETIN
LA English
DT Article
ID CONTROLLED TRIAL; SCHIZOPHRENIA; DEFINITIONS; RELAPSE
AB Little is known about the stabilization phase of schizophrenia. To address this deficiency, we studied the prescribing patterns of fluphenazine decanoate (FZD) for a cohort of schizophrenic patients recovering from an acute psychotic episode who were being followed in the Treatment Strategies in Schizophrenia (TSS) multi-site maintenance study.
Dosage data from the first 208 successfully-stabilized TSS subjects were examined. We hypothesized five groups on the basis of dosage prescribed and dosage stability over time: (1) STABLE HIGH, (2) STABLE INTERMEDIATE, (3) STABLE LOW, (4) UNSTABLE RAISING, and (5) UNSTABLE LOWERING. The dosage patterns were rated and analyzed against predictive and outcome variables.
Most of the subjects (n = 168, or 82%) fit one of the five hypothesized dosage pattern groups. Our preliminary findings are as follows: (1) all groups improved during stabilization; (2) baseline symptom severity did not distinguish among dosage pattern groups; (3) STABLE dose groups needed less time to stabilize than did the UNSTABLE groups, but the STABLE groups did not have a better medication response; (4) many of the UNSTABLE LOWERING subjects apparently received a ''loading dose'' strategy (e.g., initial FZD dose greater-than-or-equal-to 25 mg), which was paradoxically associated with a longer stabilization time.
C1 WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15261.
US FDA,ROCKVILLE,MD 20857.
NIMH,ROCKVILLE,MD 20857.
UNIV HOSP CLEVELAND,CLEVELAND,OH 44106.
RP WEIDEN, P (reprint author), ST LUKES ROOSEVELT HOSP,PSYCHIAT T8,428 W 59TH ST,NEW YORK,NY 10012, USA.
FU NIMH NIH HHS [UO1 MH40007, UO1 MH39992, UO1 MH39998]
NR 20
TC 10
Z9 10
U1 0
U2 0
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0048-5764
J9 PSYCHOPHARMACOL BULL
JI Psychopharmacol. Bull.
PY 1993
VL 29
IS 2
BP 269
EP 275
PG 7
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA MC720
UT WOS:A1993MC72000020
PM 8290676
ER
PT J
AU HYMAN, FN
KLONTZ, KC
TOLLEFSON, L
AF HYMAN, FN
KLONTZ, KC
TOLLEFSON, L
TI FOOD-AND-DRUG-ADMINISTRATION SURVEILLANCE OF THE ROLE OF FOREIGN OBJECTS
IN FOODBORNE INJURIES
SO PUBLIC HEALTH REPORTS
LA English
DT Article
ID TEAR
AB As part of its effort to assure a safe food supply, the Food and Drug Administration maintains a passive surveillance system for the reporting and followup of complaints related to food items. This surveillance system, called the Complaint Reporting System, records and investigates consumer complaints about the quality of a specific food item, its packaging, or unexpected effects following consumption of the food.
This study, relying on data gathered from the 2,726 reports of discovery of a foreign object in a food item during fiscal year 1989, develops a profile of consumer complaints, focusing on those associated with resultant injury or illness.
Fourteen percent of all reported cases of foreign object exposure cited resultant illness or injury. The most common foreign object reported in food is glass, and the most common injury is a laceration or abrasion of soft tissues of the perioral area, including the throat. There was a disproportionate representation of children younger than age 3 years with documented illness or injury.
Only 3 percent of the complaints came from attending health professionals; 82 percent were self-reported. Practitioner awareness of the system is limited primarily because literature in this area is scant.
The collection and investigation of reports of foreign objects in food are important because such reports provide early warnings of potential problems with manufacturers' food items. Although data suggest that severe injury from foreign object ingestion is rare, continued monitoring is warranted. Health professionals are encouraged to report such injuries through the existing system.
RP HYMAN, FN (reprint author), US PHS,CTR FOOD SAFETY & APPL NUTR,OFF NUTR & FOOD SCI,CLIN NUTR ASSESSMENT SECT,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 8
TC 7
Z9 7
U1 0
U2 1
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD JAN-FEB
PY 1993
VL 108
IS 1
BP 54
EP 59
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KL046
UT WOS:A1993KL04600008
PM 8434098
ER
PT J
AU SHARKNESS, CM
HAMBURGER, S
MOORE, RM
KACZMAREK, RG
AF SHARKNESS, CM
HAMBURGER, S
MOORE, RM
KACZMAREK, RG
TI PREVALENCE OF ARTIFICIAL HIP IMPLANTS AND USE OF HEALTH-SERVICES BY
RECIPIENTS
SO PUBLIC HEALTH REPORTS
LA English
DT Article
ID TRANSPLANTATION; ARTHROPLASTY; ORTHOPEDICS; IMPACT
AB Data from the 1988 Medical Device Implant Supplement to the National Health Interview Survey are used to summarize information about the prevalence of artificial hips among adults in the United States. The 1988 National Health Interview Survey was a cross-sectional survey of the civilian noninstitutionalized United States population, and included 122,310 persons in 47,485 households in a multistage probability sample. The supplement supplied the first population-based estimates of prevalence and morbidity of selected medical devices.
Projected to the United States population, the survey results indicate that an estimated 674,000 adults were using 811,000 hip implants. Hip implant recipients were significantly more likely to be older, to be white, and to have lower educational income, and activity levels than the general population of adults. After age-stratification, however, only differences in activity limitation and race remained.
Current economic outlays for hip replacement surgery are substantial. With the aging population, use of health services by patients with artificial hips will probably increase unless measures to reduce the need for replacement surgery are instituted. These measures include reducing injuries and improving biomaterials. Further investigation is needed to examine the activity limitation and racial difference in prevalence found in this study.
C1 US PHS,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV BIOMETR SCI,EPIDEMIOL BRANCH,ROCKVILLE,MD 20851.
NR 25
TC 19
Z9 20
U1 0
U2 1
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD JAN-FEB
PY 1993
VL 108
IS 1
BP 70
EP 75
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KL046
UT WOS:A1993KL04600011
PM 8434101
ER
PT J
AU SULEIMAN, OH
RUETER, FG
ANTONSEN, RG
CONWAY, BJ
SLAYTON, RJ
AF SULEIMAN, OH
RUETER, FG
ANTONSEN, RG
CONWAY, BJ
SLAYTON, RJ
TI THE SENSITOMETRIC TECHNIQUE FOR THE EVALUATION OF PROCESSING (STEP)
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper
CT WORKSHOP ON TEST PHANTOMS AND OPTIMISATION IN DIAGNOSTIC RADIOLOGY AND
NUCLEAR MEDICINE
CY JUN 15-17, 1992
CL WURZBURG, GERMANY
SP COMMISS EUROPEAN COMMUNITIES, RADIAT PROTECT ACT, GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INT COMMISS RADIAT UNITS & MEASUREMENTS, EUROPEAN FEDERAT ORG MED PHYS
AB Processing speed has been monitored using a survey method known as the Sensitometric Technique for the Evaluation of Processing (STEP). This test method has been used to evaluate over 2000 automatic film processors since 1981.
RP SULEIMAN, OH (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 11
Z9 12
U1 0
U2 0
PU NUCLEAR TECHNOLOGY PUBL
PI ASHFORD
PA PO BOX 7, ASHFORD, KENT, ENGLAND TN23 1YW
SN 0144-8420
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PY 1993
VL 49
IS 1-3
BP 105
EP 106
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA MG239
UT WOS:A1993MG23900023
ER
PT J
AU SULEIMAN, OH
ANTONSEN, R
CONWAY, BJ
MCCROHAN, JL
RUETER, FG
SLAYTON, R
AF SULEIMAN, OH
ANTONSEN, R
CONWAY, BJ
MCCROHAN, JL
RUETER, FG
SLAYTON, R
TI ASSESSING PATIENT EXPOSURE IN FLUOROSCOPY
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper
CT WORKSHOP ON TEST PHANTOMS AND OPTIMISATION IN DIAGNOSTIC RADIOLOGY AND
NUCLEAR MEDICINE
CY JUN 15-17, 1992
CL WURZBURG, GERMANY
SP COMMISS EUROPEAN COMMUNITIES, RADIAT PROTECT ACT, GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INT COMMISS RADIAT UNITS & MEASUREMENTS, EUROPEAN FEDERAT ORG MED PHYS
AB In the United States, the Conference of Radiation Control Program Directors (CRCPD), the umbrella organisation for state and local radiation control agencies, along with the federal government's Food and Drug Administration, conducts the Nationwide Evaluation of X ray Trends (NEXT) survey programme. The examination selected for the 1991 survey was the upper gastrointestinal fluoroscopy examination. The phantom developed for the 1991 survey approximates the abdominal region of a standard reference patient, is derived from a clinically validated phantom, and incorporates image quality test objects. The protocol enables the surveyor to measure fluoroscopic entrance air kerma rates (EKR) along with air kerma associated with radiographic techniques (photospot or spot film). Air kerma measurements are also made simulating barium. The assessment of patient dose from fluoroscopy and how it relates to the 1991 NEXT survey is presented.
RP SULEIMAN, OH (reprint author), US FDA,CTR DEVICES & RADIOL HLTH HFZ-240,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NUCLEAR TECHNOLOGY PUBL
PI ASHFORD
PA PO BOX 7, ASHFORD, KENT, ENGLAND TN23 1YW
SN 0144-8420
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PY 1993
VL 49
IS 1-3
BP 141
EP 143
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA MG239
UT WOS:A1993MG23900033
ER
PT J
AU PARAS, P
AF PARAS, P
TI OPERATIONAL PERFORMANCE AND QUALITY-CONTROL OF ANGER TYPE GAMMA CAMERAS
INCLUDING SPECT
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper
CT WORKSHOP ON TEST PHANTOMS AND OPTIMISATION IN DIAGNOSTIC RADIOLOGY AND
NUCLEAR MEDICINE
CY JUN 15-17, 1992
CL WURZBURG, GERMANY
SP COMMISS EUROPEAN COMMUNITIES, RADIAT PROTECT ACT, GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INT COMMISS RADIAT UNITS & MEASUREMENTS, EUROPEAN FEDERAT ORG MED PHYS
AB The goal of all nuclear medicine departments is to maintain a high level of diagnostic accuracy in producing and interpreting nuclear medicine studies. This goal can be achieved in part by ensuring the standardisation of the techniques employed, and by optimising and maintaining the performance of the devices being used. Acceptance or reference testing and routine monitoring, evaluation and maintenance, and quality control are necessary to achieve the advantages of SPECT imaging. To this end recommendations for users have been published by Radiological Health Authorities in different countries and by the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA) for planar imaging reference testing and quality control. For SPECT systems several papers have been published but no formal recommendations have been proposed. In addition, the International Electrotechnical Commission (IEC) and the National Electrical Manufacturers Association (NEMA) have published standards for manufacturers and the AAPM has published a comprehensive acceptance testing report. The American College of Nuclear Physicians (ACNP) is now attempting to standardise the measurement of performance of rotational SPECT systems in the field. They will propose Operational Guides for users and recommendations for quality control.
RP PARAS, P (reprint author), US FDA,CDRH,1390 PICCARD DR,ROCKVILLE,MD 20850, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NUCLEAR TECHNOLOGY PUBL
PI ASHFORD
PA PO BOX 7, ASHFORD, KENT, ENGLAND TN23 1YW
SN 0144-8420
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PY 1993
VL 49
IS 1-3
BP 311
EP 316
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA MG239
UT WOS:A1993MG23900075
ER
PT J
AU JENNINGS, RJ
AF JENNINGS, RJ
TI COMPUTATIONAL METHODS FOR THE DESIGN OF TEST OBJECTS AND TISSUE
SUBSTITUTES FOR RADIOLOGIC APPLICATIONS
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper
CT WORKSHOP ON TEST PHANTOMS AND OPTIMISATION IN DIAGNOSTIC RADIOLOGY AND
NUCLEAR MEDICINE
CY JUN 15-17, 1992
CL WURZBURG, GERMANY
SP COMMISS EUROPEAN COMMUNITIES, RADIAT PROTECT ACT, GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INT COMMISS RADIAT UNITS & MEASUREMENTS, EUROPEAN FEDERAT ORG MED PHYS
AB A theoretical framework has been developed for the design of tissue substitutes for use with diagnostic X rays. The theory divides naturally into a three-level hierarchy in which the number of properties of a reference material that can be matched by a substitute material increases with the number of components used in the substitute material. For a single component, the thickness can be chosen so as to match transmitted spectral shape or overall attenuation of the reference material, but not both. Two components can be combined to match both the spectral shape and overall attenuation, but not the thickness of a reference object. Use of three components permits matching of the spectral shape, overall attenuation, and thickness of the reference object, i.e. the linear attenuation coefficient of the substitute material matches that of the reference material. Examples are presented, and the theory is compared with other, similar methods.
RP JENNINGS, RJ (reprint author), US FDA,CTR DEVICES & RADIOL HLTH HFZ-142,12720 TWINBROOK PKWY,ROCKVILLE,MD 20857, USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU NUCLEAR TECHNOLOGY PUBL
PI ASHFORD
PA PO BOX 7, ASHFORD, KENT, ENGLAND TN23 1YW
SN 0144-8420
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PY 1993
VL 49
IS 1-3
BP 327
EP 332
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA MG239
UT WOS:A1993MG23900079
ER
PT J
AU CHIACCHIARINI, RP
AF CHIACCHIARINI, RP
TI PROCEEDINGS OF THE AMERICAN-STATISTICAL-ASSOCIATION CONFERENCE ON
RADIATION AND HEALTH - RADIATION RISK AND INTERACTIONS -
HILTON-HEAD-ISLAND, SOUTH-CAROLINA, JUNE 28 JULY 1, 1992 - CLOSING
COMMENTS
SO RADIATION RESEARCH
LA English
DT Editorial Material
RP CHIACCHIARINI, RP (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU RADIATION RESEARCH SOC
PI OAK BROOK
PA 2021 SPRING RD, STE 600, OAK BROOK, IL 60521
SN 0033-7587
J9 RADIAT RES
JI Radiat. Res.
PD JAN
PY 1993
VL 133
IS 1
BP 140
EP 140
PG 1
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
Nuclear Medicine & Medical Imaging
GA KK623
UT WOS:A1993KK62300018
ER
PT B
AU BARILE, MF
ROTTEM, S
AF BARILE, MF
ROTTEM, S
BE Kahane, I
Adoni, A
TI MYCOPLASMAS IN CELL-CULTURE
SO RAPID DIAGNOSIS OF MYCOPLASMAS
SE FEMS SYMPOSIUM
LA English
DT Proceedings Paper
CT FEMS Workshop on Rapid Diagnosis of Mycoplasmas
CY AUG 11-23, 1991
CL JERUSALEM, ISRAEL
SP FEDERAT EUROPEAN MICROBIOL SOC
C1 US FDA,OFF BIOL RES,MYCOPLASMA LAB,BETHESDA,MD 20014.
NR 0
TC 36
Z9 37
U1 0
U2 1
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
BN 0-306-44621-9
J9 FEMS SYMP
PY 1993
IS 62
BP 155
EP 193
PG 39
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA BZ71Z
UT WOS:A1993BZ71Z00012
ER
PT J
AU WILLIAMS, JC
PEACOCK, MG
RACE, RE
AF WILLIAMS, JC
PEACOCK, MG
RACE, RE
BE Robinet, AH
TI IMMUNIZATION OF DOGS WITH Q-FEVER VACCINES - COMPARISON OF PHASE-I,
PHASE-II AND PHASE-I CMR COXIELLA-BURNETII VACCINES
SO REVUE D ELEVAGE ET DE MEDECINE VETERINAIRE DES PAYS TROPICAUX, TOME 46
(NOUVELLE SER), NO. 1-2, 1993
LA English
DT Proceedings Paper
CT 2nd Biennial Meeting of the Society-for-Tropical-Veterinary-Medicine
CY FEB 02-06, 1993
CL ST FRANCOIS, GUADELOUPE
SP SOC TROP VET MED
DE DOG; COXIELLA-BURNETII; Q-FEVER; VACCINE; IMMUNIZATION; IMMUNE RESPONSE;
IMMUNOLOGICAL TECHNIQUES; CELL MEDIATED IMMUNITY
C1 US FDA,CTR BIOL EVALUAT & RES,OFF VACCINE RES & REVIEW,DIV VACCINES & RELATED PROD APPLICAT,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EXPANSION SCIENTIF FRANCAISE
PI PARIS
PA 15 RUE ST-BENOIT, F-75278 PARIS, FRANCE
PY 1993
BP 87
EP 94
PG 8
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA BZ92P
UT WOS:A1993BZ92P00013
ER
PT J
AU MILLER, HI
AF MILLER, HI
TI GENES ON THE MENU
SO SCIENTIFIC AMERICAN
LA English
DT Letter
RP MILLER, HI (reprint author), US FDA,OFF BIOTECHNOL,WASHINGTON,DC 20204, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SCI AMERICAN INC
PI NEW YORK
PA 415 MADISON AVE, NEW YORK, NY 10017
SN 0036-8733
J9 SCI AM
JI Sci.Am.
PD JAN
PY 1993
VL 268
IS 1
BP 12
EP 12
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KE085
UT WOS:A1993KE08500006
ER
PT J
AU FRICKE, WA
LAMB, MA
AF FRICKE, WA
LAMB, MA
TI VIRAL SAFETY OF CLOTTING FACTOR CONCENTRATES
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article
ID FACTOR-VIII CONCENTRATE; HEPATITIS-C VIRUS; NON-B HEPATITIS; FACTOR-IX
CONCENTRATE; HTLV-III; NON-A; PARVOVIRUS INFECTION; HIV TRANSMISSION;
AMERICAN ORIGIN; 1ST EXPOSURE
RP FRICKE, WA (reprint author), US FDA,CBER,HFB 440,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 61
TC 36
Z9 36
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 381 PARK AVE SOUTH, NEW YORK, NY 10016
SN 0094-6176
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PY 1993
VL 19
IS 1
BP 54
EP 61
DI 10.1055/s-2007-994006
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA KL752
UT WOS:A1993KL75200007
PM 8456324
ER
PT J
AU FRICKE, WA
LAMB, MA
AF FRICKE, WA
LAMB, MA
TI CLOTTING FACTOR CONCENTRATES IN CLINICAL-PRACTICE - PREFACE
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Editorial Material
RP FRICKE, WA (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 381 PARK AVE SOUTH, NEW YORK, NY 10016
SN 0094-6176
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PY 1993
VL 19
IS 1
BP U1
EP U1
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA KL752
UT WOS:A1993KL75200001
ER
PT B
AU KATZPER, M
AF KATZPER, M
BE Anderson, JG
Katzper, M
TI DYNAMIC STUDIES OF PHARMACOMETRIC RELATIONSHIPS
SO SIMULATION IN HEALTH SCIENCES AND SERVICES
LA English
DT Proceedings Paper
CT 1993 SCS Western Simulation Multiconference on Simulation in the Health
Sciences and Services
CY JAN 17-20, 1993
CL LA JOLLA, CA
SP SOC COMP SIMULAT
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-021-8
PY 1993
BP 65
EP 65
PG 1
WC Education, Scientific Disciplines; Health Policy & Services
SC Education & Educational Research; Health Care Sciences & Services
GA BA06B
UT WOS:A1993BA06B00011
ER
PT B
AU HARTER, JG
KATZPER, M
AF HARTER, JG
KATZPER, M
BE Anderson, JG
Katzper, M
TI THERAPEUTIC IMPLICATIONS OF EFFECTOR RESPONSE ALTERNATIVES
SO SIMULATION IN HEALTH SCIENCES AND SERVICES
LA English
DT Proceedings Paper
CT 1993 SCS Western Simulation Multiconference on Simulation in the Health
Sciences and Services
CY JAN 17-20, 1993
CL LA JOLLA, CA
SP SOC COMP SIMULAT
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-021-8
PY 1993
BP 66
EP 70
PG 5
WC Education, Scientific Disciplines; Health Policy & Services
SC Education & Educational Research; Health Care Sciences & Services
GA BA06B
UT WOS:A1993BA06B00012
ER
PT B
AU MARTINEZ, MN
KATZPER, M
AF MARTINEZ, MN
KATZPER, M
BE Anderson, JG
Katzper, M
TI A SIMULATION STUDY TO EXAMINE CURRENT VETERINARY GENERIC DRUG APPROVAL
CRITERIA TO ASSURE HUMAN FOOD SAFETY
SO SIMULATION IN HEALTH SCIENCES AND SERVICES
LA English
DT Proceedings Paper
CT 1993 SCS Western Simulation Multiconference on Simulation in the Health
Sciences and Services
CY JAN 17-20, 1993
CL LA JOLLA, CA
SP SOC COMP SIMULAT
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-021-8
PY 1993
BP 79
EP 83
PG 5
WC Education, Scientific Disciplines; Health Policy & Services
SC Education & Educational Research; Health Care Sciences & Services
GA BA06B
UT WOS:A1993BA06B00014
ER
PT J
AU SHAH, VP
BEHL, CR
FLYNN, GL
HIGUCHI, WI
SCHAEFER, H
AF SHAH, VP
BEHL, CR
FLYNN, GL
HIGUCHI, WI
SCHAEFER, H
TI PRINCIPLES AND CRITERIA IN THE DEVELOPMENT AND OPTIMIZATION OF TOPICAL
THERAPEUTIC PRODUCTS
SO SKIN PHARMACOLOGY
LA English
DT Editorial Material
DE TOPICAL DERMATOLOGICAL PRODUCTS; DEVELOPMENT OF DERMATOLOGICAL PRODUCTS;
DERMATOLOGICAL PRODUCTS; TRANSDERMAL PRODUCTS; BIOEQUIVALENCE; QUALITY
CONTROL
AB The report differentiates between dermatological and transdermal products, identifies and discusses the principles involved in the development and optimization of topical drug products. The regulatory concerns in the evaluation of topical dermatological products with respect to bioequivalence and quality control are also discussed.
C1 HOFFMANN LA ROCHE INC,PHARMACEUT RES & DEV,NUTLEY,NJ 07110.
CIRD GALDERMA,VALBONNE,FRANCE.
UNIV UTAH,COLL PHARM,SALT LAKE CITY,UT 84112.
UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109.
RP SHAH, VP (reprint author), US FDA,CTR DRUG EVALUAT & RES,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1011-0283
J9 SKIN PHARMACOL
JI Skin Pharmacol.
PY 1993
VL 6
IS 1
BP 72
EP 80
PG 9
WC Dermatology; Pharmacology & Pharmacy
SC Dermatology; Pharmacology & Pharmacy
GA KZ833
UT WOS:A1993KZ83300012
PM 8489779
ER
PT J
AU VARNER, SL
AF VARNER, SL
GP SOC PLAST ENGINEERS
TI RECYCLED CONTENT IN PLASTIC FOOD-PACKAGING - SAFETY ISSUES
SO SURVIVAL TACTICS THRU THE '90'S: SOCIETY OF PLASTICS ENGINEERINGS
RECYCLING CONFERENCE
LA English
DT Proceedings Paper
CT Recycling Conference on Survival Tactics thru the 90s
CY JUN 14-16, 1993
CL SCHAUMBURG, IL
SP SOC PLAST ENGINEERS, CHICAGO SECT, SOC PLAST ENGINEERS, RECYCLING DIV, STATE ILLINOIS, DEPT ENERGY & NAT RESOURCES
C1 US FDA,INDIRECT ADDIT BRANCH,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC PLASTICS ENGINEERS
PI BROOKFIELD CENTER
PA 14 FAIRFIELD DR, BROOKFIELD CENTER, CT 06805
PY 1993
BP 143
EP 151
PG 9
WC Engineering, Environmental; Polymer Science
SC Engineering; Polymer Science
GA BA50G
UT WOS:A1993BA50G00015
ER
PT J
AU LI, W
SOTIRIOULEVENTIS, C
SAHA, M
FU, PP
GIESE, RW
AF LI, W
SOTIRIOULEVENTIS, C
SAHA, M
FU, PP
GIESE, RW
TI SUPEROXIDE OXIDATION OF HYDROXY-POLYAROMATICS AND KETO-POLYAROMATICS
INCLUDING INTERNAL QUINONES
SO SYNTHETIC COMMUNICATIONS
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; DIOL ENANTIOMERS; MONO-OL;
BENZANTHRACENE
AB Aromatic 1,2-dicarboxylic acids can be obtained by KO2 oxidation of polyaromatics comprising analogs of 1-naphthol, sterically hindered alcohols and ketones, and, perhaps most interestingly, quinones fused on both sides to aromatic rings. A mechanism is presented to rationalize the formation of phthalic acid as the only major product from 5,12-naphthacenequinone.
C1 NORTHEASTERN UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT PHARMACEUT SCI,BOSTON,MA 02115.
NORTHEASTERN UNIV,BARNETT INST CHEM ANAL & MAT SCI,BOSTON,MA 02115.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 12
TC 6
Z9 6
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0039-7911
J9 SYNTHETIC COMMUN
JI Synth. Commun.
PY 1993
VL 23
IS 1
BP 97
EP 105
DI 10.1080/00397919308020407
PG 9
WC Chemistry, Organic
SC Chemistry
GA KJ919
UT WOS:A1993KJ91900014
ER
PT B
AU DICKEY, RW
GRANADE, HR
BENCSATH, FA
AF DICKEY, RW
GRANADE, HR
BENCSATH, FA
BE Smayda, TJ
Shimizu, Y
TI IMPROVED ANALYTICAL METHODOLOGY FOR THE DERIVATIZATION AND
HPLC-FLUOROMETRIC DETERMINATION OF OKADAIC ACID IN PHYTOPLANKTON AND
SHELLFISH
SO TOXIC PHYTOPLANKTON BLOOMS IN THE SEA
SE DEVELOPMENTS IN MARINE BIOLOGY
LA English
DT Proceedings Paper
CT 5TH INTERNATIONAL CONF ON TOXIC MARINE PHYTOPLANKTON
CY OCT 28-NOV 01, 1991
CL UNIV RHODE ISLAND, GRAD SCH OCEANOG, NEWPORT, RI
SP UNESCO, INTERGOVT OCEANOG COMMISS, SCI COMM OCEANIC RES, US EPA, OFF WETLANDS OCEAN & WATERSHEDS, US EPA, GLOBAL CHANGE RES PROGRAM, US EPA, ENVIRONM RES LAB NARRAGANSETT, NOAA, COASTAL OCEAN PROGRAM, NOAA, NATL SEA GRANT COLL PROGRAM, RHODE ISLAND SEA GRANT COLL PROGRAM, UN ENVIRONM PROGRAMME, US FDA
HO UNIV RHODE ISLAND, GRAD SCH OCEANOG
RP DICKEY, RW (reprint author), US FDA,DIV SEAFOOD RES,POB 158,DAUPHIN ISL,AL 36528, USA.
NR 0
TC 19
Z9 21
U1 0
U2 0
PU ELSEVIER SCIENCE PUBL B V
PI AMSTERDAM
PA AMSTERDAM
BN 0-444-89719-4
J9 DEV MAR BIO
PY 1993
VL 3
BP 495
EP 499
PG 5
WC Plant Sciences; Marine & Freshwater Biology; Oceanography; Toxicology
SC Plant Sciences; Marine & Freshwater Biology; Oceanography; Toxicology
GA BY50D
UT WOS:A1993BY50D00079
ER
PT J
AU PARCHMENT, RE
HUANG, M
ERICKSONMILLER, CL
AF PARCHMENT, RE
HUANG, M
ERICKSONMILLER, CL
TI ROLES FOR IN-VITRO MYELOTOXICITY TESTS IN PRECLINICAL DRUG DEVELOPMENT
AND CLINICAL-TRIAL PLANNING
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE CFU-GM; CYTOPENIA; HUMAN; CANINE; CHEMOTHERAPY; PHARMACODYNAMICS;
HEMATOPOIESIS; THERAPEUTIC INDEX
AB Myelosuppression is the dose-limiting side effect for most anti-cancer and many anti-human immunodeficiency virus agents, which can be quantitated with optimized colony-forming assays (granulocyte-macrophage, late erythroid, and megakaryocytic [for murine only] colony-forming units and early erythroid burst-forming units (BFUs)). When applied to new drug development, the assays are used for therapeutic index-based screening (e.g., less myelosuppressive analogues, structure-toxicity studies, new drug leads), interpreting efficacy data from xenotransplant models, and selecting the most accurate animal model for human hematopoietic toxicity. However, other types of assays may be required to identify the mechanism underlying myelosuppression. In clinical trial planning, in vitro colony-forming assays can be used to elucidate schedule dependency of myelotoxicity (which in turn provides clues about mechanism of action), to plan cytokine support, and to estimate dose-escalation effects. The inhibition of colony formation can be measured relative to a compound with known clinical myelotoxicity and schedule dependency to provide some idea of the toxicity expected at particular doses, and the degree of heterogeneity between individuals, during clinical trials. The predictive accuracy of the in vitro data has been proven by validation studies with alkylating agents.
RP PARCHMENT, RE (reprint author), FDA,MOD,ROOM 2023,8301 MUIRKIRK RD,LAUREL,MD 20708, USA.
FU NCI NIH HHS [CM-07361, CM-87259]
NR 0
TC 58
Z9 59
U1 0
U2 0
PU SOC TOXICOLOGIC PATHOLOGISTS
PI LAWRENCE
PA 1041 NEW HAMPSHIRE ST PO BOX 368, LAWRENCE, KS 66044
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PY 1993
VL 21
IS 2
BP 241
EP 250
PG 10
WC Pathology; Toxicology
SC Pathology; Toxicology
GA LR953
UT WOS:A1993LR95300016
PM 8210945
ER
PT J
AU COLLIER, SW
STORM, JE
BRONAUGH, RL
AF COLLIER, SW
STORM, JE
BRONAUGH, RL
TI REDUCTION OF AZO DYES DURING INVITRO PERCUTANEOUS-ABSORPTION
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
ID FD-AND-C; INTESTINAL BACTERIA; METABOLISM; SKIN; LIVER; CARCINOGENESIS;
AZOREDUCTASE; PENETRATION; BENZIDINE; COLORS
RP COLLIER, SW (reprint author), US FDA,DIV TOXICOL STUDIES,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 32
TC 63
Z9 70
U1 1
U2 8
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0041-008X
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JAN
PY 1993
VL 118
IS 1
BP 73
EP 79
DI 10.1006/taap.1993.1011
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KG763
UT WOS:A1993KG76300011
PM 8430426
ER
PT J
AU TESKE, RH
AF TESKE, RH
TI MICROBIOLOGICAL SIGNIFICANCE OF DRUG RESIDUES IN FOOD - WELCOME AND
INTRODUCTION
SO VETERINARY AND HUMAN TOXICOLOGY
LA English
DT Editorial Material
RP TESKE, RH (reprint author), US FDA,CTR VET MED,ROCKVILLE,MD 20857, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU COMPARATIVE TOXICOLOGY LAB KANSAS STATE UNIV
PI MANHATTAN
PA MANHATTAN, KS 66506
SN 0145-6296
J9 VET HUM TOXICOL
JI Vet. Human Toxicol.
PY 1993
VL 35
SU 1
BP 1
EP 2
PG 2
WC Toxicology; Veterinary Sciences
SC Toxicology; Veterinary Sciences
GA LV508
UT WOS:A1993LV50800001
PM 8236749
ER
PT J
AU MILLER, MA
FERNANDEZ, H
AF MILLER, MA
FERNANDEZ, H
TI MICROBIOLOGICAL SIGNIFICANCE OF DRUG RESIDUES IN FOOD - SYMPOSIUM
OBJECTIVES
SO VETERINARY AND HUMAN TOXICOLOGY
LA English
DT Editorial Material
RP MILLER, MA (reprint author), US FDA,CTR VET MED,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU COMPARATIVE TOXICOLOGY LAB KANSAS STATE UNIV
PI MANHATTAN
PA MANHATTAN, KS 66506
SN 0145-6296
J9 VET HUM TOXICOL
JI Vet. Human Toxicol.
PY 1993
VL 35
SU 1
BP 10
EP 11
PG 2
WC Toxicology; Veterinary Sciences
SC Toxicology; Veterinary Sciences
GA LV508
UT WOS:A1993LV50800004
PM 8236751
ER
PT J
AU MILLER, MA
GUSTAFSON, RH
KIDD, ARM
WILKINS, TD
GORBACH, SL
SCHLAES, D
LEVY, S
AF MILLER, MA
GUSTAFSON, RH
KIDD, ARM
WILKINS, TD
GORBACH, SL
SCHLAES, D
LEVY, S
TI IS MICROBIAL TESTING NECESSARY FOR NEW ANIMAL DRUG APPROVAL - DOES A
THRESHOLD OF REGULATION EXIST - PANEL DISCUSSION-I
SO VETERINARY AND HUMAN TOXICOLOGY
LA English
DT Discussion
C1 AMER CYANAMID CO,DIV AGR RES,WAYNE,NJ 07470.
TECH LAB INC,BLACKSBURG,VA 24060.
VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061.
TUFTS UNIV,SCH MED,BOSTON,MA 02111.
DEPT VET AFFAIRS MED CTR,INFECT DIS SECT,CLEVELAND,OH.
RP MILLER, MA (reprint author), US FDA,CTR VET MED,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU COMPARATIVE TOXICOLOGY LAB KANSAS STATE UNIV
PI MANHATTAN
PA MANHATTAN, KS 66506
SN 0145-6296
J9 VET HUM TOXICOL
JI Vet. Human Toxicol.
PY 1993
VL 35
SU 1
BP 28
EP 30
PG 3
WC Toxicology; Veterinary Sciences
SC Toxicology; Veterinary Sciences
GA LV508
UT WOS:A1993LV50800008
ER
PT J
AU ORIANI, JA
AF ORIANI, JA
TI RESIDUE DEPLETION OF MORANTEL TARTRATE IN GOAT TISSUE AND MILK
SO VETERINARY AND HUMAN TOXICOLOGY
LA English
DT Article; Proceedings Paper
CT 6TH WORKSHOP FOR MINOR USE ANIMAL DRUGS : FOCUS ON SMALL RUMINANTS
CY OCT 22-23, 1992
CL BETHESDA, MD
SP US DEPT HHS, CTR VET MED, US DEPT HHS, FOOD & DRUG ADM, USDA, INTERREG PROJECT ANIMAL DRUG PROGRAM
RP ORIANI, JA (reprint author), US FDA,CTR VET MED,DIV CHEM,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU COMPARATIVE TOXICOLOGY LAB KANSAS STATE UNIV
PI MANHATTAN
PA MANHATTAN, KS 66506
SN 0145-6296
J9 VET HUM TOXICOL
JI Vet. Human Toxicol.
PY 1993
VL 35
SU 2
BP 62
EP 63
PG 2
WC Toxicology; Veterinary Sciences
SC Toxicology; Veterinary Sciences
GA LW081
UT WOS:A1993LW08100015
PM 8236770
ER
PT J
AU SUNDLOF, SF
EVANS, R
KIMBERLING, C
SHORT, C
TERRY, M
TESKE, R
AF SUNDLOF, SF
EVANS, R
KIMBERLING, C
SHORT, C
TERRY, M
TESKE, R
TI CURRENT ISSUES AFFECTING DRUG APPROVAL IN SMALL RUMINANTS
SO VETERINARY AND HUMAN TOXICOLOGY
LA English
DT Discussion
C1 UPJOHN CO,KALAMAZOO,MI 49001.
COLORADO STATE UNIV,AMER ASSOC SMALL RUMINANT PRACTITIONERS,FT COLLINS,CO 80523.
LOUISIANA STATE UNIV,BATON ROUGE,LA 70803.
US FDA,CTR VET MED,WASHINGTON,DC 20204.
RP SUNDLOF, SF (reprint author), UNIV FLORIDA,GAINESVILLE,FL 32611, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU COMPARATIVE TOXICOLOGY LAB KANSAS STATE UNIV
PI MANHATTAN
PA MANHATTAN, KS 66506
SN 0145-6296
J9 VET HUM TOXICOL
JI Vet. Human Toxicol.
PY 1993
VL 35
SU 2
BP 64
EP 72
PG 9
WC Toxicology; Veterinary Sciences
SC Toxicology; Veterinary Sciences
GA LW081
UT WOS:A1993LW08100016
ER
PT S
AU FINLAYSON, JS
AF FINLAYSON, JS
BE Brown, F
TI REGULATION OF PLASMA DERIVATIVES IN THE USA
SO VIROLOGICAL SAFETY ASPECTS OF PLASMA DERIVATIVES
SE DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION
LA English
DT Proceedings Paper
CT Symposium on Virological Safety Aspects of Plasma Derivatives
CY NOV 03-06, 1992
CL CANNES, FRANCE
SP INT ASSOC BIOL STAND, WHO, COUNCIL EUROPE, EUROPEAN PHARMACOPOEIA, INT SOC BLOOD TRANSFUS, US FDA, DEPT HLTH & HUMAN SERV
DE HEPATITIS-C; IMMUNE GLOBULINS; PLASMA DERIVATIVES; REGULATION
RP FINLAYSON, JS (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA POSTFACH, CH-4009 BASEL, SWITZERLAND
SN 0301-5149
BN 3-8055-5879-1
J9 DEV BIOL STAND
JI Dev.Biol.Stand.
PY 1993
VL 81
BP 277
EP 281
PG 5
WC Virology
SC Virology
GA BZ72N
UT WOS:A1993BZ72N00039
PM 8174815
ER
PT J
AU REESINK, HW
HANFLAND, P
HERTFELDER, HJ
SCHARF, RE
HOGMAN, CF
HOPPE, PA
MOROFF, G
FRIEDMAN, LI
MASSE, M
WALSH, TJ
ALA, FA
PIETERSZ, RNI
AF REESINK, HW
HANFLAND, P
HERTFELDER, HJ
SCHARF, RE
HOGMAN, CF
HOPPE, PA
MOROFF, G
FRIEDMAN, LI
MASSE, M
WALSH, TJ
ALA, FA
PIETERSZ, RNI
TI WHAT IS THE OPTIMAL STORAGE-TEMPERATURE FOR WHOLE-BLOOD PRIOR TO
PREPARATION OF BLOOD COMPONENTS
SO VOX SANGUINIS
LA English
DT Editorial Material
ID RED-CELLS; INVIVO; SYSTEM; PLASMA
C1 UNIV BONN,INST EXPTL HAMATOL & TRANSFUS MED,D-53127 BONN,GERMANY.
UNIV HOSP UPPSALA,DEPT CLIN IMMUNOL & TRANSFUS MED,S-75185 UPPSALA,SWEDEN.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855.
CRTS BESANCON,F-25020 BESANCON,FRANCE.
BLOOD TRANSFUS SERV BOARD,DUBLIN 4,IRELAND.
RBTC W MIDLANDS,BTS,BIRMINGHAM B15 2SG,ENGLAND.
RP REESINK, HW (reprint author), RED CROSS BLOOD BANK,POB 9137,1006 AC AMSTERDAM,NETHERLANDS.
NR 31
TC 16
Z9 16
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1993
VL 65
IS 4
BP 320
EP 327
PG 8
WC Hematology
SC Hematology
GA MJ657
UT WOS:A1993MJ65700012
PM 8310685
ER
PT J
AU BURNS, DL
KESSEL, M
ARCINIEGA, JL
KARPAS, A
GOULDKOSTKA, J
AF BURNS, DL
KESSEL, M
ARCINIEGA, JL
KARPAS, A
GOULDKOSTKA, J
TI IMMUNOCHEMICAL LOCALIZATION OF A REGION OF CHAPERONIN-60 IMPORTANT FOR
PRODUCTIVE INTERACTION WITH CHAPERONIN-10
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Note
ID RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; PROTEIN; GROE;
PURIFICATION; ATP
AB An IgG, monoclonal antibody (mAb 54G8) which binds to both Bordetella pertussis chaperonin-60 (cpn60) and Escherichia coli cpn60 (GroEL) was produced. mAb 54G8 as well as Fab fragments prepared from this antibody were found to abolish the ability of chaperonin-10 (cpn10, GroES) to inhibit the ATPase activity of both B. pertussis cpn60 and E. coli cpn60. Electron microscopy was used to localize the binding site of the monoclonal antibody on the B. pertussis cpn60 molecule. In the absence of the antibody, the B. pertussis molecule exhibited the tetradecameric structure typical of cpn60. Both end views (showing 7-fold symmetry of the face of the molecule) and side views were evident. When mAb 54G8 was bound, B. pertussis cpn60 molecules appeared to be cross-linked so that they formed long chains. Only side views of the molecules were seen in these long chains. When B. pertussis cpn60 complexed with Fab fragments of mAb 54G8 was examined, chains were no longer observed. Instead, side views of B. pertussis cpn60 were often seen with Fab fragments extending from the ends of the molecule. These data indicate that mAb 54G8 appears to bind at or near the end of the B. pertussis cpn60 molecule and that binding of mAb 54G8 at this location affects the ability of cpn10 to productively interact with cpn60, most likely either by sterically blocking the binding of cpn10, by affecting the conformation of cpn60 in such a way that it no longer binds cpn10, or by inhibiting proper transduction of the effects of cpn10 binding.
C1 UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742.
RP BURNS, DL (reprint author), US FDA,DIV BACTERIAL PROD,CBER,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 21
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 25
PY 1992
VL 267
IS 36
BP 25632
EP 25635
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KD073
UT WOS:A1992KD07300004
PM 1361184
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW ANTIARRHYTHMIC APPROVED
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Note
RP NIGHTINGALE, SL (reprint author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 23
PY 1992
VL 268
IS 24
BP 3418
EP 3418
DI 10.1001/jama.268.24.3418
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KC839
UT WOS:A1992KC83900008
PM 1460725
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI CONTRACEPTIVE INJECTION APPROVED
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Note
RP NIGHTINGALE, SL (reprint author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 23
PY 1992
VL 268
IS 24
BP 3418
EP 3418
DI 10.1001/jama.268.24.3418
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KC839
UT WOS:A1992KC83900007
PM 1460725
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI PRESCRIPTION DRUG-USER FEE STATUTE ENACTED
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Note
RP NIGHTINGALE, SL (reprint author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 23
PY 1992
VL 268
IS 24
BP 3418
EP 3418
DI 10.1001/jama.268.24.3418
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KC839
UT WOS:A1992KC83900006
PM 1460725
ER
PT J
AU SHARKNESS, CM
HAMBURGER, S
KACZMAREK, RG
HAMILTON, PM
BRIGHT, RA
MOORE, RM
AF SHARKNESS, CM
HAMBURGER, S
KACZMAREK, RG
HAMILTON, PM
BRIGHT, RA
MOORE, RM
TI RACIAL-DIFFERENCES IN THE PREVALENCE OF INTRAOCULAR-LENS IMPLANTS IN THE
UNITED-STATES
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; CATARACT-SURGERY; BLINDNESS; BALTIMORE; EYE
AB We generated population-based estimates of the prevalence of intraocular lens implants by using the 1988 Medical Device Implant Supplement to the National Health Interview Survey. This national survey of a probability sample of the civilian noninstitutionalized United States population comprised 47,485 households and 122,310 persons. To produce national projections, we used survey respondent-reported data based on 1,941 reported intraocular lenses in 1,337 persons.
Projected to the United States population, an estimated 2.6 million people had a total of 3.8 million lens implants. The predominant reason for the implant was cataract. The intraocular lens replacement rate was 0.9%. The use of intraocular lens implants was statistically significantly different from the general population in persons with the following socioeconomic characteristics: age (65 years or older), race (white), gender (female), annual family income (less than $20,000, although more commonly at or above the poverty threshold), and education (less than high school). The prevalence rates per 1,000 persons according to age were as follows: 0.3 for persons 44 years old or younger, 9.9 for persons 45 to 64 years old, 33.3 for persons aged 65 to 69 years, 63.5 for persons aged 70 to 74 years, and 113.5 for persons 75 years old or older. Additionally, prevalence rates according to socioeconomic factors were as follows: 12.1 for whites and 3.3 for nonwhites, 12.9 for females and 8.4 for males, 18.2 for persons with a family income less than $20,000 and 6.7 for persons with a family income of $20,000 or more, 10.5 for persons above the poverty threshold and 8.0 for persons below the poverty threshold, and 13.2 for persons with less than 12 years of education and 10.7 for persons with at least 12 years of education. The racial difference remained after controlling for the effects of age. The underuse of intraocular lenses among nonwhites warrants further investigation, given the improvement in vision that results from cataract extraction with implantation of an intraocular lens.
C1 US FDA,CTR DEVICES & RADIOL HLTH,5600 FISHERS LN,HFZ-161,ROCKVILLE,MD 20857.
OFF INT HLTH,OFF ASSISTANT SECRETARY HLTH,ROCKVILLE,MD.
RI Bright, Roselie/D-2240-2016
NR 13
TC 7
Z9 7
U1 0
U2 1
PU OPHTHALMIC PUBL CO
PI CHICAGO
PA 77 WEST WACKER DR, STE 660, CHICAGO, IL 60601
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC 15
PY 1992
VL 114
IS 6
BP 667
EP 678
PG 12
WC Ophthalmology
SC Ophthalmology
GA KB605
UT WOS:A1992KB60500001
PM 1463035
ER
PT J
AU KANTOR, J
IRVINE, K
ABRAMS, S
SNOY, P
OLSEN, R
GREINER, J
KAUFMAN, H
EGGENSPERGER, D
SCHLOM, J
AF KANTOR, J
IRVINE, K
ABRAMS, S
SNOY, P
OLSEN, R
GREINER, J
KAUFMAN, H
EGGENSPERGER, D
SCHLOM, J
TI IMMUNOGENICITY AND SAFETY OF A RECOMBINANT VACCINIA VIRUS-VACCINE
EXPRESSING THE CARCINOEMBRYONIC ANTIGEN GENE IN A NONHUMAN PRIMATE
SO CANCER RESEARCH
LA English
DT Article
ID ACTIVE-SPECIFIC IMMUNOTHERAPY; COLORECTAL-CANCER; IMMUNE-COMPLEXES;
TUMOR-CELLS; CEA; MELANOMA; CARCINOMA; ADJUVANT; ANTIBODIES; PRODUCT
AB We have previously reported the development of a recombinant vaccinia virus vaccine expressing the human carcinoembryonic antigen (CEA) gene, designated rV(NYC)-CEA. This construct has been shown to elicit specific anti-CEA immune responses and an antitumor effect in a murine tumor model. In the studies reported here, the safety and immunogenicity of this recombinant vaccinia virus were evaluated in a rhesus monkey model.
Human CEA is a M(r) 180,000 glycoprotein expressed in approximately 90% of gastrointestinal carcinomas and in some breast and non-small cell lung carcinomas. This family also includes normal cross-reacting antigen (NCA). Rhesus monkeys, like humans, have some NCA on the surface of their granulocytes. Eight monkeys were immunized 3 or 4 times by skin scarification with the recombinant CEA vaccine and four monkeys received wild-type vaccinia virus as control.
After three vaccinations, all rV(NYC)-CEA-vaccinated animals exhibited a strong anti-CEA antibody response as measured by enzyme-linked immunosorbent assay. The functional ability of these antibodies to mediate lysis of a CEA-bearing tumor cell was demonstrated using human effector cells. This response could be enhanced by interleukin 2. Cellular immunity to CEA was measured by delayed-type hypersensitivity upon intradermal challenge with purified CEA. Only those animals receiving the recombinant vaccine displayed significant anti-CEA responses. Furthermore, peripheral blood mononuclear cells from immunized monkeys were found to proliferate in response to CEA stimulation. All vaccinated monkeys developed local skin irritation at the site of the vaccination, regional lymphadenopathy, and low-grade fevers after immunization. Following immunization with rV(NYC)-CEA, the response was consistent with the usual constitutional symptoms seen with human smallpox virus immunization. Blood counts, differentials, and hepatic and renal chemistries remained normal in all animals throughout the study and for up to 1 year following the primary vaccination. No evidence of immunological cross-reactivity to NCA was found by either a fall in the granulocyte count or analyses for anti-NCA antibodies. Thus, the rV(NYC)-CEA vaccine appears to be safe in rhesus monkeys. The administration of a CEA recombinant vaccine to rhesus monkeys induces both a humoral and a cell-mediated immune response directed against human CEA.
C1 NCI,TUMOR IMMUNOL & BIOL LAB,BLDG 10,ROOM 8B07,9000 ROCKVILLE PIKE,BETHESDA,MD 20892.
US FDA,BUR BIOL,BETHESDA,MD 20014.
NR 35
TC 87
Z9 87
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
PHILADELPHIA, PA 19106
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 1992
VL 52
IS 24
BP 6917
EP 6925
PG 9
WC Oncology
SC Oncology
GA KB979
UT WOS:A1992KB97900029
PM 1458480
ER
PT J
AU VANSEVENTER, GA
BONVINI, E
YAMADA, H
CONTI, A
STRINGFELLOW, S
JUNE, CH
SHAW, S
AF VANSEVENTER, GA
BONVINI, E
YAMADA, H
CONTI, A
STRINGFELLOW, S
JUNE, CH
SHAW, S
TI COSTIMULATION OF T-CELL RECEPTOR CD3-MEDIATED ACTIVATION OF RESTING
HUMAN CD4+ T-CELLS BY LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 LIGAND
INTERCELLULAR CELL-ADHESION MOLECULE-1 INVOLVES PROLONGED INOSITOL
PHOSPHOLIPID HYDROLYSIS AND SUSTAINED INCREASE OF INTRACELLULAR CA2+
LEVELS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY;
MEDIATED ACTIVATION; CYTOPLASMIC DOMAIN; GROWTH-FACTOR; BETA-SUBUNIT;
B-CELLS; ICAM-1; LFA-1
AB Activation of resting human CD4+ T cells mediated by mAb ligation of the TCR/CD3 complex requires costimulatory signals to result in proliferation; these can be provided by intercellular cell adhesion molecule-1 (ICAM-1, CD54) a natural ligand of leukocyte function-associated Ag-1 (LFA-1, CD11a/CD18). We analyzed early signaling events involved in T cell activation to determine the contribution by the LFA-1/ICAM-1 interaction. We studied in detail the hydrolysis of phosphatidylinositol(4,5)bisphosphate and intracellular levels of free Ca2+ during stimulation with beads coated with the CD3 mAb OKT3 alone or in combination with purified ICAM-1 protein. Our investigations show no response to LFA-1/ICAM-1 alone, but that costimulation by LFA-1/ICAM-1 interaction induces prolonged inositol phospholipid hydrolysis (up to 4 h), resulting in generation of both inositol(1,4,5)phosphate3 and inositol(1,3,4,5)phosphate4 and their derivatives. Based on studies with cycloheximide, this costimulatory effect of prolonged inositol phospholipid hydrolysis appears dependent in part on de novo protein synthesis. A sustained increase in intracellular levels of free Ca2+ level is also observed after LFA-1/ICAM-1 costimulation, which is at least partly dependent on extracellular sources of Ca2+. Kinetic studies indicate that costimulation requires a minimal period of 4 h of LFA-1/ICAM-1 interaction to provide maximal costimulation for OKT3-mediated T cell proliferation. Thus, the necessary costimulation required for OKT3-mediated proliferation in this model system may be provided by an extended LFA-1/ICAM-1 interaction that in combination with OKT3 mAb leads to signal-transducing events, resulting in prolonged phospholipase C activation and phosphatidylinositol(4,5)bisphosphate hydrolysis, and a sustained increase in intracellular levels of free Ca2+.
C1 NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892.
USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20814.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892.
NR 53
TC 114
Z9 114
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 1992
VL 149
IS 12
BP 3872
EP 3880
PG 9
WC Immunology
SC Immunology
GA KB982
UT WOS:A1992KB98200014
PM 1360995
ER
PT J
AU WILSON, KC
FINBLOOM, DS
AF WILSON, KC
FINBLOOM, DS
TI INTERFERON-GAMMA RAPIDLY INDUCES IN HUMAN MONOCYTES A DNA-BINDING FACTOR
THAT RECOGNIZES THE GAMMA-RESPONSE REGION WITHIN THE PROMOTER OF THE
GENE FOR THE HIGH-AFFINITY FC-GAMMA RECEPTOR
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID PROTEIN-KINASE-C; HUMAN IFN-GAMMA; PHENYLARSINE OXIDE; 3T3-L1
ADIPOCYTES; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION;
CYTO-TOXICITY; EXPRESSION; IMMUNOGLOBULIN; ALPHA
AB Interferon gamma (IFN-gamma) transcriptionally activates several early-response genes in monocytes that are important for the ultimate phenotype of the activated macrophage. One of these genes is the high-affinity Fc receptor for IgG (FcgammaRI). Recently, Pearse et al. [Pearse, R. N., Feinman, R. & Ravetch, J. V. (1991) Proc. Natl. Acad. Sci. USA 88, 11305-11309] defined within the promoter region of the FcgammaRI gene an element, the gamma response region, which was necessary for IFN-gamma-induced enhancement of FcgammaRI. In this report we describe the induction by IFN-gamma of a DNA-binding factor, FcRFgamma (FcgammaRI DNA-binding factor, IFN-gamma induced), that specifically recognizes the gamma response region element. Electrophoretic mobility shift assays (EMSAs) demonstrated the presence of FcRFgamma in human monocytes within 1 min after exposure to IFN-gamma. On EMSA, FcRFgamma consisted of two complexes termed FcRFy1 and FcRFgamma2. The nuclear concentration of FcRFgamma rapidly increased, peaked at 15 min, and then fell after 1-2 hr. Dose-response studies revealed (i) as little as 0.05 ng of IFN-gamma per ml induced FcRFgamma, (ii) maximum activation occurred at 1 ng/ml, and (iii) steady-state levels of FcgammaRI mRNA closely paralleled that of FcRF-gamma. Since FcRFgamma was activated in cells normally not expressing FcgammaRI RNA, other regulatory mechanisms must control FcgammaRI-restricted tissue expression. Activation of FcRFgamma by IFN-gamma was inhibited by pretreatment with 500 nM staurosporin and 25 muM phenyl arsine oxide. These data suggest that a kinase and possibly a phosphatase activity are required for IFN-gamma-induced signaling of FcRFgamma in monocytes.
C1 US FDA,CTR BIOLOG RES & EVALUAT,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20014.
RP FINBLOOM, DS (reprint author), US FDA,CTR BIOLOG RES & EVALUAT,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20014, USA.
NR 41
TC 111
Z9 111
U1 0
U2 0
PU NATL ACAD PRESS
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 15
PY 1992
VL 89
IS 24
BP 11964
EP 11968
DI 10.1073/pnas.89.24.11964
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KC844
UT WOS:A1992KC84400067
PM 1334553
ER
PT J
AU KRIEG, AM
GOURLEY, MF
KLINMAN, DM
PERL, A
STEINBERG, AD
AF KRIEG, AM
GOURLEY, MF
KLINMAN, DM
PERL, A
STEINBERG, AD
TI HETEROGENEOUS EXPRESSION AND COORDINATE REGULATION OF ENDOGENOUS
RETROVIRAL SEQUENCES IN HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID MAMMARY-TUMOR VIRUS; SYSTEMIC LUPUS-ERYTHEMATOSUS; HUMAN DNA; T-CELLS;
SJOGRENS-SYNDROME; MESSENGER-RNAS; MICE; ANTIBODIES; PROTEINS; ELEMENTS
AB This study examines the expression of human endogenous retroviral or retroviral-like (ERV) sequences in peripheral blood mononuclear cells (PBMC). Probes to 12 human ERV were used in Northern analyses of 38 patients with autoimmune muscle diseases and 31 blood donor controls. All patients and controls expressed multiple classes of ERV RNA. This expression was quite heterogenous: for each of the nine ERV classes for which expression was detected, some individuals showed high RNA levels whereas others showed low levels. ERV expression was independent of disease and autoantibody production. Statistical analysis of densitometric data indicated that expression of several classes of ERV was coordinately regulated. ERV expression in individual patients showed coordinate fluctuations with time. These studies demonstrate the heterogeneity and coordinate regulation of human ERV expression. To evaluate whether ERV expression might be affected by lymphocyte activation, PBMC were cultured with or without lymphocyte mitogens before RNA extraction. These studies demonstrated complex changes in ERV expression after lymphocyte activation. Murine ERV have several immunoregulatory activities. If human ERV have analogous effects, their heterogeneous expression and association with lymphocyte activation may have important biologic consequences.
C1 NIAMSD,CELLULAR IMMUNOL SECT,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,BETHESDA,MD 20892.
NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC MED & IMMUNOL,BUFFALO,NY 14263.
RP KRIEG, AM (reprint author), UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.
OI Perl, Andras/0000-0002-5017-1348
NR 54
TC 37
Z9 37
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 1992
VL 8
IS 12
BP 1991
EP 1998
DI 10.1089/aid.1992.8.1991
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA KF475
UT WOS:A1992KF47500007
PM 1493049
ER
PT J
AU RHEINSTEIN, PH
AF RHEINSTEIN, PH
TI HEALTHY PEOPLE 2000 INITIATIVE
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
RP RHEINSTEIN, PH (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD DEC
PY 1992
VL 46
IS 6
BP 1829
EP 1832
PG 4
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA KC180
UT WOS:A1992KC18000017
PM 1456200
ER
PT J
AU WILLIAMS, RA
AF WILLIAMS, RA
TI CONSUMER RESPONSE TO CHANGES IN FOOD LABELING - DISCUSSION
SO AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS
LA English
DT Discussion
RP WILLIAMS, RA (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER AGRICULTURAL ECONOMICS ASSOC
PI AMES
PA 1110 BUCKEYE AVE, AMES, IA 50010-8063
SN 0002-9092
J9 AM J AGR ECON
JI Am. J. Agr. Econ.
PD DEC
PY 1992
VL 74
IS 5
BP 1213
EP 1214
DI 10.2307/1242788
PG 2
WC Agricultural Economics & Policy; Economics
SC Agriculture; Business & Economics
GA KJ100
UT WOS:A1992KJ10000030
ER
PT J
AU OLDER, SA
FINBLOOM, DS
PEZESHKPOUR, GH
AF OLDER, SA
FINBLOOM, DS
PEZESHKPOUR, GH
TI COLCHICINE MYONEUROPATHY AND RENAL DYSFUNCTION
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Letter
ID MICROTUBULES; NEUROPATHY; TOXICITY; MYOPATHY
C1 US FDA,DIV CYTOKINE BIOL,BETHESDA,MD 20014.
ARMED FORCES INST PATHOL,NEUROMUSCULAR SECT,WASHINGTON,DC 20306.
RP OLDER, SA (reprint author), BROOKE ARMY MED CTR,DEPT MED,RHEUMATOL SERV,FT SAM HOUSTON,TX 78234, USA.
NR 10
TC 4
Z9 4
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD DEC
PY 1992
VL 51
IS 12
BP 1343
EP 1344
DI 10.1136/ard.51.12.1343
PG 2
WC Rheumatology
SC Rheumatology
GA KC226
UT WOS:A1992KC22600017
PM 1485821
ER
PT J
AU ANDERSEN, MR
OMIECINSKI, CJ
AF ANDERSEN, MR
OMIECINSKI, CJ
TI DIRECT EXTRACTION OF BACTERIAL PLASMIDS FROM FOOD FOR POLYMERASE
CHAIN-REACTION AMPLIFICATION
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Note
ID ESCHERICHIA-COLI; SHIGELLA-FLEXNERI; OUTBREAK; CHEESE
AB In this report we describe a simple and rapid technique using DNA affinity columns that permits direct extraction of bacterial plasmids from a variety of foods for polymerase chain reaction amplification. The procedure was used to detect virulent enteroinvasive Escherichia coli in several artificially seeded matrices, including seafoods, greens, dairy products, enrichment media, and water. Polymerase inhibitors present in both foods and enrichment media were removed efficiently.
C1 UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195.
RP ANDERSEN, MR (reprint author), US FDA,SEATTLE DIST OFF,22201 23RD DR SE,POB 3012,BOTHELL,WA 98041, USA.
FU NIEHS NIH HHS [P42 ES004696]
NR 13
TC 16
Z9 16
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD DEC
PY 1992
VL 58
IS 12
BP 4080
EP 4082
PG 3
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA KA901
UT WOS:A1992KA90100052
PM 1476448
ER
PT J
AU LYNG, J
BENTZON, MW
FERGUSON, M
FITZGERALD, EA
AF LYNG, J
BENTZON, MW
FERGUSON, M
FITZGERALD, EA
TI RABIES VACCINE STANDARDIZATION - INTERNATIONAL COLLABORATIVE STUDY FOR
THE CHARACTERIZATION OF THE 5TH INTERNATIONAL STANDARD FOR RABIES
VACCINE
SO BIOLOGICALS
LA English
DT Article
ID SINGLE-RADIAL-IMMUNODIFFUSION; VIRUS GLYCOPROTEIN; MONOCLONAL-ANTIBODY;
ENZYME-IMMUNOASSAY; POTENCY; ASSAY; RIBONUCLEOPROTEIN; INDUCTION;
ANTIGEN
C1 STATE SERUM INST,DEPT BIOSTAT,DK-2300 COPENHAGEN S,DENMARK.
NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,ENGLAND.
CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
RP LYNG, J (reprint author), STATE SERUM INST,INT LAB BIOL STAND,DK-2300 COPENHAGEN S,DENMARK.
NR 26
TC 17
Z9 17
U1 0
U2 0
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 1045-1056
J9 BIOLOGICALS
JI Biologicals
PD DEC
PY 1992
VL 20
IS 4
BP 301
EP 313
DI 10.1016/S1045-1056(05)80051-X
PG 13
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Pharmacology & Pharmacy
GA LA029
UT WOS:A1992LA02900009
PM 1305406
ER
PT J
AU HASS, BS
HART, RW
GAYLOR, DW
POIRIER, LA
LYNCOOK, BD
AF HASS, BS
HART, RW
GAYLOR, DW
POIRIER, LA
LYNCOOK, BD
TI AN INVITRO PANCREAS ACINAR CELL MODEL FOR TESTING THE MODULATING EFFECTS
OF CALORIC RESTRICTION AND AGING ON CELLULAR PROLIFERATION AND
TRANSFORMATION
SO CARCINOGENESIS
LA English
DT Article
ID DIETARY RESTRICTION; MALIGNANT TRANSFORMATION; CANCER STATISTICS;
FISCHER-344 RAT; DNA-REPAIR; MICE; CARCINOGENESIS; GROWTH; CARCINOMA;
RETARDATION
AB Pancreatic acinar cells were isolated for culture from a young (Y) and an old (O) Brown-Norway or Fischer 344 rat fed an ad libitum (AL) or calorically restricted (CR) diet. The cells were cultured and cellular growth rates were determined as a function of passage number. An overall increase in cellular growth rate and transformation frequency with age and/or AL diet relative to youth as well as a decrease with CR diet were concordant with reported responses in vivo. Transformation frequency was measured in Brown-Norway cells and followed the same pattern as the growth response: AL/O > AL/Y = CR/Y > CR/O. The cellular model is shown to fit the general multistage requirements of the carcinogenic process as well as general age and diet characteristics of pancreatic cancer. This pancreatic acinar cell age-diet approach may prove to be a valuable tool for determining mechanisms of exocrine pancreatic carcinogenesis as well as other disease states; it may also be of utility in in vitro gerontological nutritional and pharmacological studies since some of the age and diet determinants of biological effects appear to be segregable. Propensity of cells from an old and/or AL diet animal for faster growth and for cellular transformation are programmed into the cells by the time of their excision from the animal (as late as 14 months), indicating a heritable component in the model or a mechanism that is dependent upon elements that control gene expression.
C1 US FDA,DEPT HLTH & HUMAN SERV,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP HASS, BS (reprint author), US FDA,DEPT HLTH & HUMAN SERV,NATL CTR TOXICOL RES,DIV NUTR TOXICOL,JEFFERSON,AR 72079, USA.
NR 76
TC 8
Z9 8
U1 0
U2 2
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD DEC
PY 1992
VL 13
IS 12
BP 2419
EP 2425
DI 10.1093/carcin/13.12.2419
PG 7
WC Oncology
SC Oncology
GA KD322
UT WOS:A1992KD32200036
PM 1473253
ER
PT J
AU JAMES, SJ
CROSS, DR
MILLER, BJ
AF JAMES, SJ
CROSS, DR
MILLER, BJ
TI ALTERATIONS IN NUCLEOTIDE POOLS IN RATS FED DIETS DEFICIENT IN CHOLINE,
METHIONINE AND OR FOLIC-ACID
SO CARCINOGENESIS
LA English
DT Note
ID FRAGILE SITE EXPRESSION; METHYL-GROUP DEFICIENCY; DNA STRAND BREAKS;
MAMMALIAN-CELLS; CYTO-TOXICITY; FOLATE; METHOTREXATE; LYMPHOCYTES;
METABOLISM; ACCUMULATION
AB The fidelity of DNA synthesis is critically dependent on the correct balance and availability of the deoxynucleoside triphosphate (dNTP) percursors for the polymerases involved in replication and repair. Since folate-derived one-carbon groups are essential for the de novo synthesis of both purines and pyrimidines, the purpose of the present investigation was to determine whether diet-induced depletion of folates would alter intracellular dNTP pools. Fischer 344 rats were fed one of four semi-purified diets for a period of 8 weeks: (i) supplemented control; (ii) deficient in folic acid; (iii) deficient in methionine and choline; and (iv) deficient in methionine, choline and folic acid. In contrast to natural diets, semi-purified diets are nucleotide-free and consequently lack substrates for salvage pathway synthesis. This omission may place unusual stress on folate-dependent de novo nucleotide synthesis especially under conditions of dietary methyl-donor deficiency. Reversed-phase HPLC analysis of dNTP in spleen cell extracts indicated that both the thymidylate monophosphate and thymidylate triphosphate pools were decreased in spleen cells from the deficient rats consistent with a decrease in folate-dependent de novo synthesis. In addition, purine biosynthesis appeared to be negatively affect by methyl-donor deficiency as evidenced by a reduction in dGTP and dATP pools. These data indicate that deoxynucleotide pool imbalance, well known to produce cytogenetic and mutagenic events in vitro, can also be induced in this in vivo model of diet-induced carcinogenesis.
RP JAMES, SJ (reprint author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 35
TC 66
Z9 67
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD DEC
PY 1992
VL 13
IS 12
BP 2471
EP 2474
DI 10.1093/carcin/13.12.2471
PG 4
WC Oncology
SC Oncology
GA KD322
UT WOS:A1992KD32200045
PM 1473260
ER
PT J
AU LEPORE, PD
AF LEPORE, PD
TI FDAS GOOD LABORATORY PRACTICE REGULATIONS AND COMPUTERIZED DATA
ACQUISITION-SYSTEMS
SO CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS
LA English
DT Article; Proceedings Paper
CT 6TH INTERNATIONAL LABORATORY INFORMATION MANAGEMENT SYSTEMS ( LIMS )
CONF
CY JUN 08-11, 1992
CL PITTSBURGH, PA
AB The Food and Drug Administration's good laboratory practice regulations apply to computerized systems that are used to collect and process data deriving from a non-clinical laboratory study. Such systems are considered to be 'equipment' and are regulated similarly to other equipment used in a laboratory. In this regard, computerized systems are to be of appropriate design and adequate capacity to accomplish protocol directions, and their fitness for use in a study is to be documented. Written, approved standard operating procedures are to cover system testing, calibration, standardization, inspection, and maintenance, and a historical file is to contain a listing of versions and dates of implementation. The system is to accommodate the identification of each individual responsible for direct data entry at the time of entry. Data entries may be changed but an audit trail must preserve the original entry and identify the person making the change, list the date of the change, and provide a reason for the change. In view of the forgoing, FDA's inspections of computerized systems are designed to determine whether the systems operated properly in the past, whether they are currently operating properly, and whether they will continue to operate properly in the future. A satisfactory outcome can best be achieved through the development, installation, use, and maintenance of systems comporting with high quality standards.
RP LEPORE, PD (reprint author), US FDA,OFF REGULATORY AFFAIRS,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 1
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-7439
J9 CHEMOMETR INTELL LAB
JI Chemometrics Intell. Lab. Syst.
PD DEC
PY 1992
VL 17
IS 3
BP 283
EP 287
PG 5
WC Automation & Control Systems; Chemistry, Analytical; Computer Science,
Artificial Intelligence; Instruments & Instrumentation; Mathematics,
Interdisciplinary Applications; Statistics & Probability
SC Automation & Control Systems; Chemistry; Computer Science; Instruments &
Instrumentation; Mathematics
GA KF855
UT WOS:A1992KF85500004
ER
PT J
AU ARROWSMITHLOWE, J
MURPHY, MD
AF ARROWSMITHLOWE, J
MURPHY, MD
TI FDA GUIDANCE FOR HIV TRIALS IN PEDIATRIC POPULATIONS
SO CLINICAL RESEARCH
LA English
DT Meeting Abstract
C1 US FDA,CTR DRUG EVALUAT & RES,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086
SN 0009-9279
J9 CLIN RES
JI Clin. Res.
PD DEC
PY 1992
VL 40
IS 4
BP A865
EP A865
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KE141
UT WOS:A1992KE14100504
ER
PT J
AU RHODEHAMEL, EJ
AF RHODEHAMEL, EJ
TI FDA CONCERNS WITH SOUS VIDE PROCESSING
SO FOOD TECHNOLOGY
LA English
DT Article
ID LIFE REFRIGERATED FOODS; APPLYING HACCP
RP RHODEHAMEL, EJ (reprint author), US FDA,DIV MICROBIOL,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 30
TC 51
Z9 54
U1 0
U2 10
PU INST FOOD TECHNOLOGISTS
PI CHICAGO
PA SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291
SN 0015-6639
J9 FOOD TECHNOL-CHICAGO
JI Food Technol.
PD DEC
PY 1992
VL 46
IS 12
BP 73
EP 76
PG 4
WC Food Science & Technology
SC Food Science & Technology
GA KD259
UT WOS:A1992KD25900010
ER
PT J
AU MCCARTHY, SA
AF MCCARTHY, SA
TI ATTACHMENT OF LISTERIA-MONOCYTOGENES TO CHITIN AND RESISTANCE TO
BIOCIDES
SO FOOD TECHNOLOGY
LA English
DT Article
ID INACTIVATION; SANITIZERS; SHRIMP; HEAT
RP MCCARTHY, SA (reprint author), US FDA,DIV SEAFOOD RES,POB 158,DAUPHIN ISL,AL 36528, USA.
NR 16
TC 10
Z9 13
U1 0
U2 0
PU INST FOOD TECHNOLOGISTS
PI CHICAGO
PA SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291
SN 0015-6639
J9 FOOD TECHNOL-CHICAGO
JI Food Technol.
PD DEC
PY 1992
VL 46
IS 12
BP 84
EP 87
PG 4
WC Food Science & Technology
SC Food Science & Technology
GA KD259
UT WOS:A1992KD25900012
ER
PT J
AU LOPEZ, H
LOEW, MH
GOODENOUGH, DJ
AF LOPEZ, H
LOEW, MH
GOODENOUGH, DJ
TI OBJECTIVE ANALYSIS OF ULTRASOUND IMAGES BY USE OF A COMPUTATIONAL
OBSERVER
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
ID CONTRAST-DETAIL ANALYSIS; DISCRIMINATION; ROC; PERFORMANCE
AB We present a computer-based Computational Observer method for the analysis and evaluation of digitized ultrasound images of the Contrast-Detail phantom, which was developed earlier. This evaluation method evolved from image evaluation studies, which demonstrated that human observer performance is, not sufficiently consistent or accurate for objective evaluation of images or imaging SyStems. The Computational Observer measures the detection threshold for imaged targets of known contrast, and computes Contrast-Detail data from this information. We compare the results of Computational Observer image evaluations to those of human observers for the same set of digitized ultrasound images, and for similar tasks. We find that our new method meets the criteria of being objective, accurate, reproducible, transportable, and relevant to human observer image evaluations.
C1 GEORGE WASHINGTON UNIV,DEPT ELECT ENGN & COMP SCI,WASHINGTON,DC 20052.
GEORGE WASHINGTON UNIV,MED CTR,DEPT RADIOL,WASHINGTON,DC 20052.
RP LOPEZ, H (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857, USA.
NR 31
TC 17
Z9 17
U1 0
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017-2394
SN 0278-0062
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD DEC
PY 1992
VL 11
IS 4
BP 496
EP 506
DI 10.1109/42.192685
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
Biomedical; Engineering, Electrical & Electronic; Imaging Science &
Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
SC Computer Science; Engineering; Imaging Science & Photographic
Technology; Radiology, Nuclear Medicine & Medical Imaging
GA KK635
UT WOS:A1992KK63500005
PM 18222891
ER
PT J
AU HOFFMAN, T
TRIPATHI, AK
LEE, YL
LIZZIO, EF
BONVINI, E
AF HOFFMAN, T
TRIPATHI, AK
LEE, YL
LIZZIO, EF
BONVINI, E
TI STIMULATION OF HUMAN MONOCYTES BY ANTI-CD3 MONOCLONAL-ANTIBODY -
INDUCTION OF INFLAMMATORY MEDIATOR RELEASE VIA IMMOBILIZATION OF FC
RECEPTOR BY ADSORBED IMMUNOGLOBULIN AND LYMPHOCYTES-T
SO INFLAMMATION
LA English
DT Article
ID CELL ACTIVATION; CROSS-LINKING; GAMMA-RI; OKT3; MODULATION; METABOLISM;
SECRETION; TRIGGERS; ANTIGENS; INVITRO
AB Human monocytes released superoxide anion, prostaglandin E2, leukotriene B4, IL-1, and TNF when exposed to plastic surfaces coated with murine anti-CD3 monoclonal antibody, OKT 3. Stimulation of mediator release by OKT 3 was dependent on the amount of antibody immobilized onto wells of plastic tissue culture plates. Soluble antibody or antibody adsorbed to monocytes and reacted with an aggregating ("cross-linking") second antibody failed to induce mediator release. Monocytes "armed" with OKT 3 formed rosettes with T cells in a fashion indistinguishable from that seen between monocytes and T cells sensitized with OKT 3. Monocytes with adsorbed OKT 3 antibodies released IL-1beta and TNF-alpha when exposed to unsensitized T cells, although increased superoxide release could not be detected. OKT 4a, a murine IgG2a antibody that reacts with a different T cell epitope (CD4), failed to induce cytokine release from monocytes when cross-linked by T cells or a CD4 + T cell line, even in the presence of IL-2 or IFN-gamma. These data indicate that certain antibodies bound to Fc receptors (FcR) of monocytes may trigger monocyte function when reacting with cells bearing the appropriate target antigens. FcR-mediated signaling resulting in mediator release may be involved in initiating or regulating the immune response. Furthermore, systemically administered monoclonal antibodies may induce inflammatory responses and their attendant symptomatologies via their interaction with FcR-bearing inflammatory cells.
RP HOFFMAN, T (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,CELL BIOL LAB,BETHESDA,MD 20892, USA.
NR 27
TC 4
Z9 4
U1 0
U2 0
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0360-3997
J9 INFLAMMATION
JI Inflammation
PD DEC
PY 1992
VL 16
IS 6
BP 571
EP 585
DI 10.1007/BF00919341
PG 15
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA JV590
UT WOS:A1992JV59000001
PM 1334047
ER
PT J
AU FINNEGAN, A
REGAN, J
SEAMON, KB
LINDHOLM, C
AF FINNEGAN, A
REGAN, J
SEAMON, KB
LINDHOLM, C
TI IDENTIFICATION OF SINGLE AMINO-ACID SUBSTITUTIONS IN THE STAPHYLOCOCCAL
NUCLEASE PROTEIN THAT ENHANCE AND DIMINISH T-CELL CLONE RECOGNITION OF
NATURALLY PROCESSED PEPTIDES
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE ANTIGEN PRESENTATION; CLASS-II
ID MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN-PRESENTING FUNCTION; PIGEON
CYTOCHROME-C; BINDING-PROTEIN; PROLIFERATIVE RESPONSE; DETERMINANT
SELECTION; IMMUNOGENIC PEPTIDES; MHC RESTRICTION; LYMPHOCYTES-T; B-CELLS
AB It has been inferred that residue changes that affect T cell recognition of synthetic peptides will have a similar effect in the intact protein. However, since small peptides do not require antigen processing it is possible that residue changes in synthetic peptides will not have an equivalent effect in the intact protein. Mutant proteins of staphylococcal nuclease (Nase) and 15mer synthetic peptides with corresponding substitutions were compared to determine if residue changes within an immunodominant epitope have an effect on the generation of naturally processed peptides. Five different substitutions in the synthetic peptide resulted in loss of reactivity of individual Nase-specific clones. When the same single amino acid changes were made in the intact protein, the naturally-processed peptides were also unable to stimulate the Nase-specific clones. However, two other substitutions in the synthetic peptide were stimulatory for a T cell clone even though the same changes in the intact protein were non-stimulatory. These results suggest that certain residue changes affect recognition of the naturally processed peptide but not the synthetic peptide with the same amino acid change. In addition, these results demonstrate that the effects of amino acid substitutions in synthetic peptides on T cell recognition may not always reflect the effects of these substitutions in the intact protein. Substitutions located outside Nase-specific T cell epitopes were also examined. Thirty different mutant proteins were all stimulatory. Moreover, a number of these mutants proteins were 50- to 100-fold more efficient in their stimulatory capacity than the native Nase protein. These results demonstrate that residue changes not directly involved in T cell epitope recognition can enhance the processing and/or presentation of T cell epitopes. These data support the concept that recognition of T cell epitopes may directly depend on the structure of the protein in which the recognition site is processed.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
RP FINNEGAN, A (reprint author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,RHEUMATOL & IMMUNOL MICROBIOL SECT,CHICAGO,IL 60612, USA.
NR 41
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD DEC
PY 1992
VL 4
IS 12
BP 1399
EP 1406
DI 10.1093/intimm/4.12.1399
PG 8
WC Immunology
SC Immunology
GA KE105
UT WOS:A1992KE10500007
PM 1286063
ER
PT J
AU WOOD, GE
AF WOOD, GE
TI MYCOTOXINS IN FOODS AND FEEDS IN THE UNITED-STATES
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article
DE MYCOTOXINS; AFLATOXINS; CORN; PEANUTS; MILK; CONTROL PROGRAMS
ID CYCLOPIAZONIC ACID PRODUCTION; MYCO-TOXIN PRODUCTION; NATURAL
OCCURRENCE; DEOXYNIVALENOL VOMITOXIN; FUSARIUM-MONILIFORME; TISSUE
DISTRIBUTION; ERGOT ALKALOIDS; WHOLE TOMATOES; WINTER-WHEAT; DAIRY-COWS
AB Mycotoxins axe considered unavoidable contaminants in foods and feeds because agronomic technology has not yet advanced to the stage at which preharvest infection of susceptible crops by fungi can be eliminated. The aflatoxins have received greater attention than any of the other mycotoxins because of their demonstrated carcinogenic effects in susceptible animals and their acute toxic effects in humans. Since 1965, the U.S. Food and Drug Administration (FDA) has enforced regulatory limits on the concentrations of these toxins in foods and feeds involved in interstate commerce. The FDA routinely monitors the food and feed industries through compliance programs to ensure that the levels of exposure to these toxins are kept as low as practical. This report summarizes data generated from compliance programs on aflatoxins for the fiscal years 1989, 1990, and the first half of 1991. Commodities sampled included peanuts and peanut products, tree nuts, corn and corn products, cottonseed, and milk. Higher than usual levels of contamination were found in corn examined from all areas of the United States in 1989 as a result of the severe drought that affected the 1988 corn crop. The drought in parts of the South and Southeast in 1990 resulted in increased contamination in corn and peanuts from those areas. A review of the surveillance data obtained on deoxynivalenol, zearalenone, ochratoxin A, sterigmatocystin, penicillic acid, and patulin over the years along with available toxicological data for these mycotoxins indicated that no regulatory actions were warranted. The lack of sufficient surveillance data on other mycotoxins that occur in the United States can be attributed in part to the unavailability of reliable analytical methodology.
RP WOOD, GE (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 58
TC 100
Z9 101
U1 1
U2 13
PU AMER SOC ANIMAL SCIENCE
PI SAVOY
PA 1111 NORTH DUNLAP AVE, SAVOY, IL 61874
SN 0021-8812
J9 J ANIM SCI
JI J. Anim. Sci.
PD DEC
PY 1992
VL 70
IS 12
BP 3941
EP 3949
PG 9
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA KB974
UT WOS:A1992KB97400033
PM 1474031
ER
PT J
AU STIBITZ, S
GARLETTS, TL
AF STIBITZ, S
GARLETTS, TL
TI DERIVATION OF A PHYSICAL MAP OF THE CHROMOSOME OF BORDETELLA-PERTUSSIS
TOHAMA .1.
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID HEAT-LABILE TOXIN; NUCLEOTIDE-SEQUENCE; VIRULENCE FACTORS; FILAMENTOUS
HEMAGGLUTININ; ESCHERICHIA-COLI; FIMBRIAL SUBUNIT; GENETIC-ANALYSIS;
CLONING; BRONCHISEPTICA; VIR
AB We have used pulsed-field gel electrophoresis to derive a restriction map of the chromosome of Bordetella pertussis for the enzymes XbaI, SpeI, PacI, and PmeI, which cleave 25, 16, 2, and 1 times, respectively. The apparent size of the genome is 3,750 kb. The positions of genes for major virulence determinants in the vir regulon and of some housekeeping genes were determined. Apart from the previously known linkage of the vir and fha loci, no significant linkage of virulence genes was demonstrated.
RP STIBITZ, S (reprint author), US FDA,CTR BIOL EVALUAT & RES,BACTERIAL TOXINS LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 41
TC 32
Z9 32
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD DEC
PY 1992
VL 174
IS 23
BP 7770
EP 7777
PG 8
WC Microbiology
SC Microbiology
GA JZ841
UT WOS:A1992JZ84100035
PM 1447143
ER
PT J
AU CALDERWOOD, JA
JOHNSON, JM
AF CALDERWOOD, JA
JOHNSON, JM
TI A LEGAL CURRICULUM FOR THE CLINICAL PHARMACOLOGIST .1. ORDER OF
PRECEDENCE OF AUTHORITY
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
C1 US FDA,CTR DRUG EVALUAT & RES,DIV EPIDEMIOL & SURVEILLANCE,ROCKVILLE,MD 20857.
RP CALDERWOOD, JA (reprint author), ZUCKERT SCOUTT & RASENBERGER,888 17TH ST NW,SUITE 600,WASHINGTON,DC 20006, USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD DEC
PY 1992
VL 32
IS 12
BP 1073
EP 1082
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KD102
UT WOS:A1992KD10200003
PM 1487544
ER
PT J
AU FOOPHILLIPS, M
KOZAK, CA
PRINCIPATO, MAC
ABE, R
AF FOOPHILLIPS, M
KOZAK, CA
PRINCIPATO, MAC
ABE, R
TI CHARACTERIZATION OF THE MLS(F) SYSTEM .2. IDENTIFICATION OF MOUSE
MAMMARY-TUMOR VIRUS PROVIRUSES INVOLVED IN THE CLONAL DELETION OF
SELF-MLS(F)-REACTIVE T-CELLS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SUPERANTIGEN; ANTIGENS; GENES; EXPRESSION; V-BETA-11; TOLERANCE;
PRODUCTS; MICE
AB The genetic linkage of loci encoding stimulatory Mls(s) and Mls(c) determinants with proviruses of mouse mammary tumour viruses (MMTV) has been shown. We previously have reported that the ligand(s) for Vbeta5, Vbeta11, and Vbeta12 behaves as a novel minor lymphocyte-stimulating (Mls) determinant(s), Mls(f), to induce the strong proliferation of unprimed T cells, and that this ligand(s) also functions as a self-Ag for the clonal deletion of self-reactive T cells. In the accompanying paper (Part I), a unique polymorphism characteristic of the Mls(f) gene product is presented. In order to determine the genetic basis for this novel Mls system, we examined the progeny of multiple genetic crosses to identify the MMTV proviral loci involved in the clonal deletion of self-Mls(f)-reactive T cells. Results from these investigations indicated that at least three known MMTV proviruses, Mtv-8, Mtv-9, and Mtv-11 are involved in the expression of Mls(f) gene products. Presence of Mtv-9 results in the complete deletion of Vbeta5, Vbeta11, and Vbeta12; Mtv-8 is associated with the complete deletion of Vbeta12, but only a partial deletion of Vbeta11 (primarily CD4-positive T cell subset) with little or no deletion of Vbeta5; and Mtv-11 induces the complete deletion of Vbeta11 and Vbeta12, but no deletion of Vbeta5. Given the significant sequence homology in the C-terminal portion of the open reading frame (ORF) region among these three MMTV and the almost equivalent effect of these three MMTV provirus upon the Vbeta12 repertoire, their apparent hierarchic effect upon the Vbeta5 and Vbeta11 repertoires suggests that affinity differences in recognition of the same determinant by different TCR Vbeta may play a significant role in the clonal deletion of self-reactive T cells.
C1 USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,MAIL STOP 44,BETHESDA,MD 20889.
NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892.
US FDA,DIV MICROBIOL,VIRULENCE ASSESSMENT BRANCH,LAUREL,MD 20708.
NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892.
NR 27
TC 15
Z9 15
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 1992
VL 149
IS 11
BP 3440
EP 3447
PG 8
WC Immunology
SC Immunology
GA JY875
UT WOS:A1992JY87500002
PM 1331236
ER
PT J
AU KLINMAN, DM
AF KLINMAN, DM
TI CROSS-REACTIVITY OF IGM-SECRETING B-CELLS FROM NORMAL BALB/C MICE
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ANTIBODY REPERTOIRE; MONOCLONAL AUTOANTIBODIES; NATURAL AUTOANTIBODIES;
MURINE AUTOANTIBODIES; C MICE; SPECIFICITIES; ANTIGENS; ACQUISITION;
ACTIVATION; IDIOTOPES
AB Cross-reactive antibodies capable of binding to foreign and self Ag are present in the serum of normal newborn and adult animals. In our work, a chamber ELISA assay was used to quantitate the cross-reactivity of B cells actively secreting Ig in BALB/c mice of different ages. Individual lymphocytes were tested for the production of IgM antibodies capable of binding to a series of four unrelated Ag (DNA, TNP, actin, and OVA). Results indicate that nearly one-quarter of IgM secreting lymphocytes from 6-day-old animals were cross-reactive. This frequency was two- to fourfold higher than that found in adult mice. Very old animals, however, showed a selective increase in the cross-reactivity of anti-DNA (but not anti-TNP) secreting lymphocytes. Evidence from Ag inhibition experiments indicated that low concentrations of soluble Ag could block the binding of polyreactive antibodies, and that approximately one-half of "naturally" cross-reactive B cells produced antibodies capable of binding to three or more unrelated Ag.
RP KLINMAN, DM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,BLDG 29A,RM 3D10,BETHESDA,MD 20892, USA.
NR 38
TC 15
Z9 15
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 1992
VL 149
IS 11
BP 3569
EP 3573
PG 5
WC Immunology
SC Immunology
GA JY875
UT WOS:A1992JY87500020
PM 1431126
ER
PT J
AU SZABO, G
PINE, PS
WEAVER, JL
RAO, PE
ASZALOS, A
AF SZABO, G
PINE, PS
WEAVER, JL
RAO, PE
ASZALOS, A
TI CD4 CHANGES CONFORMATION UPON LIGAND-BINDING
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; AURINTRICARBOXYLIC ACID; LATERAL DIFFUSION; HIV;
RECEPTOR; SURFACE; INFECTION; MEMBRANES; FRAGMENT; CELLS
AB Aurintricarboxylic acid (ATA) has been shown to block the binding site for both HIV gp120 and mAb anti-Leu 3a on CD4. We have unexpectedly found that brief treatment with greater-than-or-equal-to 1 mug/ml ATA rapidly disengages another mAb, OKT4E, after it has been bound to CD4 on human PBL. OKT4E is specific for a discontinuous epitope overlapping the MHC class II-binding region in the N-terminal CD4 domain. Interestingly, among 10 other mAb tested, only anti-Leu 8, specific for a leukocyte homing receptor is also quickly released from the cells by ATA treatment. Disengagement of the OKT4E mAb is also seen on a CD4-positive cell line (HPB-ALL) and with recombinant soluble CD4 (sCD4) bound to immobilized OKT4E. In all of these cases, disengagement is prevented if OKT4E is cross-linked, or the Leu 3a site is blocked by the mAb, but not by gp120. Photobleaching fluorescence resonance energy transfer (pFRET) measurements suggest that OKT4E is released as an indirect consequence of ATA-evoked conformational changes of CD4. Similar changes were detected as a result of gp120 binding to PBL. These data raise the possibility of a novel type of immunomodulation: induced disengagement of a bound ligand from its Ag.
C1 US FDA,CTR DRUG EVALUAT & RES,200 C ST SW,WASHINGTON,DC 20204.
ORTHO DIAGNOST SYST INC,RARITAN,NJ 08869.
DEBRECEN UNIV MED,SCH MED,DEPT BIOPHYS,H-4012 DEBRECEN,HUNGARY.
NR 23
TC 25
Z9 25
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 1992
VL 149
IS 11
BP 3596
EP 3604
PG 9
WC Immunology
SC Immunology
GA JY875
UT WOS:A1992JY87500024
PM 1431129
ER
PT J
AU KAY, LE
BULL, TE
NICHOLSON, LK
GRIESINGER, C
SCHWALBE, H
BAX, A
TORCHIA, DA
AF KAY, LE
BULL, TE
NICHOLSON, LK
GRIESINGER, C
SCHWALBE, H
BAX, A
TORCHIA, DA
TI THE MEASUREMENT OF HETERONUCLEAR TRANSVERSE RELAXATION-TIMES IN AX3 SPIN
SYSTEMS VIA POLARIZATION-TRANSFER TECHNIQUES
SO JOURNAL OF MAGNETIC RESONANCE
LA English
DT Article
ID NUCLEAR MAGNETIC-RESONANCE; NMR-SPECTROSCOPY; PROTEINS; ENHANCEMENT;
MACROMOLECULES; SIGNALS; N-15; CONSTANTS; DYNAMICS; SPECTRA
C1 NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS,BIOPHYS LAB,BETHESDA,MD 20892.
NIDR,BONE RES BRANCH,BETHESDA,MD 20892.
UNIV FRANKFURT,INST ORGAN CHEM,W-6000 FRANKFURT 50,GERMANY.
RI Schwalbe, Harald/F-9023-2010
OI Schwalbe, Harald/0000-0001-5693-7909
NR 39
TC 69
Z9 70
U1 1
U2 10
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-2364
J9 J MAGN RESON
PD DEC
PY 1992
VL 100
IS 3
BP 538
EP 558
DI 10.1016/0022-2364(92)90058-F
PG 21
WC Biochemical Research Methods; Physics, Atomic, Molecular & Chemical;
Spectroscopy
SC Biochemistry & Molecular Biology; Physics; Spectroscopy
GA KF538
UT WOS:A1992KF53800006
ER
PT J
AU CAMPBELL, WL
FRANKLIN, W
CERNIGLIA, CE
AF CAMPBELL, WL
FRANKLIN, W
CERNIGLIA, CE
TI VALIDATION STUDIES ON AN INVITRO SEMICONTINUOUS CULTURE SYSTEM DESIGNED
TO SIMULATE A BACTERIAL ECOSYSTEM OF THE HUMAN INTESTINE
SO JOURNAL OF MICROBIOLOGICAL METHODS
LA English
DT Article
DE SEMICONTINUOUS CULTURE; INTESTINAL MICROFLORA; AZO DYE; DIRECT BLUE-15;
AZOREDUCTASE
ID AROMATIC-AMINES; METABOLISM; MICROFLORA; FLORA; BENZIDINE;
MICROORGANISMS; MICROBIOTA; BIOLOGY; MONKEY; DIET
AB A semicontinuous culture system (SCCS) inoculated with human intestinal bacteria was used to determine if the metabolic activity in the human intestine could be maintained in vitro. After 43 days, a diverse bacterial population was still present with counts above 4 x 10(9) bacteria/ml. Bacteroides spp. accounted for approximately 50% of the colonies isolated. Other isolates included Eubacterium, Fusobacterium, Peptostreptococcus, Lactobacillus, Peptococcus, Clostridium, Streptococcus, and Acidaminococcus spp. Acetic, propionic, and butyric acid made up over 90% of the volatile fatty acids. Beta-glucosidase, beta-glucuronidase, nitroreductase, and azoreductase, which were present in the inoculum, were also present after 43 days. Carbon dioxide was the predominant gas (17.81 mmol/l). Hydrogen and methane were detected at 0.66 mmol/l and 3.67 mmol/l, respectively. After 17 days, the azo dye Direct blue 15, was added to the culture and over 90% was metabolized in the first 24 h. Two metabolites, 3,3'-dimethoxybenzidine and 4-amino-3,3'-dimethoxybiphenyl, were isolated and identified by high pressure liquid chromatography (HPLC), gas chromatography and mass spectrometry. The results indicate that diverse, metabolically active cultures can be maintained for prolonged periods and used for studies of xenobiotic metabolism.
C1 US FDA,NATL CTR TOXICOL RES,DIV MICROBIOL,NCTR DR,JEFFERSON,AR 72079.
NR 29
TC 6
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-7012
J9 J MICROBIOL METH
JI J. Microbiol. Methods
PD DEC
PY 1992
VL 16
IS 4
BP 239
EP 252
DI 10.1016/0167-7012(92)90014-U
PG 14
WC Biochemical Research Methods; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA KF542
UT WOS:A1992KF54200001
ER
PT J
AU WU, ST
SHIU, GK
SIMMONS, JE
BRONAUGH, RL
SKELLY, JP
AF WU, ST
SHIU, GK
SIMMONS, JE
BRONAUGH, RL
SKELLY, JP
TI INVITRO RELEASE OF NITROGLYCERIN FROM TOPICAL PRODUCTS BY USE OF
ARTIFICIAL MEMBRANES
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
ID PERCUTANEOUS-ABSORPTION
AB An in vitro testing method for measuring the release of nitroglycerin from topical drug products was evaluated. The method involved measuring the amount of nitroglycerin that diffused from ointments and patches through various synthetic membranes into receptor fluid contained in a modified Franz diffusion cell. Plots of the amount of nitroglycerin released against the square root of time for all 10 synthetic membranes were linear. Five membranes (group I) were found to release nitroglycerin at similar rates (difference not significant; p > 0.05). Use of the other five membranes (group II) in diffusion cells resulted in release rates significantly slower than those of group I membranes (p < 0.05). Rapid permeation of nitroglycerin from a solution through a polysulfone membrane demonstrated a lack of significant diffusion barrier properties of this membrane. Rates of release of nitroglycerin from commercially available ointments were found to be similar. A comparison of three commercial nitroglycerin patches revealed that these products released nitroglycerin at different rates in vitro.
C1 US FDA,CDER,BIOPHARMACEUT RES BRANCH,200 C ST SW,WASHINGTON,DC 20204.
US FDA,CDER,OFF GENER DRUGS,WASHINGTON,DC 20204.
US FDA,CFSAN,DIV TOXICOL STUDIES,WASHINGTON,DC 20204.
US FDA,CDER,OFF RES RESOURCES,WASHINGTON,DC 20204.
NR 11
TC 11
Z9 11
U1 0
U2 3
PU AMER PHARMACEUTICAL ASSN
PI WASHINGTON
PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037
SN 0022-3549
J9 J PHARM SCI
JI J. Pharm. Sci.
PD DEC
PY 1992
VL 81
IS 12
BP 1153
EP 1156
DI 10.1002/jps.2600811204
PG 4
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA KA910
UT WOS:A1992KA91000003
PM 1491329
ER
PT J
AU APPEL, NM
ROBBINS, JD
DESOUZA, EB
SEAMON, KB
AF APPEL, NM
ROBBINS, JD
DESOUZA, EB
SEAMON, KB
TI [I-125] LABELED FORSKOLIN ANALOGS WHICH DISCRIMINATE ADENYLYL CYCLASE
AND A GLUCOSE TRANSPORTER - PHARMACOLOGICAL CHARACTERIZATION AND
LOCALIZATION OF BINDING-SITES IN RAT-BRAIN BY INVITRO RECEPTOR
AUTORADIOGRAPHY
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID 2ND MESSENGER SYSTEMS; TRANSIENT FOREBRAIN ISCHEMIA; QUANTITATIVE
AUTORADIOGRAPHY; H-3 FORSKOLIN; ALZHEIMERS-DISEASE; CYTOCHALASIN-B;
EXPRESSION; BARRIER; HIPPOCAMPUS; PROTEIN
AB Aminoalkylcarbamate derivatives of forskolin have been synthesized at the 6- and 7-hydroxyl positions which have different selectivity for adenylyl cyclase and a glucose transporter, respectively. They were radioiodinated using the Bolton-Hunter reagent to yield [I-125]-2-[3-(4-hydroxy-3-iodophenyl)propanamido]-N-ethyl-6-(aminocarbonyl)forskolin ([I-125]6-IHPP-Fsk) and [I-125]-2-[3-(4-hydroxy-3-iodophenyl)(propanamidol]-N-ethyl-7-(aminocarbonyl)-7-desacetylforskolin ([I-125]7-IHPP-Fsk) and tested as autoradiographic probes for adenylyl cyclase and a glucose transporter. In slide-mounted rat brain sections [I-125]6-IHPP-Fsk binding was potently inhibited by 1 muM 6-HPP-Fsk (95%) but unaffected by 500 mM D-glucose. In contrast, [I-125]7-IHPP-Fsk was only partially inhibited by 1 muM 6-HPP-Fsk (37%), but residual [I-125]7-IHPP-Fsk binding was further inhibited 56% by 500 mM D-glucose. These data suggest that while [I-125]6-IHPP-Fsk binds exclusively to adenylyl cyclase, a significant fraction of [I-125]7-IHPP-Fsk is binding to a glucose transporter in brain. Autoradiographic patterns of [I-125]6-IHPP-Fsk and glucose-sensitive [I-125]7-IHPP-Fsk binding were different. [I-125]6-IHPP-Fsk binding was heterogeneously distributed and resembled [H-3] forskolin binding. Highest densities of binding sites were noted in olfactory tubercle, caudate putamen, nucleus accumbens, pyramidal and granule cell layers of hippocampus, molecular layer of cerebellum and substantia nigra. In contrast, of glucose-sensitive [I-125]7-IHPP-Fsk, binding appeared more homogeneous and similar to [H-3]cytochalasin B, a compound which inhibits glucose transport. Highest densities of binding were noted in caudate putamen, nucleus accumbens, cerebral cortex and molecular layer of cerebellum. Less binding was noted in hippocampus pyramidal and granule cell layers. The data show that [I-125] 6-IHPP-Fsk and [I-125]7-IHPP-Fsk can be used, respectively, to label selectively adenylyl cyclase and glucose transporter. These compounds may have potential as in vivo diagnostic probes to reveal brain pathology or as sites of action of physiological insults or drugs which affect signal transduction or brain metabolism.
C1 US FDA,CTR BIOL EVALUAT & RES,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
US FDA,CTR DRUG EVALUAT & RES,DIV RES & TESTING HFD472,LAUREL,MD.
DUPONT MERCK PHARMACEUT CO,CENT NERVOUS SYST DIS RES,WILMINGTON,DE.
NR 41
TC 14
Z9 14
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD DEC
PY 1992
VL 263
IS 3
BP 1415
EP 1423
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KD194
UT WOS:A1992KD19400068
PM 1469642
ER
PT J
AU VICK, JA
AF VICK, JA
TI POISONOUS SNAKES - REPLY
SO MILITARY MEDICINE
LA English
DT Letter
RP VICK, JA (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSN MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD DEC
PY 1992
VL 157
IS 12
BP A8
EP A8
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA KB925
UT WOS:A1992KB92500007
ER
PT J
AU ZAPATA, GA
VANN, WF
RUBINSTEIN, Y
FRASCH, CE
AF ZAPATA, GA
VANN, WF
RUBINSTEIN, Y
FRASCH, CE
TI IDENTIFICATION OF VARIABLE REGION DIFFERENCES IN NEISSERIA-MENINGITIDIS
CLASS-3 PROTEIN SEQUENCES AMONG 5 GROUP-B SEROTYPES
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID OUTER-MEMBRANE PROTEINS; CLASS 2 PROTEIN; STRUCTURAL GENE;
MONOCLONAL-ANTIBODIES; PORIN PROTEIN; INFANT RAT; CLONING; VACCINE; DNA;
GONORRHOEAE
AB Strains of Neisseria meningitidis express one of two porin proteins. These porins have been identified as the class 2 and class 3 proteins, and express serotype-specific epitopes. The gene for the class 3 protein was amplified by the polymerase chain reaction from the DNA of a serotype 4 strain as a 1025 bp fragment. The nucleotide sequence of this gene was determined and compared with two recently published sequences. On the basis of this comparison we have identified two major variable regions in the translated protein sequence, VR1 and VR2, that may be associated with serotype specificity. Three other variable regions were also identified. The sequences in the VR1 and VR2 regions from five additional group B N. meningitidis strains of serotypes 1, 4, 8,12, and 15, all expressing class 3 proteins, were determined. The VR1 and VR2 regions were variable and were flanked by highly conserved regions among eight different class 3 sequences. These two variable regions of 15 and 9 amino acids are predicted to be in surface-exposed loops.
C1 CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892.
NR 31
TC 23
Z9 24
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD DEC
PY 1992
VL 6
IS 23
BP 3493
EP 3499
DI 10.1111/j.1365-2958.1992.tb01784.x
PG 7
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA KB926
UT WOS:A1992KB92600005
PM 1335540
ER
PT J
AU BERLYNE, G
KACZMAREK, RG
HAMBURGER, S
HAMILTON, P
MOORE, RM
CHARNEY, AN
KAHN, T
GRUBER, M
KAUFMAN, CE
GOFFINET, J
BERNARD, MA
AF BERLYNE, G
KACZMAREK, RG
HAMBURGER, S
HAMILTON, P
MOORE, RM
CHARNEY, AN
KAHN, T
GRUBER, M
KAUFMAN, CE
GOFFINET, J
BERNARD, MA
TI SEROPREVALENCE OF ANTIBODIES TO THE HUMAN-IMMUNODEFICIENCY-VIRUS IN
DIALYSIS WORKERS - RESULTS OF A MULTICENTER STUDY
SO NEPHRON
LA English
DT Article
DE HUMAN IMMUNODEFICIENCY VIRUS; OCCUPATIONAL MEDICINE; DIALYSIS WORKERS
ID HEALTH-CARE WORKERS; AIDS
AB The Center for Devices and Radiological Health, in collaboration with the Department of Veterans Affairs Medical Center, Brooklyn, N.Y., conducted a multi-center, multi-institutional study of the seroprevalence of antibodies to the human immunodeficiency virus (HIV) among dialysis workers. Seven dialysis units and 112 dialysis workers participated in the study over a period of 2 years. Participation was limited to dialysis workers who, by questionnaire, denied non-occupational risk factors for HIV infection. The vast majority of the study participants were drawn from areas where the prevalence of HIV infection and AIDS cases are substantially greater than the national average. Study participants received the ELISA test for HIV antibodies. All 112 of the participants tested negative for HIV antibodies. These results are encouraging, as they failed to reveal unrecognized occupational transmission of HIV infection among dialysis workers.
C1 US FDA,CTR DEVICES & RADIOL HLTH,HFZ-161,SUITE 405,1801 ROCKVILLE PIKE,ROCKVILLE,MD 20852.
DEPT VET AFFAIRS MED CTR,BROOKLYN,NY.
ST JOHNS HOSP,MED CTR,DEPT VET AFFAIRS,FAR ROCKAWAY,NY.
MED CTR,DEPT VET AFFAIRS,BRONX,NY.
MED CTR,DEPT VET AFFAIRS,NORTHPORT,NY.
MED CTR,DEPT VET AFFAIRS,OKLAHOMA CITY,OK.
MED CTR,DEPT VET AFFAIRS,W HAVEN,CT.
MED CTR,DEPT VET AFFAIRS,NEW YORK,NY.
NR 10
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0028-2766
J9 NEPHRON
JI Nephron
PD DEC
PY 1992
VL 62
IS 4
BP 441
EP 443
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA JZ219
UT WOS:A1992JZ21900012
PM 1300440
ER
PT J
AU MEYER, MC
STRAUGHN, AB
JARVI, EJ
WOOD, GC
PELSOR, FR
SHAH, VP
AF MEYER, MC
STRAUGHN, AB
JARVI, EJ
WOOD, GC
PELSOR, FR
SHAH, VP
TI THE BIOINEQUIVALENCE OF CARBAMAZEPINE TABLETS WITH A HISTORY OF CLINICAL
FAILURES
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE CARBAMAZEPINE; HUMAN; BIOAVAILABILITY; PHARMACOKINETICS; DISSOLUTION
ID FORMULATIONS
AB The bioavailability of three lots of a generic 200-mg carbamazepine tablet, which had been withdrawn from the market, was compared to the bioavailability of one lot of the innovator product in 24 healthy volunteers. Fifty-three lots of the generic product had been recalled by the manufacturer because of concerns over reports of clinical failures for several of the lots. The three generic lots tested in this study exhibited a wide range of bioavailability, as well as large differences in the in vitro dissolution rates. The mean maximum carbamazepine plasma concentrations for two of the generic lots were only 61-74% that of the innovator product, while the third lot was 142% of the innovator. The mean areas under the plasma concentration-time curve for the three generic lots ranged from 60 to 113% that of the innovator product. The results clearly indicate a significant difference in the rate and extent of absorption of the generic products compared to the innovator, as well as among the generic lots. A good relationship was found between the in vivo parameters and the in vitro dissolution results for the four dosage forms.
C1 IDAHO STATE UNIV,COLL PHARM,DEPT PHARMACEUT SCI,POCATELLO,ID 83201.
US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
RP MEYER, MC (reprint author), UNIV TENNESSEE CTR HLTH SCI,COLL PHARM,DEPT PHARMACEUT,874 UNION AVE,MEMPHIS,TN 38163, USA.
FU PHS HHS [223-87-1802]
NR 7
TC 102
Z9 104
U1 1
U2 16
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD DEC
PY 1992
VL 9
IS 12
BP 1612
EP 1616
DI 10.1023/A:1015872626887
PG 5
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA KB948
UT WOS:A1992KB94800015
PM 1488405
ER
PT J
AU CARRINGTON, CD
BOLGER, PM
AF CARRINGTON, CD
BOLGER, PM
TI AN ASSESSMENT OF THE HAZARDS OF LEAD IN FOOD
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
ID BLOOD LEAD; CALCIUM-METABOLISM; PRESSURE; PREGNANCY; EXPOSURE; CHILDREN;
WOMEN; MILK
RP CARRINGTON, CD (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV TOXICOL REVIEW & EVALUAT,WASHINGTON,DC 20204, USA.
NR 25
TC 41
Z9 42
U1 4
U2 5
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0273-2300
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD DEC
PY 1992
VL 16
IS 3
BP 265
EP 272
DI 10.1016/0273-2300(92)90006-U
PG 8
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA KF482
UT WOS:A1992KF48200006
PM 1293643
ER
PT J
AU KITTNER, SJ
SHARKNESS, CM
SLOAN, MA
PRICE, TR
DAMBROSIA, JM
TUHRIM, S
WOLF, PA
MOHR, JP
HIER, DB
AF KITTNER, SJ
SHARKNESS, CM
SLOAN, MA
PRICE, TR
DAMBROSIA, JM
TUHRIM, S
WOLF, PA
MOHR, JP
HIER, DB
TI FEATURES ON INITIAL COMPUTED-TOMOGRAPHY SCAN OF INFARCTS WITH A CARDIAC
SOURCE OF EMBOLISM IN THE NINDS-STROKE-DATA-BANK
SO STROKE
LA English
DT Article
DE CEREBRAL ISCHEMIA; CEREBROVASCULAR DISORDERS; EMBOLISM; TOMOGRAPHY,
EMISSION COMPUTED
ID CEREBRAL EMBOLISM; REGISTRY
AB Background and Purpose: The lack of valid criteria for the clinical diagnosis of cardiogenic embolism is a major problem in both patient care and research. The aim of this study was to identify features on the initial computed tomogram of the brain that discriminate between patient groups with and without a cardiac source of embolism. To gain insight into the neuroradiological features relevant to the diagnosis of cardiac embolic stroke, we studied the initial computed tomogram of the 1,267 patients with ischemic stroke and such a scan in the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Data Bank.
Methods: We analyzed the initial computed tomographic data from 1,267 patients with ischemic stroke in the NINDS Stroke Data Bank. Based solely on the presence of cardiac sources of embolism, we defined groups with high (n=244), medium (n=165), and low (n=858) risk for cardiogenic embolism and compared the features on the initial computed tomogram among these three groups.
Results: Patients in the high-risk group were significantly more likely (p<0.001) to have infarcts involving one half lobe or larger or infarcts involving both superficial and deep structures than patients in the medium- or low-risk groups. In contrast, deep small infarcts had a negative association (p = 0.004) with the presence of a cardiac source of embolism. There was no significant trend across risk groups in the percent with hemorrhagic infarction, regardless of whether patients with anticoagulant use at the time of the stroke were excluded.
Conclusion: Although some features of the initial computed tomogram had highly significant associations with the presence of a cardiac source of embolism, the predictive value of these features for an embolic source was low.
C1 UNIV MARYLAND,DEPT NEUROL,BALTIMORE,MD 21201.
UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892.
MT SINAI MED CTR,NEW YORK,NY 10029.
BOSTON UNIV,SCH MED,BOSTON,MA 02118.
COLUMBIA PRESBYTERIAN MED CTR,INST NEUROL,NEW YORK,NY 10032.
UNIV ILLINOIS HOSP,CHICAGO,IL 60612.
FU NINDS NIH HHS [N01-NS-2-2399, N01-NS-2-2384, N01-NS-2-2302]
NR 13
TC 22
Z9 23
U1 0
U2 0
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0039-2499
J9 STROKE
JI Stroke
PD DEC
PY 1992
VL 23
IS 12
BP 1748
EP 1751
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA KA151
UT WOS:A1992KA15100009
PM 1448825
ER
PT J
AU GAYLOR, DW
RAZZAGHI, M
AF GAYLOR, DW
RAZZAGHI, M
TI PROCESS OF BUILDING BIOLOGICALLY BASED DOSE-RESPONSE MODELS FOR
DEVELOPMENTAL DEFECTS
SO TERATOLOGY
LA English
DT Article
ID RISK ASSESSMENT
AB The problem of developing biologically-based dose-response models is addressed for predicting the prevalence of birth defects at low doses of toxic chemicals administered during pregnancy. To illustrate the process of incorporating biological information, a model is postulated to predict the prevalence of cleft palate for a chemical that reduces embryonic/fetal growth, which results in inadequate palatal cells for closure. Experimental bioassay data examining the prevalence of cleft palate in mice exposed to the herbicide 2,4,5-T are used to illustrate the process. With the limited data available, it is necessary to assume a model for cell growth and the relationship between the cell growth rate parameter and dose of 2,4,5-T. Also, a relationship between cleft palate prevalence and growth is assumed and then checked with experimental data. The purpose of the paper is not to provide a universal biologically based dose-response model for cleft palate, but rather to demonstrate the extent, and type of information and data required. It remains to be seen if the form of the model is appropriate for chemicals that primarily produce embryo/fetal malformations or death via reduced or delayed cellular growth.
C1 BLOOMSBURG UNIV,BLOOMSBURG,PA 17815.
RP GAYLOR, DW (reprint author), US FDA,NATL CTR TOXICOL RES,BIOMETRY STAFF,HFT-20,JEFFERSON,AR 72079, USA.
NR 7
TC 22
Z9 22
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0040-3709
J9 TERATOLOGY
JI Teratology
PD DEC
PY 1992
VL 46
IS 6
BP 573
EP 581
DI 10.1002/tera.1420460607
PG 9
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA KE112
UT WOS:A1992KE11200006
PM 1290158
ER
PT J
AU HAYES, TJ
CAVAGNARO, JA
AF HAYES, TJ
CAVAGNARO, JA
TI PROGRESS AND CHALLENGES IN THE PRECLINICAL ASSESSMENT OF CYTOKINES
SO TOXICOLOGY LETTERS
LA English
DT Article; Proceedings Paper
CT 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY : TOXICOLOGY FROM DISCOVERY AND
EXPERIMENTATION TO THE HUMAN PERSPECTIVE
CY JUN 28-JUL 03, 1992
CL ROME, ITALY
DE BIOTECHNOLOGY; REGULATIONS; TOXICOLOGY; CYTOKINES; SAFETY EVALUATIONS;
DRUG DEVELOPMENT
AB This presentation focuses on the history and status of the preclinical toxicologic assessment of recombinant proteins. Cytokines and growth factors are used as examples. There has been an evolution of thought over the past dozen years on the testing of these substances that has ranged from their being considered nontoxic, human-specific proteins for which no predictive testing could be done in animals, to the present view that they can be toxic, relevant testing may be possible in animals, and assessment approaches should be science-based and case-by-case. The challenge of appropriate testing of recombinant proteins has caused toxicologists in both industry and in regulatory authorities to reconsider not only testing procedures but the purpose of preclinical assessment. The form of regulatory guidelines (guidance vs. inflexible testing protocols) has been questioned, and the need for interaction between scientists in industry and regulatory agencies has been strengthened. This process has advanced the science of toxicology.
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
RP HAYES, TJ (reprint author), HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD DEC
PY 1992
VL 64-5
SI SI
BP 291
EP 297
DI 10.1016/0378-4274(92)90201-T
PG 7
WC Toxicology
SC Toxicology
GA KE526
UT WOS:A1992KE52600036
PM 1471184
ER
PT J
AU KADERLIK, RK
LIN, DX
LANG, NP
KADLUBAR, FF
AF KADERLIK, RK
LIN, DX
LANG, NP
KADLUBAR, FF
TI ADVANTAGES AND LIMITATIONS OF LABORATORY METHODS FOR MEASUREMENT OF
CARCINOGEN-DNA ADDUCTS FOR EPIDEMIOLOGIC STUDIES
SO TOXICOLOGY LETTERS
LA English
DT Article
DE CHEMICAL CARCINOGENESIS; CANCER EPIDEMIOLOGY; DNA ADDUCTS; IMMUNOASSAYS
ID WHITE BLOOD-CELLS; COKE-OVEN WORKERS; P-32-POSTLABELING ANALYSIS;
ORAL-MUCOSA; CANCER; ASSAY; IDENTIFICATION; QUANTITATION; EXPOSURE;
SMOKERS
AB In molecular epidemiological studies, the measurement of carcinogen-DNA adducts in human tissues can provide direct evidence of current exposure to chemical carcinogens. Moreover, data on steady state DNA adduct levels and the rate of cell proliferation can be related not only to carcinogen-target tissue dosimetry but may also be useful in assessment of human cancer risk. Thus far, laboratory methods for adduct detection have primarily utilized P-32-postlabelling, immunoassays, and mass spectrometry. However, accurate quantitation of DNA adducts requires knowledge of the structural identity and chemical properties of carcinogen-base adducts, the availability of synthetic standards for recovery determinations, and the development of complementary methods to corroborate analytical findings.
C1 NATL CTR TOXICOL RES, JEFFERSON, AR 72079 USA.
UNIV ARKANSAS MED SCI HOSP, LITTLE ROCK, AR 72205 USA.
NR 46
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD DEC
PY 1992
VL 64-5
SI SI
BP 469
EP 475
DI 10.1016/0378-4274(92)90221-5
PG 7
WC Toxicology
SC Toxicology
GA KE526
UT WOS:A1992KE52600056
PM 1471199
ER
PT J
AU TALASKA, G
SCHAMER, M
BAILEY, JR
ALI, SF
SCALLET, AC
SLIKKER, W
PAULE, MG
AF TALASKA, G
SCHAMER, M
BAILEY, JR
ALI, SF
SCALLET, AC
SLIKKER, W
PAULE, MG
TI NO INCREASE IN CARCINOGEN-DNA ADDUCTS IN THE LUNGS OF MONKEYS EXPOSED
CHRONICALLY TO MARIJUANA SMOKE
SO TOXICOLOGY LETTERS
LA English
DT Article
DE CARCINOGEN-DNA ADDUCTS; LUNG; MARIJUANA; P-32-POSTLABELING
ID P-32-POSTLABELING ASSAY; CIGARETTE-SMOKE; URINARY-BLADDER;
YOUNG-PATIENTS; HEAVY SMOKERS; TOBACCO; CELLS; ACTIVATION; ONCOGENE;
AGENTS
AB Rhesus monkeys exposed to marijuana smoke either 7 or 2 days/weeks (HI and LO groups, respectively), or ethanol-extracted marijuana smoke for 7 days/week (EM) or sham treatment (SH) for 1 year were sacrificed 7 months following the last exposure. Pulmonary levels of carcinogen-DNA adducts were determined. Although mean or median adduct levels were not statistically different, 15 of 22 adduct measures were highest in the EM group and lowest 12 of 22 times in the SH group. The levels of aromatic carcinogen-DNA adducts seem no higher in the lungs of animals exposed to marijuana smoke than in untreated animals. Ethanol-extracted marijuana may have effects greater than marijuana itself.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
RP TALASKA, G (reprint author), UNIV CINCINNATI,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267, USA.
FU NIEHS NIH HHS [1P30 ES 06096-01]; PHS HHS [22483-005]
NR 49
TC 5
Z9 5
U1 1
U2 3
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD DEC
PY 1992
VL 63
IS 3
BP 321
EP 332
DI 10.1016/0378-4274(92)90094-Z
PG 12
WC Toxicology
SC Toxicology
GA KB052
UT WOS:A1992KB05200010
PM 1488780
ER
PT J
AU KELLY, DW
HOLDER, CL
KORFMACHER, WA
GETEK, TA
LAY, JO
CASCIANO, DA
SHADDOCK, JG
DUHART, HM
SLIKKER, W
AF KELLY, DW
HOLDER, CL
KORFMACHER, WA
GETEK, TA
LAY, JO
CASCIANO, DA
SHADDOCK, JG
DUHART, HM
SLIKKER, W
TI METABOLISM OF METHAPYRILENE BY FISCHER-344 RAT AND B6C3F1 MOUSE
HEPATOCYTES
SO XENOBIOTICA
LA English
DT Article
ID PYRILAMINE MALEATE; ANTIHISTAMINES; HYDROCHLORIDE; INVITRO; ASSAY;
LYMPHOMA; THENYLDIAMINE; GENOTOXICITY; ELIMINATION; TOXICITY
AB 1. Suspension cultures of freshly isolated F344 rat and B6C3F1 mouse hepatocytes were compared for their ability to transform various concentrations of methapyrilene (MP).
2. MP metabolites were isolated and purified by h.p.l.c., and were identified by comparing their chromatographic and mass spectral properties with those of authentic standards.
3. Both rat and mouse hepatocytes transformed MP to tentatively identified 2-thiophenecarboxylic acid (I), and definitively identified mono-N-desmethyl methapyrilene glucuronide (II), methapyrilene glucuronide (III), methapyrilene N-oxide (V), and mono-N-desmethyl methapyrilene (VII).
C1 NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,PHARMACODYNAM BRANCH,HFT-132,JEFFERSON,AR 72079.
RI Lay, Jackson/G-1007-2011
OI Lay, Jackson/0000-0003-3789-2527
NR 32
TC 13
Z9 13
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI LONDON
PA ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE
SN 0049-8254
J9 XENOBIOTICA
JI Xenobiotica
PD DEC
PY 1992
VL 22
IS 12
BP 1367
EP 1381
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KG283
UT WOS:A1992KG28300003
PM 1494883
ER
PT J
AU BEHRMAN, RE
KAMMERMAN, LA
FEIGAL, DW
AF BEHRMAN, RE
KAMMERMAN, LA
FEIGAL, DW
TI CONTINUED ZIDOVUDINE OR DIDANOSINE FOR HUMAN-IMMUNODEFICIENCY-VIRUS
INFECTION
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
RP BEHRMAN, RE (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 26
PY 1992
VL 327
IS 22
BP 1598
EP 1599
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA JZ432
UT WOS:A1992JZ43200018
PM 1435893
ER
PT J
AU CANELLOS, GP
ANDERSON, JR
PROPERT, KJ
NISSEN, N
COOPER, MR
HENDERSON, ES
GREEN, MR
GOTTLIEB, A
PETERSON, BA
AF CANELLOS, GP
ANDERSON, JR
PROPERT, KJ
NISSEN, N
COOPER, MR
HENDERSON, ES
GREEN, MR
GOTTLIEB, A
PETERSON, BA
TI CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP
ALTERNATING WITH ABVD
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID TERM FOLLOW-UP; COMBINATION CHEMOTHERAPY; PROGNOSTIC FACTORS;
DACARBAZINE ABVD; BLEOMYCIN; VINBLASTINE; SURVIVAL; ADRIAMYCIN;
TOXICITY; THERAPY
AB Background and Methods. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial, we compared three regimens of primary systemic therapy for newly diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12 cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first relapse after radiation therapy were eligible. No additional radiation therapy was given. Patients who did not have a complete response or who had a relapse with either MOPP alone or ABVD alone were switched to the opposite regimen.
Results. Of 361 eligible patients, 123 received MOPP, 123 received MOPP alternating with ABVD, and 115 received ABVD alone. The patients were stratified according to age, stage, previous radiation, histologic features, and performance status. The overall response rate was 93 percent, with complete responses in 77 percent: 67 percent in the MOPP group, 82 percent in the ABVD group, and 83 percent in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the other two regimens, both of which contained doxorubicin). The rates of failure-free survival at five years were 50 percent for MOPP, 61 percent for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and regimen influenced failure-free survival significantly. Overall survival at five years was 66 percent for MOPP, 73 percent for ABVD, and 75 percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the doxorubicin regimens). MOPP had more severe toxic effects on bone marrow than ABVD and was associated with greater reductions in the prescribed dose.
Conclusions. In this trial, ABVD therapy for 6 to 8 months was as effective as 12 months of MOPP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP.
C1 SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY.
UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455.
HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115.
UNIV NEBRASKA,MED CTR,OMAHA,NE 68105.
HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115.
RIGSHOSP,DEPT HEMATOL,DK-2100 COPENHAGEN,DENMARK.
WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103.
US FDA,ROCKVILLE,MD 20857.
UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093.
RP CANELLOS, GP (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.
FU NCI NIH HHS [CA 31946]
NR 29
TC 676
Z9 695
U1 1
U2 5
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 19
PY 1992
VL 327
IS 21
BP 1478
EP 1484
DI 10.1056/NEJM199211193272102
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA JY165
UT WOS:A1992JY16500002
PM 1383821
ER
PT J
AU KORNBLITH, AB
ANDERSON, J
CELLA, DF
TROSS, S
ZUCKERMAN, E
CHERIN, E
HENDERSON, ES
CANELLOS, GP
KOSTY, MP
COOPER, R
WEISS, RB
GOTTLIEB, A
HOLLAND, JC
AF KORNBLITH, AB
ANDERSON, J
CELLA, DF
TROSS, S
ZUCKERMAN, E
CHERIN, E
HENDERSON, ES
CANELLOS, GP
KOSTY, MP
COOPER, R
WEISS, RB
GOTTLIEB, A
HOLLAND, JC
TI COMPARISON OF PSYCHOSOCIAL ADAPTATION AND SEXUAL FUNCTION OF SURVIVORS
OF ADVANCED HODGKIN DISEASE TREATED BY MOPP, ABVD, OR MOPP ALTERNATING
WITH ABVD
SO CANCER
LA English
DT Article
DE PSYCHOSOCIAL ADAPTATION; PSYCHOSEXUAL; HODGKIN DISEASE; CANCER
SURVIVORS; MOPP; ABVD
ID ILLNESS SCALE PAIS; CANCER SURVIVORS; TESTIS CANCER; TELEPHONE;
CHEMOTHERAPY; INTERVIEW; ADJUSTMENT; CHILDHOOD; ANXIETY
AB Background. Survivors of advanced Hodgkin disease, who were assigned randomly to treatment by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP); doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); or MOPP alternating with ABVD in a clinical trial of the Cancer and Leukemia Group B (protocol 8251), were compared in terms of their psychosocial adaptation and psychosexual function an average of 2.2 years after completion of treatment (range, 1-5 years). The study was undertaken to determine if there were differences among treatments in these functional areas as a consequence of differential long-term gonadal damage in the three regimens.
Methods. Ninety-three disease-free survivors of advanced Hodgkin disease (56 men and 37 women) were studied (a minimum of 1 year after completion of treatment) by an interview conducted over the telephone. Standardized measures were used to assess their psychologic, sexual, family, and vocational functioning, including the following tests: the Psychosocial Adjustment to Illness Scale-Self Report, the Brief Symptom Inventory, the Profile of Mood States, and the Impact of Event Scale.
Results. Contrary to expectation, no statistically significant differences in survivors' psychosocial adaptation or psychosexual function were found by treatment arm. Infertility (based on survivors' reports of medical test results and perceptions) and lower income 1 year before the diagnosis of cancer were significant predictors of poorer adjustment. Most survivors reported a range of problems that they attributed to having had cancer: 35%, proven or perceived infertility; 24%, sexual problems; 31%, health and life insurance problems; 26%, a negative socioeconomic effect; and 51%, conditioned nausea, associated with visual or olfactory reminders of chemotherapy.
Conclusions. No significant long-term advantage in psychosocial adaptation or psychosexual function was found for survivors of Hodgkin disease treated by the less gonadally toxic ABVD regimen 1 to 5 years after completion of treatment.
C1 UNIV NEBRASKA,MED CTR,OMAHA,NE 68105.
RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612.
UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103.
US FDA,ROCKVILLE,MD.
HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115.
SCRIPPS CLIN & RES FDN,SAN DIEGO,CA.
BOWMAN GRAY MED CTR,WINSTON SALEM,NC.
WALTER REED ARMY MED CTR,WASHINGTON,DC 20307.
SUNY SYRACUSE,HLTH SCI CTR,SYRACUSE,NY.
RP KORNBLITH, AB (reprint author), MEM SLOAN KETTERING CANC CTR,PSYCHIAT SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.
FU NCI NIH HHS [CA 03927, CA 32291, CA31946]
NR 50
TC 49
Z9 49
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0008-543X
J9 CANCER
JI Cancer
PD NOV 15
PY 1992
VL 70
IS 10
BP 2508
EP 2516
DI 10.1002/1097-0142(19921115)70:10<2508::AID-CNCR2820701020>3.0.CO;2-V
PG 9
WC Oncology
SC Oncology
GA JX894
UT WOS:A1992JX89400019
PM 1384949
ER
PT J
AU DALY, JW
CACERES, J
MONI, RW
GUSOVSKY, F
MOOS, M
SEAMON, KB
MILTON, K
MYERS, CW
AF DALY, JW
CACERES, J
MONI, RW
GUSOVSKY, F
MOOS, M
SEAMON, KB
MILTON, K
MYERS, CW
TI FROG SECRETIONS AND HUNTING MAGIC IN THE UPPER AMAZON - IDENTIFICATION
OF A PEPTIDE THAT INTERACTS WITH AN ADENOSINE RECEPTOR
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
AB A frog used for "hunting magic" by several groups of Panoan-speaking Indians in the borderline between Brazil and Peru is identified as Phyllomedusa bicolor. This frog's skin secretion, which the Indians introduce into the body through fresh burns, is rich in peptides. These include vasoactive peptides, opioid peptides, and a peptide that we have named adenoregulin, with the sequence GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV as determined from mass spectrometry and Edman degradation. The natural peptide may contain a D amino acid residue, since it is not identical in chromatographic properties to the synthetic peptide. Adenoregulin enhances binding of agonists to A1 adenosine receptors; it is accompanied in the skin secretion by peptides that inhibit binding. The vasoactive peptide sauvagine, the opioid peptides, and adenoregulin and related peptides affect behavior in mice and presumably contribute to the behavioral sequelae observed in humans.
C1 US FDA,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720.
AMER MUSEUM NAT HIST,DEPT HERPETOL & ICHTHYOL,NEW YORK,NY 10024.
RP DALY, JW (reprint author), NIDDKD,BIOORGAN CHEM LAB,BETHESDA,MD 20892, USA.
RI Moos, Malcolm/F-3673-2011
OI Moos, Malcolm/0000-0002-9575-9938
NR 14
TC 85
Z9 90
U1 0
U2 14
PU NATL ACAD PRESS
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 15
PY 1992
VL 89
IS 22
BP 10960
EP 10963
DI 10.1073/pnas.89.22.10960
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JY874
UT WOS:A1992JY87400082
PM 1438301
ER
PT J
AU MILLER, HI
AF MILLER, HI
TI ALTERED FOOD
SO NATURE
LA English
DT Letter
RP MILLER, HI (reprint author), US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20867, USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW
SN 0028-0836
J9 NATURE
JI Nature
PD NOV 12
PY 1992
VL 360
IS 6400
BP 101
EP 101
DI 10.1038/360101b0
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JX752
UT WOS:A1992JX75200023
ER
PT J
AU KADLUBAR, FF
AF KADLUBAR, FF
TI DETECTION OF HUMAN DNA CARCINOGEN ADDUCTS
SO NATURE
LA English
DT Article
ID SENSITIVITY
RP KADLUBAR, FF (reprint author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 8
TC 6
Z9 6
U1 0
U2 0
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW
SN 0028-0836
J9 NATURE
JI Nature
PD NOV 12
PY 1992
VL 360
IS 6400
BP 189
EP 189
DI 10.1038/360189a0
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JX752
UT WOS:A1992JX75200070
PM 1436097
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI ALERT ON CHANGES IN STANDARDIZED CAT ALLERGEN EXTRACT PRODUCTS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 11
PY 1992
VL 268
IS 18
BP 2491
EP 2491
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JW616
UT WOS:A1992JW61600006
PM 1328699
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI PROPOSAL TO PROVIDE MORE PEDIATRIC USE INFORMATION IN DRUG LABELING
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 11
PY 1992
VL 268
IS 18
BP 2491
EP 2491
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JW616
UT WOS:A1992JW61600004
PM 1328699
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI 1ST DRUG AVAILABLE UNDER PARALLEL TRACK POLICY
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 11
PY 1992
VL 268
IS 18
BP 2491
EP 2491
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JW616
UT WOS:A1992JW61600005
PM 1328699
ER
PT J
AU FUJII, N
MINETTI, CASA
NAKHASI, HL
CHEN, SW
BARBEHENN, E
NUNES, PH
NGUYEN, NY
AF FUJII, N
MINETTI, CASA
NAKHASI, HL
CHEN, SW
BARBEHENN, E
NUNES, PH
NGUYEN, NY
TI ISOLATION, CDNA CLONING, AND CHARACTERIZATION OF AN 18-KDA HEMAGGLUTININ
AND AMEBOCYTE AGGREGATION FACTOR FROM LIMULUS-POLYPHEMUS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID C-REACTIVE PROTEIN; AMINO-ACID-SEQUENCE; HORSESHOE-CRAB; INHIBITORY
ACTIVITY; COMPLEMENT-SYSTEM; BINDING PROTEIN; PURIFICATION; PEPTIDE;
CONSUMPTION; SIMILARITY
AB An 18-kDa hemagglutinin which possesses the property of inducing both aggregation of amebocytes and agglutination of erythrocytes has been isolated from Limulus polyphemus amebocytes and purified by ion exchange chromatography. This nonglycosylated, single chain polypeptide with an M(r) of 18,506 and isoelectric point of 8.3 is stored exclusively in the large secretory granules of amebocytes. Based on the partial N-terminal amino acid sequence of 63 residues, DNA probes have been synthesized for screening a pBR322 cDNA library constructed from Limulus amebocytes. The cDNA coding for this protein reveals the presence of a 19-residue signal peptide preceding the 153-residue open reading frame. Northern blot analysis indicates the presence of a single mRNA species. The primary structure derived from the corresponding cDNA sequence reveals an internal homology consisting of two consensus sequences, Val-Asn-Asp/Ser-Trp-Asp and Glu-Asp-Arg-Arg-Trp. The formation of 5 disulfide bonds between 10 half-cysteines divides the molecule into three looped domains each containing the Glu-Asp-Arg-Arg-Trp repeating unit. One of the novel features of this protein is that it shares 37% identity with a 22-kDa mammalian extracellular matrix protein isolated from fetal bovine skin (Neame, P. J., Choi, H. U., and Rosenberg, L. C. (1989) J. Biol. Chem. 264, 5474-5479). The two proteins exhibit a similar pattern of looped domains, each domain containing a homologous consensus sequence (i.e. Glu-Asp-Arg-Arg-Trp). The overall structure of both proteins seems to be highly related, with the exception of an N-terminal tyrosine-rich region present only in the mammalian extracellular matrix protein. The functional properties of the two proteins are similar in that the Limulus 18-kDa protein agglutinates horse erythrocytes and aggregates Limulus amebocytes, and the mammalian 22-kDa protein is an effective adhesion promoter for dermal fibroblasts. On the basis of these unique properties, the newly characterized hemagglutinin has been termed Limulus 18K agglutination-aggregation factor (18K-LAF).
C1 US FDA,DIV CYTOKINE BIOL,CYTOKINE RES LAB,BLDG 29A,RM 2A-09,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
RI Minetti, Conceicao/B-5077-2009
OI Minetti, Conceicao/0000-0002-9682-2898
NR 56
TC 29
Z9 33
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 5
PY 1992
VL 267
IS 31
BP 22452
EP 22459
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JW719
UT WOS:A1992JW71900073
PM 1429596
ER
PT J
AU YUN, CH
HAMMONS, GJ
JONES, G
MARTIN, MV
HOPKINS, NE
ALWORTH, WL
GUENGERICH, FP
AF YUN, CH
HAMMONS, GJ
JONES, G
MARTIN, MV
HOPKINS, NE
ALWORTH, WL
GUENGERICH, FP
TI MODIFICATION OF CYTOCHROME-P450 1A2 ENZYMES BY THE MECHANISM-BASED
INACTIVATOR 2-ETHYNYLNAPHTHALENE AND THE PHOTOAFFINITY LABEL
4-AZIDOBIPHENYL
SO BIOCHEMISTRY
LA English
DT Article
ID OXIDATIVE DRUG-METABOLISM; LIVER MICROSOMAL CYTOCHROME-P-450C;
SITE-DIRECTED MUTAGENESES; CHEMICAL MODIFICATION; GENETIC-POLYMORPHISM;
BINDING SITE; N-OXIDATION; PURIFICATION; CYTOCHROMES-P-450;
IDENTIFICATION
AB 2-Ethynylnaphthalene (2EN) had previously been demonstrated to be a mechanism-based inactivator of rat cytochrome P450 (P450) 1A2 [Hammons, G.J., Alworth, W.L., Hopkins, N.E., Guengerich, F.P., & Kadlubar, F.F. (1989) Chem. Res. Toxicol. 2,367-374]. In this work 2EN was also demonstrated to be a useful inactivator of rabbit P450 1A2 (k(inactivation) 0.094 min-1, K(i) 11 muM) but it did not inactivate human P450 1A2, although the sequences of the three proteins are approximately 80% identical. Rat and rabbit P450 1A2 were modified by incubation with NADPH-P450 reductase, NADPH, and [H-3]2EN to levels of 0.35 and 0.47 nmol of adduct (nmol of P450)-1, respectively. In each case only a single tryptic peptide was labeled; recovery of labeled peptides was low under the acidic HPLC conditions. The rabbit P450 1A2 peptide FQELMAAVGR (positions 175-184) and the rat P450 1A2 peptide L(S)QQYGDVLQIR (positions 67-78) were identified. 4-Azidobiphenyl (4-N3BP) was developed as a photoaffinity label for P-450 1A2 proteins because of its similarity to 4-aminobiphenyl, a known substrate for the enzymes. 4-N3BP was shown to be photolyzed with 350-nm light and radioactive label could be incorporated into rat P450 1A2. Labeling of the protein was found to be saturable with increasing concentrations of 4-N3BP and up to 0.59 nmol of label could be incorporated (nmol P450 1A2)-1. The substrate 4-aminobiphenyl and the competitive inhibitor 7,8-benzoflavone blocked photolabeling of P450 1A2 with 4-N3BP, and 4-N3BP inhibited N-hydroxylation of 4-aminobiphenyl by P450 1A2 in the usual enzyme assay. SEEMLNLVK (positions 212-220) was isolated as the only labeled peptide from modified rat P450 1A2. With 4-N3BP-modified rabbit P450 1A2, only a very hydrophobic portion was labeled and this binding was not attenuated by 4-aminobiphenyl. The results indicate quite different labeling patterns for three P450s having a high degree of primary sequence similarity. On the basis of the predictions of others about three-dimensional locations of the residues in P450 1A2 proteins, the regions 67-78 and 175-184 might respectively correspond to the so-called A and D helices of P450 101 [Poulos, T. L. (1988) Pharm. Res. 5, 67-751. It is of interest that the region of rat P450 1A2 modified by 4-N3BP (212-220) is near a corresponding site of mouse P450 2A5 where mutagenesis has been shown to modulate both catalytic specificity and heme distal ligation [Iwasaki, M., Juvonen, R., Lindberg, R., & Negishi, M. (1991) J. Biol. Chem. 266, 3380-3382].
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232.
TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118.
VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232.
FU NCI NIH HHS [CA 44353, CA 38192]; NIEHS NIH HHS [ES 00267]
NR 62
TC 57
Z9 59
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD NOV 3
PY 1992
VL 31
IS 43
BP 10556
EP 10563
DI 10.1021/bi00158a019
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JW440
UT WOS:A1992JW44000019
PM 1420171
ER
PT J
AU WEICK, MD
AF WEICK, MD
TI PHYSICAL RESTRAINTS - AN FDA UPDATE
SO AMERICAN JOURNAL OF NURSING
LA English
DT Article
RP WEICK, MD (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,DIV SURVEILLANCE,OFF COMPLIANCE & SURVEILLANCE,WASHINGTON,DC, USA.
NR 11
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0002-936X
J9 AM J NURS
JI Am. J. Nurs.
PD NOV
PY 1992
VL 92
IS 11
BP 74
EP &
DI 10.2307/3426944
PG 0
WC Nursing
SC Nursing
GA JW590
UT WOS:A1992JW59000023
PM 1485634
ER
PT J
AU ABASSI, ZA
TATE, J
HUNSBERGER, S
KLEIN, H
TRACHEWSKY, D
KEISER, HR
AF ABASSI, ZA
TATE, J
HUNSBERGER, S
KLEIN, H
TRACHEWSKY, D
KEISER, HR
TI PHARMACOKINETICS OF ANF AND URODILATIN DURING CANF RECEPTOR BLOCKADE AND
NEUTRAL ENDOPEPTIDASE INHIBITION
SO AMERICAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE URODILATIN; ATRIAL NATRIURETIC FACTOR; NEUTRAL ENDOPEPTIDASE INHIBITOR;
CLEARANCE ATRIAL NATRIURETIC FACTOR RECEPTOR LIGAND; METABOLIC CLEARANCE
RATE; VOLUME OF DISTRIBUTION; HALF-TIME; HYDROLYSIS OF URODILATIN;
HYDROLYSIS OF ATRIAL NATRIURETIC FACTOR
ID ATRIAL-NATRIURETIC-FACTOR; BLOOD-PRESSURE; HEART-FAILURE; CYCLIC-GMP;
PEPTIDE; RATS; KIDNEY; MEMBRANES; METALLOENDOPEPTIDASE; ENKEPHALINASE
AB Urodilatin is a new member of the family of natriuretic peptides. It is of renal origin. Previous reports indicate that urodilatin is natriuretic in lower doses than atrial natriuretic factor (ANF)-(99-126) and that it might be more effective than ANF in the treatment of cardiovascular edema. The present study was designed to compare the pharmacokinetics of the hydrolysis and clearance of I-125-labeled urodilatin and I-125-ANF. In control rats, the volume of distribution (V(ss)), metabolic clearance rate (MCR), and distribution half-life (distribution t1/2) of urodilatin in plasma were not significantly different from those of ANF. Infusion of clearance (c)ANF-(4-23), a specific ligand for receptors that clear ANF in excess amounts (i.e., a bolus injection of 100 mug/kg followed by a continuous infusion of 10 mug.kg-1-min-1), increased the amount of intact peptide in the plasma to the same extent for both urodilatin and ANF. In addition, cANF-(4-23) decreased the V(ss) and the MCR and increased the distribution t1/2 of both peptides to about the same degree. Prior treatment of rats with SQ-28,603, a specific neutral endopeptidase (NEP; EN 3.4.24.11) inhibitor, was without significant effect on the metabolic clearance of urodilatin, whereas it decreased the clearance of ANF by 65%. Furthermore, an infusion of SQ-28, 603 suppressed the appearance of the hydrolytic products of ANF in blood but not of urodilatin. Moreover, the inhibitor increased the total amount of ANF recovered in the kidneys to five times the control values, whereas it did not alter the renal uptake of urodilatin. These data demonstrate that urodilatin is removed from the circulation mainly by cANF receptors, whereas circulating ANF-(99-126) is cleared by both cANF receptors and NEP. This may contribute to the differences in the natriuretic potency of these two peptides, despite similar distribution t1/2, MCR, and V(ss).
C1 US FDA,CTR DRUG EVALUAT,ROCKVILLE,MD 20857.
US FDA,COLL RES STAFF,ROCKVILLE,MD 20857.
RP ABASSI, ZA (reprint author), NHLBI,HYPERTENS ENDOCRINE BRANCH,BLDG 10,RM 8C103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 39
TC 29
Z9 29
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0002-9513
J9 AM J PHYSIOL
JI Am. J. Physiol.
PD NOV
PY 1992
VL 263
IS 5
BP E870
EP E876
PN 1
PG 7
WC Physiology
SC Physiology
GA JZ778
UT WOS:A1992JZ77800033
PM 1443119
ER
PT J
AU POTHULURI, JV
FREEMAN, JP
EVANS, FE
CERNIGLIA, CE
AF POTHULURI, JV
FREEMAN, JP
EVANS, FE
CERNIGLIA, CE
TI FUNGAL METABOLISM OF ACENAPHTHENE BY CUNNINGHAMELLA-ELEGANS
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; MICROBIAL-METABOLISM; DETOXIFICATION;
CONTAMINANTS; NAPHTHALENE; OXIDATION
AB The filamentous fungus Cunninghamella elegans ATCC 36112 metabolized within 72 h of incubation approximately 64% of the [1,8-C-14]acenaphthene added. The radioactive metabolites were extracted with ethyl acetate and separated by thin-layer chromatography and reversed-phase high-performance liquid chromatography. Seven metabolites were identified by H-1 nuclear magnetic resonance, UV, and mass spectral techniques as 6-hydroxyacenaphthenone (24.8%), 1,2-acenaphthenedione (19.9%), trans-1,2-dihydroxyacenaphthene (10.3%), 1,5-dihydroxyacenaphthene (2.7%), 1-acenaphthenol (2.4%), 1-acenaphthenone (2.1%), and cis-1,2-dihydroxyacenaphthene (1.8%). Parallel experiments with rat liver microsomes indicated that the major metabolite formed from acenaphthene by rat liver microsomes was 1-acenaphthenone. The fungal metabolism of acenaphthene was similar to bacterial and mammalian metabolism, since the primary site of enzymatic attack was on the two carbons of the five-member ring.
C1 US FDA,NATL CTR TOXICOL RES,DIV MICROBIOL,JEFFERSON,AR 72079.
NR 30
TC 26
Z9 28
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD NOV
PY 1992
VL 58
IS 11
BP 3654
EP 3659
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA JW473
UT WOS:A1992JW47300031
PM 1482186
ER
PT J
AU SU, SY
SHIU, GK
SIMMONS, J
VISWANATHAN, CT
SKELLY, JP
AF SU, SY
SHIU, GK
SIMMONS, J
VISWANATHAN, CT
SKELLY, JP
TI HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF 6 CONJUGATED AND
UNCONJUGATED ESTROGENS IN SERUM
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article
ID HORMONE REPLACEMENT; MENOPAUSE; PHARMACOKINETICS; NONSMOKERS; SMOKERS;
TABLETS; WOMEN
AB Six estrogens-estrone, equilin, estradiol, sodium estrone sulphate, sodium equilin sulphate and sodium 17-alpha-dihydroequilin sulphate in dog serum were successfully separated and quantified by a high performance liquid chromatographic method developed in our laboratories. The mobile phase was optimized by studying the effects of an organic modifier (acetonitrile) and an ion pairing reagent (tetrabutylammonium hydroxide). The serum sample work-up procedure was designed to recover both conjugated and unconjugated estrogens. The optimum method involved acetonitrile to precipitate serum proteins/peptides and extract estrogens. Residues were reconstituted in 50% acetonitrile in water for injection. The detection limits for these six estrogens via UV detection ranged from 0.5 to 5 ng on-column with a signal-to-noise ratio (S/N) of 10 for a 20 muL injection and via fluorescence 0.1 ng on-column for 17-beta-estradiol. Validation data are included for all six estrogens.
C1 US FDA,BIOPHARMACEUT RES BRANCH,WASHINGTON,DC 20204.
US FDA,DIV BIOPHARMACEUT,ROCKVILLE,MD 20857.
US FDA,OFF RES RESOURCES,WASHINGTON,DC 20204.
US FDA,OFF GENER DRUGS,ROCKVILLE,MD 20855.
NR 20
TC 7
Z9 7
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0269-3879
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD NOV-DEC
PY 1992
VL 6
IS 6
BP 265
EP 268
DI 10.1002/bmc.1130060604
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA JZ662
UT WOS:A1992JZ66200003
PM 1337486
ER
PT J
AU JACKSON, AJ
AF JACKSON, AJ
TI INAPPROPRIATE INCLUSION OF NONQUANTIFIABLE PLASMA-CONCENTRATIONS IN THE
ESTIMATION OF EXTENT OF ABSORPTION
SO BIOPHARMACEUTICS & DRUG DISPOSITION
LA English
DT Note
DE ABSORPTION; NONQUANTIFIABLE PLASMA CONCENTRATIONS
ID PHARMACOKINETICS; BIOEQUIVALENCE; FORMULATIONS
RP JACKSON, AJ (reprint author), US FDA,DIV BIOEQUIVALENCE,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857, USA.
NR 11
TC 2
Z9 2
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0142-2782
J9 BIOPHARM DRUG DISPOS
JI Biopharm. Drug Dispos.
PD NOV
PY 1992
VL 13
IS 8
BP 629
EP 634
DI 10.1002/bdd.2510130808
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA JV901
UT WOS:A1992JV90100007
PM 1421054
ER
PT J
AU KREITMAN, RJ
CHAUDHARY, VK
KOZAK, RW
FITZGERALD, DJP
WALDMANN, TA
PASTAN, I
AF KREITMAN, RJ
CHAUDHARY, VK
KOZAK, RW
FITZGERALD, DJP
WALDMANN, TA
PASTAN, I
TI RECOMBINANT TOXINS CONTAINING THE VARIABLE DOMAINS OF THE ANTI-TAC
MONOCLONAL-ANTIBODY TO THE INTERLEUKIN-2 RECEPTOR KILL MALIGNANT-CELLS
FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA
SO BLOOD
LA English
DT Article
ID MULTIVARIATE SURVIVAL ANALYSIS; PSEUDOMONAS EXOTOXIN; DIPHTHERIA-TOXIN;
FUSION PROTEIN; CYTO-TOXICITY; TARGET-CELLS; FRAGMENT-A; IMMUNOTOXIN;
CYTOTOXICITY; EXPRESSION
C1 NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892.
NCI,DIV CANC BIOL DIAG & CTR,METAB BRANCH,BETHESDA,MD 20892.
US FDA,CBER,DIV CYTOKINE BIOL,BETHESDA,MD 20014.
NR 32
TC 44
Z9 46
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 1
PY 1992
VL 80
IS 9
BP 2344
EP 2352
PG 9
WC Hematology
SC Hematology
GA JW436
UT WOS:A1992JW43600026
PM 1421405
ER
PT J
AU POIRIER, MC
BELAND, FA
AF POIRIER, MC
BELAND, FA
TI DNA ADDUCT MEASUREMENTS AND TUMOR-INCIDENCE DURING CHRONIC CARCINOGEN
EXPOSURE IN ANIMAL-MODELS - IMPLICATIONS FOR DNA ADDUCT-BASED HUMAN
CANCER RISK ASSESSMENT
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID DOSE-RESPONSE RELATIONSHIP; MOLECULAR DOSIMETRY; CHEMICAL
CARCINOGENESIS; RAT-LIVER; BLADDER; 2-ACETYLAMINOFLUORENE; AFLATOXIN-B1;
4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; DIETHYLNITROSAMINE;
INDUCTION
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
RP POIRIER, MC (reprint author), NCI,DIV CANC ETIOL,BLDG 37,ROOM 3B25,BETHESDA,MD 20892, USA.
NR 38
TC 156
Z9 157
U1 2
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0893-228X
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD NOV-DEC
PY 1992
VL 5
IS 6
BP 749
EP 755
DI 10.1021/tx00030a003
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA KB009
UT WOS:A1992KB00900004
PM 1489923
ER
PT J
AU HERRENOSAENZ, D
EVANS, FE
HEINZE, T
LEWTAS, J
FU, PP
AF HERRENOSAENZ, D
EVANS, FE
HEINZE, T
LEWTAS, J
FU, PP
TI INVITRO METABOLISM AND DNA ADDUCT FORMATION FROM THE MUTAGENIC
ENVIRONMENTAL CONTAMINANT 2-NITROFLUORANTHENE
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; PARTICULATE ORGANIC-MATTER; MICROSOMAL
METABOLISM; 2-NITROPYRENE; 1-NITROPYRENE; BINDING; 3-NITROFLUORANTHENE;
CARCINOGENICITY; DEOXYGUANOSINE; FLUORANTHENE
AB The metabolism and DNA adduct formation by the mutagenic environmental contaminant 2-nitrofluoranthene (2-NFA) were studied. Incubation under aerobic conditions with liver microsomes of rats pretreated with 3-methylcholanthrene yielded trans-7,8-dihydroxy-7,8-dihydro-2-nitrofluoranthene, trans-9,10-dihydroxy-9,10-dihydro-2-nitrofluoranthene, and 7-, 8-, and 9-phenolic metabolites. When the epoxide hydrolase inhibitor 3,3,3-trichloropropylene was present in the incubation, only phenolic metabolites were detected. Under hypoxic conditions, 2-aminofluoranthene was obtained, together with a trace of the ring-oxidized metabolites. The activated metabolite, N-hydroxy-2-aminofluoranthene, was prepared in situ and reacted with calf thymus DNA. Upon enzymatic hydrolysis of the DNA and purification by HPLC, a C8-substituted deoxyguanosine adduct, N-(deoxyguanosin-8-yl)-2-aminofluoranthene, was identified by mass and proton NMR spectral analysis. This adduct was also formed at a level of 10 pmol/mg of DNA when 2-NFA was metabolized by xanthine oxidase, 6 pmol/mg of DNA from incubation with liver microsomes of rats pretreated with 3-methylcholanthrene, and 3-pmol/mg of DNA from metabolism by liver microsomes of rats pretreated with phenobarbital.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
US EPA,DIV GENET TOXICOL,RES TRIANGLE PK,NC 27711.
NR 34
TC 15
Z9 15
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0893-228X
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD NOV-DEC
PY 1992
VL 5
IS 6
BP 863
EP 869
DI 10.1021/tx00030a021
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA KB009
UT WOS:A1992KB00900022
PM 1489938
ER
PT J
AU LUMPKIN, MM
BURLINGTON, DB
PECK, CC
KESSLER, D
AF LUMPKIN, MM
BURLINGTON, DB
PECK, CC
KESSLER, D
TI GUIDELINES FOR THE EVALUATION OF ANTIINFECTIVE DRUG PRODUCTS - PREFACE -
FDA
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 US FDA,CTR DRUG EVALUAT & RES,WASHINGTON,DC 20204.
RP LUMPKIN, MM (reprint author), US FDA,DIV ANTIINFECT DRUG PROD,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV
PY 1992
VL 15
SU 1
BP S3
EP S3
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA JX586
UT WOS:A1992JX58600002
ER
PT J
AU KADLUBAR, FF
BUTLER, MA
KADERLIK, KR
CHOU, HC
LANG, NP
AF KADLUBAR, FF
BUTLER, MA
KADERLIK, KR
CHOU, HC
LANG, NP
TI POLYMORPHISMS FOR AROMATIC AMINE METABOLISM IN HUMANS - RELEVANCE FOR
HUMAN CARCINOGENESIS
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID LIVER UDP-GLUCURONOSYLTRANSFERASES; PLATELET PHENOL SULFOTRANSFERASE;
N-HYDROXY ARYLAMINES; HETEROCYCLIC AMINES; CIGARETTE-SMOKING;
URINARY-BLADDER; ACETYLATION PHENOTYPE; COLORECTAL-CARCINOMA; HEMOGLOBIN
ADDUCTS; CAFFEINE CLEARANCE
AB The metabolic pathways associated with carcinogenic aromatic amines in humans provide an excellent example of polymorphisms that appear to be relevant to human carcinogenesis. In this regard, the N-acetylation of arylamines and the O-acetylation of their N-hydroxy metabolites are catalyzed preferentially by a genetically polymorphic acetyltransferase, high activity of which has been correlated with decreased risk for urinary bladder cancer and increased susceptibility to colorectal cancer. Cytochrome P450IA2, the principal liver enzyme involved in aromatic amine N-oxidation, exhibits a wide interindividual variation that appears trimodal in several populations and is clearly inducible by cigarette smoking and probably other host factors as well. UDP-Glucuronosyltransferases, which catalyze the N-glucuronidation of N-hydroxyarylamines and are likely to be responsible for their transport to the colon, show widely varied but unimodal distributions in humans. In contrast, human liver sulfotransferase activity for N-hydroxyarylamines, which would be expected to decrease their transport through the circulation, is catalyzed by a polymorphic enzyme(s) that is expressed at higher levels in blacks, as compared to whites, and could contribute to their relatively lower incidence of urinary bladder cancer. Peroxidative activation of aromatic amines can also occur, especially from prostaglandin H synthase in the urinary bladder and myeloperoxidase in the lungs of cigarette smokers, and both show considerable individual variability, apparently due to the extent of tissue inflammation. In a pilot study, we have examined two of these polymorphisms, acetyltransferase and cytochrome P450IA2, in colorectal cancer/polyp cases (n = 38) and controls (n = 100) and found that, individuals who are both rapid acetylators and rapid N-oxidizers are indeed more prevalent (p < 0.008) among cases (37%) than among controls (16%).
C1 UNIV ARKANSAS MED SCI HOSP, ARKANSAS CANC RES CTR, DEPT SURG, LITTLE ROCK, AR 72205 USA.
RP KADLUBAR, FF (reprint author), NATL CTR TOXICOL RES, OFF RES, JEFFERSON, AR 72079 USA.
NR 68
TC 209
Z9 211
U1 2
U2 5
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 1992
VL 98
BP 69
EP 74
DI 10.2307/3431249
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA KG637
UT WOS:A1992KG63700009
PM 1486865
ER
PT J
AU GUENGERICH, FP
SHIMADA, T
RANEY, KD
YUN, CH
MEYER, DJ
KETTERER, B
HARRIS, TM
GROOPMAN, JD
KADLUBAR, FF
AF GUENGERICH, FP
SHIMADA, T
RANEY, KD
YUN, CH
MEYER, DJ
KETTERER, B
HARRIS, TM
GROOPMAN, JD
KADLUBAR, FF
TI ELUCIDATION OF CATALYTIC SPECIFICITIES OF HUMAN CYTOCHROME-P450 AND
GLUTATHIONE-S-TRANSFERASE ENZYMES AND RELEVANCE TO MOLECULAR
EPIDEMIOLOGY
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID PYRROLIZIDINE ALKALOID SENECIONINE; HUMAN-LIVER; OXIDATION; METABOLISM;
RAT; BIOACTIVATION; AFLATOXIN-B1; FORMS; CARCINOGENS; ACTIVATION
AB A number of different approaches have been used to determine the catalytic selectivity of individual human enzymes toward procarcinogens. Studies with cytochrome P450 (P450) enzymes and glutathione S-transferases are summarized here, and recent work with pyrrolizidine alkaloids, aflatoxins, 4,4'-methylenebis(2-chloroaniline), and ethyl carbamate is discussed. In some cases a single enzyme can catalyze both activation and detoxication reactions of a chemical. The purification and characterization of human lung P4501A1 and the development of a noninvasive assay for human P4502E1 are also described.
C1 VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232.
VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37235.
VANDERBILT UNIV,SCH MED,DEPT CHEM,NASHVILLE,TN 37235.
UNIV LONDON MIDDLESEX HOSP,CRC,MOLEC TOXICOL RES GRP,LONDON W1P 6DB,ENGLAND.
JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,DIV ENVIRONM CHEM,BALTIMORE,MD 21205.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP GUENGERICH, FP (reprint author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.
FU NCI NIH HHS [CA 44353]; NIEHS NIH HHS [T32 ES007028, ES 00267, ES 07028]
NR 27
TC 44
Z9 45
U1 0
U2 1
PU NATL INST ENVIRON HEALTH SCI
PI RES TRIANGLE PK
PA PO BOX 12233, RES TRIANGLE PK, NC 27709
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 1992
VL 98
BP 75
EP 80
DI 10.2307/3431250
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA KG637
UT WOS:A1992KG63700010
PM 1486866
ER
PT J
AU KETTERER, B
HARRIS, JM
TALASKA, G
MEYER, DJ
PEMBLE, SE
TAYLOR, JB
LANG, NP
KADLUBAR, FF
AF KETTERER, B
HARRIS, JM
TALASKA, G
MEYER, DJ
PEMBLE, SE
TAYLOR, JB
LANG, NP
KADLUBAR, FF
TI THE HUMAN GLUTATHIONE-S-TRANSFERASE SUPERGENE FAMILY, ITS POLYMORPHISM,
AND ITS EFFECTS ON SUSCEPTIBILITY TO LUNG-CANCER
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID HUMAN-LIVER; CLASS-MU; SUBUNIT CDNA; DNA ADDUCTS; EXPRESSION; GENE;
METABOLISM; LOCUS; PI; IDENTIFICATION
AB Cytosolic glutathione S-transferases (GSTs) are a supergene family of dimeric enzymes capable of detoxifying a number of carcinogenic electrophiles. Of the numerous components of tobacco smoke, the polycyclic aromatic hydrocarbons appear to be the principal compounds that yield substrates for these enzymes, GSTM1-1 being effective with those PAH derivatives so far studied; however, the gene locus for GSTM1 is polymorphic, containing two well-characterized expressing genes and a null allele. Use of cDNA for GSTM1-1 or appropriate fragments of genomic clones as probes in Southern blots indicated that the null allele is due to the absence of GSTM1. In preliminary experiments, described here, with lung tissue from smokers, levels of P-32-postlabeled nuclease P1-enhanced DNA adducts were inversely correlated with levels of antigen cross-reacting with antibody to GSTM1-1, suggesting that initiation depends on the expression of GSTM1-1. Since similar quantities of DNA adducts and GSTM1-1 activity have been shown to occur in bronchial and peripheral lung, however, the development of malignancy, which is usually in the bronchial region, presumably depends on additional factors that bring about promotion and progression, which are not necessarily affected by GSTM1 expression. Two epidemiological studies have been carried out in which a possible correlation between the absence of GSTM1 and lung cancer incidence is considered. In the first, involving a U.S. population sample, smokers with and without lung cancer were phenotyped, and a highly significant correlation between the absence of GSTM1-1 activity and adenocarcinoma of the lung was observed. In the second, involving genotyping of a British population, the correlation between the homozygous GSTM1 null genotype and lung cancer was much less significant and concerned squamous-cell carcinoma.
C1 UNIV CINCINNATI, DEPT ENVIRONM HLTH, DIV IND & ENVIRONM HYG, CINCINNATI, OH 45267 USA.
UNIV ARKANSAS MED SCI HOSP, DEPT SURG, LITTLE ROCK, AR 72205 USA.
NATL CTR TOXICOL RES, JEFFERSON, AR 72079 USA.
RP KETTERER, B (reprint author), UCL, DEPT BIOCHEM, CANC RES CAMPAIGN MOLEC TOXICOL RES GRP, WINDEYER BLDG, CLEVELAND ST, LONDON W1P 6DB, ENGLAND.
NR 42
TC 203
Z9 208
U1 0
U2 3
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 1992
VL 98
BP 87
EP 94
DI 10.2307/3431252
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA KG637
UT WOS:A1992KG63700012
PM 1486868
ER
PT J
AU GAYLOR, DW
KADLUBAR, FF
BELAND, FA
AF GAYLOR, DW
KADLUBAR, FF
BELAND, FA
TI APPLICATION OF BIOMARKERS TO RISK ASSESSMENT
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID CARCINOGEN-DNA ADDUCTS; BLADDER; CANCER; 2-ACETYLAMINOFLUORENE
AB Due to difficulties in conducting epidemiological studies, most estimates of cancer risk are based on data from animal bioassays. Extrapolation of cancer risk estimates in animals to humans requires an assumption of equal potency across species based on the average daily dose. The purpose of this paper is to examine the ability to predict tumor incidence across species from DNA adduct concentrations resulting from exposure to carcinogens. A 100-fold range of structurally diverse adduct concentrations corresponding to the same tumor incidence raises questions about quantitative predictability across chemical classes and across species. Differences in adduct structure, mutagenic efficiency, adduct repair rates, and cellular proliferation could account for some of the differences. For specific carcinogen-DNA adducts, the steady-state levels associated with a 50% tumor incidence appear to vary over a narrower range. An equal incidence of liver tumors was obtained at equal concentrations of aflatoxin B1-DNA adducts for rats and trout. A 2- to 3-fold range of 4-aminobiphenyl-DNA adduct concentrations between mice and dogs appears to be associated with nearly equal bladder tumor incidence, on the basis of limited data. In humans, a 5-fold higher concentration of a 4-aminobiphenyl-DNA adduct in bladders of smokers than of nonsmokers is compatible with the relative risk of bladder cancer due to smoking. DNA adduct concentrations certainly can be used to improve quantification of chemical exposures for epidemiological studies. Although promising, more data are needed to judge the usefulness of DNA adduct concentrations to predict cancer incidence across species.
RP GAYLOR, DW (reprint author), US FDA,NATL CTR TOXICOL RES,BIOMETRY STAFF,JEFFERSON,AR 72079, USA.
NR 10
TC 15
Z9 15
U1 0
U2 0
PU NATL INST ENVIRON HEALTH SCI
PI RES TRIANGLE PK
PA PO BOX 12233, RES TRIANGLE PK, NC 27709
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 1992
VL 98
BP 139
EP 141
DI 10.2307/3431260
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA KG637
UT WOS:A1992KG63700020
PM 1486842
ER
PT J
AU RUHL, S
SCHWABE, M
PLUZNIK, DH
AF RUHL, S
SCHWABE, M
PLUZNIK, DH
TI INTERLEUKIN-1 AUGMENTS THE EXPRESSION OF THE INTERLEUKIN-2 RECEPTOR
ALPHA-CHAIN IN INTERLEUKIN-6-STIMULATED MYELOID CELLS BY A
TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL MECHANISM
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
DE INTERLEUKIN-2 RECEPTOR; INTERLEUKIN-6; INTERLEUKIN-1; TRANSCRIPTIONAL;
POSTTRANSCRIPTIONAL REGULATION
ID PERIPHERAL-BLOOD MONOCYTES; COLONY-STIMULATING FACTOR; GENE-EXPRESSION;
IL-2 RECEPTORS; LEUKEMIA CELLS; GROWTH-FACTOR; BETA-CHAIN; GM-CSF;
DIFFERENTIATION; SUBUNIT
AB We have recently shown that interleukin 6 (IL-6) induces transient expression of the alpha-chain of the interleukin 2 receptor (IL-2Ralpha) in the murine leukemia myeloid M1 cell line. Others have reported that IL-6 and interleukin 1 (IL-1) synergistically enhance the expression of IL-2Ralpha in T cells. Thus, in the present study, we investigated whether IL-1 affects the kinetics of IL-6-induced IL-2Ralpha expression in M1 cells. By cytofluorometry, we find that surface expression of IL-2Ralpha at 24 h after induction by IL-6 is strongly enhanced by IL-1. However, IL-1 does not change the transient kinetics of expression of IL-2Ralpha. Binding data and Scatchard analysis support these results and show an increase from 3100 to 17,620 low-affinity IL-2 binding sites per cell without any change in affinity after induction of M1 cells by the combination of IL-6 and IL-1. By Northern analysis, we find that the increase in IL-2Ralpha surface expression after treatment with IL-6 and IL-1 occurs in parallel with an increase in IL-2Ralpha but not IL-2Rbeta mRNA expression. By nuclear run-on analysis and actinomycin-D chase experiments, we find that the increase in IL-2Ralpha mRNA expression is due to both an increase in IL-2Ralpha gene transcription and to an increase in IL-2Ralpha mRNA stability. These data suggest that the IL-6-induced expression of IL-2Ralpha can be specifically up-regulated by IL-1, however, without affecting the transient nature in expression of IL-2Ralpha.
C1 US FDA,CTR BIOL EVALUT & RES,DIV CYTOKINE BIOL,HFB-800,BLDG 29A,ROOM 3B-19,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NCI,FREDERICK CANC RES FACIL,BIOCHEM PHYSIOL LAB,BIOL RESPONSE MODIFIER PROGRAM,FREDERICK,MD 21701.
NR 41
TC 4
Z9 4
U1 0
U2 0
PU CARDEN JENNINGS PUBL CO LTD
PI CHARLOTTESVILLE
PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD NOV
PY 1992
VL 20
IS 10
BP 1208
EP 1215
PG 8
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA JW994
UT WOS:A1992JW99400011
PM 1426100
ER
PT J
AU LABORDE, JB
HANSEN, DK
YOUNG, JF
SHEEHAN, DM
HOLSON, RR
AF LABORDE, JB
HANSEN, DK
YOUNG, JF
SHEEHAN, DM
HOLSON, RR
TI PRENATAL DEXAMETHASONE EXPOSURE IN RATS - EFFECTS OF DOSE, AGE AT
EXPOSURE, AND DRUG-INDUCED HYPOPHAGIA ON MALFORMATIONS AND FETAL ORGAN
WEIGHTS
SO FUNDAMENTAL AND APPLIED TOXICOLOGY
LA English
DT Article
ID PITUITARY-ADRENAL ACTIVITY; INDUCED CLEFT-PALATE; GROWTH;
CORTICOSTERONE; BETAMETHASONE; NICOTINE; CORTISOL; FETUSES; PLASMA
RP LABORDE, JB (reprint author), NATL CTR TOXICOL RES,DIV REPRODUCT & DEV TOXICOL,JEFFERSON,AR 72079, USA.
NR 62
TC 37
Z9 39
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0272-0590
J9 FUND APPL TOXICOL
JI Fundam. Appl. Toxicol.
PD NOV
PY 1992
VL 19
IS 4
BP 545
EP 554
DI 10.1016/0272-0590(92)90093-W
PG 10
WC Toxicology
SC Toxicology
GA JY649
UT WOS:A1992JY64900010
PM 1426713
ER
PT J
AU ERNEY, DR
GILVYDIS, DM
AF ERNEY, DR
GILVYDIS, DM
TI DETERMINATION OF TETRAHYDROPHTHALIMIDE IN MILK BY GAS-CHROMATOGRAPHY AND
NITROGEN SELECTIVE DETECTION
SO HRC-JOURNAL OF HIGH RESOLUTION CHROMATOGRAPHY
LA English
DT Note
DE GC; NITROGEN PHOSPHORUS DETECTION; FUSED SILICA OPEN TUBULAR COLUMNS;
SOLID PHASE EXTRACTION; TETRAHYDROPHTHALIMIDE; MILK
ID CAPTAN
RP ERNEY, DR (reprint author), US FDA,PESTICIDES & IND CHEM RES CTR,1560 E JEFFERSON AVE,DETROIT,MI 48207, USA.
NR 10
TC 2
Z9 2
U1 0
U2 0
PU DR ALFRED HUTHIG VERLAG GMBH
PI HEIDELBERG 1
PA POSTFACH 102869, W-69018 HEIDELBERG 1, GERMANY
SN 0935-6304
J9 HRC-J HIGH RES CHROM
JI HRC-J. High Resolut. Chromatogr.
PD NOV
PY 1992
VL 15
IS 11
BP 773
EP 775
PG 3
WC Chemistry, Analytical
SC Chemistry
GA KC391
UT WOS:A1992KC39100013
ER
PT J
AU SAROSI, GA
THOMAS, PM
EGERTON, M
PHILLIPS, AF
KIM, KW
BONVINI, E
SAMELSON, LE
AF SAROSI, GA
THOMAS, PM
EGERTON, M
PHILLIPS, AF
KIM, KW
BONVINI, E
SAMELSON, LE
TI CHARACTERIZATION OF THE T-CELL ANTIGEN RECEPTOR-P60FYN PROTEIN TYROSINE
KINASE ASSOCIATION BY CHEMICAL CROSS-LINKING
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE DIGITONIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION
ID PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; CD4 RECEPTOR;
MONOCLONAL-ANTIBODIES; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; P56LCK;
STIMULATION
AB Engagement of the TCR by specific antigen results in activation of a tyrosine kinase pathway. A candidate for the kinase responsible for the rapid tyrosine phosphorylation detected with T cell activation is p60fyn, a member of the src kinase family. In an earlier study [Samelson et al. (1990) Proc. Natl Acad. Sci. USA 87:43581 this enzyme was co-immunoprecipitated with the TCR from T cells solubilized in digitonin. In that study a sensitive in vitro kinase assay was used to detect the associated p60fyn. It was subsequently found that the reproducibility of the interaction depended on lot-to-lot variations in digitonin. To eliminate the possibility that the association of antigen receptor and kinase is an artifact of solubilization with ill-defined digitonin preparations, a cross-linking protocol was developed to stabilize the interaction between the TCR and p60fyn. T cells were permeabilized with tetanolysin and proteins were cross-linked with the water soluble chemical cross-linker, 3,3' dithiobis(sulfosuccinimidylpropionate). These experiments allowed the confirmation of the interaction between the TCR, p60fyn, and several additional proteins. The cross-linking studies also enabled the mapping of the interaction of p60fyn and associated proteins to the TCR zeta-chain. This technique should have a general use in stabilizing interactions between other receptors and molecules required for intracellular signaling.
C1 NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892.
FDA,CBER,CELL BIOL LAB,BETHESDA,MD 20892.
NR 44
TC 42
Z9 42
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD NOV
PY 1992
VL 4
IS 11
BP 1211
EP 1217
DI 10.1093/intimm/4.11.1211
PG 7
WC Immunology
SC Immunology
GA JZ112
UT WOS:A1992JZ11200002
PM 1472474
ER
PT J
AU BLACK, PL
HARTMANN, D
PENNINGTON, R
PHILLIPS, H
SCHNEIDER, M
TRIBBLE, HR
TALMADGE, JE
AF BLACK, PL
HARTMANN, D
PENNINGTON, R
PHILLIPS, H
SCHNEIDER, M
TRIBBLE, HR
TALMADGE, JE
TI EFFECT OF TUMOR BURDEN AND ROUTE OF ADMINISTRATION ON THE
IMMUNOTHERAPEUTIC PROPERTIES OF POLYINOSINIC POLYCYTIDYLIC ACID
STABILIZED WITH POLY-L-LYSINE IN CARBOXYMETHYL CELLULOSE [POLY(I,C)-LC]
SO INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY
LA English
DT Article
ID MURINE OSTEOGENIC-SARCOMA; KILLER CELL ACTIVITY; I-C; INTERFERON
INDUCERS; CANCER-PATIENTS; MICE; POLYRIBONUCLEOTIDES; AUGMENTATION;
MACROPHAGES; METASTASIS
AB We examined the immunomodulatory and therapeutic activities of poly(I,C) - LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C) - LC treatment was initiated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C) - LC treatment significantly increased antitumor effector cell functions in a variety of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C) - LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.
C1 NIPPON LAROCHE,KANAGAWA 247,JAPAN.
NIH,FREDERICK CANC RES,PRECLIN SCREENING LAB,FREDERICK,MD 21702.
SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406.
UNIV NEBRASKA,MED CTR,OMAHA,NE 68198.
RP BLACK, PL (reprint author), US FDA,DIV ANTIVIRAL DRUG PROD,HFD 530,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
RI Talmadge, James/A-5916-2008
OI Talmadge, James/0000-0002-6328-6056
FU PHS HHS [N01-23910]
NR 59
TC 9
Z9 9
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0192-0561
J9 INT J IMMUNOPHARMACO
JI Int. J. Immunopharmacol.
PD NOV
PY 1992
VL 14
IS 8
BP 1341
EP 1353
DI 10.1016/0192-0561(92)90005-6
PG 13
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA JZ257
UT WOS:A1992JZ25700005
PM 1464467
ER
PT J
AU VOLPE, DA
DU, DL
ZURLO, MG
MONGELLI, N
MURPHY, MJ
AF VOLPE, DA
DU, DL
ZURLO, MG
MONGELLI, N
MURPHY, MJ
TI COMPARATIVE INVITRO MYELOTOXICITY OF FCE-24517, A DISTAMYCIN DERIVATIVE,
TO HUMAN, CANINE AND MURINE HEMATOPOIETIC PROGENITOR CELLS
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE FCE-24517; MYELOTOXICITY; INVITRO; HUMAN; CANINE; MURINE
ID EARLY CLINICAL-TRIALS; ANTITUMOR-ACTIVITY; CONDITIONED MEDIUM; COLONY
FORMATION; CULTURE SYSTEM; FCE 24517; CFU-E; DNA; TOXICOLOGY; BINDING
AB FCE 24517, a derivative of distamycin A, exhibits an unusual antitumor profile in experimental models. As part of its preclinical development, we evaluated the in vitro myelotoxicity of FCE 24517 to human, canine and murine hematopoietic cells. Marrow cells were exposed to the agent (2.7 x 10(-5) - 2.7 nM) for 4 h and then assayed in capillary (human) or Petri dish (canine, murine) clonal cultures. FCE 24517 inhibited myeloid (CFU-gm), erythroid (BFU-e, CFU-e) and megakaryocytic (CFU-meg) colony formation in a concentration-dependent manner. The progenitor cells were generally similar in their response to FCE 24517 within a species. Comparing the different progenitor cell response to FCE 24517, canine CFU-gm and CFU-e were 26- to 221-fold more sensitive to this drug's toxic effects than their human and murine counterparts. This was demonstrated by extremely low IC70 values for the canine CFU-gm (0.001 nM) and CFU-e (0.007 nM). Murine progenitors displayed 1.3- to 10.9-times higher IC70 values than human CFU-gm, BFU-e and CFU-e following 4 hr exposure to FCE 24517. The data demonstrated that a mouse model may better predict human in vitro myelotoxicity to FCE 24517 than beagle dogs.
C1 HIPPLE CANC RES CTR,4100 S KETTERING BLVD,DAYTON,OH 45439.
FARMITALIA CARLO ERBA SPA,MILAN,ITALY.
US FDA,ROCKVILLE,MD 20857.
INST BASIC MED SCI,BEIJING,PEOPLES R CHINA.
NR 19
TC 18
Z9 18
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0167-6997
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD NOV
PY 1992
VL 10
IS 4
BP 255
EP 261
DI 10.1007/BF00944178
PG 7
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA KF634
UT WOS:A1992KF63400002
PM 1487398
ER
PT J
AU BELLO, AC
AF BELLO, AC
TI RAPID ISOLATION OF THE STEROL FRACTION IN EDIBLE OILS USING A SILICA
CARTRIDGE
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A commercial silica cartridge was used successfully to separate the fraction of the unsaponifiable components of edible oils containing the sterols and some related compounds. Analysis by gas chromatography indicates that there is good agreement between the results from samples obtained by the new rapid method and those isolated using the time-consuming thin-layer chromatographic technique. This paper presents comparison data for 7 vegetable oils (peanut, soy, corn, rapeseed, olive, sesame, and coconut), a 2-component blend (olive and soy), and a commercial milk product erroneously labeled cholesterol-free.
RP BELLO, AC (reprint author), US FDA,US CUSTOMHOUSE,ROOM 900,PHILADELPHIA,PA 19106, USA.
NR 6
TC 10
Z9 10
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1992
VL 75
IS 6
BP 1120
EP 1123
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA JZ460
UT WOS:A1992JZ46000027
ER
PT J
AU MARKUS, JR
ORANGERS, J
AF MARKUS, JR
ORANGERS, J
TI ANIMAL DRUGS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP MARKUS, JR (reprint author), US FDA,CTR VET MED,ROCKVILLE,MD 20855, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1992
VL 75
IS 6
BP 1128
EP 1128
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA JZ460
UT WOS:A1992JZ46000030
ER
PT J
AU MARKUS, J
SHERMA, J
AF MARKUS, J
SHERMA, J
TI METHOD-I - LIQUID-CHROMATOGRAPHIC FLUORESCENCE
QUANTITATIVE-DETERMINATION OF ALBENDAZOLE RESIDUES IN CATTLE LIVER
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
C1 LAFAYETTE COLL,DEPT CHEM,EASTON,PA 18042.
RP MARKUS, J (reprint author), US FDA,DEPT HLTH & HUMAN SERV,CTR VET MED,OFF NEW ANIM DRUG EVALUAT,7500 STANDISH PL,ROCKVILLE,MD 20855, USA.
NR 2
TC 14
Z9 14
U1 0
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1992
VL 75
IS 6
BP 1129
EP 1134
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA JZ460
UT WOS:A1992JZ46000031
ER
PT J
AU MARKUS, J
SHERMA, J
AF MARKUS, J
SHERMA, J
TI METHOD-II - GAS-CHROMATOGRAPHIC MASS-SPECTROMETRIC CONFIRMATORY METHOD
FOR ALBENDAZOLE RESIDUES IN CATTLE LIVER
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
C1 LAFAYETTE COLL,DEPT CHEM,EASTON,PA 18042.
RP MARKUS, J (reprint author), US FDA,DEPT HLTH & HUMAN SERV,CTR VET MED,OFF NEW ANIM DRUG EVALUAT,7500 STANDISH PL,ROCKVILLE,MD 20855, USA.
NR 2
TC 8
Z9 8
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1992
VL 75
IS 6
BP 1135
EP 1137
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA JZ460
UT WOS:A1992JZ46000032
ER
PT J
AU HAUSER, J
LEVINE, AS
ENNIS, DG
CHUMAKOV, KM
WOODGATE, R
AF HAUSER, J
LEVINE, AS
ENNIS, DG
CHUMAKOV, KM
WOODGATE, R
TI THE ENHANCED MUTAGENIC POTENTIAL OF THE MUCAB PROTEINS CORRELATES WITH
THE HIGHLY EFFICIENT PROCESSING OF THE MUCA PROTEIN
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID ULTRAVIOLET-LIGHT MUTAGENESIS; ESCHERICHIA-COLI K-12; RECA PROTEIN;
SALMONELLA-TYPHIMURIUM; DNA-REPAIR; SOS MUTAGENESIS; UV-MUTAGENESIS;
HEMOPHILUS-INFLUENZAE; REPRESSOR CLEAVAGE; DEPENDENT CLEAVAGE
AB Inducible mutagenesis in Escherichia coli requires the direct action of the chromosomally encoded UmuDC proteins or functional homologs found on certain naturally occurring plasmids. Although structurally similar, the five umu-like operons that have been characterized at the molecular level vary in their ability to enhance cellular and phage mutagenesis; of these operons, the mucAB genes from the N-group plasmid pKM101 are the most efficient at promoting mutagenesis. During the mutagenic process, UmuD is posttranslationally processed to an active form, UmuD'. To explain the more potent mutagenic efficiency of mucAB compared with that of umuDC it has been suggested that unlike UmuD, intact MucA is functional for mutagenesis. To examine this possibility, we have overproduced and purified the MucA protein. Although functionally similar to UmuD, MucA was cleaved much more rapidly both in vitro and in vivo than UmuD. In vivo, restoration of mutagenesis functions to normally nonmutable recA430, recA433, recA435, or recA730 DELTA(umuDC)595::cat strains by either MucA+ or mutant MucA protein correlated with the appearance of the cleavage product, MucA'. These results suggest that most of the differences in mutagenic phenotype exhibited by MucAB and UmuDC correlate with the efficiency of posttranslational processing of MucA and UmuD rather than an inherent activity of the unprocessed proteins.
C1 NICHHD,VIRUSES & CELLULAR BIOL SECT,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT RES,BETHESDA,MD 20892.
NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892.
NR 62
TC 47
Z9 47
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD NOV
PY 1992
VL 174
IS 21
BP 6844
EP 6851
PG 8
WC Microbiology
SC Microbiology
GA JW091
UT WOS:A1992JW09100016
PM 1400235
ER
PT J
AU MANCHCITRON, JN
ALLEN, J
MOOS, M
LONDON, J
AF MANCHCITRON, JN
ALLEN, J
MOOS, M
LONDON, J
TI THE GENE ENCODING A PREVOTELLA-LOESCHEII LECTIN-LIKE ADHESIN CONTAINS AN
INTERRUPTED SEQUENCE WHICH CAUSES A FRAMESHIFT
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID ORAL BACTERIA; DNA; COAGGREGATIONS; HYBRIDIZATION; PURIFICATION;
CLONING; VECTORS
AB We cloned and sequenced the Prevotella loescheii gene plaA, which encodes a lectin-like adhesin that mediates the coaggregation of P. loescheii 1295 with Streptococcus oralis 34. A probe derived from the N-terminal amino acid sequence of the purified adhesin was used to identify the plaA gene from a P. loescheii genomic library constructed in lambda GEM-11. Sequence analysis of plaA indicates that the initial translation product contains a 22-amino-acid leader. The reading frame of the plaA gene is interrupted after amino acid 28 of the mature protein by a TAA termination codon. Amplification of the P. loescheii genomic DNA in the region surrounding this codon by the polymerase chain reaction followed by DNA sequencing of the cloned DNA fragment established that this stop codon was not an experimental artifact. A frameshift beginning 29 bp downstream of the ochre terminator was required to access the only large open reading frame in the gene. Amino acid sequences of six purified peptides derived by limited proteolysis of adhesin with endoproteinase Lys-C matched the downstream amino acid sequence derived by translation of the large open reading frame. The gene coding sequence of 2.4 kb contains sufficient information for the synthesis of an 89-kDa protein. A putative rho-independent terminator (DELTAG = -25.5 kcal/mol [ca. -107 kJ/mol]) was detected 38 bp downstream from the plaA stop codon.
C1 US FDA,CTR BIOL EVALUAT & RES,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
RP MANCHCITRON, JN (reprint author), NATL INST DENTAL RES,MICROBIAL ECOL LAB,BETHESDA,MD 20892, USA.
RI Moos, Malcolm/F-3673-2011
OI Moos, Malcolm/0000-0002-9575-9938
FU NIDCR NIH HHS [5F32DEO5554]
NR 27
TC 16
Z9 17
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD NOV
PY 1992
VL 174
IS 22
BP 7328
EP 7336
PG 9
WC Microbiology
SC Microbiology
GA JY560
UT WOS:A1992JY56000035
PM 1429455
ER
PT J
AU SHOMBERT, DG
AF SHOMBERT, DG
TI MEASUREMENT OF STEADY-FLOW INSTABILITY AND TURBULENCE LEVELS IN DACRON
VASCULAR GRAFTS
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
ID HEART-VALVE PROSTHESES; VELOCITY DISTRIBUTION; PULSATILE FLOW; SHEAR;
VICINITY
AB Fluid dynamic properties of Dacron vascular grafts were studied under controlled steady-flow conditions over a Reynolds number range of 800 to 4500. Knitted and woven grafts having nominal diameters of 6 mm and 10 mm were studied. Thermal anemometry was used to measure centerline velocity at the downstream end of the graft, pressure drop across the graft was also measured. Transition from laminar flow to turbulent flow was observed, and turbulence intensity and turbulent stresses (Reynolds normal stresses) were measured in the turbulent regime. Knitted grafts were found to have greater pressure drop than the woven grafts, and one sample was found to have a critical Reynolds number (R(c)) of less than one-half the value of R(c) for a smooth-walled tube.
RP SHOMBERT, DG (reprint author), US FDA, CTR DEVICES & RADIOL HLTH, OFF SCI & TECHNOL, DIV PHYS SCI, ROCKVILLE, MD 20857 USA.
NR 25
TC 1
Z9 1
U1 0
U2 0
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0148-0731
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD NOV
PY 1992
VL 114
IS 4
BP 521
EP 526
DI 10.1115/1.2894105
PG 6
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA KB055
UT WOS:A1992KB05500015
PM 1487906
ER
PT J
AU STORY, WC
CARUSO, JA
HEITKEMPER, DT
PERKINS, L
AF STORY, WC
CARUSO, JA
HEITKEMPER, DT
PERKINS, L
TI ELIMINATION OF THE CHLORIDE INTERFERENCE ON THE DETERMINATION OF ARSENIC
USING HYDRIDE GENERATION INDUCTIVELY COUPLED PLASMA MASS-SPECTROMETRY
SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
LA English
DT Article
ID GAS-LIQUID SEPARATOR; ATOMIC EMISSION-SPECTROMETRY; POLYATOMIC ION
INTERFERENCES; MEMBRANE GAS; SPECIATION; CHROMATOGRAPHY; SPECTROSCOPY;
ABSORPTION; SELENIUM
C1 UNIV CINCINNATI,DEPT CHEM,CINCINNATI,OH 45221.
US FDA,NATL FORENS CHEM CTR,CINCINNATI,OH 45202.
PROCTER & GAMBLE CO,MIAMI VALLEY LABS,CINCINNATI,OH 45247.
FU NIEHS NIH HHS [ES 03221, ES 04908]
NR 21
TC 72
Z9 73
U1 0
U2 2
PU PRESTON PUBLICATIONS INC
PI NILES
PA 7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648
SN 0021-9665
J9 J CHROMATOGR SCI
JI J. Chromatogr. Sci.
PD NOV
PY 1992
VL 30
IS 11
BP 427
EP 432
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA JX772
UT WOS:A1992JX77200001
PM 1474130
ER
PT J
AU SMITH, PD
SAINI, SS
RAFFELD, M
MANISCHEWITZ, JF
WAHL, SM
AF SMITH, PD
SAINI, SS
RAFFELD, M
MANISCHEWITZ, JF
WAHL, SM
TI CYTOMEGALOVIRUS INDUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY HUMAN
MONOCYTES AND MUCOSAL MACROPHAGES
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE CYTOMEGALOVIRUS; TUMOR NECROSIS FACTOR; AIDS; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD MONOCYTES;
PLATELET-ACTIVATING FACTOR; AIDS-RELATED COMPLEX; GENE-EXPRESSION;
MONONUCLEAR-CELLS; BOWEL NECROSIS; INTERLEUKIN-1; INFECTION; TYPE-1
AB Cytomegalovirus (CMV) is a major cause of inflammatory organ disease in immunosuppressed persons. To elucidate the mechanisms of CMV-induced inflammation, we investigated whether tumor necrosis factor-alpha (TNF-alpha) was involved in the pathogenesis of CMV colitis in patients with AIDS. In in situ hybridization experiments, TNF-alpha mRNA was shown to be abundantly present in colonic mucosa from AIDS patients with CMV colitis but not in colonic mucosa from control (AIDS and normal) subjects. The TNF-alpha transcripts, identified in macrophage-like cells containing cytomegalic inclusions, were positively associated with CMV, but not HIV-1, within the mucosa. In in vitro experiments, a patient-derived isolate of CMV, but not HIV-1Ba-L, induced human monocytes to express TNF-alpha mRNA and to release increased levels of TNF-alpha peptide following stimulation. CMV induction of TNF-alpha may play a critical role in CMV-induced inflammation and, since TNF-alpha upregulates expression of HIV-1, offers a mechanism by which CMV could serve as a co-factor for HIV-1 expression without both viruses infecting the same cell.
C1 US FDA,CTR BIOL & RES,BETHESDA,MD 20892.
NCI,PATHOL LAB,HEMATOPATHOL SECT,BETHESDA,MD 20892.
RP SMITH, PD (reprint author), NIDR,IMMUNOL LAB,CELLULAR IMMUNOL SECT,BLDG 30,ROOM 322,BETHESDA,MD 20892, USA.
NR 49
TC 122
Z9 123
U1 0
U2 0
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 1992
VL 90
IS 5
BP 1642
EP 1648
DI 10.1172/JCI116035
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA JZ475
UT WOS:A1992JZ47500002
PM 1331170
ER
PT J
AU FENG, P
AF FENG, P
TI COMMERCIAL ASSAY SYSTEMS FOR DETECTING FOODBORNE SALMONELLA - A REVIEW
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID CONVENTIONAL CULTURE PROCEDURE; DEOXYRIBONUCLEIC-ACID HYBRIDIZATION;
NATURALLY CONTAMINATED FOODS; RAPID SCREENING METHOD; GRID
MEMBRANE-FILTER; 1-2 TEST SYSTEM; DNA HYBRIDIZATION; ENZYME-IMMUNOASSAY;
ICE NUCLEATION; EF-18 AGAR
AB Recent advances in diagnostic technology have dramatically altered testing methods for foodborne Salmonella. Many commercial assay systems and kits that use newer technologies are now available to facilitate the identification of Salmonella in foods. These systems include miniaturized biochemical tests, new media formulations, automated instrumentation, DNA probe- and antibody-dependent assays. The technologies used for each system, except miniaturized biochemical tests, are described, and the various assay kit formats are compared. A selected number of comparative studies using foods are discussed. Most commercial assay systems are rapid, simple, and equally as sensitive as standard methods for the detection of Salmonella species.
RP FENG, P (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 45
TC 69
Z9 73
U1 2
U2 3
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD NOV
PY 1992
VL 55
IS 11
BP 927
EP 934
PG 8
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA JY442
UT WOS:A1992JY44200018
ER
PT J
AU MORRIS, SL
NAIR, J
ROUSE, DA
AF MORRIS, SL
NAIR, J
ROUSE, DA
TI THE CATALASE-PEROXIDASE OF MYCOBACTERIUM-INTRACELLULARE -
NUCLEOTIDE-SEQUENCE ANALYSIS AND EXPRESSION IN ESCHERICHIA-COLI
SO JOURNAL OF GENERAL MICROBIOLOGY
LA English
DT Article
ID AVIUM COMPLEX INFECTION; VACCINATED GUINEA-PIGS; HYDROGEN-PEROXIDE;
SALMONELLA-TYPHIMURIUM; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS;
TUBERCULOSIS; BCG; GENE; CLONING
AB The activation of catalase genes in response to oxidative stress may contribute to the intracellular survival of mycobacteria. In this report, the nucleotide sequence of a mycobacterial catalase gene is described. The deduced protein sequence of this Mycobacterium intracellulare gene (MI85) was 60% identical to the Escherichia coli hydroperoxidase I (HPI) protein, 59% identical to the Salmonella typhimurium (HPI) catalase, and 47% identical to a Bacillus stearothermophilus peroxidase. The MI85 protein, expressed in E. coli, has also been shown to have peroxidase and catalase activities. Furthermore, Southern blot hybridizations, which demonstrated that a MI85 gene probe hybridizes with chromosomal DNA from thirteen different strains of mycobacteria, suggest that this catalase-peroxidase gene is prevalent in the mycobacterial genus. The availability of catalase gene probes should permit an evaluation, at the molecular level, of the role of catalase in mycobacterial pathogenesis.
RP MORRIS, SL (reprint author), US FDA,CTR BIOL EVALUAT & RES,MYCOBACTERIA LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 38
TC 35
Z9 36
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1287
J9 J GEN MICROBIOL
JI J. Gen. Microbiol.
PD NOV
PY 1992
VL 138
BP 2363
EP 2370
PN 11
PG 8
WC Microbiology
SC Microbiology
GA JY118
UT WOS:A1992JY11800014
PM 1336034
ER
PT J
AU GABRIELSEN, B
MONATH, TP
HUGGINS, JW
KEFAUVER, DF
PETTIT, GR
GROSZEK, G
HOLLINGSHEAD, M
KIRSI, JJ
SHANNON, WM
SCHUBERT, EM
DARE, J
UGARKAR, B
USSERY, MA
PHELAN, MJ
AF GABRIELSEN, B
MONATH, TP
HUGGINS, JW
KEFAUVER, DF
PETTIT, GR
GROSZEK, G
HOLLINGSHEAD, M
KIRSI, JJ
SHANNON, WM
SCHUBERT, EM
DARE, J
UGARKAR, B
USSERY, MA
PHELAN, MJ
TI ANTIVIRAL (RNA) ACTIVITY OF SELECTED AMARYLLIDACEAE ISOQUINOLINE
CONSTITUENTS AND SYNTHESIS OF RELATED SUBSTANCES
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID ANTINEOPLASTIC AGENTS; THERAPEUTIC ACTIVITY; RAUSCHER LEUKEMIA;
NATURAL-PRODUCTS; ALKALOIDS; RIBAVIRIN; LYCORINE; (+)-LYCORICIDINE;
(+/-)-LYCORINE; SELENAZOFURIN
AB A series of 23 Amaryllidaceae isoquinoline alkaloids and related synthetic analogues were isolated or synthesized and subsequently evaluated in cell culture against the RNA-containing flaviviruses (Japanese encephalitis, yellow fever, and dengue viruses), bunyaviruses (Punta Toro, sandfly fever, and Rift Valley fever viruses), alphavirus (Venezuelan equine encephalomyelitis virus), lentivirus (human immunodeficiency virus-type 1) and the DNA-containing vaccinia virus. Narciclasine [1], lycoricidine [2], pancratistatin [4], 7-deoxypancratistatin [5], and acetates 6-8, isonarciclasine [13a], cis-dihydronarciclasine [14a], trans-dihydronarciclasine [15a], their 7-deoxy analogues 13b-15b, lycorines 16 and 17, and pretazettine [18] exhibited consistent in vitro activity against all three flaviviruses and against the bunyaviruses, Punta Toro and Rift Valley fever virus. Activity against sandfly fever virus was only observed with 7-deoxy analogues. In most cases, however, selectivity of the active compounds was low, with toxicity in uninfected cells (TC50) occurring at concentrations within 10-fold that of the viral inhibitory concentrations (IC50). No activity was observed against human immunodeficiency virus-type 1, Venezuelan equine encephalomyelitis virus, or vaccinia viruses. Pancratistatin [4] and its 7-deoxy analogue 5 were evaluated in two murine Japanese encephalitis mouse models (differing in viral dose challenge, among other factors). In two experiments (low LD50 viral challenge, variant I), prophylactic administration of 4 at 4 and 6 mg/kg/day (2% EtOH/saline, sc, once daily for 7 days, day -1 to +5) increased survival of Japanese-encephalitis-virus-infected mice to 100% and 90%, respectively. In the same model, prophylactic administration of 5 at 40 mg/kg/day in hydroxypropylcellulose (sc, once daily for 7 days, day -1 to +5) increased survival of Japanese-encephalitis-virus-infected mice to 80%. In a second variant (high LD50 viral challenge), administration of 4 at 6 mg/kg/day (ip, twice daily for 9 days, day -1 to +7) resulted in a 50% survival rate. In all cases, there was no survival in the diluent-treated control mice. Thus, 4 and 5 demonstrated activity in mice infected with Japanese encephalitis virus but only at near toxic concentrations. To our knowledge, however, this represents a rare demonstration of chemotherapeutic efficacy (by a substance other than an interferon inducer) in a Japanese-encephalitis-virus-infected mouse model.
C1 USA,MED RES INST INFECT DIS,FT DETRICK,FREDERICK,MD 21702.
ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287.
ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287.
SO RES INST,BIRMINGHAM,AL 35255.
PHARMECO LABS,SIMI VALLEY,CA 93065.
US FDA,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20855.
NR 56
TC 164
Z9 168
U1 3
U2 13
PU AMER SOC PHARMACOGNOSY
PI CINCINNATI
PA LLOYD LIBRARY & MUSEUM 917 PLUM ST, CINCINNATI, OH 45202
SN 0163-3864
J9 J NAT PROD
JI J. Nat. Prod.
PD NOV
PY 1992
VL 55
IS 11
BP 1569
EP 1581
DI 10.1021/np50089a003
PG 13
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA JZ557
UT WOS:A1992JZ55700003
PM 1336040
ER
PT J
AU BENDER, MM
DERBY, BM
AF BENDER, MM
DERBY, BM
TI PREVALENCE OF READING NUTRITION AND INGREDIENT INFORMATION ON FOOD
LABELS AMONG ADULT AMERICANS - 1982-1988
SO JOURNAL OF NUTRITION EDUCATION
LA English
DT Article
AB Comparisons of five Food and Drug Administration Health and Diet Surveys conducted in the 1980s provide estimates of the numbers of consumers who report that they pay attention to ingredient lists and nutrition labels and identify trends based on replicated measures. Recent estimates indicate that more than four out of five U.S. consumers report that they pay attention to one or both types of label information, with just under three-fourths reporting use of each individual information source. There was no net increase in consumer use of the food label ingredient list from 1982 to 1986, but use of the nutrition label increased significantly. Consumers who use both types of labels are more likely to be young (25-34), white, female, better educated, and to follow a self-initiated or doctor-prescribed low-sodium or low-cholesterol diet. Educators now face a challenge-to address remaining knowledge gaps, particularly among population groups who are less likely to use labels, and to develop practical strategies to help all consumers make more effective use of food label information in dietary management.
RP BENDER, MM (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV CONSUMER STUDIES,200 C ST,WASHINGTON,DC 20204, USA.
NR 0
TC 54
Z9 55
U1 1
U2 6
PU DECKER PERIODICALS INC
PI HAMILTON
PA 4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA
SN 0022-3182
J9 J NUTR EDUC
JI J. Nutr. Educ.
PD NOV-DEC
PY 1992
VL 24
IS 6
BP 292
EP 297
PG 6
WC Education, Scientific Disciplines; Nutrition & Dietetics
SC Education & Educational Research; Nutrition & Dietetics
GA KF652
UT WOS:A1992KF65200002
ER
PT J
AU CARROLL, GJ
THURNAU, RC
LEE, JW
WATERLAND, LR
DELLINGER, B
TAYLOR, PH
AF CARROLL, GJ
THURNAU, RC
LEE, JW
WATERLAND, LR
DELLINGER, B
TAYLOR, PH
TI PILOT-SCALE EVALUATION OF AN INCINERABILITY RANKING SYSTEM FOR HAZARDOUS
ORGANIC-COMPOUNDS
SO JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION
LA English
DT Article
AB The U.S. Environmental Protection Agency's (EPA) hazardous waste incinerator performance standards specify a minimum destruction and removal efficiency (DRE) for principal organic hazardous constituents (POHCs) designated in the incinerator waste feed. In the past, selection of appropriate POHCs for incinerator trial burns has been based largely on their heats of combustion. Attempting to improve upon this approach, the University of Dayton Research Institute (UDRI), under contract to the EPA Risk Reduction Engineering Laboratory, has developed a thermal stability-based ranking of compound "incinerability". The subject study was conducted to evaluate the laboratory-developed ranking system in a pilot-scale incinerator.
Mixtures of POHCs, spanning the ranking scale from most- to least-difficult to destroy (Class 1 to Class 7, respectively), were prepared and combined with a clay-based sorbent matrix. These mixtures were then fed into the rotary kiln incineration system at the U.S. EPA Incineration Research Facility (IRF). In a series of five tests, the following conditions were evaluated: baseline/typical operation; thermal failure (quenching); mixing failure (overcharging); matrix failure (low feed H/Cl ratio); and a worst-case combination of the three failure modes.
Under baseline conditions, mixing failure, and matrix failure, kiln-exit DREs for each compound were comparable from test to test. Operating conditions in these 3 modes appeared to be sufficient to effect considerable destruction (greater than 99.99 percent DRE) of all compounds. As a result, separation of the highest-ranked POHCs from the lowest-ranked POHCs according to observed DRE was not possible; a correlation between POHC ranking and DRE could not be confirmed.
A correlation between predicted and observed incinerability was more evident for the thermal failure and worst-case conditions. Kiln-exit DREs for the four POHCs predicted to be most stable (those in Classes 1 and 2) ranged from 99% to 99.99% under these conditions, and were generally lower than DREs for the POHCs predicted to be more easily destroyed. Statistically-significant correlations above the 99 percent and 93 percent confidence intervals were identified for the thermal-failure and worst-case tests, respectively.
C1 NCTR,IRF,JEFFERSON,AR 72079.
ACUREX CORP,JEFFERSON,AK.
UNIV DAYTON,RES INST,DIV MAT ENGN,ENVIRONM SCI GRP,DAYTON,OH 45469.
RP CARROLL, GJ (reprint author), US EPA,RISK REDUCT ENGN LAB,CINCINNATI,OH 45268, USA.
NR 5
TC 3
Z9 3
U1 0
U2 0
PU AIR & WASTE MANAGEMENT ASSOC
PI PITTSBURGH
PA PO BOX 2861, PITTSBURGH, PA 15230
SN 1047-3289
J9 J AIR WASTE MANAGE
JI J. Air Waste Manage. Assoc.
PD NOV
PY 1992
VL 42
IS 11
BP 1430
EP 1436
PG 7
WC Engineering, Environmental; Environmental Sciences; Meteorology &
Atmospheric Sciences
SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric
Sciences
GA JZ291
UT WOS:A1992JZ29100005
ER
PT J
AU SCHOEN, FJ
LEVY, RJ
HILBERT, SL
BIANCO, RW
AF SCHOEN, FJ
LEVY, RJ
HILBERT, SL
BIANCO, RW
TI ANTIMINERALIZATION TREATMENTS FOR BIOPROSTHETIC HEART-VALVES -
ASSESSMENT OF EFFICACY AND SAFETY
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID BOVINE PERICARDIUM; DYSTROPHIC CALCIFICATION; FAILURE; MINERALIZATION;
MECHANISMS; PREVENTION; FIXATION; MODEL
AB Since calcification limits the durability of contemporary bioprosthetic heart valves, antimineralization treatments are being widely investigated. Potential antimineralization treatments must have sustained prevention of mineralization without adverse effects. The preclinical investigation of efficacy and safety of antimineralization treatments comprises four essential steps: (1) subcutaneous implantation in small animals, (2) in vitro biomechanical studies of hemodynamics and durability, (3) morphology of unimplanted valves, and (4) circulatory implants in large animals.
C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115.
UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48104.
UNIV MICHIGAN,SCH MED,DEPT COMMUNICABLE DIS,ANN ARBOR,MI 48104.
UNIV MICHIGAN,SCH MED,DEPT PHARMACEUT,ANN ARBOR,MI 48104.
US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,ROCKVILLE,MD 20857.
UNIV MINNESOTA,DEPT SURG,MINNEAPOLIS,MN 55455.
RP SCHOEN, FJ (reprint author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.
NR 29
TC 54
Z9 57
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD NOV
PY 1992
VL 104
IS 5
BP 1285
EP 1288
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA JX174
UT WOS:A1992JX17400016
PM 1434707
ER
PT J
AU PEGUES, DA
BECKSAGUE, CM
WOOLLEN, SW
GREENSPAN, B
BURNS, SM
BLAND, LA
ARDUINO, MJ
FAVERO, MS
MACKOW, RC
JARVIS, WR
AF PEGUES, DA
BECKSAGUE, CM
WOOLLEN, SW
GREENSPAN, B
BURNS, SM
BLAND, LA
ARDUINO, MJ
FAVERO, MS
MACKOW, RC
JARVIS, WR
TI ANAPHYLACTOID REACTIONS ASSOCIATED WITH REUSE OF HOLLOW-FIBER
HEMODIALYZERS AND ACE INHIBITORS
SO KIDNEY INTERNATIONAL
LA English
DT Article
ID CONVERTING-ENZYME INHIBITORS; FLUX MEMBRANE DIALYSIS; ANAPHYLATOXIN
FORMATION; COMPLEMENT ACTIVATION; DIALYZER; HYPERSENSITIVITY; MECHANISMS
AB From July 18 through November 27, 1989, 12 anaphylactoid reactions (ARs) occurred in 10 patients at a hemodialysis center in Virginia. One patient required hospitalization; no patients died. ARs occurred within minutes of initiating dialysis and were characterized by peripheral numbness and tingling, laryngeal edema or angioedema, facial or generalized sensation of warmth, and/or nausea or vomiting. All 12 ARs occurred with dialyzers that had been reprocessed with an automated reprocessing system. A cohort study, including all patients undergoing dialysis sessions on the six days when an AR occurred, showed that the patients who experienced ARs were significantly more likely than patients who did not to be treated with angiotensin-converting enzyme (ACE) inhibitors (7/10 vs. 3/33; relative risk = 7.9; 95% confidence interval = 2.5 to 25.2) and to have been exposed to reused dialyzers rather than to new dialyzers (12/70 sessions vs. 0/31; P = 0.016). In those sessions using a reused dialyzer, the mean number of dialyzer uses in case-sessions was significantly higher than for noncase-sessions (10.3 vs. 6.2; P = 0.016). After reuse of dialyzers was discontinued at the center, no further ARs occurred, despite the continued administration of ACE inhibitors. This is the first report of an outbreak of ARs associated exclusively with reused dialyzers. We hypothesize that interactions between a dialyzer that has been repeatedly reprocessed and reused, blood, and additional factors, such as ACE inhibitors, increased the risk of developing ARs.
C1 CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A07,ATLANTA,GA 30333.
US FDA,FAIRFAX,VA.
CONTINENTAL DIALYSIS SPRINGFIELD FAIRFAX,SPRINGFIELD,VA.
RI Arduino, Matthew/C-1461-2012
OI Arduino, Matthew/0000-0001-7072-538X
NR 33
TC 63
Z9 63
U1 0
U2 0
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD NOV
PY 1992
VL 42
IS 5
BP 1232
EP 1237
DI 10.1038/ki.1992.409
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA JR518
UT WOS:A1992JR51800022
PM 1453608
ER
PT J
AU CHIARELLI, MP
LAY, JO
AF CHIARELLI, MP
LAY, JO
TI MASS-SPECTROMETRY FOR THE ANALYSIS OF CARCINOGEN-DNA ADDUCTS
SO MASS SPECTROMETRY REVIEWS
LA English
DT Review
ID FAST-ATOM-BOMBARDMENT; CALF THYMUS DNA; DESORPTION CHEMICAL IONIZATION;
BENZOPYRENE DIOL EPOXIDE; NUCLEIC-ACID COMPONENTS; INVITRO REACTION;
REACTION-PRODUCTS; PHOSPHORAMIDE MUSTARD; LIQUID-CHROMATOGRAPHY;
GAS-CHROMATOGRAPHY
C1 NATL CTR TOXICOL RES,DIV CHEM,JEFFERSON,AR 72079.
UNIV ARKANSAS,DEPT CHEM,LITTLE ROCK,AR 72204.
RI Lay, Jackson/G-1007-2011
OI Lay, Jackson/0000-0003-3789-2527
NR 141
TC 56
Z9 56
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0277-7037
J9 MASS SPECTROM REV
JI Mass Spectrom. Rev.
PD NOV
PY 1992
VL 11
IS 6
BP 447
EP 493
DI 10.1002/mas.1280110602
PG 47
WC Spectroscopy
SC Spectroscopy
GA KH559
UT WOS:A1992KH55900001
ER
PT J
AU JUDDE, JG
MAX, EE
AF JUDDE, JG
MAX, EE
TI CHARACTERIZATION OF THE HUMAN-IMMUNOGLOBULIN KAPPA GENE 3 ENHANCER -
FUNCTIONAL IMPORTANCE OF 3 MOTIFS THAT DEMONSTRATE B-CELL-SPECIFIC
INVIVO FOOTPRINTS
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID LIGATION MEDIATED PCR; TRANSCRIPTION FACTORS; DNA-SEQUENCE; SITE;
EXPRESSION; REPRESSOR; ELEMENT; REGION; BINDS; NUCLEOSOMES
AB Using a combination of in vivo footprinting and site-directed mutagenesis, we have functionally characterized an enhancer located 12 kb downstream of the human immunoglobulin kappa constant-region gene. The core enhancer region is highly homologous to the murine 3'kappa enhancer. However, in addition to two regulatory elements homologous to the functional motifs of the murine enhancer, we find a third positive regulatory element in the human enhancer. This element is associated with an 11/12-bp direct repeat (DR) that is well conserved in the murine locus but was not recognized as functionally important in the murine enhancer. Mutation of any of the three motifs of the human enhancer decreases its activity to 3 to 20% of the wild-type level, indicating cooperative interaction between these elements. The DR motif does not resemble any known enhancer element and does not appear to function as a transcriptional activator on its own when present in multiple copies. Interestingly, nuclear extracts from both B- and T-cell lines contain factors binding to DR in vitro, but in vivo footprinting shows no evidence of protein-DNA binding in the T-cell line. This finding suggests that an additional regulatory mechanism, such as the effect of chromatin configuration on accessibility, may be involved in the B-cell-restricted activity of the human 3'kappa enhancer.
C1 US FDA,CTR BIOL EVALUAT & RES,MOLEC IMMUNOL LAB,BETHESDA,MD 20892.
NR 34
TC 38
Z9 38
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 1992
VL 12
IS 11
BP 5206
EP 5216
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA JT845
UT WOS:A1992JT84500042
PM 1406692
ER
PT J
AU MELLERICK, DM
KASSIS, JA
ZHANG, SD
ODENWALD, WF
AF MELLERICK, DM
KASSIS, JA
ZHANG, SD
ODENWALD, WF
TI CASTOR ENCODES A NOVEL ZINC FINGER PROTEIN REQUIRED FOR THE DEVELOPMENT
OF A SUBSET OF CNS NEURONS IN DROSOPHILA
SO NEURON
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MEDIATED ENHANCER DETECTION; GROWTH CONE
GUIDANCE; GENE FUSHI-TARAZU; EARLY NEUROGENESIS; NUCLEAR-PROTEIN;
MESSENGER-RNA; NOTCH LOCUS; CELL FATES; MELANOGASTER
AB Using an enhancer detection screen, we have identified castor, a new gene required for embryonic CNS development in Drosophila. Embryos that lack castor expression have a diminished CNS axonal network and express engrailed aberrantly late in CNS development. castor is unique among the previously described genes involved in Drosophila neurogenesis in that its expression is restricted to a subset of delaminated CNS neuroblasts and to ventral midline glial precursor cells. The putative castor gene product contains a novel zinc-binding domain and multiple transcriptional activation domains, suggesting that it acts as a transcription factor necessary for the development of a subset of CNS neuronal precursors.
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20205.
RP MELLERICK, DM (reprint author), NINCDS,NEUROCHEM LAB,NEUROGENET UNIT,BETHESDA,MD 20892, USA.
OI Kassis, Judith/0000-0001-9268-3213
NR 67
TC 79
Z9 80
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138
SN 0896-6273
J9 NEURON
JI Neuron
PD NOV
PY 1992
VL 9
IS 5
BP 789
EP 803
DI 10.1016/0896-6273(92)90234-5
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA JY552
UT WOS:A1992JY55200001
PM 1418995
ER
PT J
AU SCHANTZ, SL
FERGUSON, SA
BOWMAN, RE
AF SCHANTZ, SL
FERGUSON, SA
BOWMAN, RE
TI EFFECTS OF 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN ON BEHAVIOR OF MONKEYS IN
PEER GROUPS
SO NEUROTOXICOLOGY AND TERATOLOGY
LA English
DT Article
DE 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; TCDD; MONKEY; PERINATAL EXPOSURE;
PEER GROUP SOCIAL BEHAVIOR
ID DELAYED SPATIAL ALTERNATION; POSTNATAL LEAD-EXPOSURE;
POLYCHLORINATED-BIPHENYLS; TOXICITY; TCDD; TRILLION; PLACENTA; PARTS;
MILK; PLAY
AB Adult female rhesus monkeys were fed diets containing 0, 5, or 25 ppt 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for approximately 4 years. They were bred to unexposed males during TCDD exposure (Experiment 1) and again after TCDD exposure ended (Experiment 2). Offspring from both experiments were weaned at 4 months and socialized for 1.5 h/day in groups of four monkeys each beginning at approximately 8 months of age. Each social group contained both control and TCDD-exposed monkeys. In Experiment 2, the offspring were later placed in new social groups containing only monkeys from the same TCDD exposure condition. The TCDD-exposed offspring born concurrent with maternal TCDD exposure (Experiment 1) initiated more rough-tumble play, retreated less during play bouts, and were less often displaced from preferred positions in the playroom. They also engaged in more self-directed behaviors. The behavior of offspring born after maternal TCDD exposure ended (Experiment 2) was not altered when they were socialized with control monkeys. However, some behavioral changes did emerge when they were placed in social groups containing only TCDD-''posed monkeys.
C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
UNIV WISCONSIN,HARLOW PRIMATE LAB,MADISON,WI 53715.
RP SCHANTZ, SL (reprint author), UNIV ILLINOIS,INST ENVIRONM STUDIES,1101 W PEABODY,URBANA,IL 61801, USA.
FU NIEHS NIH HHS [ES07015, ES05377]
NR 39
TC 52
Z9 52
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0892-0362
J9 NEUROTOXICOL TERATOL
JI Neurotoxicol. Teratol.
PD NOV-DEC
PY 1992
VL 14
IS 6
BP 433
EP 446
DI 10.1016/0892-0362(92)90054-E
PG 14
WC Neurosciences; Toxicology
SC Neurosciences & Neurology; Toxicology
GA KE163
UT WOS:A1992KE16300008
PM 1488038
ER
PT J
AU CHEN, ML
AF CHEN, ML
TI AN ALTERNATIVE APPROACH FOR ASSESSMENT OF RATE OF ABSORPTION IN
BIOEQUIVALENCE STUDIES
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE BIOEQUIVALENCE; ABSORPTION RATE; PARTIAL AUC; TRUNCATED AUC; PEAK
CONCENTRATION; TIME TO PEAK
ID BIOAVAILABILITY
AB The partial area method was investigated for evaluation of equivalency in the rate of absorption of immediate release formulations. The applicability of the method was demonstrated with four drugs with different pharmacokinetic/pharmacodynamic characteristics. The confidence interval approach currently employed for bioequivalence determinations was applied to the relevant absorption parameters, including C(max) and partial AUCs. The method was found to be more discriminating than C(max) and/or T(max) in the evaluation of the absorption rate of drugs. The cutoff time or point for partial AUC calculation may vary with the type of drug under study, depending on its clinical use and onset of action. The method was shown to be useful in the assessment of rate of absorption in bioequivalence studies.
RP CHEN, ML (reprint author), US FDA,CTR DRUG EVALUAT & RES,OFF GENER DRUGS,DIV BIOEQUIVALENCE,HFD-655,ROCKVILLE,MD 20857, USA.
NR 14
TC 60
Z9 60
U1 0
U2 0
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD NOV
PY 1992
VL 9
IS 11
BP 1380
EP 1385
DI 10.1023/A:1015842425553
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA KB024
UT WOS:A1992KB02400002
PM 1475222
ER
PT J
AU BICKEL, M
IWAI, Y
PLUZNIK, DH
COHEN, RB
AF BICKEL, M
IWAI, Y
PLUZNIK, DH
COHEN, RB
TI BINDING OF SEQUENCE-SPECIFIC PROTEINS TO THE ADENOSINE-RICH PLUS
URIDINE-RICH SEQUENCES OF THE MURINE GRANULOCYTE MACROPHAGE
COLONY-STIMULATING FACTOR MESSENGER-RNA
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID 3' UNTRANSLATED REGION; CELLS; EXPRESSION; STABILITY; IDENTIFICATION;
LYMPHOKINE; CYTOKINE; INVITRO
AB Adenosine + uridine (AU)-rich sequences in the 3' untranslated region (3'UTR) of the mRNA of many cytokines and oncogenes play an important role in mediating RNA degradation. Among the cytokines containing such AU-rich sequences in their 3'UTR is the hematopoietic growth factor granulocyte/macrophage colony-stimulating factor (GM-CSF). GM-CSF gene expression in T cells is regulated by modulation of mRNA half-life. Transfection studies using murine EL-4 thymoma cells have demonstrated that degradation depends on the presence of specific elements in the 3'UTR, including the AU-rich sequences. A number of AU-binding factors have recently been discovered, suggesting that specific regulation may occur through specific protein-mRNA interaction(s). We present evidence from gel-shift analyses and label-transfer experiments that murine cells contain proteins that bind specifically to AU-rich sequences. Three major proteins of 33, 39.5, and 42 kDa are detected. Phorbol ester treatment of cells does not alter the abundance or apparent binding affinity of the proteins. The 33-kDa protein is present in the cytoplasm of murine and human cells, whereas the 39.5- and 42-kDa proteins are present in murine extracts only. Constitutively expressed AU-binding proteins of the type that we describe may function by directing mRNA degradation in the absence of a stimulus to the contrary.
C1 US FDA, CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20014 USA.
RP UNIV BERN, SCH DENT MED, CH-3000 BERN, SWITZERLAND.
NR 25
TC 55
Z9 55
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 1
PY 1992
VL 89
IS 21
BP 10001
EP 10005
DI 10.1073/pnas.89.21.10001
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JW798
UT WOS:A1992JW79800006
PM 1438189
ER
PT J
AU DOERGE, DR
BAJIC, S
AF DOERGE, DR
BAJIC, S
TI ANALYSIS OF PESTICIDES USING LIQUID-CHROMATOGRAPHY ATMOSPHERIC-PRESSURE
CHEMICAL IONIZATION MASS-SPECTROMETRY
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
AB Seventeen pesticides in five chemical classes (triazines, phenylureas, carbamates, organophosphates, miscellaneous) from the US Environmental Protection Agency's National Pesticide Survey of groundwater contaminants were selected for analysis by atmospheric pressure chemical ionization (APCI-MS). The spectra obtained from most compounds consisted solely of [M + H]+ in positive-ion mode. One example, p-nitrophenol produced only the [M - H]- ion in negative-ion mode. Increasing the potential on the sampling cone effected voltage-dependent fragmentation of all carbamates and alachlor to form diagnostic daughter ions. Detection limits (Limit of detection (LOD), signal-to-noise ratio = 3) in full-scan or selected-ion monitoring mode varied from 0.8-10 ng or 0.01-1 ng, respectively, and calibration curves were highly linear from the LOD to 100 ng. Mobile phase composition (50-100% acetonitrile in water) and flow rate (0.25 and 1.25 mL/min) had small effects on sensitivity of response. These results suggest that the sensitivity of APCI-MS is affected less than that for thermospray and particle beam LC/MS by chemical differences in analyte structure for the pesticide classes tested. The low detection limits, high degree of linearity, the ability to produce diagnostic fragment ions using cone voltage fragmentation and the inter-class versatility suggest that APCI is a valuable technique for multi-residue confirmations of pesticides in groundwater.
C1 VG BIOTECH,ALTRINCHAM WA14 5RZ,CHESHIRE,ENGLAND.
RP DOERGE, DR (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 14
TC 56
Z9 57
U1 4
U2 13
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV
PY 1992
VL 6
IS 11
BP 663
EP 666
DI 10.1002/rcm.1290061107
PG 4
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA JY584
UT WOS:A1992JY58400006
ER
PT J
AU ABIAN, J
STONE, A
MORROW, MG
CREER, MH
FINK, LM
LAY, JO
AF ABIAN, J
STONE, A
MORROW, MG
CREER, MH
FINK, LM
LAY, JO
TI THERMOSPRAY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRIC
DETERMINATION OF CYCLOSPORINS
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID WHOLE-BLOOD; METABOLITES; ELUCIDATION
AB The cyclic undecapeptides cyclosporin (Csp) A, CspD and dihydro CspC (HCspC) were analyzed by high-performance liquid chromatography/thermospray-mass spectrometry (HPLC/TSP-MS) on line with a UV detector. Positive ion partial (1000-1300 u) mass spectra of these compounds could be obtained with 1-2 pmol injected on column. Mass spectra were characterized by signals corresponding to the [M + H]+ ion as well as fragment ions derived from the loss of 112 (CspA and CspD) or 44, 114 and 114 + 44 (HCspC) mass units from the parent ion. The same qualitative profile was observed for negative-ion acquisition where the ions were formed by proton abstraction. The application of the technique to the characterization of CspA and its major hydroxylated and dealkylated metabolites in human blood samples is presented.
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205.
JOHN L MCCLELLAN VET ADM MED CTR,DEPT PATHOL,DIV TOXICOL,LITTLE ROCK,AR 72205.
RI Lay, Jackson/G-1007-2011; Abian, Joaquin/M-1965-2014
OI Lay, Jackson/0000-0003-3789-2527; Abian, Joaquin/0000-0003-2823-5429
NR 14
TC 12
Z9 12
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV
PY 1992
VL 6
IS 11
BP 684
EP 689
DI 10.1002/rcm.1290061111
PG 6
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA JY584
UT WOS:A1992JY58400010
PM 1467551
ER
PT J
AU YEI, S
YU, MW
TANKERSLEY, DL
AF YEI, S
YU, MW
TANKERSLEY, DL
TI PARTITIONING OF HEPATITIS-C VIRUS DURING COHN-ONCLEY FRACTIONATION OF
PLASMA
SO TRANSFUSION
LA English
DT Article
ID NON-B-HEPATITIS; POLYMERASE CHAIN-REACTION; CHRONIC NON-A; INTRAVENOUS
IMMUNOGLOBULIN; VIRAL-RNA; ANTIBODY; GENOME; HEMOPHILIACS; SEQUENCES
AB Because of concern about the safety of immune globulins with respect to transmission of hepatitis C, the partitioning of hepatitis C virus (HCV) during alcohol fractionation of a plasma pool prepared exclusively from anti-HCV-reactive donations was examined. Quantitation of HCV RNA was accomplished by nested polymerase chain reaction (PCR) at limiting dilutions. One PCR unit was arbitrarily defined as the minimum amount of HCV-RNA from which an amplified product could be detected. The starting plasma pool contained 1.4 x 10(5) PCR units per mL. Most of the HCV RNA was found in cryoprecipitate and in Cohn fractions I and III, but it was also detected in fraction II, which is used for immunoglobulin G preparations. A 3.4-percent solution of IgG prepared from this fraction II contained 30 PCR units per mL. The fractionation process leading to immune globulin resulted in overall reduction in HCV RNA by a factor of 4.7 x 10(4). Although the presence of HCV RNA in the final product does not necessarily imply the presence of infectious virus, this work suggests that the safety of immune globulins with respect to HCV transmission is not due solely to the partitioning of HCV away from the immunoglobulin fraction.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,PLASMA DERIVATIVES LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 24
TC 74
Z9 77
U1 0
U2 2
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD NOV-DEC
PY 1992
VL 32
IS 9
BP 824
EP 828
DI 10.1046/j.1537-2995.1992.32993110753.x
PG 5
WC Hematology
SC Hematology
GA KC094
UT WOS:A1992KC09400007
PM 1335184
ER
PT J
AU FENG, P
KEASLER, SP
HILL, WE
AF FENG, P
KEASLER, SP
HILL, WE
TI DIRECT IDENTIFICATION OF YERSINIA-ENTEROCOLITICA IN BLOOD BY POLYMERASE
CHAIN-REACTION AMPLIFICATION
SO TRANSFUSION
LA English
DT Article
ID THERMOSTABLE DNA-POLYMERASE; TRANSFUSION; SEPSIS; PROBE; GENE
AB Primers based on the nucleotide sequence of the virF gene in the pYV plasmid and the chromosomal ail gene were used in polymerase chain reaction (PCR) amplifications to directly, identify Yersinia enterocolitica in blood. Approximately 500 bacteria seeded into 100 muL of blood can be extracted and amplified by PCR to yield positive results. PCR analyses of seven Y. enterocolitica isolates previously implicated in blood contaminations showed that only one isolate harbored the plasmid-borne virF gene; however, all seven isolates were identified effectively by the PCR product amplified from the chromosomal gene. The PCR assay has the potential for use in the identification of Y. enterocolitica contamination in stored units of blood or in the rapid diagnosis of transfusion-related bacteremia caused by Y. enterocolitica.
RP FENG, P (reprint author), US FDA,DIV MICROBIOL,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 25
TC 59
Z9 62
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD NOV-DEC
PY 1992
VL 32
IS 9
BP 850
EP 854
DI 10.1046/j.1537-2995.1992.32993110759.x
PG 5
WC Hematology
SC Hematology
GA KC094
UT WOS:A1992KC09400015
PM 1471250
ER
PT J
AU RONG, Y
LEE, N
LIANG, SM
AF RONG, Y
LEE, N
LIANG, SM
TI ANALYSIS OF IL-2 FUNCTIONAL STRUCTURE BY MULTIPLE CYSTEINE SUBSTITUTIONS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID HUMAN INTERLEUKIN-2; T-CELLS; B-CELLS; RECEPTOR; INVITRO; LYMPHOCYTES;
MUTAGENESIS; RESIDUES; ANTIGEN; GROWTH
RP RONG, Y (reprint author), US FDA,CTR BIOLOGICS EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20014, USA.
NR 21
TC 5
Z9 5
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 30
PY 1992
VL 188
IS 2
BP 949
EP 955
DI 10.1016/0006-291X(92)91147-I
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA JV618
UT WOS:A1992JV61800067
PM 1445335
ER
PT J
AU BALINT, E
GRIMLEY, PM
MICHALIC, R
ASZALOS, A
AF BALINT, E
GRIMLEY, PM
MICHALIC, R
ASZALOS, A
TI MODULATION OF THE ANTIPROLIFERATIVE SIGNAL OF INTERFERON-ALPHA BY
TAMOXIFEN IN U937 CELLS
SO CANCER LETTERS
LA English
DT Article
DE INTERFERON-ALPHA; TAMOXIFEN; U937 CELLS; ANTIPROLIFERATIVE SIGNAL
ID PROTEIN-KINASE-C; INDUCTION; BINDING; ACTIVATION; RECEPTORS; GAMMA;
BRAIN
AB Several clinical protocols are attempting to utilize the combined anti-proliferative signal of interferon-alpha (INF-alpha) and tamoxifen on cancer cells. We demonstrated here that the effect of these two agents on the growth of the premacrophage U937 cells is antagonistic. This antagonistic effect is paralleled by the ability of tamoxifen to modulate the INF-alpha-induced hyperpolarization in these cells. INF-alpha-induced hyperpolarization was shown before to be an integral part of the anti-proliferative signal of this agent. Tamoxifen liberates Ca2+ from intracellular stores of U937 cells but this effect of the drug is not the cause of its antagonistic effect with the anti-proliferative signal of IFN-alpha. We suggest therefore, that the combined effect of these two anti-cancer drugs could also be advantageous for macrophage proliferation.
C1 ATTILA JOZSEF UNIV,INST BIOPHYS,H-6701 SZEGED,HUNGARY.
UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814.
NATL INST HAEMATOL,BUDAPEST,HUNGARY.
RP BALINT, E (reprint author), US FDA,DIV RES & TESTING,WASHINGTON,DC 20204, USA.
NR 27
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD OCT 30
PY 1992
VL 67
IS 1
BP 13
EP 19
DI 10.1016/0304-3835(92)90003-E
PG 7
WC Oncology
SC Oncology
GA JZ550
UT WOS:A1992JZ55000002
PM 1423240
ER
PT J
AU HOLCOMB, M
WILSON, DM
TRUCKSESS, MW
THOMPSON, HC
AF HOLCOMB, M
WILSON, DM
TRUCKSESS, MW
THOMPSON, HC
TI DETERMINATION OF AFLATOXINS IN FOOD-PRODUCTS BY CHROMATOGRAPHY
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Review
ID THIN-LAYER CHROMATOGRAPHY; PERFORMANCE LIQUID-CHROMATOGRAPHY;
POST-COLUMN DERIVATIZATION; LINKED IMMUNOSORBENT-ASSAY; GEL-PACKED
FLOWCELL; PEANUT BUTTER; POSTCOLUMN DERIVATIZATION; FLUORESCENCE
DETECTION; GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY
AB Several chromatographic methods for the determination of aflatoxins in agricultural and food products are reviewed. During the past two decades, identification and determination of aflatoxins were done by thin-layer chromatography (TLC) because it was easy, fast and inexpensive. However, high-performance liquid chromatography (HPLC) using fluorescence detection is now the method of choice for determining aflatoxins and is also growing in popularity for their identification. The reasons for selecting HPLC over TLC can be summarized as the ability to analyze for a wide variety of compounds, including compounds that are easily degraded by heat, light or air, the ease of adaptation to confirmatory procedures, the potential for automation and the dramatic improvement in instrumentation, including the development of increasingly sensitive fluorescence and electrochemical detectors and short, high-resolution, reversed-phase columns.
C1 UNIV GEORGIA,COLL AGR,DEPT PLANT PATHOL,TIFTON,GA 31793.
US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
RP HOLCOMB, M (reprint author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 94
TC 34
Z9 35
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PD OCT 30
PY 1992
VL 624
IS 1-2
BP 341
EP 352
DI 10.1016/0021-9673(92)85687-O
PG 12
WC Chemistry, Analytical
SC Chemistry
GA KE610
UT WOS:A1992KE61000019
PM 1494012
ER
PT J
AU PERSHING, LK
LAMBERT, LD
SHAH, VP
LAM, SY
AF PERSHING, LK
LAMBERT, LD
SHAH, VP
LAM, SY
TI VARIABILITY AND CORRELATION OF CHROMAMETER AND TAPE-STRIPPING METHODS
WITH THE VISUAL SKIN BLANCHING ASSAY IN THE QUANTITATIVE ASSESSMENT OF
TOPICAL 0.05-PERCENT BETAMETHASONE DIPROPIONATE BIOAVAILABILITY IN
HUMANS
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE TOPICAL CORTICOSTEROID; BIOEQUIVALENCE; HUMAN SKIN; VASOCONSTRICTION
ID COMPARATIVE BIO-AVAILABILITY; CORTICOSTEROID PREPARATIONS;
PERCUTANEOUS-ABSORPTION; VASOCONSTRICTOR ASSAYS; CREAMS; OINTMENTS;
RESERVOIR; EFFICACY
AB Bioavailability between five commercial 0.05% betamethasone diproprionate formulations in human skin is demonstrated with three methods; visual skin blanching, tape-stripping and a chromameter. Reproducibility of each method is evaluated for both intra- and inter-subject variability. The variability (coefficient of variation) in the intra-subject studies is consistently less than that in the inter-Subject studies for all methods evaluated. The variability in the subjective visual skin blanching assay increases as a function of time. Variability in the tape-stripping technique performed at one time point only ranges from 7 to 30% in the intra-subject study to greater than 70% in the inter-subject study. Variability in the a scale on the chromamater is consistent over time (approx. 24%). The b scale on the chromameter demonstrates an inter-subject variation of about 15%, while the luminosity scale demonstrates a variability of approx. 6%. The rank order of 0.05% betamethasone diproprionate formulation potency is similar between the visual skin blanching assay, tape-stripping and the a scale on the chromameter. Further, the rank correlation between tape-stripping and the a scale on the chromameter with the subjective visual skin blanching assay is moderate to excellent (r = 0.6, and - 0.9, respectively). Thus, tape-stripping and the chromameter offer the investigator two objective, standardized and noninvasive methods with which to compare bioequivalence of topical corticosteroids.
C1 US FDA,DEPT BIOPHARMACEUT,OFF GENET DRUGS,ROCKVILLE,MD 20857.
RP PERSHING, LK (reprint author), UNIV UTAH,DIV DERMATOL,SALT LAKE CITY,UT 84132, USA.
NR 15
TC 39
Z9 39
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD OCT 26
PY 1992
VL 86
IS 2-3
BP 201
EP 210
DI 10.1016/0378-5173(92)90198-B
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA JY663
UT WOS:A1992JY66300014
ER
PT J
AU ANDERSON, LW
PARKER, RJ
COLLINS, JM
AHLGREN, JD
WILKINSON, D
STRONG, JM
AF ANDERSON, LW
PARKER, RJ
COLLINS, JM
AHLGREN, JD
WILKINSON, D
STRONG, JM
TI GAS-CHROMATOGRAPHIC MASS-SPECTROMETRIC METHOD FOR ROUTINE MONITORING OF
5-FLUOROURACIL IN PLASMA OF PATIENTS RECEIVING LOW-LEVEL PROTRACTED
INFUSIONS
SO JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS
LA English
DT Article
ID ISOTOPE-DILUTION; SENSITIVE METHOD
AB A gas chromatographic-mass spectrometric (GC-MS) method is described which quantitates 5-fluorouracil (5-FU) plasma levels ranging from 0.5 to 50 ng/ml. The analysis uses two internal standards, 1,3-[N-15(2)]-5-fluorouracil and 5-chlorouracil. Extraction and derivatization of the pyrimidine bases were accomplished in a single step using acetonitrile. Compounds were analyzed as their 1,3-dipentafluorobenzyl derivatives by electron-impact MS, and the GC-MS analysis was automated with respect to sample injection and data reduction. Stability of the analysis was demonstrated by continuous unattended analysis of 5-FU in human plasma for periods of up to three days with no deterioration of the quantitative results. The method is applicable to quantitating 5-FU plasma levels in patients receiving protracted infusions of the drug for colorectal cancer or other malignancies.
C1 US FDA,CTR DRUG EVALUAT & RES,DIV CLIN PHARMACOL,4 RES COURT,ROCKVILLE,MD 20850.
GEORGE WASHINGTON UNIV,MED CTR,DIV HEMATOL ONCOL,WASHINGTON,DC 20037.
GEORGE WASHINGTON UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20037.
NR 17
TC 28
Z9 28
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4347
J9 J CHROMATOGR-BIOMED
JI J. Chromatogr.-Biomed. Appl.
PD OCT 23
PY 1992
VL 581
IS 2
BP 195
EP 201
DI 10.1016/0378-4347(92)80272-R
PG 7
WC Chemistry, Analytical
SC Chemistry
GA JV691
UT WOS:A1992JV69100004
PM 1452610
ER
PT J
AU GUEST, GB
AF GUEST, GB
TI USE OF ANIMAL DRUGS
SO SCIENCE
LA English
DT Letter
RP GUEST, GB (reprint author), US FDA,CTR VET MED,ROCKVILLE,MD 20857, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 16
PY 1992
VL 258
IS 5081
BP 381
EP 381
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JT775
UT WOS:A1992JT77500003
PM 1411531
ER
PT J
AU MACKEY, EA
GORDON, GE
LINDSTROM, RM
ANDERSON, DL
AF MACKEY, EA
GORDON, GE
LINDSTROM, RM
ANDERSON, DL
TI USE OF SPHERICAL TARGETS TO MINIMIZE EFFECTS OF NEUTRON-SCATTERING BY
HYDROGEN IN NEUTRON-CAPTURE PROMPT GAMMA-RAY ACTIVATION-ANALYSIS
SO ANALYTICAL CHEMISTRY
LA English
DT Article
AB For hydrogenous targets that are thinner than they are wide, element sensitivities (counts.s-1.mg-1) for determining concentrations of elements by neutron capture prompt gamma-ray activation analysis (PGAA) are enhanced relative to sensitivities obtained from measurements on nonhydrogenous materials. These enhancements are caused mainly by elastic neutron scattering by H, which changes the average neutron fluence rate within the matrix. The magnitude of the effect depends on the macroscopic scattering and absorption cross sections and on the size, shape, and orientation of the target with respect to the neutron beam. Sensitivities increase linearly with H density for thin targets of constant size and shape and also vary with target shape. Theoretical work was shown that element sensitivities for hydrogenous targets in the form of spheres are least affected by neutron scattering. Methods were devised for creating solid spheres and for containing liquids in spherical shapes. Element sensitivities were determined for spheres and disks of several hydrogenous materials. For H, B, Cl, K, Br, and Cd, sensitivities for spheres were found to be less affected by neutron scattering. Exceptions were Sm and Gd sensitivities measured in liquids contained in quartz globes.
C1 UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLL PK,MD 20742.
US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204.
RP MACKEY, EA (reprint author), US TECHNOL ADM,NATL INST STAND & TECHNOL,DIV INORGAN ANALYT RES,GAITHERSBURG,MD 20899, USA.
NR 15
TC 29
Z9 29
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 15
PY 1992
VL 64
IS 20
BP 2366
EP 2371
DI 10.1021/ac00044a012
PG 6
WC Chemistry, Analytical
SC Chemistry
GA JU109
UT WOS:A1992JU10900013
PM 1466451
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI FDA PROPOSES TO PROHIBIT 415 INGREDIENTS FROM OTC DRUG PRODUCTS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 14
PY 1992
VL 268
IS 14
BP 1828
EP 1828
DI 10.1001/jama.268.14.1828
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JR439
UT WOS:A1992JR43900009
PM 1404696
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI UPDATE ON EMS AND L-TRYPTOPHAN
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 14
PY 1992
VL 268
IS 14
BP 1828
EP 1828
DI 10.1001/jama.268.14.1828
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JR439
UT WOS:A1992JR43900008
PM 1404696
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI FDAS ELECTRONIC BULLETIN BOARD
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 14
PY 1992
VL 268
IS 14
BP 1828
EP 1828
DI 10.1001/jama.268.14.1828
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JR439
UT WOS:A1992JR43900010
PM 1404696
ER
PT J
AU DURFOR, CN
SCRIBNER, CL
AF DURFOR, CN
SCRIBNER, CL
TI AN FDA PERSPECTIVE OF MANUFACTURING CHANGES FOR PRODUCTS IN HUMAN USE
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article
RP DURFOR, CN (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BIOL INVEST NEW DRUGS,BETHESDA,MD 20892, USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 E 63RD ST, NEW YORK, NY 10021
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD OCT 13
PY 1992
VL 665
BP 356
EP 363
DI 10.1111/j.1749-6632.1992.tb42598.x
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JV459
UT WOS:A1992JV45900030
PM 1416614
ER
PT J
AU CHO, BP
BELAND, FA
MARQUES, MM
AF CHO, BP
BELAND, FA
MARQUES, MM
TI NMR STRUCTURAL STUDIES OF A 15-MER DNA-SEQUENCE FROM A RAS
PROTOONCOGENE, MODIFIED AT THE 1ST BASE OF CODON-61 WITH THE CARCINOGEN
4-AMINOBIPHENYL
SO BIOCHEMISTRY
LA English
DT Article
ID NUCLEAR MAGNETIC-RESONANCE; DEOXYRIBONUCLEIC-ACID; PROTON RESONANCES;
B-DNA; CONFORMATION; ADDUCT; 2-(ACETYLAMINO)FLUORENE;
2-ACETYLAMINOFLUORENE; 2-AMINOFLUORENE; DEOXYGUANOSINE
AB Proton NMR studies were conducted on the complementary 15-mer duplex d(5'-TACTCTTCTTGACCT).(5'-AGGTCAAGAAGAGTA) (designated as unmodified 15-mer duplex) spanning a portion of the mouse c-Ha-ras protooncogene centered around codon 61. Identical studies were carried out on the same sequence, after specific modification with a reactive derivative of the carcinogen 4-aminobiphenyl (ABP), which resulted in incorporation of a single N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dG-C8-ABP) adduct in the noncoding strand (designated as ABP-modified 15-mer duplex). The adduct was located at the position corresponding to the first base of codon 61. The NMR data for the unmodified 15-mer duplex were fully consistent with a standard right-handed B-type DNA duplex conformation, with the possible exception of the frayed terminal base pairs. The ABP-modified 15-mer duplex was found to adopt one major conformation, although at least one additional conformation could be detected especially near room temperature. The major form, which exhibited strikingly similar NOE patterns as to those of the parent oligomer, both in H2O and D2O Spectra, assumed a standard Watson-Crick base pairing throughout the entire length of the duplex, including the modification site and its flanking base pairs. Although some local perturbation of the helix could be detected in the vicinity of the modified guanosine, the NOE distance constraints established that the helix was globally right-handed and that the glycosidic torsion angles had the normal anti orientation, both at the modified base and its partner cytidine. Furthermore, the absence of strong NOE interactions between protons in the ABP moiety, which was rapidly rotating, and the nucleic acid protons was consistent with positioning of the arylamine moiety in the major groove of a weakly distorted double-helical structure. Although insufficient data prevented a detailed characterization of the minor conformer(s), the observation of significant shieldings for all the arylamine protons indicated a different orientation at the modified site in the minor contributor(s), possibly with extensive stacking between the ABP fragment and the neighboring bases.
C1 NATL CTR TOXICOL RES, DIV BIOCHEM TOXICOL, JEFFERSON, AR 72079 USA.
Univ Tecn Lisboa, QUIM ESTRUTURAL, INST SUPER TECN, P-1096 LISBON, PORTUGAL.
RI Marques, M. Matilde/E-2535-2012
OI Marques, M. Matilde/0000-0002-7526-4962
NR 47
TC 60
Z9 60
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 13
PY 1992
VL 31
IS 40
BP 9587
EP 9602
DI 10.1021/bi00155a011
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JT518
UT WOS:A1992JT51800011
PM 1327120
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI MEDICINE AND WAR
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
RP NIGHTINGALE, SL (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 4
TC 2
Z9 2
U1 0
U2 0
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 8
PY 1992
VL 327
IS 15
BP 1097
EP 1098
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA JR321
UT WOS:A1992JR32100015
PM 1522850
ER
PT J
AU MUJEEB, A
KERWIN, SM
EGAN, W
KENYON, GL
JAMES, TL
AF MUJEEB, A
KERWIN, SM
EGAN, W
KENYON, GL
JAMES, TL
TI A POTENTIAL GENE TARGET IN HIV-1 - RATIONALE, SELECTION OF A CONSERVED
SEQUENCE, AND DETERMINATION OF NMR DISTANCE AND TORSION ANGLE
CONSTRAINTS
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR MAGNETIC-RESONANCE; OVERHAUSER
EFFECT SPECTRA; RELAXATION MATRIX ANALYSIS; 2-DIMENSIONAL NOE
SPECTROSCOPY; PROTON COUPLING-CONSTANTS; PEAK FINE-STRUCTURES;
REVERSE-TRANSCRIPTASE; CONFORMATIONAL-ANALYSIS; INTERPROTON DISTANCES
AB Recently, the capability for determining the high-resolution, sequence-dependent structure of oligonucleotides in solution via careful analysis of multidimensional NMR spectra and structure refinement procedures has been developed. Consequently, the rationale for selection of a genome sequence as a target for drug design based on the detailed three-dimensional structure of the target is presented. The concept is illustrated by the successful search for a highly conserved region of the HIV-1 genome's long terminal repeat which could serve as a molecular target. A compound which could selectively bind the target sequence could inhibit both RNA transcription from the integrated provirus and the reverse transcription process. Of 148 unique HIV-1 sequences examined, 147 exhibit a 21 -base conserved sequence (nucleotides 70-90 in HIVHXB2R) in the R region of the long terminal repeat. The only exception, a minor constituent for one individual, bas a change in the penultimate base. A 13 base pair duplex sequence, [d(AGCTTGCCTTGAG).d(CTCAAGGCAAGCT)], from this conserved region was selected and synthesized for NMR structure studies. Phase-sensitive proton two-dimensional nuclear Overhauser enhancement (2D NOE) and double-quantum-filtered correlation (2QF-COSY) spectra were obtained at 500 MHz for the DNA duplex. Exchangeable and nonexchangeable proton resonances were assigned. Quantitative assessments of the 2D NOE cross-peak intensities for different mixing times were carried out using conventional Fourier transform NMR and the maximum likelihood method (MLM). Distance constraints, along with upper and lower bounds, were obtained from the 2D NOE intensities using the iterative complete relaxation matrix algorithm MARDIGRAS. Distances entailing both exchangeable and nonexchangeable protons were determined: 7-11 experimental distance constraints per residue including interresidue and interstrand distances. Simulations of the scalar coupling effects manifest in 2QF-COSY cross-peaks by means of the program SPHINX/LINSHA were compared with experimental data to yield torsion angle constraints for the sugar rings. A single conformer was inadequate to describe any of the sugar puckers, but a rapid two-state equilibrium with one conformer strongly dominant (75-95%) provided a good fit of the 2QF-COSY cross-peaks. The sugar pucker of the major conformer exhibited significant variability for the various nucleotides but was roughly 2'-endo. Though derived independently and subject to different time-averaging effects, the 2QF-COSY and 2D NOE results are in accord.
C1 UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143.
US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
OI Kerwin, Sean/0000-0001-8432-6558
FU NIGMS NIH HHS [GM 39552, GM 39247]
NR 69
TC 28
Z9 28
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 6
PY 1992
VL 31
IS 39
BP 9325
EP 9338
DI 10.1021/bi00154a002
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JR320
UT WOS:A1992JR32000002
PM 1327112
ER
PT J
AU GLINSMANN, WH
AF GLINSMANN, WH
TI WHY IS THE FOOD AND DRUG ADMINISTRATION INTERESTED IN DIETARY
FATTY-ACIDS AND THROMBOSIS
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
RP US FDA, DIV NUTR, HFF-260, 200 C ST SW, WASHINGTON, DC 20204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 1992
VL 56
IS 4
SU S
BP 785
EP 785
PG 1
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA JV008
UT WOS:A1992JV00800002
ER
PT J
AU FREDD, S
AF FREDD, S
TI WHICH SURROGATE END-POINTS ARE VALID FOR ASSESSING THROMBOTIC TENDENCY
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
RP US FDA, DIV GASTROINTESTINAL & COAGULAT DRUG PROD, HFD-180, ROOM 1092, ROCKVILLE, MD 20857 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 1992
VL 56
IS 4
SU S
BP 814
EP 814
PG 1
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA JV008
UT WOS:A1992JV00800021
ER
PT J
AU ALAYASH, AI
FRATANTONI, JC
BONAVENTURA, C
BONAVENTURA, J
BUCCI, E
AF ALAYASH, AI
FRATANTONI, JC
BONAVENTURA, C
BONAVENTURA, J
BUCCI, E
TI CONSEQUENCES OF CHEMICAL MODIFICATIONS ON THE FREE-RADICAL REACTIONS OF
HUMAN HEMOGLOBIN
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
ID LIPID-PEROXIDATION; BINDING-SITE; IRON; HBXL99-ALPHA; REAGENT; CHAINS;
DAMAGE
C1 DUKE UNIV,CTR MARINE BIOMED,BEAUFORT,NC 28516.
UNIV MARYLAND,DEPT BIOL CHEM,BALTIMORE,MD 21201.
RP ALAYASH, AI (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
FU NIEHS NIH HHS [2 P30 ESO-1908, 5 ROI ESO-4287]
NR 39
TC 46
Z9 48
U1 0
U2 3
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD OCT
PY 1992
VL 298
IS 1
BP 114
EP 120
DI 10.1016/0003-9861(92)90101-2
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA JN143
UT WOS:A1992JN14300016
PM 1524419
ER
PT J
AU ROSENKRANZ, HS
MATTHEWS, EJ
KLOPMAN, G
AF ROSENKRANZ, HS
MATTHEWS, EJ
KLOPMAN, G
TI RELATIONSHIPS BETWEEN CELLULAR TOXICITY, THE MAXIMUM TOLERATED DOSE,
LIPOPHILICITY AND ELECTROPHILICITY
SO ATLA-ALTERNATIVES TO LABORATORY ANIMALS
LA English
DT Article
DE MAXIMUM TOLERATED DOSE; CYTOTOXICITY; LIPOPHILICITY; ELECTROPHILICITY
ID HAMSTER OVARY CELLS; CHROMATID EXCHANGE TESTS;
NATIONAL-TOXICOLOGY-PROGRAM; UNITED-STATES NTP; CHEMICAL-STRUCTURE;
CHROMOSOME ABERRATION; CARCINOGENICITY; MUTAGENICITY; INVITRO;
SALMONELLA
AB Results on cellular toxicity and maximum tolerated dose (MTD) for rats and mice were available for approximately 175 chemicals tested by the US National Toxicology Program. Additionally, the computed log P (log octanol-water partition coefficient) and the lowest unoccupied molecular orbital (LUMO) energy values, a measure of electrophilicity were also available for most of these chemicals. Analysis of the chemicals on the basis of their physical and quantum chemical properties and their toxic effects on cultured cells and rodents showed that: 1) as a group, the more toxic chemicals showed a trend towards higher LUMO energies (i.e. less electrophilic); 2) cytotoxic chemicals exhibited increased lipophilicity; and 3) cytotoxic chemicals were associated with increase systemic toxicity (as measured by the MTD). None of these relationships was expressed in a significant linear fashion as a function of the concentration at which the chemicals exhibited cytotoxicity.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
CASE WESTERN RESERVE UNIV,DEPT CHEM,CLEVELAND,OH 44106.
RP ROSENKRANZ, HS (reprint author), UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT ENVIRONM & OCCUPAT HLTH,PITTSBURGH,PA 15261, USA.
NR 28
TC 20
Z9 20
U1 0
U2 0
PU FRAME
PI NOTTINGHAM
PA RUSSELL & BURCH HOUSE 96-98 NORTH SHERWOOD ST, NOTTINGHAM, NOTTS,
ENGLAND NG1 4EE
SN 0261-1929
J9 ATLA-ALTERN LAB ANIM
JI ATLA-Altern. Lab. Anim.
PD OCT
PY 1992
VL 20
IS 4
BP 549
EP 562
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA JW658
UT WOS:A1992JW65800006
ER
PT J
AU GREEN, S
AF GREEN, S
TI INVITRO TEST VALIDATION AND REGULATORY ANIMAL TESTING - A HOUSE BUILT ON
SAND VERSUS A HOUSE OF CARDS
SO ATLA-ALTERNATIVES TO LABORATORY ANIMALS
LA English
DT Note
RP GREEN, S (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 9
TC 12
Z9 12
U1 0
U2 0
PU FRAME
PI NOTTINGHAM
PA RUSSELL & BURCH HOUSE 96-98 NORTH SHERWOOD ST, NOTTINGHAM, NOTTS,
ENGLAND NG1 4EE
SN 0261-1929
J9 ATLA-ALTERN LAB ANIM
JI ATLA-Altern. Lab. Anim.
PD OCT
PY 1992
VL 20
IS 4
BP 567
EP 570
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA JW658
UT WOS:A1992JW65800009
ER
PT J
AU ZAPISEK, WF
CRONIN, GM
LYNCOOK, BD
POIRIER, LA
AF ZAPISEK, WF
CRONIN, GM
LYNCOOK, BD
POIRIER, LA
TI THE ONSET OF ONCOGENE HYPOMETHYLATION IN THE LIVERS OF RATS FED
METHYL-DEFICIENT, AMINO-ACID-DEFINED DIETS
SO CARCINOGENESIS
LA English
DT Article
ID DNA METHYLATION; DIETHYLNITROSAMINE INITIATION; S-ADENOSYLHOMOCYSTEINE;
CHOLINE; CANCER; HEPATOCARCINOGENESIS; METHIONINE; EXPRESSION;
ADENOSYLMETHIONINE; SEQUENCES
AB This study examines proto-oncogene hypomethylation in rat livers during the early stages of hepatocarcinogenesis by dietary methyl deprivation in the presence and absence of initiation by diethylnitrosamine (DEN). Male weanling F344 rats were fed a complete diet, or a diet deficient in methionine and choline (MDD). Half the animals in each dietary group were given a single initiating dose of DEN (20 mg/kg). Animals from each of the treatment groups were killed at 1, 3, 8, 16 and 32 weeks, and hepatic DNA was isolated. This DNA was digested with the restriction enzymes MspI and HpaII to determine the extent of methylation of the CCGG sequences in c-Ha-ras, c-Ki-ras and c-fos proto-oncogenes. The results indicate that the administration of the MDD produced hypomethylation of these proto-oncogenes at all times investigated, independent of DEN initiation. The methylation changes in the c-Ha-ras gene increased in intensity throughout the experiment until at 32 weeks they were similar to the patterns seen in both neoplastic and preneoplastic livers of rats fed the deficient diet for 18 months. These results demonstrate that early, selective hypomethylation of some, but not all, CCGG sites occurs in rats undergoing hepatocarcinogenesis by dietary methyl deprivation.
C1 NATL CTR TOXICOL RES,DIV NUTR TOXICOL,JEFFERSON,AR 72079.
NR 32
TC 58
Z9 59
U1 1
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 1992
VL 13
IS 10
BP 1869
EP 1872
DI 10.1093/carcin/13.10.1869
PG 4
WC Oncology
SC Oncology
GA JU195
UT WOS:A1992JU19500029
PM 1330345
ER
PT J
AU FLAMMANG, TJ
COUCH, LH
LEVY, GN
WEBER, WW
WISE, CK
AF FLAMMANG, TJ
COUCH, LH
LEVY, GN
WEBER, WW
WISE, CK
TI DNA ADDUCT LEVELS IN CONGENIC RAPID AND SLOW ACETYLATOR MOUSE STRAINS
FOLLOWING CHRONIC ADMINISTRATION OF 4-AMINOBIPHENYL
SO CARCINOGENESIS
LA English
DT Article
ID N-ACETYLTRANSFERASE PHENOTYPE; HEMOGLOBIN ADDUCTS; URINARY-BLADDER;
AROMATIC-AMINES; HUMAN-LIVER; P-32-POSTLABELING ANALYSIS; CARCINOGEN;
MICE; SMOKING; RATS
AB 4-Aminobiphenyl (4-ABP) is a human and mouse bladder carcinogen. Epidemiological studies have shown that individuals with a slow acetylator phenotype, especially those exposed to high levels of carcinogenic aromatic amines, show an increased susceptibility to bladder cancer. In order to determine if a slow acetylator phenotype results in increased DNA damage, congenic mouse strains C57BL/6J and B6.A-Nat(s), which differ genetically at the acetyltransferase (EC 2.3.1.5) locus as homozygous rapid (Nat(r)/Nat(r)) and homozygous slow (Nat(s)/Nat(s)) acetylators respectively, were continuously administered 4-ABP.HCI (55-300 p.p.m.) in their drinking water for 28 days. The levels of covalently bound N-(deoxyguanosin-8-yl)-4-ABP-DNA adducts, which are believed to be critical for the initiation of tumors, were quantitated in the liver and bladder by P-32-postlabeling analysis. The levels of the hepatic DNA adduct increased with dose in both sexes, but were independent of the mouse acetylator genotype. At comparable doses, however, the levels of DNA adducts were 2-fold higher in the liver of the female as compared to the male animals. The DNA adducts also increased with dose in bladder of the male mice, but in contrast to the liver, the adduct levels were approximately 2-fold lower in the bladder DNA of the female mice. Also in contrast to the liver, the levels of bladder DNA adducts were significantly higher (P less-than-or-equal-to 0.03) in the phenotypic rapid acetylator females compared to the slow acetylators at both 75 and 150 p.p.m. doses; the median levels of adducts were 10 - 20% higher in the phenotypic slow acetylator male bladders compared to their rapid acetylator counterparts. The results of these studies are consistent with the increased carcinogenicity of 4-ABP to the liver of female mice and the bladder of male mice. They further suggest that factors other than acetylator phenotype limit the extent of DNA adduct formation from 4-ABP in these mice.
C1 UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & INTERDISCIPLINARY TOXICOL,LITTLE ROCK,AR 72205.
UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109.
RP FLAMMANG, TJ (reprint author), NATL CTR TOXICOL RES,HFT-110,JEFFERSON,AR 72079, USA.
FU NCI NIH HHS [CA39018]
NR 46
TC 22
Z9 22
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 1992
VL 13
IS 10
BP 1887
EP 1891
DI 10.1093/carcin/13.10.1887
PG 5
WC Oncology
SC Oncology
GA JU195
UT WOS:A1992JU19500032
PM 1423849
ER
PT J
AU LIANG, SM
LEE, N
CHEN, YY
LIANG, CM
AF LIANG, SM
LEE, N
CHEN, YY
LIANG, CM
TI EFFECTS OF GLUTATHIONE ON THE SYNTHESIS AND TURNOVER OF INTERLEUKIN-2
RECEPTORS
SO CELLULAR IMMUNOLOGY
LA English
DT Article
ID CELL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HIGH-AFFINITY; T-CELLS;
IL-2 RECEPTOR; BETA-CHAIN; BUTHIONINE SULFOXIMINE; MONOCLONAL-ANTIBODY;
MOLECULAR-CLONING; GENE-EXPRESSION
RP LIANG, SM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,ROOM 3C-22,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 65
TC 10
Z9 10
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PD OCT 1
PY 1992
VL 144
IS 1
BP 131
EP 142
DI 10.1016/0008-8749(92)90231-D
PG 12
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA JP541
UT WOS:A1992JP54100012
PM 1394435
ER
PT J
AU LEE, SC
PROSKY, L
AF LEE, SC
PROSKY, L
TI DIETARY FIBER ANALYSIS FOR NUTRITION LABELING
SO CEREAL FOODS WORLD
LA English
DT Article
ID COLLABORATIVE TRIALS; CEREAL PRODUCTS; FOOD-PRODUCTS; WALL
C1 US FDA,DIV NUTR,EXPTL NUTR BRANCH,LAUREL,MD.
RP LEE, SC (reprint author), KELLOGG CO,BATTLE CREEK,MI, USA.
NR 33
TC 15
Z9 15
U1 1
U2 2
PU AMER ASSOC CEREAL CHEMISTS
PI ST PAUL
PA 3340 PILOT KNOB RD, ST PAUL, MN 55121-2097
SN 0146-6283
J9 CEREAL FOOD WORLD
JI Cereal Foods World
PD OCT
PY 1992
VL 37
IS 10
BP 765
EP &
PG 0
WC Food Science & Technology
SC Food Science & Technology
GA JV175
UT WOS:A1992JV17500004
ER
PT J
AU HORVATH, JA
MOSTOWSKI, HS
OKUMURA, K
BLOOM, ET
AF HORVATH, JA
MOSTOWSKI, HS
OKUMURA, K
BLOOM, ET
TI PORE-FORMING PROTEIN IN INDIVIDUAL CYTOTOXIC LYMPHOCYTES-T - THE EFFECT
OF SENESCENCE PROVIDES A PROBE FOR UNDERSTANDING THE LYTIC MECHANISM
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID AGE-RELATED DECLINE; CYTO-TOXICITY; GENE-EXPRESSION; KILLER-CELLS; OLD
MICE; PERFORIN; ACTIVATION; CD4+
AB The senescent decline of cytolytic T lymphocyte (CTL) activity was examined (a) to learn more about the effect of aging on the immune system, and (b) to probe the mechanism of cell-mediated cytolysis. The effect of age on the generation of pore-forming protein (Pfp) was examined at the cellular level in a murine model using CTL stimulated in allogeneic mixed lymphocyte culture (MLC). Pfp expression was analyzed by immunocytochemistry and enzyme-linked immunosorbent assay (ELISA). Immunocytochemical analyses of Pfp in MLC-stimulated splenic T cells from a large number of mice revealed that although stimulated cells from aged mice exhibited fewer Pfp-producing cells than those from young, the diminution in the proportion of Pfp+ cells was small compared to the age-related decrease in lytic activities (approximately 2-fold vs. approximately 7.4-fold, respectively). Time-course analysis disclosed similar kinetics for the generation of Pfp+ cells among responding cells from young and aged mice. No significant age-related difference in the proportion of Pfp+ cells was observed in MLC-stimulated lymph node cells despite a large and significant difference in lytic activity (approximately 6.5-fold). Purified CD8+ T cells demonstrated a large age-related difference in CTL activity (approximately 3-11-fold) and accounted for virtually all the Pfp. Although little difference in the proportion of Pfp+ CD8+ T cells could be detected between age groups, stimulated CD8+ cells or whole splenic T cells from old mice consistently exhibited a striking reduction in both the intensity of Pfp staining and the apparent numbers of granules per cell. This difference in Pfp was examined by ELISA and total Pfp levels were found to be approximately 12-fold greater in CTL generated from splenic T cells of young compared to aged mice.The results demonstrate that Pfp levels are reduced in CTL from aged compared to young mice at the level of the individual cells and suggest the possibility that a threshold level of Pfp may be required for potency of effector cell function.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL 6HFB 826,CELLULAR IMMUNOL LAB,BLDG 29A,BETHESDA,MD 20892.
JUNTENDO UNIV,DEPT IMMUNOL,TOKYO 113,JAPAN.
NR 25
TC 13
Z9 13
U1 0
U2 0
PU VCH PUBLISHERS INC
PI DEERFIELD BEACH
PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD OCT
PY 1992
VL 22
IS 10
BP 2649
EP 2654
DI 10.1002/eji.1830221026
PG 6
WC Immunology
SC Immunology
GA JV594
UT WOS:A1992JV59400025
PM 1396969
ER
PT J
AU SANDSTROM, G
SJOSTEDT, A
JOHANSSON, T
KUOPPA, K
WILLIAMS, JC
AF SANDSTROM, G
SJOSTEDT, A
JOHANSSON, T
KUOPPA, K
WILLIAMS, JC
TI IMMUNOGENICITY AND TOXICITY OF LIPOPOLYSACCHARIDE FROM
FRANCISELLA-TULARENSIS LVS
SO FEMS MICROBIOLOGY IMMUNOLOGY
LA English
DT Article
DE LIPOPOLYSACCHARIDE; TULAREMIA; FRANCISELLA-TULARENSIS; ENDOTOXIN; TNF;
IL-1
ID TUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODIES; OUTER-MEMBRANE; ENDOTOXIN;
INTERLEUKIN-1; HETEROGENEITY; PURIFICATION; LYMPHOCYTES; TULAREMIA;
PROTEINS
AB Lipopolysaccharide (LPS) from the live vaccine strain of Francisella tularensis (F. tularensis LVS) was isolated and purified. The LPS did not stimulate lymphocytes from previously tularaemia-vaccinated individuals or lymphocytes from non-primed individuals. However, serum antibodies from tularaemia vaccinees reacted with the LPS whereas virtually no reactivity was found with antibodies from individuals not exposed to F. tularensis LVS. Antibodies of immunoglobulin class M displayed the antibody reactivity predominantly. The LPS failed to induce the mononuclear cell-derived cytokine interleukin-1 and only low levels of tumour necrosis factor were detected. Furthermore, no LPS endotoxin properties were found in galactosamine-treated mice or in the Limulus amoebocyte lysate assay. From these results it can be concluded that F. tularensis LVS possesses a lipopolysaccharide-like molecule, which does not exhibit properties of a classical endotoxin.
C1 US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20014 USA.
UMEA UNIV, DEPT INFECT DIS, S-90187 UMEA, SWEDEN.
USA, MED RES INST INFECT DIS, INTRACELLULAR PATHOGENS BRANCH, FREDERICK, MD 21701 USA.
RP SANDSTROM, G (reprint author), NATL DEF RES ESTAB, DIV MICROBIOL, S-90182 UMEA, SWEDEN.
NR 52
TC 29
Z9 32
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-8534
J9 FEMS MICROBIOL IMMUN
PD OCT
PY 1992
VL 105
IS 4
BP 201
EP 210
DI 10.1111/j.1574-6968.1992.tb05902.x
PG 10
WC Immunology; Microbiology
SC Immunology; Microbiology
GA JV997
UT WOS:A1992JV99700005
ER
PT J
AU GOERING, PL
GALLOWAY, WD
CLARKSON, TW
LORSCHEIDER, FL
BERLIN, M
ROWLAND, AS
AF GOERING, PL
GALLOWAY, WD
CLARKSON, TW
LORSCHEIDER, FL
BERLIN, M
ROWLAND, AS
TI TOXICITY ASSESSMENT OF MERCURY-VAPOR FROM DENTAL AMALGAMS
SO FUNDAMENTAL AND APPLIED TOXICOLOGY
LA English
DT Article
ID PITUITARY-HORMONE RESPONSE; SILVER TOOTH FILLINGS; ORAL AIR MERCURY;
OCCUPATIONAL EXPOSURE; ALZHEIMERS-DISEASE; INORGANIC MERCURY; ELEMENTAL
MERCURY; SPONTANEOUS-ABORTIONS; TRACE-ELEMENT; FETAL TISSUES
C1 UNIV CALGARY,FAC MED,DEPT MED PHYSIOL,CALGARY T2N 4N1,ALBERTA,CANADA.
UNIV ROCHESTER,SCH MED,CTR ENVIRONM HLTH SCI,ROCHESTER,NY 14642.
UNIV LUND,INST ENVIRONM MED,S-22101 LUND,SWEDEN.
NIEHS,RES TRIANGLE PK,NC 27709.
RP GOERING, PL (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,ROCKVILLE,MD 20857, USA.
NR 93
TC 41
Z9 42
U1 4
U2 11
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0272-0590
J9 FUND APPL TOXICOL
JI Fundam. Appl. Toxicol.
PD OCT
PY 1992
VL 19
IS 3
BP 319
EP 329
DI 10.1016/0272-0590(92)90169-I
PG 11
WC Toxicology
SC Toxicology
GA JU086
UT WOS:A1992JU08600001
PM 1360929
ER
PT J
AU PRIVAL, MJ
CEBULA, TA
AF PRIVAL, MJ
CEBULA, TA
TI SEQUENCE-ANALYSIS OF MUTATIONS ARISING DURING PROLONGED STARVATION OF
SALMONELLA-TYPHIMURIUM
SO GENETICS
LA English
DT Article
ID OLIGODEOXYRIBONUCLEOTIDE COLONY HYBRIDIZATION; ESCHERICHIA-COLI;
MUTAGENS; TRANSVERSIONS; CARCINOGENS; REVERTANTS; REQUIRES; GENE
AB We have examined the effects of prolonged histidine deprivation on the reversion of Salmonella typhimurium histidine auxotrophs containing either hisG46, a missense mutation (CTC --> CCC), or hisG428, an ochre mutation (CAA --> TAA). Both of these mutants can revert to His+ via intragenic and extragenic mechanisms. Whereas the hisG46 mutant site consists of G/C base pairs, extragenic suppression of hisG46 requires mutation at an A/T site. Conversely, the hisG428 site itself contains only A/T base pairs, and extragenic suppression of hisG428 occurs principally at G/C sites. Thus, by examining the mutational spectrum of hisG46 and hisG428 revertants that occurred in the presence and in the absence of histidine, it was possible to determine the effects of histidine starvation on mutations at G/C vs. A/T sites as well as on intragenic sites vs. extragenic suppressor sites. Using DNA-colony hybridization, we determined the DNA sequences of over 1300 hisG46 and hisG428 revertants. Histidine-independent revertants that arose during growth in liquid medium that contained histidine included both intragenic and extragenic suppressor mutations. The relative frequency of such extragenic suppressors was greatly reduced among the His+ revertants that were isolated after 5-10 days of histidine starvation on agar medium. Moreover, DNA sequence analysis revealed striking differences in the distribution of particular transversions at the hisG428 locus in revertants arising after prolonged histidine starvation as compared to those arising after growth in the presence of histidine.
C1 US FDA,MOLEC BIOL BRANCH,WASHINGTON,DC 20204.
RP PRIVAL, MJ (reprint author), US FDA,GENET TOXICOL BRANCH,WASHINGTON,DC 20204, USA.
NR 29
TC 45
Z9 45
U1 1
U2 4
PU GENETICS
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202
SN 0016-6731
J9 GENETICS
JI Genetics
PD OCT
PY 1992
VL 132
IS 2
BP 303
EP 310
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA JQ146
UT WOS:A1992JQ14600003
PM 1427030
ER
PT J
AU SHINDO, M
AKATSUKA, T
DIBISCEGLIE, AM
DONETS, M
SCAGLIONE, L
HOOFNAGLE, JH
FEINSTONE, SM
AF SHINDO, M
AKATSUKA, T
DIBISCEGLIE, AM
DONETS, M
SCAGLIONE, L
HOOFNAGLE, JH
FEINSTONE, SM
TI A CAPTURE ASSAY FOR HCV RNA USING A HUMAN MONOSPECIFIC ANTIBODY TO CORE
ANTIGEN OF HEPATITIS-C VIRUS (HCV)
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 NIH,HEPATITIS STUDIES SECT,BETHESDA,MD 20892.
US FDA,CBER,HEPATITIS RES LAB,BETHESDA,MD 20014.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1992
VL 16
IS 4
BP A70
EP A70
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JR380
UT WOS:A1992JR38000103
ER
PT J
AU WILLIAMS, RL
AF WILLIAMS, RL
TI BIOEQUIVALENCE OF TOPICAL CORTICOSTEROIDS - A REGULATORY PERSPECTIVE
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID GLUCOCORTICOIDS
AB After reviewing the history of generic drug substitution policy in the United States, this paper discusses issues of equivalence as they apply to topical drug products. Documentation of bioequivalence of topical products has been problematic, and current methods are being re-evaluated by the Food and Drug Administration. The FDA is currently evaluating various extensions of the basic methodology of the Stoughton-McKenzie vasoconstrictor assay, in order to develop a more comprehensive pharmacodynamic methodology for documenting topical drug bioequivalence. A modern pharmacodynamic model is described, based on nonlinear dose-response relationship, a baseline effect, and a maximum or plateau effect. The Agency's goal is a bioequivalent methodology that will be simple, readily performed, and based on more objective methods of measuring the vasoconstrictor response.
RP WILLIAMS, RL (reprint author), US FDA,OFF GENER DRUGS,MPN 2,HFD-600,7500 STANDISH PL,ROCKVILLE,MD 20855, USA.
NR 5
TC 5
Z9 5
U1 1
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0011-9059
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD OCT
PY 1992
VL 31
SU 1
BP 2
EP 5
DI 10.1111/j.1365-4362.1992.tb04004.x
PG 4
WC Dermatology
SC Dermatology
GA JT271
UT WOS:A1992JT27100002
PM 1428462
ER
PT J
AU SHAH, VP
AF SHAH, VP
TI TOPICAL CORTICOSTEROIDS - QUALITY-CONTROL CONSIDERATIONS
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID HYDROCORTISONE CREAMS; PENETRATION; RELEASE
AB A simple procedure is developed, which can be used as a quality control test. The method utilizes commercially available diffusion cell assembly, synthetic membrane, and an appropriate receptor phase. The amount of drug released over time is determined using an HPLC method. From this, the drug release rate, flux, mug/cm2/min0.5 is calculated. This drug release rate can serve as a good quality control test to assure batch-to-batch uniformity.
RP SHAH, VP (reprint author), US FDA,OFF GENER DRUGS,MPN 2,HFD-602,5600 FISHERS LANE,ROCKVILLE,MD 20855, USA.
NR 6
TC 3
Z9 3
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0011-9059
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD OCT
PY 1992
VL 31
SU 1
BP 34
EP 37
DI 10.1111/j.1365-4362.1992.tb04011.x
PG 4
WC Dermatology
SC Dermatology
GA JT271
UT WOS:A1992JT27100009
PM 1428466
ER
PT J
AU KLINMAN, DM
STEIMER, KS
CONOVER, J
AF KLINMAN, DM
STEIMER, KS
CONOVER, J
TI COMPARATIVE IMMUNOGENICITY OF GP120-DERIVED PROTEINS AND THEIR INDUCTION
OF ANTI-V3 LOOP REGION ANTIBODIES
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE CROSS-REACTIVE; GP120; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; ANTI-V3 LOOP
REGION ANTIBODIES
ID NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEINS; MONOCLONAL-ANTIBODIES;
HTLV-III/LAV; HIV-1 GP120; INHIBITION; EPITOPE; CD4
AB This report compares the immunogenicity of three different preparations of gpl20 [the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) virus]: (a) native, fully glycosylated gpl20; (b) a nonglycosylated, denatured form of gp120; and (c) a nonglycosylated peptide representing the "immunodominant" third hypervariable region of the gp120 molecule. Results indicate that the native glycosylated form of gp120 induces a maximal anti-HIV response in which a majority of B cells bind to conformation-dependent epitopes but less than one-fifth recognize the V3 loop region.
C1 CHIRON CORP,EMERYVILLE,CA.
RP KLINMAN, DM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,BLDG 29A,ROOM 3 D 10,BETHESDA,MD 20892, USA.
NR 12
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD OCT
PY 1992
VL 5
IS 10
BP 1005
EP 1008
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA JN550
UT WOS:A1992JN55000007
PM 1280682
ER
PT J
AU MOREHOUSE, KM
KU, Y
AF MOREHOUSE, KM
KU, Y
TI GAS-CHROMATOGRAPHIC AND ELECTRON-SPIN-RESONANCE INVESTIGATIONS OF
GAMMA-IRRADIATED SHRIMP
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
ID RADIOLYSIS PRODUCTS; FROG LEGS; IDENTIFICATION; FOOD; SPECTROSCOPY;
FOODSTUFFS; PARAMETERS; DOSIMETRY; RADIATION; BONES
AB When fats are irradiated, some of the major stable products formed are hydrocarbons. The most abundant radiolytic hydrocarbons are formed during various free-radical reactions as the result of the loss of CO2. An extraction procedure followed by capillary gas chromatography (GC) to monitor the formation of these radiolytic hydrocarbons in gamma-irradiated shrimp has been developed. Shrimp contain appreciable amounts of palmitic, palmitoleic, stearic, oleic, and linoleic acids. When irradiated, these fatty acids form the hydrocarbons pentadecane, 8-pentadecene, heptadecane, 8-heptadecene, and 6,9-heptadecadiene, respectively. The yield of these radiolytic hydrocarbons was found to be linear with absorbed dose. Data indicating the utility of the capillary GC technique for identifying radiation-treated shrimp are presented. The potential use of electron spin resonance (ESR) spectroscopy, another irradiation detection technique, to monitor the formation of free radicals trapped in irradiated shrimp shell and problems associated with using ESR spectroscopy are also described.
RP MOREHOUSE, KM (reprint author), US FDA,DIV FOOD CHEM & TECHNOL,WASHINGTON,DC 20204, USA.
NR 47
TC 30
Z9 32
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD OCT
PY 1992
VL 40
IS 10
BP 1963
EP 1971
DI 10.1021/jf00022a047
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
Technology
SC Agriculture; Chemistry; Food Science & Technology
GA JU517
UT WOS:A1992JU51700048
ER
PT J
AU GERGEN, PJ
TURKELTAUB, PC
AF GERGEN, PJ
TURKELTAUB, PC
TI THE ASSOCIATION OF INDIVIDUAL ALLERGEN REACTIVITY WITH
RESPIRATORY-DISEASE IN A NATIONAL SAMPLE - DATA FROM THE 2ND
NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1976-80 (NHANES-II)
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE ASTHMA; ALLERGIC RHINITIS; CHRONIC RHINITIS; SINUSITIS; ALLERGY;
NHANES-II
ID SKIN-TEST REACTIVITY; HOUSE-DUST MITE; UNITED-STATES POPULATION;
ASTHMATIC-CHILDREN; CHANGING PATTERNS; CHILDHOOD ASTHMA; POLLEN
ALLERGENS; IGE ANTIBODIES; RAGWEED POLLEN; GRASS-POLLEN
AB The independent association of individual allergen reactivity with respiratory disease was evaluated with use of the second National Health and Nutrition Examination Survey, a sample of the U.S. white civilian population, ages 6 to 24 years (n = 4295). Eight, 1:20 wt/vol, 50% glycerol, unstandardized extracts were administered by prick puncture. Allergen reactivity was reported as the percent with a mean erythema diameter 10.5 mm or greater at 20 minutes. Only the prevalence of asthma and allergic rhinitis increased with the increasing number of positive allergen skin tests. The independent association of individual allergen reactivity with respiratory disease was quantified with logistic models that included other allergen reactivity, age, sex, smoking, and region. Asthma was associated with reactivity to house dust (odds ratio, 2.9; 95% confidence interval [CI] 1.7 to 5) and Alternaria (odds ratio, 5.1; 95% CI: 2.9 to 8.9). Allergic rhinitis was associated with reactivity to ragweed (odds ratio, 2.3; 95% CI: 1.5 to 3.3); ryegrass (odds ratio, 2.8; 95% CI: 1.8 to 4.3); house dust (odds ratio, 2.5; 95% CI: 1.6 to 3.9); Alternaria (odds ratio, 2.3; 95% CI: 1.5 to 3.4). Asthma only (without allergic rhinitis) was associated with dust and Alternaria. Allergic rhinitis only (without asthma) was associated with ryegrass, ragweed, and house dust. When both asthma and allergic rhinitis were present, only house dust and Alternaria remained associated. These findings highlight the association of specific allergens with upper and lower respiratory diseases and the interactions among coexisting respiratory diseases.
C1 US FDA,CTR BIOL EVALUAT & RES,ALLERGY & IMMUNOCHEM LAB,BETHESDA,MD 20014.
RP GERGEN, PJ (reprint author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,SOLAR ROOM 4A29,BETHESDA,MD 20892, USA.
NR 42
TC 169
Z9 171
U1 0
U2 8
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD OCT
PY 1992
VL 90
IS 4
BP 579
EP 588
DI 10.1016/0091-6749(92)90130-T
PN 1
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA JT995
UT WOS:A1992JT99500003
PM 1401641
ER
PT J
AU PASTOR, RW
SZABO, A
AF PASTOR, RW
SZABO, A
TI LANGEVIN DYNAMICS OF A LINEAR ROTOR IN A MAIER-SAUPE POTENTIAL - KRAMERS
TURNOVER OF THE FLIPPING RATE
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID COMPUTER-SIMULATION
AB The frictional dependence of the flipping rate of a linear rotor in a Maier-Saupe potential is evaluated from Langevin dynamics simulations. By assuming that the azimuthal angular velocity is rapidly thermalized, an approximate analytic expression for the rate is obtained within the framework of the Mel'nikov-Meshkov treatment of the Kramers turnover problem for one-dimensional bistable potentials. The predictions of this expression are in good agreement with the accurate simulation results.
C1 NIDDKO,CHEM PHYS LAB,BETHESDA,MD 20892.
RP PASTOR, RW (reprint author), US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
RI Szabo, Attila/H-3867-2012
NR 21
TC 12
Z9 12
U1 0
U2 3
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD OCT 1
PY 1992
VL 97
IS 7
BP 5098
EP 5100
DI 10.1063/1.463830
PG 3
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA JR338
UT WOS:A1992JR33800053
ER
PT J
AU NERURKAR, SG
DIGHE, SV
WILLIAMS, RL
AF NERURKAR, SG
DIGHE, SV
WILLIAMS, RL
TI BIOEQUIVALENCE OF RACEMIC DRUGS
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
ID PHARMACOKINETICS; DISPOSITION; STEREOSELECTIVITY; STEREOCHEMISTRY;
STEREOISOMERS; ENANTIOMERS; HUMANS
AB Although pharmacokinetic and pharmacodynamic differences between the enantiomers of a chiral drug have been known or suspected for many years, racemate drugs have frequently been developed and approved without clinical pharmacologic consideration of their chiral components. In the late 1970s, the technology to isolate, manufacture, and detect pure enantiomers of racemate drugs became generally available. This availability has created new demands on both pharmaceutical firms and regulatory agencies. To prepare for this new technology, the Center for Drug Evaluation and Research at the Food and Drug Administration is formulating a policy statement to guide evaluation of flew chiral drugs. At this time, it appears that whatever new policies are developed will not necessarily be applied retroactively to previously approved racemate drugs. Additional policies to guide the development and approval of generic and OTC chiral drugs may be required. In the Office of Generic Drugs in the Center, abbreviated new drug or antibiotic applications are approved on the basis of adequate chemistry, manufacturing, and control procedures and comparative pharmacokinetics (bioequivalence). The generic drug must be a racemate or single enantiomer if the corresponding innovator drug is a racemate or single enantiomer respectively. Whether a generic firm will be required to provide bioequivalence information on enantiomers of a racemate is determined on a case-by-case basis. Although it might be claimed that a generic drug product should be required only to undergo the same general kind of pharmaceutical evaluation as did the innovator, there may be instances when the approval of a generic drug or antibiotic will require measurement of specific enantiomers of a chiral drug.
C1 US FDA,OFF GENER DRUGS,ROCKVILLE,MD 20857.
NR 28
TC 36
Z9 38
U1 0
U2 3
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD OCT
PY 1992
VL 32
IS 10
BP 935
EP 943
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA JU005
UT WOS:A1992JU00500011
PM 1447402
ER
PT J
AU SULLIVANJONES, P
HANSEN, DK
SHEEHAN, DM
HOLSON, RR
AF SULLIVANJONES, P
HANSEN, DK
SHEEHAN, DM
HOLSON, RR
TI THE EFFECT OF TERATOGENS ON MATERNAL CORTICOSTERONE LEVELS AND CLEFT
INCIDENCE IN A/J MICE
SO JOURNAL OF CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE CLEFT PALATE; PHENYTOIN; HALOPERIDOL; GLUCOCORTICOID; STRESS;
2,4,5-TRICHLOROPHENYOXYACETIC ACID; RECEPTOR
ID PLASMA-CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; PALATE; PHENYTOIN;
INDUCTION; DEPRIVATION; RESTRAINT; FOOD; ACID
AB It is unknown whether orofacial clefting, one consequence of teratogenic exposure, results from a direct interaction between the teratogen and the embryonic palate, or indirectly from maternal alterations caused by the teratogen. In the current study pregnant A/J mice were exposed to one of three cleft-inducing agents in order to examine the relationship between drug-induced clefting and the response of maternal plasma corticosterone to drug administration. The agents used, haloperidol (HAL), 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), or phenytoin (PHT), were administered in teratogenic doses between 0800 and 0930 on gestational day 10 (GD 10). For corticosterone determinations, mice were dosed on GD 10, and blood was collected at 1, 4, 24, or 48 hr after dosing. For fetal evaluation of cleft lip and/or cleft palate, mice were dosed on GD 10 and killed on GD 18. Phenytoin was the most potent inducer of cleft lip and palate and induced a sustained elevation of plasma corticosterone in maternal animals. The other treatments, in order of decreasing potency to induce clefting and/or cause an elevation of corticosterone in plasma were 2,4,5-T > HAL > controls. Correlations between maternal corticosterone levels and clefting incidence were very high at all time points examined; total exposure (area under the curve) was also highly correlated. A linear relationship between drug-induced increases in maternal corticosterone levels and the incidence of clefting in A/J mice was evident. Based on these findings, we believe that increased maternal corticosterone levels may play a role in orofacial clefting in A/J mice.
RP SULLIVANJONES, P (reprint author), NATL CTR TOXICOL RES,FOOD & DRUG ADM,DEPT HLTH & HUMAN SERV,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079, USA.
NR 38
TC 15
Z9 15
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0270-4145
J9 J CRAN GENET DEV BIO
JI J. Craniofac. Genet. Dev. Biol.
PD OCT-DEC
PY 1992
VL 12
IS 4
BP 183
EP 189
PG 7
WC Anatomy & Morphology; Developmental Biology; Genetics & Heredity
SC Anatomy & Morphology; Developmental Biology; Genetics & Heredity
GA KB868
UT WOS:A1992KB86800001
PM 1494023
ER
PT J
AU MADDEN, JM
AF MADDEN, JM
TI MICROBIAL PATHOGENS IN FRESH PRODUCE - THE REGULATORY PERSPECTIVE
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID CLOSTRIDIUM-BOTULINUM; TOXIN PRODUCTION; OUTBREAK; OUTGROWTH
AB The potential for microbial contamination of fruits and vegetables is high because of the wide variety of conditions to which the produce is exposed during growth, harvest, and distribution. Heat treatment may also destroy the protective barriers (peels, husks, rinds) of fruits and vegetables, permitting the entry of microbial pathogens into the produce and providing them access to nutrients essential for their growth and proliferation. Proper refrigeration, storage, and shipping conditions as well as removal of soil from fresh produce by washing with chlorinated water are recommended to prevent contamination.
RP MADDEN, JM (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 19
TC 69
Z9 69
U1 0
U2 5
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD OCT
PY 1992
VL 55
IS 10
BP 821
EP 823
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA JV444
UT WOS:A1992JV44400014
ER
PT J
AU BRUNSWICK, M
BURKHARDT, A
FINKELMAN, F
BOLEN, J
MOND, JJ
AF BRUNSWICK, M
BURKHARDT, A
FINKELMAN, F
BOLEN, J
MOND, JJ
TI COMPARISON OF TYROSINE KINASE ACTIVATION BY MITOGENIC AND NONMITOGENIC
ANTI-IGD ANTIBODIES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID B-CELL ACTIVATION; CROSS-LINKING; LYMPHOCYTES-B; MONOCLONAL-ANTIBODIES;
MEMBRANE IGM; PHOSPHOLIPASE-C; PROTEIN-KINASES; LYMPHOMA CELLS;
IMMUNOGLOBULIN; PHOSPHORYLATION
AB Low concentrations of anti-Ig dextran conjugates that stimulate very high levels of B cell proliferation and Ig secretion stimulate no detectable increases in tyrosine phosphorylation. To study this point further, we compared tyrosine phosphorylation patterns induced by mitogenic and nonmitogenic anti-Ig antibodies. Whereas the mitogenic, strongly cross-linking, antibody H-delta(a)/1 induced greater levels of tyrosine phosphorylation than did the nonmitogenic antibody FF1-4D5, the pattern of substrate phosphorylation was equivalent. At lower concentrations of H-delta(a)/1, which were still mitogenic, the degree of phosphorylation that was induced was similar to that induced by high concentrations of FF1-4D5. Both antibodies stimulated comparable increases in the kinase activity of the three src-related kinases present in normal B cells and linked to the IgR, i.e., Blk, Fyn, and Lyn. These results suggest that the extent of tyrosine kinase activation is proportional to mIg cross-linking, that induction of B cell DNA synthesis may require little tyrosine kinase activation, and that activation of tyrosine kinase per se does not necessarily lead to B cell DNA synthesis.
C1 BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543.
UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814.
RP BRUNSWICK, M (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,CELL BIOL LAB,ROOM 232,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
FU NIAID NIH HHS [R01 AI27465, R01 AI24273, R01 AI21328]
NR 39
TC 12
Z9 12
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 1992
VL 149
IS 7
BP 2249
EP 2254
PG 6
WC Immunology
SC Immunology
GA JP189
UT WOS:A1992JP18900002
PM 1326578
ER
PT J
AU DEBELL, KE
CONTI, A
ALAVA, MA
HOFFMAN, T
BONVINI, E
AF DEBELL, KE
CONTI, A
ALAVA, MA
HOFFMAN, T
BONVINI, E
TI MICROFILAMENT ASSEMBLY MODULATES PHOSPHOLIPASE-C-MEDIATED SIGNAL
TRANSDUCTION BY THE TCR/CD3 IN MURINE T-HELPER LYMPHOCYTES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CELL ANTIGEN RECEPTOR; CYTOPLASMIC FREE CALCIUM; PROTEIN KINASE-C;
CYTOCHALASIN-B; MONOCLONAL-ANTIBODIES; PHORBOL ESTER; ACTIN; COMPLEX;
BINDING; HYDROLYSIS
AB Cytoskeletal involvement in the response to TCR/CD3 ligation and in signal transduction was investigated in a murine Th cell type 2 clone. Cells coated with the hamster anti-CD3 mAb, 145-2C11 (2C11 mAb), and exposed to goat anti-hamster demonstrated an increase in polymerized actin as well as an increase in inositol phospholipid hydrolysis mediated by activation of phospholipase C. Pretreatment with cytochalasins (Cyt) (D or B), drugs that interact with cellular actin, prevented actin polymerization, and augmented the initial rate and total amount of inositol phosphates produced. Drugs modifying microtubule function were ineffective. The intracellular Ca2+ rise attributed to InsP3 and InsP4 generated in response to CD3 perturbation was augmented by CytD. CytD treatment did not affect inositol phosphate generation resulting from the stimulation of guanine nucleotide-binding proteins with aluminium tetrafluoride, indicating that the action of CytD was specific for receptor-mediated inositol phospholipids. CytD decreased the rate of anti-CD3-induced receptor internalization. These data suggest that the assembly of microfilaments plays a role in CD3 internalization and that a CytD-sensitive mechanism uncouples the TCR/CD3 complex from phospholipase C-mediated signaling.
RP DEBELL, KE (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,CELL BIOL LAB,BLDG 29,RM 231,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 48
TC 41
Z9 41
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 1992
VL 149
IS 7
BP 2271
EP 2280
PG 10
WC Immunology
SC Immunology
GA JP189
UT WOS:A1992JP18900005
PM 1388187
ER
PT J
AU KAY, LE
BULL, TE
AF KAY, LE
BULL, TE
TI HETERONUCLEAR TRANSVERSE RELAXATION IN AMX, AX(2), AND AX(3) SPIN
SYSTEMS
SO JOURNAL OF MAGNETIC RESONANCE
LA English
DT Note
ID 3-DIMENSIONAL NMR-SPECTROSCOPY; C-13; PROTEINS; MACROMOLECULES;
RESONANCE; N-15; H-1; ELUCIDATION; ASSIGNMENT; DIPOLAR
C1 UNIV TORONTO,DEPT BIOCHEM & CHEM,TORONTO M5S 1A8,ONTARIO,CANADA.
US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS,BETHESDA,MD 20892.
RP KAY, LE (reprint author), UNIV TORONTO,DEPT MED GENET,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA.
NR 32
TC 28
Z9 28
U1 3
U2 8
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-2364
J9 J MAGN RESON
JI J. Magn. Reson.
PD OCT 1
PY 1992
VL 99
IS 3
BP 615
EP 622
DI 10.1016/0022-2364(92)90218-V
PG 8
WC Biochemical Research Methods; Physics, Atomic, Molecular & Chemical;
Spectroscopy
SC Biochemistry & Molecular Biology; Physics; Spectroscopy
GA JU677
UT WOS:A1992JU67700017
ER
PT J
AU SHAH, VP
BEHL, CR
FLYNN, GL
HIGUCHI, WI
SCHAEFER, H
AF SHAH, VP
BEHL, CR
FLYNN, GL
HIGUCHI, WI
SCHAEFER, H
TI PRINCIPLES AND CRITERIA IN THE DEVELOPMENT AND OPTIMIZATION OF TOPICAL
THERAPEUTIC PRODUCTS
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Editorial Material
C1 HOFFMANN LA ROCHE INC,PHARMACEUT RES & DEV,NUTLEY,NJ 07110.
UNIV UTAH,COLL PHARM,SALT LAKE CITY,UT 84112.
US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109.
CTR INT RES DERMATOL GALDERMA,F-06565 VALBONNE,FRANCE.
NR 0
TC 10
Z9 11
U1 0
U2 2
PU AMER PHARMACEUTICAL ASSN
PI WASHINGTON
PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037
SN 0022-3549
J9 J PHARM SCI
JI J. Pharm. Sci.
PD OCT
PY 1992
VL 81
IS 10
BP 1051
EP 1054
DI 10.1002/jps.2600811020
PG 4
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA JQ818
UT WOS:A1992JQ81800019
PM 1432620
ER
PT J
AU GARRISON, DL
CONRAD, SM
EILERS, PP
WALDRON, EM
AF GARRISON, DL
CONRAD, SM
EILERS, PP
WALDRON, EM
TI CONFIRMATION OF DOMOIC ACID PRODUCTION BY PSEUDONITZSCHIA-AUSTRALIS
(BACILLARIOPHYCEAE) CULTURES
SO JOURNAL OF PHYCOLOGY
LA English
DT Note
DE AMNESIC SHELLFISH POISONING; BACILLARIOPHYCEAE; DOMOIC ACID;
NITZSCHIA-PSEUDOSERIATA; PSEUDONITZSCHIA-AUSTRALIS; TOXIC BLOOMS
ID DIATOM NITZSCHIA-PUNGENS; MARINE DIATOM; CANADA; BAY
AB Single clone isolates of Pseudonitzschia australis Frenguelli (= Nitzschia pseudoseriata Hasle) isolated from a toxic bloom in Monterey Bay, California produced domoic acid in culture. Although long-term historical records do not indicate previous blooms of this species on the Pacific coast, this is probably because it has been often misidentified as Nitzschia seriata Hasle; previous evidence for toxicity is lacking. Hydrographic data suggest that areas such as Monterey Bay might be "hot spots" for domoic acid-producing blooms.
C1 US FDA,OFF SEAFOOD,WASHINGTON,DC 20204.
RP GARRISON, DL (reprint author), UNIV CALIF SANTA CRUZ,INST MARINE SCI,SANTA CRUZ,CA 95064, USA.
NR 20
TC 110
Z9 115
U1 1
U2 7
PU PHYCOLOGICAL SOC AMER INC
PI LAWRENCE
PA 810 EAST 10TH ST, LAWRENCE, KS 66044
SN 0022-3646
J9 J PHYCOL
JI J. Phycol.
PD OCT
PY 1992
VL 28
IS 5
BP 604
EP 607
DI 10.1111/j.0022-3646.1992.00604.x
PG 4
WC Plant Sciences; Marine & Freshwater Biology
SC Plant Sciences; Marine & Freshwater Biology
GA JU831
UT WOS:A1992JU83100004
ER
EF